PharmGKB_ID,RS_ID,Allele_ID,Allele,Phenotype
PA166134802,rs10030044,1043858880,GG,Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
PA166134802,rs10030044,1043858879,GT,Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
PA166134802,rs10030044,1043858878,TT,Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
PA166134666,rs10036156,982030874,CC,Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134666,rs10036156,982030875,CT,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134666,rs10036156,982030876,TT,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166135983,rs10046,1447681814,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of  triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166135983,rs10046,1447681815,AG,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with GG genotypes and increased levels as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166135983,rs10046,1447681816,GG,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166135984,rs10046,1447681821,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135984,rs10046,1447681822,AG,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotypes and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole in combination with a statin."
PA166135984,rs10046,1447681823,GG,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135988,rs1008805,1448615174,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135988,rs1008805,1448615175,AG,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotype and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135988,rs1008805,1448615176,GG,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166163646,rs1008805,1448615169,AA,Postmenopausal women with HR+breast cancer and the GG genotype may have a decreased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole. 
PA166163646,rs1008805,1448615170,AG,Postmenopausal women with HR+breast cancer and the AG genotype may have a increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole. 
PA166163646,rs1008805,1448615171,GG,Postmenopausal women with HR+breast cancer and the GG genotype may have a increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole. 
PA166136519,rs1001179,1447946092,CC,Patients with the CC genotype may be at decreased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism. 
PA166136519,rs1001179,1447946091,CT,"Patients with the CT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism. "
PA166136519,rs1001179,1447946090,TT,Patients with the TT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for alcoholism. 
PA166135098,rs10042486,1183630571,CC,"Patients with the CC genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
PA166135098,rs10042486,1183630572,CT,"Patients with the CT genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
PA166135098,rs10042486,1183630573,TT,"Patients with the TT genotype and schizophrenia may have a better response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
PA166134176,rs10042486,655384863,CC,"Patients with the CC genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134176,rs10042486,655384864,CT,"Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134176,rs10042486,655384865,TT,"Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166136325,rs1006737,1444704765,AA,Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram. 
PA166136325,rs1006737,1444704766,AG,"Patients with the AG genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype or may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram. "
PA166136325,rs1006737,1444704767,GG,"Patients with the GG genotype and major depression may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram. "
PA166136326,rs10121600,1444704777,CC,Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136326,rs10121600,1444704778,CT,Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype or may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136326,rs10121600,1444704779,TT,Patients with the TT genotype may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136495,rs10140457,1448106494,AA,"Women with the AA genotype were not studied. However, women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss."
PA166136495,rs10140457,1448106495,AC,Women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
PA166136495,rs10140457,1448106496,CC,Women with the CC genotype and breast neoplasms may have an increased risk of bone density loss when exposed to letrozole as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
PA166134225,rs10192566,655385101,CC,"Patients with the CC genotype and type 2 diabetes who are treated with rosiglitazone may have the smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
PA166134225,rs10192566,655385100,CG,"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
PA166134225,rs10192566,655385099,GG,"Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
PA166135894,rs10161126,1448106240,AA,Patients with the AA genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.
PA166135894,rs10161126,1448106241,AG,Patients with the AG genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.
PA166135894,rs10161126,1448106242,GG,Patients with the GG genotype and osteoporosis or osteopenia may have a better response when treated with alendronate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to alendronate.
PA166135564,rs10197559,1184748885,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
PA166135564,rs10197559,1184748886,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
PA166135564,rs10197559,1184748887,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
PA166136375,rs10210302,1445401327,CC,Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.
PA166136375,rs10210302,1445401328,CT,Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.
PA166136375,rs10210302,1445401329,TT,Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.
PA166161889,rs1021737,1448525561,GG,Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS. 
PA166161889,rs1021737,1448525562,GT,Pediatric patients with the GT genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS. 
PA166161889,rs1021737,1448525563,TT,Pediatric patients with the TT genotype who are undergoing hematopoietic stem cell transplantation may have an increased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for SOS. 
PA166152734,rs1019385,1447960950,AA,Patients with the AA genotype and epilepsy may require an increased dose of valproic acid as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
PA166152734,rs1019385,1447960951,AC,"Patients with the AC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of valproic acid."
PA166152734,rs1019385,1447960952,CC,Patients with the CC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
PA166134447,rs1024323,827864160,CC,"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
PA166134447,rs1024323,827864161,CT,"In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
PA166134447,rs1024323,827864162,TT,"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
PA166136327,rs1024323,1444704788,CC,"Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil."
PA166136327,rs1024323,1444704787,CT,"Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil."
PA166136327,rs1024323,1444704786,TT,Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.
PA166135599,rs10267099,1184987050,AA,Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135599,rs10267099,1184987051,AG,Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135599,rs10267099,1184987052,GG,Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135097,rs10248420,1183630685,AA,Patients with the AA genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135097,rs10248420,1183630686,AG,"Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine."
PA166135097,rs10248420,1183630687,GG,Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135175,rs10248420,1183619308,AA,"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135175,rs10248420,1183619309,AG,"Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135175,rs10248420,1183619310,GG,"Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166134734,rs10276036,982036613,CC,"Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134734,rs10276036,982036614,CT,"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134734,rs10276036,982036615,TT,"Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135337,rs10264272,1183699863,CC,"Transplant recipients with the CC (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus and require a higher dose of the drug as compared to patients with the CT or TT (*1/*6 or *6/*6) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements."
PA166135337,rs10264272,1183699864,CT,"Transplant recipients with the CT (CYP3A5 *1/*6) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the CC (*1/*1) genotype, and have increased metabolism and require a higher dose of the drug as compared to patients with the TT (*6/*6) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements."
PA166135337,rs10264272,1183699865,TT,"Transplant recipients with the TT (CYP3A5 *6/*6) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the CT or CC (*1/*6 or *1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements."
PA166135833,rs10279545,1444704797,CC,"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166135833,rs10279545,1444704798,CT,"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype or may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166135833,rs10279545,1444704799,TT,Patients with the TT genotype may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135096,rs1029489,1183630757,AA,Patients with the AA genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135096,rs1029489,1183630758,AG,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135096,rs1029489,1183630759,GG,Patients with the GG genotype and asthma may have a reduced frequency of asthma exacerbationse when treated with pitrakinra as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135176,rs10280101,1183619304,AA,"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135176,rs10280101,1183619305,AC,"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135176,rs10280101,1183619306,CC,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135930,rs10305420,1446898011,CC,Women with the CC genotype and obesity and polycystic ovarian syndrome (PCOS) may have an increased response to liraglutide as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
PA166135930,rs10305420,1446898012,CT,Women with the CT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
PA166135930,rs10305420,1446898013,TT,Women with the TT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
PA166135753,rs10306135,1444700911,AA,"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs."
PA166135753,rs10306135,1444700912,AT,"Patients with the AT genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs."
PA166135753,rs10306135,1444700913,TT,"Patients with the TT genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype AA or AT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs."
PA166134822,rs10306114,1446909061,AA,"Patients with the AA genotype may have a decreased, but not absent, risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
PA166134822,rs10306114,1446909062,AG,Patients with the AG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
PA166134822,rs10306114,1446909063,GG,Patients with the GG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
PA166135692,rs10306114,1444667728,AA,Patients with the AA genotype and open-angle glaucoma may have an increased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed. 
PA166135692,rs10306114,1444667729,AG,Patients with the AG genotype and open-angle glaucoma may have a decreased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost.
PA166135692,rs10306114,1444667730,GG,Patients with the GG genotype and open-angle glaucoma may have a decreased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed. 
PA166134811,rs10306114,1183685523,AA,"Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166134811,rs10306114,1183685524,AG,Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134811,rs10306114,1183685525,GG,Patients with the GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166136191,rs1042136,1444667514,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136191,rs1042136,1444667515,AC,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136191,rs1042136,1444667516,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136192,rs1042151,1444667544,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136192,rs1042151,1444667545,AG,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136192,rs1042151,1444667546,GG,Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166152861,rs1041983,1447964073,CC,Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
PA166152861,rs1041983,1447964074,CT,"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity."
PA166152861,rs1041983,1447964075,TT,Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
PA166135266,rs10423928,1447952963,AA,Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135266,rs10423928,1447952964,AT,"Patients with the AT genotype may have decreased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. However, patients with the AT genotype may have increased severity of weight gain as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine."
PA166135266,rs10423928,1447952965,TT,Patients with the TT genotype may have decreased plasma insulin levels and decreased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135754,rs1042580,1444700918,CC,Patients with the CC genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
PA166135754,rs1042580,1444700919,CT,Patients with the CT genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
PA166135754,rs1042580,1444700920,TT,Patients with the TT genotype may have increased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
PA166134964,rs1042173,1184136749,AA,Patients with the AA genotype who are treated with ondansetron may have  increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166134964,rs1042173,1184136750,AC,Patients with the AC genotype who are treated with ondansetron may have  decreased treatment response among patients carrying the SLC6A4  promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166134964,rs1042173,1184136751,CC,Patients with the CC genotype who are treated with ondansetron may have  decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166134846,rs1042597,1447945032,CC,"Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
PA166134846,rs1042597,1447945033,CG,"Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
PA166134846,rs1042597,1447945034,GG,"Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
PA166160314,rs1042597,1448259319,CC,Post menopausal women with the CC genotype and schizophrenia may have increased response to raloxifene compared to patients with the CG genotype. Other genetic and clinical factors may affect response to raloxifene. 
PA166160314,rs1042597,1448259320,CG,Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene. 
PA166160314,rs1042597,1448259321,GG,No patients with the GG genotype were studied.
PA166136090,rs1042640,1448106294,CC,Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
PA166136090,rs1042640,1448106295,CG,Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in people with HIV who are taking atazanavir and ritonavir.
PA166136090,rs1042640,1448106296,GG,Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
PA166135094,rs1042640,1183614856,CC,Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135094,rs1042640,1183614857,CG,Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135094,rs1042640,1183614858,GG,Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135095,rs1042640,1183614869,CC,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135095,rs1042640,1183614870,CG,Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135095,rs1042640,1183614871,GG,Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135267,rs10426377,1448109825,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
PA166135267,rs10426377,1448109826,AC,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
PA166135267,rs10426377,1448109827,CC,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
PA166160487,rs1042718,1448263287,AA,"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane."
PA166160487,rs1042718,1448263288,AC,"Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane."
PA166160487,rs1042718,1448263289,CC,"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane."
PA166134349,rs1042522,1448266883,CC,Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166134349,rs1042522,1448266884,CG,Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166134349,rs1042522,1448266885,GG,Patients with the GG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166135384,rs1042919,1183700260,AA,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better event-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135384,rs1042919,1183700259,AT,Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135384,rs1042919,1183700261,TT,Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135657,rs1042927,1448617076,AA,Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.
PA166135657,rs1042927,1448617077,CA,Patients with the CA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype and increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.
PA166135657,rs1042927,1448617078,CC,Patients with the CC genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's survival probability.
PA166135269,rs1043620,1448105718,CC,Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
PA166135269,rs1043620,1448105719,CT,Patients with the CT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
PA166135269,rs1043620,1448105720,TT,Patients with the TT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
PA166135231,rs1042858,1183630267,AA,Patients with the AA genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment. 
PA166135231,rs1042858,1183630268,AG,Patients with the AG genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment. 
PA166135231,rs1042858,1183630269,GG,Patients with the GG genotype and breast cancer who are treated with gemcitabine may have an increased risk of side effects including neutropenia as compared to patients with the AA or AG genotype combined with the G allele at rs9937. This association was not seen in a seperate study in patients with pancreatic cancer.Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment. 
PA166136332,rs1044397,1444704871,CC,Male patients with the CC genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136332,rs1044397,1444704872,CT,Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136332,rs1044397,1444704873,TT,Male patients with the TT genotype may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136328,rs1045280,1444704814,CC,Patients with the CC genotype may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
PA166136328,rs1045280,1444704813,CT,Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
PA166136328,rs1045280,1444704812,TT,Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
PA166134042,rs1042714,1444667300,CC,Patients with the CC genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134042,rs1042714,1444667301,CG,Patients with the CG genotype and heart failure may have a poorer response to  carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134042,rs1042714,1444667302,GG,Patients with the GG genotype and heart failure may have a better response to carvedilol treatment as compared to patients with the CC or CG genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166135092,rs1042714,1183630591,CC,Patients with the CC genotype and left ventricular hypertrophy may have a smaller percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index. 
PA166135092,rs1042714,1183630592,CG,Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index. 
PA166135092,rs1042714,1183630593,GG,Patients with the GG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index. 
PA166152668,rs1042714,1447960198,CC,Patients with the CC genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
PA166152668,rs1042714,1447960199,CG,Patients with the CG genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
PA166152668,rs1042714,1447960200,GG,Patients with the GG genotype may experience slower desensitization to effects of terbutaline as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
PA166152669,rs1042714,1447960206,CC,Patients with the CC genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia. 
PA166152669,rs1042714,1447960207,CG,Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia. 
PA166152669,rs1042714,1447960208,GG,Patients with the GG genotype and hypertension may have an increased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia. 
PA166152749,rs1044457,1447981380,CC,"Patients with the CC genotype and cancer may have longer overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have decreased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the TT genotype. Other genetic and clinical factors may also influence survival times."
PA166152749,rs1044457,1447981381,CT,Patients with the CT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
PA166152749,rs1044457,1447981382,TT,"Patients with the TT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Patients with the TT genotype may also have increased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the CC genotype.Other genetic and clinical factors may also influence survival times."
PA166136204,rs10455872,1444827827,AA,Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors and (according to one study) a decreased risk of coronary artery disease as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. 
PA166136204,rs10455872,1444827828,AG,Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors and (according to one study) a decreased risk of coronary artery disease as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors and an increased risk of coronary artery disease as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. 
PA166136204,rs10455872,1444827829,GG,Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors and (according to one study) an increased risk of coronary artery disease as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. 
PA166135729,rs10465180,1444700364,CC,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135729,rs10465180,1444700365,CT,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135729,rs10465180,1444700366,TT,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135683,rs1047840,1444667229,AA,Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
PA166135683,rs1047840,1444667230,AG,Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
PA166135683,rs1047840,1444667231,GG,Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
PA166134262,rs1044396,982035371,AA,The AA genotype was found less often in smokers as compared to the GG genotype. In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166134262,rs1044396,982035372,AG,The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166134262,rs1044396,982035373,GG,The GG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.28). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166135966,rs1044396,1446908547,AA,Patients with the AA genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
PA166135966,rs1044396,1446908546,AG,Patients with the AG genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
PA166135966,rs1044396,1446908545,GG,Patients with the GG genotype and Tobacco Use Disorder who are treated with varenicline may have a decreased response to varenicline as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
PA166152672,rs1048101,1447960233,AA,Patients with the AA genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
PA166152672,rs1048101,1447960234,AG,Patients with the AG genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
PA166152672,rs1048101,1447960235,GG,Patients with the GG genotype and hypertension may have a lesser reduction in systolic blood pressure when treated with nifedipine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
PA166135090,rs1048943,1183614836,AA,Women with the AA genotype and breast cancer may have decreased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135090,rs1048943,1183614837,AG,Women with the AG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135090,rs1048943,1183614838,GG,Women with the GG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166161948,rs10485058,1448526042,AA,Patients with the AA genotype who are opioid-dependent may have a better response to treatment with methadone as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone response.
PA166161948,rs10485058,1448526043,AG,Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone response.
PA166161948,rs10485058,1448526044,GG,Patients with the GG genotype who are opioid-dependent may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone response.
PA166135597,rs10157410,1184986999,CC,Patients with the CC genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135597,rs10157410,1184987000,CG,Patients with the CG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CC genotype and an increased risk of hypercholesteremia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135597,rs10157410,1184987001,GG,Patients with the GG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166134611,rs104894539,981239533,AA,"Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166134611,rs104894539,981239534,AC,"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166134611,rs104894539,981239535,CC,Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.
PA166135268,rs1042713,1183632178,AA,Patients with the AA genotype may have decreased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166135268,rs1042713,1183632177,AG,Patients with the AG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166135268,rs1042713,1183632176,GG,Patients with the GG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166135363,rs1042713,1183697634,AA,"Patients with the AA genotype and asthma may have a poorer response when treated with methacholine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methacholine."
PA166135363,rs1042713,1183697636,AG,"Patients with the AG genotype and asthma may have a better response when treated with methacholine as compared to patients with the AA genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine."
PA166135363,rs1042713,1183697635,GG,"Patients with the GG genotype and asthma may have a better response when treated with methacholine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methacholine."
PA166135386,rs1042713,1447953299,AA,Patients with the AA genotype and asthma who are treated with corticosteroids may have an increased risk for uncontrolled asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids. 
PA166135386,rs1042713,1447953300,AG,Patients with the AG genotype and asthma who are treated with corticosteroids may have an increased risk for uncontrolled asthma as compared to patients with the GG genotype or may have a reduced risk for uncontrolled asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids. 
PA166135386,rs1042713,1447953301,GG,Patients with the GG genotype and asthma who are treated with corticosteroids may have a reduced risk for uncontrolled asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids. 
PA166135387,rs1042713,1183700401,AA,Children with the AA genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.  
PA166135387,rs1042713,1183700402,AG,Children with the AG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype or may have a reduced risk of exacerbations as compared to children with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.  
PA166135387,rs1042713,1183700403,GG,Children with the GG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have a reduced risk of exacerbations as compared to children with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.  
PA166135093,rs1042713,1183630607,AA,"Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure."
PA166135093,rs1042713,1183630608,AG,"Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure."
PA166135093,rs1042713,1183630609,GG,"Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure."
PA166134226,rs1042713,1446905300,AA,"Children with the AA genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to children with the GG genotype. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient's response to treatment. 
"
PA166134226,rs1042713,1446905301,AG,Children with the AG genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to children with the GG genotype or may have a better response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to patients with the AA genotype. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134226,rs1042713,1446905302,GG,Children with the GG genotype with asthma who are treated with salmeterol or salbutamol may have a better response to treatment (as measured by a decreased risk of asthma excerbations and higher quality of life scores) as compared to children with the AA genotype. This association does not seem to apply to lung function measurements. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135730,rs1042713,1444700356,AA,Patients with the AA genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
PA166135730,rs1042713,1444700357,AG,Patients with the AG genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
PA166135730,rs1042713,1444700358,GG,Patients with the GG genotype may have decreased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
PA166152623,rs1042713,1447959517,AA,Patients with the AA genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to propranolol.
PA166152623,rs1042713,1447959518,AG,"Patients with the AG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the GG genotype, but decreased response compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to propranolol."
PA166152623,rs1042713,1447959519,GG,Patients with the GG genotype and Cirrhosis may have a decreased response when treated with propranolol as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to propranolol.
PA166152667,rs1042713,1447960186,AA,Patients with the AA genotype and heart failure may have decreased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
PA166152667,rs1042713,1447960187,AG,"Patients with the AG genotype and heart failure may have decreased emergency department (ED) visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the GG genotype, and increased ED visits and hospital utilization as compared to those with the AA genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs."
PA166152667,rs1042713,1447960188,GG,Patients with the GG genotype and heart failure may have increased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
PA166135900,rs1042713,1448263278,AA,"Women with the AA genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine."
PA166135900,rs1042713,1448263279,AG,"Women with the AG genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype, or a lower dose as compared to women with the AA genotype. Other genetic and clinical factors may also influence dose of phenylephrine."
PA166135900,rs1042713,1448263280,GG,"Women with the GG genotype who are undergoing cesarean delivery may require a lower dose of phenylephrine as compared to women with the AA genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine."
PA166136155,rs1042713,1444666303,AA,Patients with the AA genotype and asthma may have a better response to treatment with tiotropium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tiotropium. 
PA166136155,rs1042713,1444666304,AG,Patients with the AG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium. 
PA166136155,rs1042713,1444666305,GG,Patients with the GG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium. 
PA166135688,rs1047626,1444667463,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135688,rs1047626,1444667464,AG,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135688,rs1047626,1444667465,GG,Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166134612,rs104894540,981239545,AA,Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.
PA166134612,rs104894540,981239546,AG,"Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166134612,rs104894540,981239547,GG,"Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166136516,rs10490162,1447945994,CC,Patients with the CC genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
PA166136516,rs10490162,1447945995,CT,Patients with the CT genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
PA166136516,rs10490162,1447945996,TT,Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
PA166136022,rs10490924,1447946021,GG,"Patients with the GG genotype and age-related macular degeneration who are treated with bevacizumab may have poorer improvement in visual acuity as compared to patients with the GT or TT genotype. However, another study finds that those with the GG genotype have better improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment."
PA166136022,rs10490924,1447946022,GT,Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.
PA166136022,rs10490924,1447946023,TT,"Patients with the TT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. However, another study finds that those with the TT genotype have poorer improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment."
PA166134613,rs104894541,981239557,CC,"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166134613,rs104894541,981239558,CT,"Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166134613,rs104894541,981239559,TT,Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.
PA166152636,rs10494227,1448106268,AA,Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152636,rs10494227,1448106269,AG,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152636,rs10494227,1448106270,GG,Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166135521,rs1048977,1444698363,CC,"Patients with cancer and the CC genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine. "
PA166135521,rs1048977,1444698364,CT,"Patients with cancer and the CT genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine. "
PA166135521,rs1048977,1444698365,TT,"Patients with cancer and the TT genotype may have decreased metabolism of gemcitabine as compared to patients with the CC genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine. "
PA166163765,rs1048977,1448616982,CC,Patients with cancer and the CC genotype who are treated with capecitabine may have decreased (but not absent) risk of hyperbilirubinemia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine. 
PA166163765,rs1048977,1448616983,CT,Patients with cancer and the CT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine. 
PA166163765,rs1048977,1448616984,TT,Patients with cancer and the TT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine. 
PA166135533,rs10497203,1184514205,AA,Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135533,rs10497203,1184514204,AC,"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. "
PA166135533,rs10497203,1184514203,CC,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166136251,rs10499563,1444687008,CC,"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136251,rs10499563,1444687006,CT,"Patients with the CT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136251,rs10499563,1444687007,TT,"Patients with the TT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166134949,rs10494366,1183491002,GG,"Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation."
PA166134949,rs10494366,1183491001,TG,Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
PA166134949,rs10494366,1183491000,TT,Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
PA166134183,rs10494366,655384899,GG,Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
PA166134183,rs10494366,655384900,GT,"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
PA166134183,rs10494366,655384901,TT,"Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
PA166159191,rs10494366,1448103820,GG,Patients with the GG genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
PA166159191,rs10494366,1448103821,GT,Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
PA166159191,rs10494366,1448103822,TT,Patients with the TT genotype and hypertension may have a decreased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
PA166159203,rs10494366,1448103937,GG,Patients with the GG genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to repaglinide. 
PA166159203,rs10494366,1448103938,GT,"Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide. "
PA166159203,rs10494366,1448103939,TT,Patients with the TT genotype and type 2 diabetes may have a better response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide. 
PA166135409,rs10501087,1183702960,CC,Patients with the CC genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics. 
PA166135409,rs10501087,1183702961,CT,Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics. 
PA166135409,rs10501087,1183702962,TT,Patients with the TT genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics. 
PA166135374,rs1050152,1444667989,CC,Patients with the CC genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.
PA166135374,rs1050152,1444667990,CT,Patients with the CT genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.
PA166135374,rs1050152,1444667991,TT,Patients with the TT genotype and cancer may have a poorer response to treatment with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to progression.
PA166134614,rs104894542,981239569,AA,Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.
PA166134614,rs104894542,981239570,AC,"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166134614,rs104894542,981239571,CC,"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
PA166158998,rs10509373,1448100663,CC,Patients with the CC genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
PA166158998,rs10509373,1448100664,CT,Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
PA166158998,rs10509373,1448100665,TT,Patients with the TT genotype and breast cancer may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
PA166134796,rs1050891,1043858736,AA,Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
PA166134796,rs1050891,1043858735,AG,Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
PA166134796,rs1050891,1043858734,GG,Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
PA166135349,rs1049353,1446898842,CC,"Patients with the CC genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have an increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CT and CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain."
PA166135349,rs1049353,1446898843,CT,"Patients with the CT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain."
PA166135349,rs1049353,1446898844,TT,"Patients with the TT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have a decreased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain."
PA166134867,rs10509680,1043880376,GG,Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
PA166134867,rs10509680,1043880377,TG,Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
PA166134867,rs10509680,1043880378,TT,Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
PA166134624,rs1050828,1446905333,CC,"Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) a decreased, but not absent, risk of hemolysis and severe/ unsafe hemoglobin decreases 2) decreased, but not absent, risk of requiring a blood transfusion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone."
PA166134624,rs1050828,1446905334,CT,"Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. This association was contradicted in another study showing no association of the CT genotype with increased risk of unsafe hemoglobin decreases or requirement for a blood transfusion when treated with artesunate, chlorproguanil and dapsone compared to to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone."
PA166134624,rs1050828,1446905335,TT,"Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) an increased risk of hemolysis and severe/ unsafe hemoglobin decreases 2) an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone."
PA166135180,rs1050828,1183621040,CC,"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis. "
PA166135180,rs1050828,1183621041,CT,"Children with the CT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis. "
PA166135180,rs1050828,1183621042,TT,"Children with the TT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis. "
PA166134609,rs1050828,982032372,CC,"Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine."
PA166134609,rs1050828,982032373,CT,"Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine."
PA166134609,rs1050828,982032374,TT,"Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine."
PA166152757,rs10511905,1447961131,AA,Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152757,rs10511905,1447961132,AG,"Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152757,rs10511905,1447961133,GG,Patients with the GG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166153058,rs10510050,1448106551,AA,"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153058,rs10510050,1448106552,AG,"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153058,rs10510050,1448106553,GG,"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166136177,rs1051298,1447960845,AA,Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.
PA166136177,rs1051298,1447960846,AG,"Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time."
PA166136177,rs1051298,1447960847,GG,Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.
PA166134052,rs10509681,1446908889,CC,Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
PA166134052,rs10509681,1446908890,CT,Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
PA166134052,rs10509681,1446908891,TT,Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
PA166134144,rs10509681,1448605617,CC,"Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone, a smaller change in HbA1c, and a decreased risk of edema as compared to patients with the TT genotype (CYP2C8*1/*1). One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels."
PA166134144,rs10509681,1448605618,CT,"Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone and a decreased risk of edema compared to patients with the TT genotype (CYP2C8*1/*1). No association was found when considering blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels."
PA166134144,rs10509681,1448605619,TT,"Patients with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of rosiglitazone, a larger change in HbA1c, and an increased risk of edema as compared to patients with the CC (CYP2C8*3/*3) or CT (CYP2C8*3/*1) genotype. One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels."
PA166134455,rs10509681,978639597,CC,"Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels."
PA166134455,rs10509681,978639598,CT,"Individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide."
PA166134455,rs10509681,978639599,TT,"Individuals with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide."
PA166134171,rs10509681,655384839,CC,"Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134171,rs10509681,655384840,CT,"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134171,rs10509681,655384841,TT,"Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166151938,rs10514475,1447953104,AA,Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
PA166151938,rs10514475,1447953105,AG,Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
PA166151938,rs10514475,1447953106,GG,Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
PA166134446,rs1051375,827863929,AA,"Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134446,rs1051375,827863930,AG,"Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134446,rs1051375,827863931,GG,"Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134865,rs1051685,1043880326,AA,Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166134865,rs1051685,1043880325,AG,Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166134865,rs1051685,1043880324,GG,Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166135934,rs10517,1448267375,AA,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.
PA166135934,rs10517,1448267376,AG,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.
PA166135934,rs10517,1448267377,GG,Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA and GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.
PA166135203,rs1051640,1448616431,AA,"Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166135203,rs1051640,1448616432,AG,"Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166135203,rs1051640,1448616433,GG,Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
PA166135518,rs1052536,1184348775,CC,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135518,rs1052536,1184348776,CT,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135518,rs1052536,1184348777,TT,"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. "
PA166135514,rs1051740,1184348709,CC,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar  risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135514,rs1051740,1184348710,CT,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135514,rs1051740,1184348711,TT,"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 1-4 nephrotoxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. "
PA166134302,rs1051740,655385990,CC,Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.
PA166134302,rs1051740,655385991,CT,Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134302,rs1051740,655385992,TT,Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134607,rs1051740,1447679978,CC,"Patients with the CC genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
PA166134607,rs1051740,1447679979,CT,"Patients with the CT genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the TT genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
PA166134607,rs1051740,1447679980,TT,"Patients with the TT genotype and Epilepsy may have lower metabolism of carbamazepine and may require a decreased dose of carbamazepine as compared to patients with the the CC or CT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
PA166152673,rs1051740,1447960240,CC,"Patients with the CC genotype may have a greater likelihood of being overanticoagulated when treated with phenprocoumon, and may require a decreased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon."
PA166152673,rs1051740,1447960241,CT,"Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon."
PA166152673,rs1051740,1447960242,TT,"Patients with the TT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon."
PA166158784,rs10538494,1448099225,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158784,rs10538494,1448099226,AT,Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158784,rs10538494,1448099227,TT,Patients with nasopharyngeal cancer and the TT genotype who are treated with docetaxel may have a increased severity of neutropenia as compared to patients with the AT or AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166134695,rs1051730,982031884,AA,Patients with the AA genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.
PA166134695,rs1051730,982031885,AG,Patients with the AG genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.
PA166134695,rs1051730,982031886,GG,Patients with the GG genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.
PA166135733,rs1051730,1444700406,AA,"Patients with the AA genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine."
PA166135733,rs1051730,1444700407,AG,"Patients with the AG genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype or a decreased risk for nicotine dependency and decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine."
PA166135733,rs1051730,1444700408,GG,"Patients with the GG genotype may have an decreased risk for nicotine dependency, increased lung function when exposed to nicotine, but may experience decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine."
PA166136468,rs1051730,1446908570,AA,Patients with the AA genotype and pain who are receiving Opium alkaloids and derivatives may have an increased severity of Substance-Related Disorders as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
PA166136468,rs1051730,1446908571,AG,Patients with the AG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
PA166136468,rs1051730,1446908572,GG,Patients with the GG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
PA166159194,rs1051730,1448103841,AA,Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
PA166159194,rs1051730,1448103842,AG,"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism."
PA166159194,rs1051730,1448103843,GG,Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
PA166136527,rs1053129,1447946240,AA,"No patients with the AA genotype were available for analysis, but patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate."
PA166136527,rs1053129,1447946241,AC,"Patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate."
PA166136527,rs1053129,1447946242,CC,"Patients with the CC genotype and osteosarcoma who are receiving methotrexate may have an increased risk for metastasis, as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate."
PA166136368,rs1056515,1448102829,GG,"Patients with the GG genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
PA166136368,rs1056515,1448102830,GT,"Patients with the GT genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon.  Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
PA166136368,rs1056515,1448102831,TT,"Patients with the TT genotype and colorectal cancer may have a better response when treated with FOLFIRI and bevacizumab as compared to patients with the GG or GT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
PA166136181,rs1052555,1444666888,AA,Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166136181,rs1052555,1444666889,AG,Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166136181,rs1052555,1444666890,GG,Patients with the GG genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135354,rs1051266,1183697536,CC,Patients with the CC genotype and metastatic colorectal cancer may have increased rapid response to treatment containing irinotecan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
PA166135354,rs1051266,1183697537,CT,Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
PA166135354,rs1051266,1183697538,TT,Patients with the TT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
PA166134338,rs1051266,1448099616,CC,Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may have 1) a decreased response to the drug and 2) an increased risk for toxicity as compared to patients with the TT genotype. These associations have not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy and risk for toxicity. 
PA166134338,rs1051266,1448099617,CT,Patients with the CT genotype and rheumatoid arthritis who are treated with methotrexate may have 1) a decreased response to the drug and 2) an increased risk for toxicity as compared to patients with the TT genotype. These associations have not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy and risk for toxicity. 
PA166134338,rs1051266,1448099618,TT,Patients with the TT genotype and rheumatoid arthritis who are treated with methotrexate may have 1) an increased response to the drug and 2) a decreased risk for toxicity as compared to patients with the CC or CT genotype. These associations have not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy and risk for toxicity. 
PA166134608,rs1051266,1448126204,CC,"Cancer patients with the CC genotype who are treated with methotrexate may have 1) a decreased likelihood of drug toxicity as compared to those with the CT or TT genotype, 2) a better response as compared to those with the CT or TT genotype and 3) decreased concentrations of methotrexate as compared to those with the TT genotype. However, multiple incidences of negative or contradictory evidence exists for all three of these associations. Other genetic or clinical factors may influence a patient's response to methotrexate. 
"
PA166134608,rs1051266,1448126205,CT,"Cancer patients with the CT genotype who are treated with methotrexate may have 1) a decreased likelihood of drug toxicity as compared to those with the TT genotype, and an increased likelihood as compared to those with the CC genotype 2) a poorer response as compared to those with the CC genotype and 3) decreased concentrations of methotrexate as compared to those with the TT genotype. However, multiple incidences of negative or contradictory evidence exists for all three of these associations. Other genetic or clinical factors may influence a patient's response to methotrexate. 
"
PA166134608,rs1051266,1448126206,TT,"Cancer patients with the TT genotype who are treated with methotrexate may have 1) an increased likelihood of drug toxicity as compared to those with the CC or CT genotype, 2) a poorer response as compared to those with the CC genotype and 3) increased concentrations of methotrexate as compared to those with the CC or CT genotype. However, multiple incidences of negative or contradictory evidence exists for all three of these associations. Other genetic or clinical factors may influence a patient's response to methotrexate. 
"
PA166151928,rs1059150,1447952821,GG,"Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
PA166151928,rs1059150,1447952822,GT,"Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
PA166151928,rs1059150,1447952823,TT,"Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
PA166134116,rs1056892,652779373,AA,Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134116,rs1056892,652779374,AG,Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134116,rs1056892,652779375,GG,Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166135736,rs1059288,1444700461,AA,Patients with the AA genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. 
PA166135736,rs1059288,1444700462,AG,Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. 
PA166135736,rs1059288,1444700463,GG,Patients with the GG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. 
PA166134130,rs1056836,1448101573,CC,"Patients with the CC genotype may have worse response to taxane regimens as compared to patients with the GG genotype, however four studies reported no association between response and genotype. Other genetic and clinical factors may also influence a patient's response to taxanes. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166134130,rs1056836,1448101574,CG,"Patients with the CG genotype have increased response to taxane regimens as compared to patients with the GG and CC genotype, although one study found decreased response compared to GG and one found increased response compared to CC. Furthermore several studies found no association between response and genotype. Other genetic and clinical factors may also influence a patient's response to taxanes. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166134130,rs1056836,1448101575,GG,"Patients with prostate or breast cancer and the GG genotype may have improved response to taxanes as compared to patients with the CG or CC genotype, however several studies found no association between response and genotype. Other genetic and clinical factors may also influence a patient's response to taxanes. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136364,rs1056836,1448102823,CC,"Patients with the CC genotype and breast cancer may have a poorer response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136364,rs1056836,1448102824,CG,"Patients with the CG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136364,rs1056836,1448102825,GG,"Patients with the GG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136021,rs1056836,1448102853,CC,"Patients with the CC genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136021,rs1056836,1448102854,CG,"Patients with the CG genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype, or an increased chance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136021,rs1056836,1448102855,GG,"Patients with the GG genotype and breast cancer may have an increased chance of experiencing sensory neuropathy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
PA166136493,rs1059751,1447813541,AA,Individuals with the AA genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or GG genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir. 
PA166136493,rs1059751,1447813542,AG,Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir. 
PA166136493,rs1059751,1447813543,GG,Individuals with the GG genotype and HIV may have a increased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or AA genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir. 
PA166135602,rs10485828,1448106288,CC,Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166135602,rs10485828,1448106289,CG,Patients with the CG genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166135602,rs10485828,1448106290,GG,Patients with the GG genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166135737,rs1061018,1444700506,AA,"Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166135737,rs1061018,1444700505,AG,"Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
PA166135737,rs1061018,1444700504,GG," Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166135944,rs1061472,1446899951,CC,"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166135944,rs1061472,1446899952,CT,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166135944,rs1061472,1446899953,TT,"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166135823,rs1061622,1447959176,GG,"Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GT or TT genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
PA166135823,rs1061622,1447959177,GT,"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
PA166135823,rs1061622,1447959178,TT,"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
PA166135308,rs1057868,1448573275,CC,"Patients with the CC (POR *1/*1) genotype and Kidney Transplantation who are treated with tacrolimus 1) may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation, 2) in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3  (rs776746) may require a decreased dose of tacrolimus as compared to patients with the CT and TT (*1/*28 and *28/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. "
PA166135308,rs1057868,1448573276,CT,"Patients with the CT (POR *1/*28) genotype and Kidney Transplantation who are treated with tacrolimus 1) may have an increased risk for developing new-onset diabetes after transplantation, 2) in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3  (rs776746) may require an increased dose of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. "
PA166135308,rs1057868,1448573277,TT,"Patients with the TT (POR *28/*28) genotype and Kidney Transplantation who are treated with tacrolimus 1) may have an increased risk for developing new-onset diabetes after transplantation, 2) in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3  (rs776746) may require an increased dose of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. "
PA166134963,rs1057868,1183491217,CC,"Patients with the CC genotype may have an decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with an increased metabolic ratio of midazolam as compared to patients with the CT genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam."
PA166134963,rs1057868,1183491216,CT,"Patients with the TC genotype may have a decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with a decreased metabolic ratio of midazolam as compared to patients with the CC genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam."
PA166134963,rs1057868,1183491215,TT,Patients with the TT genotype may have an increased metabolic ratio of midazolam as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.
PA166136223,rs1057868,1447945823,CC,"Patients with the CC genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
PA166136223,rs1057868,1447945824,CT,"Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
PA166136223,rs1057868,1447945825,TT,"Patients with the TT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have decreased trough concentrations of cyclosporine as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
PA166136389,rs1057868,1445401967,CC,Patients with the CC genotype (POR *1/*1) and familial hypercholesterolemia may have a greater decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CT (*1/*28) or TT (*28/*28) genotype. Other genetic and clinical factors may also influence response to atorvastatin.
PA166136389,rs1057868,1445401968,CT,Patients with the CT genotype (POR *1/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (*1/*1). Other genetic and clinical factors may also influence response to atorvastatin.
PA166136389,rs1057868,1445401969,TT,Patients with the TT genotype (POR *28/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (POR *1/*1). Other genetic and clinical factors may also influence response to atorvastatin.
PA166152779,rs1057868,1447962605,CC,Patients with the CC genotype who are also CYP2A6 normal metabolizers may have decreased metabolism of nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
PA166152779,rs1057868,1447962606,CT,Patients with the CT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
PA166152779,rs1057868,1447962607,TT,Patients with the TT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
PA166162474,rs1057868,1448567799,CC,Patients with the CC genotype who underwent kidney transplantation may have increased trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations. 
PA166162474,rs1057868,1448567800,CT,Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations. 
PA166162474,rs1057868,1448567801,TT,Patients with the TT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations. 
PA166136295,rs1061170,1448100736,CC,"Patients with the CC genotype and macular degeneration may have a poorer improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CT or TT genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab."
PA166136295,rs1061170,1448100737,CT,"Patients with the CT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab."
PA166136295,rs1061170,1448100738,TT,"Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab."
PA166152675,rs1061170,1447960264,CC,"Patients with the CC genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy."
PA166152675,rs1061170,1447960265,CT,"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy."
PA166152675,rs1061170,1447960266,TT,"Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy."
PA166136106,rs1061170,1444607329,CC,No patients with the CC genotype available for analysis.
PA166136106,rs1061170,1444607328,CT,Patients with the CT genotype and age-related macular degeneration may require a greater number of bevacizumab injections as compared to those with the TT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.
PA166136106,rs1061170,1444607327,TT,Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.
PA166160430,rs1061781,1448262547,CC,Patients with the CC genotype may have higher on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166160430,rs1061781,1448262548,CT,Patients with the CT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166160430,rs1061781,1448262549,TT,Patients with the TT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166136490,rs1062033,1447682302,CC,"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CG or GG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
PA166136490,rs1062033,1447682303,CG,"Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
PA166136490,rs1062033,1447682304,GG,"Post-menopausal women with breast cancer and the GG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC or CG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
PA166135612,rs1063320,1184988841,CC,Patients with asthma and the CC genotype may have an increased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CG and GG genotypes. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
PA166135612,rs1063320,1184988842,CG,Patients with asthma and the CG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
PA166135612,rs1063320,1184988843,GG,Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
PA166135116,rs1062613,1183630693,CC,Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135116,rs1062613,1183630694,CT,"Patients with the CT genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype, or may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine."
PA166135116,rs1062613,1183630695,TT,Patients with the TT genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166134794,rs1062535,1043858704,AA,Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134794,rs1062535,1043858705,AG,Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134794,rs1062535,1043858706,GG,"Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166134821,rs1062535,1446909055,AA,Patients with the AA genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
PA166134821,rs1062535,1446909056,AG,Patients with the AG genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
PA166134821,rs1062535,1446909057,GG,"Patients with the GG genotype may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin."
PA166152676,rs1065634,1447960271,CC,"No patients with the CC genotype are available for analysis, but patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients. "
PA166152676,rs1065634,1447960272,CT,Patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients. 
PA166152676,rs1065634,1447960273,TT,Patients with the TT genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents and gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients. 
PA166135825,rs1061631,1444704337,AA,Patients with the AA genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135825,rs1061631,1444704338,AG,Patients with the AG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135825,rs1061631,1444704339,GG,Patients with the GG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135089,rs1065852,1183614831,AA,Patients with the AA genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.
PA166135089,rs1065852,1183614832,AG,Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.
PA166135089,rs1065852,1183614833,GG,Patients with the GG genotype and schizophrenia may have an increased QTc interval when treated with iloperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval.
PA166136114,rs1065852,1444700530,AA,Patients with the AA genotype and depression may have a decreased response and remission rate when treated with escitalopram as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also effect patients response.
PA166136114,rs1065852,1444700531,AG,Patients with the AG genotype and depression may have a increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients response.
PA166136114,rs1065852,1444700532,GG,Patients with the GG genotype and depression may have a increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients response.
PA166151929,rs1072388,1447952827,AA,Patients with the AA genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166151929,rs1072388,1447952828,AG,Patients with the AG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166151929,rs1072388,1447952829,GG,Patients with the GG genotype and schizophrenia may have a worse response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135952,rs10739150,1446902922,GG,Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.
PA166135952,rs10739150,1446902923,GT,Patients with the GT genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.
PA166135952,rs10739150,1446902924,TT,Patients with the TT genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to atenolol.
PA166136373,rs10737062,1445401305,AA,Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.
PA166136373,rs10737062,1445401306,AG,Patients with the AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
PA166136373,rs10737062,1445401307,GG,Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
PA166163257,rs10741657,1448602936,AA,"Patients with the AA genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
PA166163257,rs10741657,1448602937,AG,"Patients with the AG genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
PA166163257,rs10741657,1448602938,GG,"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
PA166136194,rs1074373,1444667580,AA,Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136194,rs1074373,1444667581,AC,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136194,rs1074373,1444667582,CC,Patients with asthma and the CC genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136200,rs10747673,1444668288,AA,"In healthy volunteers as well as patients with diabetes mellitus the AA genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166136200,rs10747673,1444668289,AG,"In healthy volunteers as well as patients with diabetes mellitus the AG genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the GG genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166136200,rs10747673,1444668290,GG,"In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166136372,rs10752271,1445401298,AA,Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.
PA166136372,rs10752271,1445401299,AG,Patients with the AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
PA166136372,rs10752271,1445401300,GG,Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
PA166135398,rs10757274,1183700537,AA,"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs."
PA166135398,rs10757274,1183700538,AG,"Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs."
PA166135398,rs10757274,1183700539,GG,"Patients with the GG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs."
PA166134413,rs1057910,769181842,AA,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
PA166134413,rs1057910,769181843,AC,Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
PA166134413,rs1057910,769181844,CC,Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
PA166134907,rs1057910,1045153884,AA,Patients with the AA (CYP2C9*1/*1) genotype may have lower plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or CC (CYP2C9*3/*3) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics. 
PA166134907,rs1057910,1045153883,AC,Patients with the AC (CYP2C9*1/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics. 
PA166134907,rs1057910,1045153882,CC,Patients with the CC (CYP2C9*3/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics. 
PA166134908,rs1057910,1047434905,AA,Patients with the AA genotype who are treated with simvastatin and warfarin may require an increased dose of warfarin as compared to patients with the CC or AC genotype (patients with the CYP2C9*3 allele). Simvastatin did not seem to affect warfarin dose in patients who did not have the C allele (CYP2C9*3). This variant does not seem to be associated with response to simvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's required warfarin dosage and response to simvastatin. 
PA166134908,rs1057910,1047434912,AC,Patients with the AC genotype (carriers of CYP2C9*3) who are treated with simvastatin and warfarin may require a decreased dose of warfarin  as compared to patients with the AA genotype (patients who do not have the CYP2C9*3 allele). This variant does not seem to be associated with response to simvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's required warfarin dosage and response to simvastatin. 
PA166134908,rs1057910,1047434918,CC,Patients with the CC genotype (CYP2C9*3/*3) who are treated with simvastatin and warfarin may require a decreased dose of warfarin as compared to patients with the AA  genotype (patients who do not have the CYP2C9*3 allele). This variant does not seem to be associated with response to simvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's required warfarin dosage and response to simvastatin. 
PA166134154,rs1057910,1448431553,AA,Patients with the AA genotype: 1) may require an increased dose of warfarin as compared to patients with the AC or CC genotype 2) may have a decreased risk for adverse events as compared to patients with the AC or CC genotype. Patients with the AA genotype may still be at risk for adverse events when taking warfarin based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134154,rs1057910,1448431554,AC,Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.
PA166134154,rs1057910,1448431555,CC,Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.
PA166134443,rs1057910,1183693355,AA,Patients with the AA (CYP2C9 *1/*1) genotype may have increased metabolism of celecoxib as compared to patients with the AC or CC (*1/*3 or *3/*3) genotype. Other genetic and clinical factors may also influence a metabolism of celecoxib. 
PA166134443,rs1057910,1183693356,AC,"Patients with the AC (CYP2C9 *1/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA (*1/*1) genotype, and increased metabolism as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib. "
PA166134443,rs1057910,1183693357,CC,Patients with the CC (CYP2C9 *3/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA or AC (*1/*1 or *1/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib. 
PA166134604,rs1057910,981238438,AA,"Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."
PA166134604,rs1057910,981238439,AC,"Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."
PA166134604,rs1057910,981238440,CC,"Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."
PA166134605,rs1057910,1043737391,AA,Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.
PA166134605,rs1057910,1043737392,AC,Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
PA166134605,rs1057910,1043737393,CC,Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
PA166134606,rs1057910,981238502,AA,"Patients with the AA genotype and with Epilepsy who are treated with phenytoin may have an increased metabolism, decreased plasma free phenytoin concentration, and decreased, but not absent, risk of Drug Toxicity as compared to patients with the AC and CC genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin."
PA166134606,rs1057910,981238503,AC,"Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin."
PA166134606,rs1057910,981238504,CC,"Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin."
PA166134741,rs1057910,1448278850,AA,"Patients with the AA genotype may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AC or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.  "
PA166134741,rs1057910,1448278851,AC,"Patients with the AC genotype may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.  "
PA166134741,rs1057910,1448278852,CC,"Patients with the CC genotype may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.  "
PA166134288,rs1057910,1184986535,AA,Patients with the AA genotype who are treated with sulfonylurea: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be more likely to have failure of therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.
PA166134288,rs1057910,1184986536,AC,Results from patients with the AC genotype were not statistically significant.
PA166134288,rs1057910,1184986537,CC,Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.
PA166153433,rs1057910,1447990145,AA,"Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension. "
PA166153433,rs1057910,1447990146,AC,"Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension. "
PA166152641,rs10760397,1448106280,CC,Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152641,rs10760397,1448106281,CT,"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152641,rs10760397,1448106282,TT,Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152674,rs1060896,1447960252,AA,Patients with the AA genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
PA166152674,rs1060896,1447960253,AC,Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
PA166152674,rs1060896,1447960254,CC,Patients with the CC genotype and cancer may have decreased survival time and a decreased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
PA166158980,rs1076560,1448100446,AA,Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline. 
PA166158980,rs1076560,1448100447,AC,Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline. 
PA166158980,rs1076560,1448100448,CC,Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline. 
PA166152818,rs1076560,1447963236,AA,Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cocaine-related death.
PA166152818,rs1076560,1447963237,AC,"Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death."
PA166152818,rs1076560,1447963238,CC,Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.
PA166136509,rs1076560,1447943734,AA,Patients with genotype AA and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
PA166136509,rs1076560,1447943735,AC,Patients with genotype AC and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
PA166136509,rs1076560,1447943736,CC,Patients with genotype CC and schizophrenia may have decreased response to olanzapine compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
PA166135755,rs10771973,1444700960,AA,Patients with the AA genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
PA166135755,rs10771973,1444700961,AG,Patients with the AG genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
PA166135755,rs10771973,1444700962,GG,Patients with the GG genotype may have decreased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
PA166161172,rs10782001,1448423705,AA,Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161172,rs10782001,1448423706,AG,Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161172,rs10782001,1448423707,GG,Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166136014,rs1079597,1447944776,CC,"Patients with the CC genotype and schizophrenia may have an increased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride."
PA166136014,rs1079597,1447944777,CT,"Patients with the CT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride."
PA166136014,rs1079597,1447944778,TT,"Patients with the TT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to amisulpride."
PA166135739,rs10792367,1444700540,CC,Patients with the CC genotype and hypertension may have more blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
PA166135739,rs10792367,1444700539,CG,Patients with the CG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
PA166135739,rs10792367,1444700538,GG,Patients with the GG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
PA166134279,rs1079598,655385484,AA,"Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects."
PA166134279,rs1079598,655385485,AG,Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
PA166134279,rs1079598,655385486,GG,Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
PA166135400,rs1080985,1183700813,CC,Patients with the CC genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine. 
PA166135400,rs1080985,1183700814,CG,Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine. 
PA166135400,rs1080985,1183700815,GG,Patients with the GG genotype may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine. 
PA166135403,rs1080985,1183701071,CC,Patients with the CC genotype may have a higher thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
PA166135403,rs1080985,1183701070,CG ,Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
PA166135403,rs1080985,1183701069,GG,Patients with the GG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
PA166134756,rs1065776,1043818279,CC,"Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may also influence a patient's response to aspirin. "
PA166134756,rs1065776,1043818280,CT,"Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. "
PA166134756,rs1065776,1043818281,TT,"Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. "
PA166134639,rs10800397,1183700532,CC,Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
PA166134639,rs10800397,1183700533,CT,Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
PA166134639,rs10800397,1183700534,TT,Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
PA166134151,rs10811661,655384705,CC,Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134151,rs10811661,655384706,CT,Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.
PA166134151,rs10811661,655384707,TT,Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.
PA166135513,rs1045642,1447953258,AA,"Patients with the AA genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the AG or GG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics. "
PA166135513,rs1045642,1447953259,AG,"Patients with the AG genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the GG genotype and may have reduced clearance of efavirenz as compared to patients with the AA genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics. "
PA166135513,rs1045642,1447953260,GG,"Patients with the GG genotype and HIV infection who are treated with efavirenz may have reduced clearance of efavirenz as compared to patients with the AG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics. "
PA166134400,rs1045642,655388023,AA,Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
PA166134400,rs1045642,655388024,AG,Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
PA166134400,rs1045642,655388025,GG,Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
PA166135091,rs1045642,1183614841,AA,Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels. 
PA166135091,rs1045642,1183614842,AG,Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels. 
PA166135091,rs1045642,1183614843,GG,Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels. 
PA166134558,rs1045642,981204458,AA,"Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin."
PA166134558,rs1045642,981204457,AG,"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin."
PA166134558,rs1045642,981204456,GG,"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin."
PA166135244,rs1045642,1183631481,AA,Patients with the AA genotype may have increased clearance of talinolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of talinolol.
PA166135244,rs1045642,1183631482,AG,Patients with the AG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.
PA166135244,rs1045642,1183631483,GG,Patients with the GG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.
PA166135271,rs1045642,1183632191,AA,Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
PA166135271,rs1045642,1183632192,AG,Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
PA166135271,rs1045642,1183632193,GG,Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
PA166135272,rs1045642,1446896673,AA,Patients with genotype AA may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135272,rs1045642,1446896674,AG,Patients with genotype AG may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135272,rs1045642,1446896675,GG,Patients with genotype GG may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135340,rs1045642,1183690893,AA,"Patients with the AA genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART."
PA166135340,rs1045642,1183690894,AG,"Patients with the AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART."
PA166135340,rs1045642,1183690895,GG,"Patients with the GG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART."
PA166135357,rs1045642,1183697571,AA,Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
PA166135357,rs1045642,1183697572,AG,Women with the AG genotype and breast cancer may have an increased chance of disease recurrence when treated with tamoxifen as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
PA166135357,rs1045642,1183697573,GG,Women with the GG genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
PA166135549,rs1045642,1444695580,AA,"Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG, or GG genotype. Other genetic and clinical factors may also influence serum creatine kinase levels. "
PA166135549,rs1045642,1444695581,AG,Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels. 
PA166135549,rs1045642,1444695582,GG,Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels. 
PA166135595,rs1045642,1184986765,AA,The AA genotype is not clearly associated with risk of opioid-related disorder. 
PA166135595,rs1045642,1184986766,AG,Patients with the AG genotype may have a greater risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids. 
PA166135595,rs1045642,1184986767,GG,Patients with the GG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids. 
PA166135635,rs1045642,1447814187,AA,"Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166135635,rs1045642,1447814188,AG,"Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166135635,rs1045642,1447814189,GG,"Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166136032,rs1045642,1184749276,AA,Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment. 
PA166136032,rs1045642,1184749277,AG,Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment. 
PA166136032,rs1045642,1184749278,GG,Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased likelihood of event-free survival as compared to patients with the AA genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment. 
PA166134306,rs1045642,655386029,AA,Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
PA166134306,rs1045642,655386030,AG,Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
PA166134306,rs1045642,655386031,GG,Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
PA166134308,rs1045642,1446897972,AA,"Patients with the AA genotype may have 1) increased exposure to doxorubicin metabolites and 2) increased response to anthracycline regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens."
PA166134308,rs1045642,1446897973,AG,"Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens."
PA166134308,rs1045642,1446897974,GG,"Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens."
PA166134333,rs1045642,655386245,AA,"Patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment."
PA166134333,rs1045642,655386246,AG,"While patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the influence of one A allele with the G allele is. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment."
PA166134333,rs1045642,655386247,GG,Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.
PA166134918,rs1045642,1140962194,AA,Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134918,rs1045642,1140962200,AG,Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) as compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134918,rs1045642,1140962202,GG,Patients with the GG genotype who are treated with atorvastatin may have a reduced response to treatment (as measured by a lower reduction in LDL-cholesterol or total cholesterol) as compared to patients with the AG or AA genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134920,rs1045642,1143306660,AA,Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
PA166134920,rs1045642,1143306672,AG,"Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia."
PA166134920,rs1045642,1143306677,GG,Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
PA166134921,rs1045642,1142401281,AA,Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134921,rs1045642,1142401284,AG,Patients with the AG genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype or may have a reduced response (measured by a lower reduction in total cholesterol) as compared to patients with the AA genotype.  In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134921,rs1045642,1142401290,GG,Patients with the GG genotype who are treated with simvastatin may have a reduced response to treatment (measured by a lower reduction in total cholesterol) compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134922,rs1045642,1143176300,AA,Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
PA166134922,rs1045642,1143176306,AG,Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
PA166134922,rs1045642,1143176309,GG,Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
PA166134546,rs1045642,1448263838,AA,Patients with the AA genotype may have increased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype GG. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.
PA166134546,rs1045642,1448263839,AG,Patients with the AG genotype may have increased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype GG. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.
PA166134546,rs1045642,1448263840,GG,Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.
PA166134547,rs1045642,1448106031,AA,"Genotype AA may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel."
PA166134547,rs1045642,1448106032,AG,"Genotype AG may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel."
PA166134547,rs1045642,1448106033,GG,"Genotype GG may be associated with increased disease control rate and increased overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel."
PA166134548,rs1045642,1444706014,AA,"Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
PA166134548,rs1045642,1444706015,AG,"Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
PA166134548,rs1045642,1444706016,GG,"Patients with genotype GG may have decreased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
PA166134549,rs1045642,981204309,AA,"Patients with genotype AA may have decreased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype GG. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin."
PA166134549,rs1045642,981204308,AG,"Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin."
PA166134549,rs1045642,981204307,GG,"Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patient's response to phenytoin."
PA166134550,rs1045642,981204318,AA,"Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin."
PA166134550,rs1045642,981204319,AG,"Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin."
PA166134550,rs1045642,981204320,GG,"Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin."
PA166134551,rs1045642,1447679959,AA,"Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
PA166134551,rs1045642,1447679960,AG,"Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
PA166134551,rs1045642,1447679961,GG,"Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
PA166134552,rs1045642,1446908964,AA,"People with AA  genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
PA166134552,rs1045642,1446908965,AG,"People with AG  genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
PA166134552,rs1045642,1446908966,GG,"People with GG  genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
PA166134553,rs1045642,981204373,AA,Patients with AA  genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG  genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.
PA166134553,rs1045642,981204374,AG,Patients with AG  genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG  genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.
PA166134553,rs1045642,981204375,GG,Patients with GG  genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.
PA166134554,rs1045642,1448522447,AA,Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
PA166134554,rs1045642,1448522448,AG,Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
PA166134554,rs1045642,1448522449,GG,Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
PA166134555,rs1045642,1448522442,AA,Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.
PA166134555,rs1045642,1448522443,AG,Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.
PA166134555,rs1045642,1448522444,GG,Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.
PA166134556,rs1045642,981204436,AA,"Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
PA166134556,rs1045642,981204435,AG,"Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
PA166134556,rs1045642,981204434,GG,"Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
PA166134557,rs1045642,1184468582,AA,"Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported."
PA166134557,rs1045642,1184468583,AG,"Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported."
PA166134557,rs1045642,1184468584,GG,"Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported."
PA166134559,rs1045642,981204469,AA,"Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
PA166134559,rs1045642,981204468,AG,"Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
PA166134559,rs1045642,981204467,GG,"Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
PA166136180,rs1045642,1444666857,AA,Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
PA166136180,rs1045642,1444666858,AG,Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
PA166136180,rs1045642,1444666859,GG,Patients with the GG genotype and schizophrenia may have a shorter QTc interval when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
PA166135700,rs1045642,1444672834,AA,Patients with the AA genotype and acid-related disorders with Helicobacter pylori (H. pylori) infections may have a higher chance of eradication when treated with omeprazole or pantoprazole as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence H. pylori infection eradication.
PA166135700,rs1045642,1444672835,AG,Patients with the AG genotype and acid-related disorders with Helicobacter pylori (H. pylori) infections may have a lower chance of eradication when treated with omeprazole or pantoprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence H. pylori infection eradication.
PA166135700,rs1045642,1444672836,GG,Patients with the GG genotype and acid-related disorders with Helicobacter pylori (H. pylori) infections may have a lower chance of eradication when treated with omeprazole or pantoprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence H. pylori infection eradication.
PA166136257,rs1045642,1448612365,AA,"Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus. "
PA166136257,rs1045642,1448612366,AG,"Patients with the AG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance of tacrolimus as compared to patients with the AA genotype, and decreased dose requirements of tacrolimus as compared to patients with the GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus. "
PA166136257,rs1045642,1448612367,GG,"Patients with the GG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance and dose requirements of tacrolimus, as compared to patients with the AA or AG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus. "
PA166135500,rs1045642,1184134275,AA,Patients with the AA genotype may have increased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence response to morphine.
PA166135500,rs1045642,1184134276,AG,Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.
PA166135500,rs1045642,1184134277,GG,Patients with the GG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.
PA166134485,rs1045642,1444607339,AA,"Genotype AA may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics."
PA166134485,rs1045642,1444607340,AG,"Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics."
PA166134485,rs1045642,1444607341,GG,"Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics."
PA166134720,rs1045642,982034832,AA,Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134720,rs1045642,982034833,AG,Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134720,rs1045642,982034834,GG,Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134728,rs1045642,982036239,AA,Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
PA166134728,rs1045642,982036240,AG,Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
PA166134728,rs1045642,982036241,GG,Patients with the GG genotype may have decreased metabolism of verapamil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
PA166134173,rs1045642,982033861,AA,Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.
PA166134173,rs1045642,982033862,AG,"Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment."
PA166134173,rs1045642,982033863,GG,"Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment."
PA166134174,rs1045642,1448099253,AA,Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
PA166134174,rs1045642,1448099254,AG,Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
PA166134174,rs1045642,1448099255,GG,Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
PA166134274,rs1045642,1446898304,AA,"Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. However, one study found an increased risk of adverse drug events for carriers of the A allele, though this was not significant after multiple comparison correction. Other genetic and clinical factors may also influence a patient's risk of adverse drug events when treated with methotrexate."
PA166134274,rs1045642,1446898305,AG,"Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, although one study found that the AG genotype was associated with an increased likelihood of GI toxicity. Other genetic and clinical factors may also influence a patient's risk of adverse drug events when treated with methotrexate."
PA166134274,rs1045642,1446898306,GG,"Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of adverse drug events as compared to patients with the AA or AG genotype. However, one study found a decreased risk of adverse drug events for carriers of the G allele, though this was not significant after multiple comparison correction. Other genetic and clinical factors may also influence a patient's risk of adverse drug events when treated with methotrexate."
PA166134286,rs1045642,1444608048,AA,"Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
PA166134286,rs1045642,1444608049,AG,"Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
PA166134286,rs1045642,1444608050,GG,"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
PA166135725,rs1045642,1448573639,AA,"Patients with the AA genotype and ulcerative colitis may have a better chance at achieving remission when treated with tacrolimus as compared to patients with the AG or GG genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
PA166135725,rs1045642,1448573640,AG,"Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
PA166135725,rs1045642,1448573641,GG,"Patients with the GG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
PA166136258,rs1045642,1444694611,AA,"Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
PA166136258,rs1045642,1444694612,AG,"Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
PA166136258,rs1045642,1444694613,GG,"Patients with the GG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
PA166135728,rs1045642,1444694623,AA,Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
PA166135728,rs1045642,1444694624,AG,Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk of hypokalemia when treated with tacrolimus as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
PA166135728,rs1045642,1444694625,GG,Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
PA166135763,rs1045642,1444702826,AA,Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital. 
PA166135763,rs1045642,1444702825,AG,Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital. 
PA166135763,rs1045642,1444702824,GG,Patients with genotype GG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital. 
PA166135912,rs1045642,1445585158,AA,"Patients with the AA genotype may decreased clearance of daptomycin, resulting in increased concentrations of the drug, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of daptomycin."
PA166135912,rs1045642,1445585159,AG,"Patients with the AG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin."
PA166135912,rs1045642,1445585160,GG,"Patients with the GG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin."
PA166152670,rs1045642,1447960213,AA,Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166152670,rs1045642,1447960214,AG,Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166152670,rs1045642,1447960215,GG,Patients with the GG genotype and non-small-cell lung cancer may have a better response to platinum-based chemotherapy as compared to patients with the AA or AG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166152671,rs1045642,1447960220,AA,"Patients with the AA genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole."
PA166152671,rs1045642,1447960221,AG,"Patients with the AG genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype, or increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole."
PA166152671,rs1045642,1447960222,GG,"Patients with the GG genotype may have increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole."
PA166152967,rs1045642,1448102928,AA,Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
PA166152967,rs1045642,1448102929,AG,"Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity."
PA166152967,rs1045642,1448102930,GG,Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
PA166153097,rs1045642,1447983820,AA,Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics. 
PA166153097,rs1045642,1447983821,AG,"Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics. "
PA166153097,rs1045642,1447983822,GG,Patients with the GG genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics. 
PA166136501,rs1045642,1447943593,AA,"Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine."
PA166136501,rs1045642,1447943594,AG,"Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine."
PA166136501,rs1045642,1447943595,GG,"Patients with the GG genotype and depressive disorder may have an increased response to agomelatine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to agomelatine."
PA166152860,rs1045642,1447964032,AA,Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.
PA166152860,rs1045642,1447964033,AG,"Patients with the AG genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity."
PA166152860,rs1045642,1447964034,GG,Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.
PA166136508,rs1045642,1447943702,AA,Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.
PA166136508,rs1045642,1447943703,AG,Patients with genotype AG and narcolepsy may have increased response to modafinil compared to patients with genotypes AA or GG. Other clinical and genetic factors may affect a patient's response to modafinil.
PA166136508,rs1045642,1447943704,GG,Patients with genotype GG and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.
PA166159573,rs1045642,1448123003,AA,Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.
PA166159573,rs1045642,1448123004,AG,Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.
PA166159573,rs1045642,1448123005,GG,Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.
PA166161245,rs1045642,1448427561,AA,"Patients with the AA genotype may have increased clozapine plasma concentrations, as well as an increased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity. "
PA166161245,rs1045642,1448427562,AG,"Patients with the AG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity. "
PA166161245,rs1045642,1448427563,GG,"Patients with the GG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity. "
PA166161265,rs1045642,1448427835,AA,Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to granisetron.
PA166161265,rs1045642,1448427836,AG,Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to granisetron.
PA166161265,rs1045642,1448427837,GG,Patients with the GG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to granisetron.
PA166136329,rs1045642,1444704820,AA,Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine. 
PA166136329,rs1045642,1444704821,AG,Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine. 
PA166136329,rs1045642,1444704822,GG,Patients with the GG genotype may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine. 
PA166136330,rs1045642,1446899255,AA,"Patients with the AA genotype may experience improved efficacy of fentanyl, methadone, morphine, tramadol, oxycodone, or other opioids and thus may require a decreased dose those drugs as compared to patients with the AG and GG genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's dose of, or response to, opioids or drugs used to treat opioid disorders."
PA166136330,rs1045642,1446899256,AG,"Patients with the AG genotype may experience decreased efficacy of fentanyl, methadone, morphine, tramadol, oxycodone or other opioids and thus may require an increased dose those drugs as compared to patients with the the AA genotype and an improved efficacy and decreased dose of as compared to patients with the GG genotype, athough this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's dose of, or response to, opioids or drugs used to treat opioid disorders."
PA166136330,rs1045642,1446899257,GG,"Patients with the GG genotype may experience decreased efficacy of fentanyl, methadone, morphine, tramadol, oxycodone or other opioids and thus may require an increased dose those drugs as compared to patients with the the AA or AG genotype, athough this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's dose of, or response to, opioids or drugs used to treat opioid disorders."
PA166136333,rs1045642,1444704883,AA,"Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone."
PA166136333,rs1045642,1444704884,AG,Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
PA166136333,rs1045642,1444704885,GG,Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
PA166136334,rs1045642,1444704918,AA,Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
PA166136334,rs1045642,1444704917,AG,Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
PA166136334,rs1045642,1444704916,GG,Patients with the GG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have increased metabolism of etoposide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
PA166136376,rs1045642,1447945950,AA,"Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
PA166136376,rs1045642,1447945951,AG,"Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
PA166136376,rs1045642,1447945952,GG,"Patients with the GG genotype and renal cell carcinoma may have an increased risk for adverse effects when treated with sunitinib as compared to patients with the AA or AG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
PA166136388,rs1045642,1448266858,AA,"Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine."
PA166136388,rs1045642,1448266859,AG,"Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine."
PA166136388,rs1045642,1448266860,GG,"Patients with the GG genotype and epilepsy may have decreased metabolism of carbamazepine and may need a decreased dose as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine."
PA166136010,rs1045642,1447943715,AA,People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.
PA166136010,rs1045642,1447943716,AG,People with genotype AG may have decreased exposure to silibinin compared to people with genotypes GG. Other clinical and genetic factors may affect a person's exposure to silibinin.
PA166136010,rs1045642,1447943717,GG,People with genotype GG may have increased exposure to silibinin compared to people with genotypes AA or AG. Other clinical and genetic factors may affect a person's exposure to silibinin.
PA166136502,rs1045642,1447943599,AA,Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
PA166136502,rs1045642,1447943600,AG,Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
PA166136502,rs1045642,1447943601,GG,Patients with genotype GG and depressive disorder may have increased response to venlafaxine compared to patients with genotype AA or AG. Patients with GG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
PA166136005,rs1045642,1447943610,AA,Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
PA166136005,rs1045642,1447943611,AG,Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
PA166136005,rs1045642,1447943612,GG,Patients with the GG genotype and depressive disorder may have increased response to serotonin reuptake inhibitors compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
PA166136026,rs1045642,1447949307,AA,Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR. 
PA166136026,rs1045642,1447949308,AG,"Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR. "
PA166136026,rs1045642,1447949309,GG,Patients who receive a kidney with the GG genotype may have increased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AA or AG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR. 
PA166136081,rs1045642,1184998965,AA,Patients with the AA genotype who are treated with morphine may have higher levels of morphine-3-glucuronide formation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine. 
PA166136081,rs1045642,1184998966,AG,Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine. 
PA166136081,rs1045642,1184998967,GG,Patients with the GG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine. 
PA166135636,rs1045642,1448617141,AA,"Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in two studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis.  Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV. "
PA166135636,rs1045642,1448617142,AG,"Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in two studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis.  Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV. "
PA166135636,rs1045642,1448617143,GG,"Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in two studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis.  Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV. "
PA166136102,rs1045642,1448124380,AA,Patients with the AA genotype and lymphoma or leukemia who are treated with methotrexate may have increased concentrations of the drug and may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicities. 
PA166136102,rs1045642,1448124381,AG,"Patients with the AG genotype and lymphoma or leukemia who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicities. "
PA166136102,rs1045642,1448124382,GG,"Patients with the GG genotype and lymphoma or leukemia who are treated with methotrexate may have lower concentrations of the drug and may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicities. "
PA166135643,rs1045642,1448612725,AA,"Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
PA166135643,rs1045642,1448612726,AG,"Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
PA166135643,rs1045642,1448612727,GG,"Patients with the GG genotype and chronic myeloid leukemia may have an increased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the AA or AG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
PA166136127,rs1045642,1444607805,AA,Patients with the AA genotype and Psychotic Disorders who are treated with olanzapine may have increased social and clinical needs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
PA166136127,rs1045642,1444607806,AG,Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
PA166136127,rs1045642,1444607807,GG,Patients with the GG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
PA166162404,rs1045642,1448532192,AA,"People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran."
PA166162404,rs1045642,1448532193,AG,"People with the AG genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran."
PA166162404,rs1045642,1448532194,GG,"People with the GG genotype may have decreased exposure to dabigatran compared to patients with the AA and AG genotypes, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran."
PA166163651,rs1045642,1448615321,AA,Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel. 
PA166163651,rs1045642,1448615322,AG,Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel. 
PA166163651,rs1045642,1448615323,GG,Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel. 
PA166162405,rs1045642,1448532198,AA,People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
PA166162405,rs1045642,1448532199,AG,People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
PA166162405,rs1045642,1448532200,GG,People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
PA166163643,rs1045642,1448615143,AA,Postmenopausal women with HR+ breast cancer and the AA genotype may be less likely to experience arthralgia when treated with anastrozole as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole. 
PA166163643,rs1045642,1448615144,AG,Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole. 
PA166163643,rs1045642,1448615145,GG,Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole. 
PA166163681,rs1045642,1448615585,AA,"Patients with the AA genotype who are treated with clopidogrel may have decreased platelet reactivity as compared to patients with the AG genotype, however this is contradicted in one study where AA was found to be associated with increased platelet reactivity as compared to AG and GG genotypes. No association was found in the majority of studies. Other clinical and and genetic factors may also influence platelet reactivity in patients who are treated with clopidogrel.  "
PA166163681,rs1045642,1448615586,AG,"Patients with the AG genotype who are treated with clopidogrel may have increased platelet reactivity as compared to patients with the AA and GG genotypes, however this is contradicted in one study where AA was found to be associated with increased platelet reactivity as compared to the AG and GG genotypes. No association was found in the majority of studies. Other clinical and and genetic factors may also influence platelet reactivity in patients who are treated with clopidogrel.  "
PA166163681,rs1045642,1448615587,GG,"Patients with the GG genotype who are treated with clopidogrel may have decreased platelet reactivity as compared to patients with the AA and AG genotypes, however no association was found in the majority of studies. Other clinical and and genetic factors may also influence platelet reactivity in patients who are treated with clopidogrel.  "
PA166152639,rs10819043,1447959735,CC,Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152639,rs10819043,1447959734,CT,"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype, or a decreased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152639,rs10819043,1447959733,TT,Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166134276,rs10821936,655385472,CC,Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
PA166134276,rs10821936,655385473,CT,Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
PA166134276,rs10821936,655385474,TT,Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
PA166134697,rs10835210,982032695,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134697,rs10835210,982032696,AC,Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134697,rs10835210,982032697,CC,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134115,rs10836235,652595206,CC,Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134115,rs10836235,652595207,CT,Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134115,rs10836235,652595209,TT,Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166160592,rs10846744,1448264190,CC,"Patients with the CC genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response."
PA166160592,rs10846744,1448264189,CG,"Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response."
PA166160592,rs10846744,1448264188,GG,"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes CC or CG. Other genetic and clinical factors may also influence peginterferon response."
PA166153173,rs10851907,1448106376,AA,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153173,rs10851907,1448106377,AG,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153173,rs10851907,1448106378,GG,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166159166,rs10853728,1448102811,CC,Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
PA166159166,rs10853728,1448102812,CG,"Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response."
PA166159166,rs10853728,1448102813,GG,Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
PA166159174,rs10877012,1448102793,GG,"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
PA166159174,rs10877012,1448102794,GT,"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
PA166159174,rs10877012,1448102795,TT,"Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
PA166135841,rs10848635,1444705193,AA,Patients with the AA genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135841,rs10848635,1444705194,AT,"Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
PA166135841,rs10848635,1444705195,TT,"Patients with the TT genotype and major depression may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
PA166135678,rs10878232,1444666683,GG,Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135678,rs10878232,1444666684,GT,Patients with the GT genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135678,rs10878232,1444666685,TT,Patients with the TT genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166134409,rs10879346,699642191,CC,Patients with the CC genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
PA166134409,rs10879346,699642192,CT,Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
PA166134409,rs10879346,699642193,TT,Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.
PA166136268,rs10871454,1444700554,CC,Patients with the CC genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage. 
PA166136268,rs10871454,1444700553,CT,Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage. 
PA166136268,rs10871454,1444700552,TT,Patients with the TT genotype who are treated with phenprocoumon may require a decreased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage. 
PA166134209,rs10871454,655385019,CC,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.
PA166134209,rs10871454,655385018,CT,Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.
PA166134209,rs10871454,655385017,TT,Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.
PA166158875,rs10898815,1448099073,AA,Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers. 
PA166158875,rs10898815,1448099074,AG,"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers. "
PA166158875,rs10898815,1448099075,GG,Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers. 
PA166136270,rs10912675,1444700568,CC,Patients with the CC genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
PA166136270,rs10912675,1444700569,CT,Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
PA166136270,rs10912675,1444700570,TT,Patients with the TT genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
PA166153006,rs10916852,1447981412,GG,Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
PA166153006,rs10916852,1447981413,GT,Patients with the GT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
PA166153006,rs10916852,1447981414,TT,Patients with the TT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
PA166134640,rs10919035,981478134,CC,Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
PA166134640,rs10919035,981478133,CT,Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
PA166134640,rs10919035,981478132,TT,Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
PA166134182,rs10918594,655384897,CC,"Patients with the CC genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
PA166134182,rs10918594,655384896,CG,"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
PA166134182,rs10918594,655384895,GG,Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
PA166135397,rs10919563,1183700530,AA,"Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics."
PA166135397,rs10919563,1183700529,AG,"Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics."
PA166135397,rs10919563,1183700528,GG,"Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics."
PA166136272,rs10931910,1444700585,AA,Patients with the AA genotype and solid tumors may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
PA166136272,rs10931910,1444700584,GA,Patients with the AG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype or may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
PA166136272,rs10931910,1444700583,GG,Patients with the GG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
PA166136089,rs10929303,1448260853,CC,Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir. 
PA166136089,rs10929303,1448260854,CT,Patients with the CT genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the TT genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir. 
PA166136089,rs10929303,1448260855,TT,Patients with the TT genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir. 
PA166135087,rs10929303,1183614817,CC,Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135087,rs10929303,1183614818,CT,Human liver microsomes with the CT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135087,rs10929303,1183614819,TT,Human liver microsomes with the TT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135088,rs10929303,1183614826,CC,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135088,rs10929303,1183614827,CT,Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135088,rs10929303,1183614828,TT,Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166158728,rs10934498,1448097457,AA,Patients with the AA genotype and colonic neoplasms may have decreased area under the curve of irinotecan-based therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the AUC of irinotecan.
PA166158728,rs10934498,1448097458,AG,Patients with the AG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.
PA166158728,rs10934498,1448097459,GG,Patients with the GG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.
PA166136290,rs10711,1444700952,GG,Patients with the GG genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
PA166136290,rs10711,1444700953,GT,Patients with the GT genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
PA166136290,rs10711,1444700954,TT,Patients with the TT genotype may have decreased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
PA166136469,rs10937158,1446908584,CC,"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea."
PA166136469,rs10937158,1446908583,CT,"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 34 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea."
PA166136469,rs10937158,1446908582,TT,"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 34 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea."
PA166158981,rs10945919,1448100453,AA,Rheumatoid Arthritis patients with the genotype AA may be more likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
PA166158981,rs10945919,1448100454,AG,"Rheumatoid Arthritis patients with the genotype AG may be more likely to respond to TNF inhibitors compared with patients with genotype GG, or less likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response."
PA166158981,rs10945919,1448100455,GG,Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
PA166160698,rs10946737,1448265575,AA,Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160698,rs10946737,1448265576,AG,Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160698,rs10946737,1448265577,GG,Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160697,rs10946739,1448265567,CC,Patients with the CC genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160697,rs10946739,1448265568,CT,Patients with the CT genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160697,rs10946739,1448265569,TT,Patients with the TT genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the CC genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166134127,rs10932125,655384560,CC,Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.
PA166134127,rs10932125,655384561,CG,Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.
PA166134127,rs10932125,655384562,GG,Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.
PA166159956,rs10948059,1448256095,CC,Patients with the CC genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT.
PA166159956,rs10948059,1448256094,CT,Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.
PA166159956,rs10948059,1448256093,TT,Patients with the TT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.
PA166159503,rs10964552,1448112609,AA,Patients with the AA genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
PA166159503,rs10964552,1448112610,AC,Patients with the AC genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
PA166159503,rs10964552,1448112611,CC,Patients with the CC genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AC genotypes. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
PA166162512,rs10995,1448568156,AA,Patients with AA genotype may have decreased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166162512,rs10995,1448568155,AG,Patients with AG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166162512,rs10995,1448568154,GG,Patients with GG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135842,rs10975641,1444705202,CC,Patients with the CC genotype and major depression may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
PA166135842,rs10975641,1444705201,CG,Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
PA166135842,rs10975641,1444705200,GG,Patients with the GG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
PA166158947,rs10997242,1448100167,CC,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158947,rs10997242,1448100168,CT,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158947,rs10997242,1448100169,TT,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
PA166159012,rs10994982,1448100889,AA,Patients with the AA genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166159012,rs10994982,1448100890,AG,"Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate."
PA166159012,rs10994982,1448100891,GG,Patients with the GG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166135411,rs11030104,1183702970,AA,Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
PA166135411,rs11030104,1183702971,AG,Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
PA166135411,rs11030104,1183702972,GG,Patients with the GG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
PA166135741,rs11030918,1444700599,CC,Patients with the CC genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
PA166135741,rs11030918,1444700600,CT,Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
PA166135741,rs11030918,1444700601,TT,Patients with the TT genotype who are treated with gemcitabine and platinum compounds may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
PA166135740,rs11023197,1444700591,AA,Patients with the AA genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
PA166135740,rs11023197,1444700592,AG,Patients with the AG genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype or may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
PA166135740,rs11023197,1444700593,GG,Patients with the GG genotype and breast neoplasms may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
PA166134896,rs11039149,1043880786,AA,"Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events."
PA166134896,rs11039149,1043880785,GA,Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
PA166134896,rs11039149,1043880784,GG,Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
PA166136450,rs10929302,1446905048,AA,"Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the AA or GG genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136450,rs10929302,1446905049,AG,"Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the AA or GG genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136450,rs10929302,1446905050,GG,"Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AG or GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the AA or GG genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166134663,rs10929302,1448531612,AA,"The AA genotype may be associated with a greater risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AG and GG genotypes. "
PA166134663,rs10929302,1448531613,AG,"The AG genotype may be associated with a reduced risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AA genotype. "
PA166134663,rs10929302,1448531614,GG,"The GG genotype may be associated with a reduced risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AA genotype. "
PA166135951,rs1104514,1446902914,AA,Patients with the AA genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.
PA166135951,rs1104514,1446902915,AG,Patients with the AG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.
PA166135951,rs1104514,1446902916,GG,Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.
PA166134340,rs11042725,655386448,AA,Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134340,rs11042725,655386449,AC,Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134340,rs11042725,655386450,CC,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a decreased response as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166136337,rs11045872,1444706128,AA,Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype.  Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
PA166136337,rs11045872,1444706127,AG,Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
PA166136337,rs11045872,1444706126,GG,Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
PA166134583,rs11045585,981237872,AA,"Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel."
PA166134583,rs11045585,981237873,AG,"Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel."
PA166134583,rs11045585,981237874,GG,"Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel."
PA166136338,rs11045821,1444706156,AA,Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
PA166136338,rs11045821,1444706157,AG,Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
PA166136338,rs11045821,1444706158,GG,Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
PA166134132,rs11045819,655384586,AA,Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.
PA166134132,rs11045819,655384585,AC,Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.
PA166134132,rs11045819,655384584,CC,Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.
PA166158880,rs11045819,1448099120,AA,"No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance. "
PA166158880,rs11045819,1448099121,AC,Patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance. 
PA166158880,rs11045819,1448099122,CC,Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance. 
PA166159494,rs11052877,1448112488,AA,Patients with the AA genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to tocilizumab. 
PA166159494,rs11052877,1448112489,AG,Patients with the AG genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to tocilizumab. 
PA166159494,rs11052877,1448112490,GG,Patients with the GG genotype and rheumatoid arthritis may have a decreased response to tocilizumab compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect response to tocilizumab. 
PA166135232,rs10981694,1448616426,GG,Patients with the GG genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity. 
PA166135232,rs10981694,1448616427,GT,Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity. 
PA166135232,rs10981694,1448616428,TT,Patients with the TT genotype and NSCLC who are treated with cisplatin may have an reduced risk of severe ototoxicity as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity. 
PA166136273,rs11078659,1444700607,AA,Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
PA166136273,rs11078659,1444700608,AG,Patients with the AG genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype or may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
PA166136273,rs11078659,1444700609,GG,Patients with the GG genotype with colorectal neoplasms who are treated with celecoxib may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
PA166135396,rs1105525,1183700525,CC,Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135396,rs1105525,1183700524,TC,Patients with the TC genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135396,rs1105525,1183700523,TT,Patients with the TT genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135395,rs11080344,1183700520,CC,Patients with the CC genotype may have increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
PA166135395,rs11080344,1183700519,TC,Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
PA166135395,rs11080344,1183700518,TT,Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
PA166134398,rs11045879,1448100856,CC,"Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2)  may have a decreased, but not absent, risk for GI toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity when treated with methotrexate."
PA166134398,rs11045879,1448100857,CT,Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype and decreased clearance as compared to the TT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC genotype and decreased risk as compared to the TT genotype.
PA166134398,rs11045879,1448100858,TT,Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC or CT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC or CT genotype.
PA166135085,rs1110470,1183630739,AA,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135085,rs1110470,1183630740,AG,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135085,rs1110470,1183630741,GG,Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166152782,rs111033610,1447962631,AA,Patients with the AA genotype and stomach cancer may have increased metabolism of tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
PA166152782,rs111033610,1447962630,AG,"Patients with the AG genotype and stomach cancer may have decreased metabolism of tegafur as compared to patients with the AA genotype, or increased metabolism as compared to patients with the GG gentoype. Other genetic and clinical factors may also influence metabolism of tegafur."
PA166152782,rs111033610,1447962629,GG,Patients with the GG genotype and stomach cancer may have decreased metabolism of tegafur as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
PA166163201,rs11124945,1448602387,AA,Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
PA166163201,rs11124945,1448602388,AG,Patients with hypertension and the AG genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
PA166163201,rs11124945,1448602389,GG,Patients with hypertension and the GG genotype may have decreased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
PA166160647,rs11125,1448265176,AA,"Patients with the AA genotype may have a decreased, but not absent, risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics. "
PA166160647,rs11125,1448265177,AT,Patients with the AT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics. 
PA166160647,rs11125,1448265178,TT,Patients with the TT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics. 
PA166136291,rs11125035,1444700978,AA,Patients with the AA genotype may have increased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype TT or AT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
PA166136291,rs11125035,1444700979,AT,Patients with the AT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
PA166136291,rs11125035,1444700980,TT,Patients with the TT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
PA166136472,rs11122576,1446908610,CC,Patients with the CC genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
PA166136472,rs11122576,1446908611,CT,Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
PA166136472,rs11122576,1446908612,TT,No information were reported regarding patients with the TT genotype.
PA166136473,rs11122576,1446908617,CC,"Patients with the CC genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease."
PA166136473,rs11122576,1446908618,CT,"Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease."
PA166136473,rs11122576,1446908619,TT,No information were reported regarding patients with the TT genotype.
PA166134584,rs1105879,1448107611,AA,Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
PA166134584,rs1105879,1448107612,AC,Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
PA166134584,rs1105879,1448107613,CC,Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
PA166161862,rs11126740,1448522756,AA,Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161862,rs11126740,1448522757,AG,Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161862,rs11126740,1448522758,GG,Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166135086,rs11064426,1183630583,AA,Women with the AA genotype and hypertension may have a better blood pressure response when treated with atenolol as compared to those with the AC or CC genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
PA166135086,rs11064426,1183630584,AC,Women with the AC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to women with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
PA166135086,rs11064426,1183630585,CC,Women with the CC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to patients with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
PA166135253,rs11144870,1183631795,CC,"Patients with the CC genotype may have increased response to citalopram or escitalopram in people with depression as compared to patients with the TT or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram. "
PA166135253,rs11144870,1183631794,CT,"Patients with the CT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram. "
PA166135253,rs11144870,1183631793,TT,"Patients with the TT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram. "
PA166134403,rs1113129,699639329,CC,Patients with the CC genotype may have  increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134403,rs1113129,699639330,CG,Patients with the CG genotype may have  decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134403,rs1113129,699639331,GG,Patients with the GG genotype may have  decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166136383,rs1113129,1445401826,CC,Patients with the CC genotype and breast cancer may have a decreased risk for anemia when treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for anemia.
PA166136383,rs1113129,1445401827,CG,Patients with the CG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
PA166136383,rs1113129,1445401828,GG,Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
PA166135656,rs11141915,1444607968,AA,Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
PA166135656,rs11141915,1444607969,AC,Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype and decreased risk of leukopenia as compared to patients with the AA. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
PA166135656,rs11141915,1444607970,CC,Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
PA166158789,rs11185647,1448106418,AA,Patients with nasopharyngeal cancer and the AA genotype may have less severe anemia and neutropenia as compared to patients with the AG genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158789,rs11185647,1448106419,AG,Patients with nasopharyngeal cancer and the AG genotype may have more severe anemia and neutropenia as compared to patients with the AA genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166134868,rs11150606,1448105602,CC,Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134868,rs11150606,1448105603,CT,Patients with the CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134868,rs11150606,1448105604,TT,Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166158889,rs11185648,1448099305,CC,Patients with nasopharyngeal cancer and the CC genotype may have less severe anemia as compared to patients with the CT genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158889,rs11185648,1448099306,CT,Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158790,rs11185648,1448098341,CC,Patients with nasopharyngeal cancer and the CC genotype may have less severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158790,rs11185648,1448098342,CT,Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia as compared to patients with the CC genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166135970,rs111888148,1447992177,AA,"Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135970,rs111888148,1447992178,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develop Malignant Hyperthermia."
PA166135970,rs111888148,1447992179,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136407,rs11189015,1445601680,CC,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136407,rs11189015,1445601681,CG,Patients with the CG genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the GG genotype and an increased response as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136407,rs11189015,1445601682,GG,Patients with the GG genotype and and essential hypertension may have an increased response when treated with hypertension as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135939,rs11155012,1446899666,AA,Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances. 
PA166135939,rs11155012,1446899667,AG,Women with breast cancer and the AG genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the GG genotypes and an increased likelihood of survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances. 
PA166135939,rs11155012,1446899668,GG,Women with breast cancer and the GG genotype may have an increased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances. 
PA166135394,rs11189381,1183700515,CC,Patients with the CC genotype may have  decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135394,rs11189381,1183700514,TC,Patients with the TC genotype may have  increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135394,rs11189381,1183700513,TT,Patients with the TT genotype may have  increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135347,rs11191561,1183693444,CC,Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135347,rs11191561,1183693445,CG,Patients with the CG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135347,rs11191561,1183693446,GG,Patients with the GG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166152977,rs11200638,1447981097,AA,"Patients with the AA genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab."
PA166152977,rs11200638,1447981098,AG,"Patients with the AG genotype and age-related macular degeneration may have greater improvement in visual acuity when treated with bevacizumab as compared to patients with the AA or GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab."
PA166152977,rs11200638,1447981099,GG,"Patients with the GG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab."
PA166161169,rs11209026,1448423684,AA,"No patients with the AA genotype were available for analysis, but patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions."
PA166161169,rs11209026,1448423685,AG,Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161169,rs11209026,1448423686,GG,Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166134407,rs11209716,699639348,CC,"Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors."
PA166134407,rs11209716,699639349,CT,Patients with the genotype have not been studied.
PA166134407,rs11209716,699639350,TT,Patients with the TT genotype and hypertension who are treated with ACE inhibitors may have an increased risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.
PA166134387,rs11188072,982030629,CC,"Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134387,rs11188072,982030630,CT,"Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134387,rs11188072,982030631,TT,"Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134386,rs11188072,655387746,CC,"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134386,rs11188072,655387747,CT,"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134386,rs11188072,655387748,TT,"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166135143,rs11188072,1183631923,CC,"Patients with the CC genotype (CYP2C19*1/*1) and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the CT or TT genotype (CYP2C19*1/*17 or *17/*17). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. "
PA166135143,rs11188072,1183631924,CT,"Patients with the CT genotype (CYP2C19*1/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype  (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. "
PA166135143,rs11188072,1183631925,TT,"Patients with the TT genotype (CYP2C19*17/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype  (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. "
PA166135498,rs11211524,1444695568,AA,"Patients with the AA genotype and solid tumors, may have increased response to gemcitabine compared to the CC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
PA166135498,rs11211524,1444695569,AC,"Patients with the AC genotype and solid tumors, may have increased response to gemcitabine compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
PA166135498,rs11211524,1444695570,CC,"Patients with the CC genotype and solid tumors, may have decreased response to gemcitabine compared to the AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
PA166135517,rs11226,1184348741,AA,Patients with the AA genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135517,rs11226,1184348742,AG,"Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. "
PA166135517,rs11226,1184348743,GG,Patients with the GG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166136348,rs11231809,1444843386,AA,"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT or AT. Other genetic and clinical factors may also influence the response to methotrexate."
PA166136348,rs11231809,1444843385,AT,"Patients with the AT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
PA166136348,rs11231809,1444843384,TT,"Patients with the TT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
PA166134205,rs1123617,982035269,AA,Patients with the AA genotype who are treated with nifedipine may have larger changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
PA166134205,rs1123617,982035270,AG,Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
PA166134205,rs1123617,982035271,GG,Patients with the GG genotype who are treated with nifediping may have smaller changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
PA166134585,rs11212617,1183574218,AA,"Patients with the AA genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin."
PA166134585,rs11212617,1183574219,AC,"Patients with the AC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype.  An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin."
PA166134585,rs11212617,1183574220,CC,"Patients with the CC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype.  An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin."
PA166135317,rs11231825,1183684135,CC,"Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135317,rs11231825,1183684134,CT,"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135317,rs11231825,1183684133,TT,"Patients with the TT genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135350,rs1124493,1183693530,GG,Female patients with the GG genotype may have decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135350,rs1124493,1183693529,GT,Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135350,rs1124493,1183693528,TT,Female patients with the TT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166161296,rs1124491,1448428135,AA,Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166161296,rs1124491,1448428136,AG,Patients with the AG genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166161296,rs1124491,1448428137,GG,Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166153024,rs11253043,1447982690,AA,Patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
PA166153024,rs11253043,1447982691,AG,"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane."
PA166153024,rs11253043,1447982692,GG,Patients with the GG genotype may have increased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
PA166134760,rs11252394,1183685519,AA,"Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
"
PA166134760,rs11252394,1183685520,AG,Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134760,rs11252394,1183685521,GG,Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166152751,rs112445441,1448432263,AC,"Patients with colorectal cancer with the AC genotype (G13V) may have similar response when treated with cetuximab or panitumumab as compared to patients with the CC genotype (""wild type KRAS"") and improved response as compared to patients with other KRAS mutations although some studies did not observe this benefit and fewer studies have looked at this genotype as compared to CT (G13D). However current guidelines still recommend not using anti-EGFR treatments in these patients. Other genetic and clinical factors may also influence response to cetuximab or panitumumab."
PA166152751,rs112445441,1448432264,CC,"Patients with the colorectal cancer with the CC genotype (""wild type KRAS"") and no other KRAS mutations may have increased response when treated with cetuximab or panitumumab as compared to patients with KRAS mutations although some studies suggest that the CT genotype at this locus has similar response to CC. Other genetic and clinical factors may also influence response to cetuximab or panitumumab."
PA166152751,rs112445441,1448432265,CT,"Patients with colorectal cancer with the CT genotype (G13D) may have similar response when treated with cetuximab or panitumumab as compared to patients with the CC genotype (""wild type KRAS"") and improved response as compared to patients with other KRAS mutations although some studies did not observe this benefit. However current guidelines still recommend not using anti-EGFR treatments in these patients. Other genetic and clinical factors may also influence response to cetuximab or panitumumab."
PA166136274,rs112561475,1444700629,AA,Patients with the AA genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
PA166136274,rs112561475,1444700628,GA,Patients with the GA genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
PA166136274,rs112561475,1444700627,GG,Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
PA166159237,rs1125394,1448104038,CC,Patients with the CC genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
PA166159237,rs1125394,1448104039,CT,"Patients with the CT genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction."
PA166159237,rs1125394,1448104040,TT,Patients with the TT genotype have a decreased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
PA166135661,rs1126442,1444608233,AA,"Individuals with the AA genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine."
PA166135661,rs1126442,1444608234,AG,"Individuals with the AG genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine."
PA166135661,rs1126442,1444608235,GG,"Individuals with the GG genotype who are addicted to methamphetamine may be more likely to experience psychosis when taking methamphetamine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine."
PA166136362,rs112563513,1448615838,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. "
PA166136362,rs112563513,1448615839,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG, although this is contradicted in some studies. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. "
PA166136362,rs112563513,1448615840,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG, although this is contradicted in some studies. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. "
PA166135878,rs11264359,1448106228,AA,"Patients with the AA genotype may have an increased response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response. "
PA166135878,rs11264359,1448106229,AG,"Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response. "
PA166135878,rs11264359,1448106230,GG,"Patients with the GG genotype may have a decreased response to bisphosphonate treatment, or may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response. "
PA166136275,rs1126510,1444700643,AA,Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.
PA166136275,rs1126510,1444700642,AG,"Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin."
PA166136275,rs1126510,1444700641,GG,"Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin."
PA166136239,rs11265572,1444686818,GG,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype may have increased metabolism of tacrolimus, as compared to patients with the GT or TT genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus."
PA166136239,rs11265572,1444686819,GT,"Patients undergoing liver transplantation who receive a donor liver with the GT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus."
PA166136239,rs11265572,1444686820,TT,"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus."
PA166161956,rs11265618,1448526100,CC,Patients with the CC genotype and rheumatoid arthritis may have a better response when treated with tocilizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tocilizumab response.
PA166161956,rs11265618,1448526101,CT,Patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.
PA166161956,rs11265618,1448526102,TT,Patients with the TT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.
PA166135947,rs1126647,1446901293,AA,Patients with renal cell carcinoma and the AA genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
PA166135947,rs1126647,1446901294,AT,Patients with renal cell carcinoma and the AT genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
PA166135947,rs1126647,1446901295,TT,Patients with renal cell carcinoma and the TT genotype may have an increased likelihood of hypertension when taking sunitinib as compared to patients with the AA and AT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
PA166135664,rs1126757,1444608379,CC,"Patients with the CC genotype and depression may not respond as well to treatment with escitalopram, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to escitalopram."
PA166135664,rs1126757,1444608380,CT,"Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram."
PA166135664,rs1126757,1444608381,TT,"Patients with the TT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram."
PA166135084,rs11269124,1183630677,GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC,Patients with the GGGG.../GGGG... genotype and liver cirrhosis with refractory ascites may be less likely to respond to treatment with clonidine as compared to patients with the GGGG.../del or del/del genotype. Other genetic and clinical factors may also influence response to clonidine.
PA166135084,rs11269124,1183630678,GGGGAGCTTTCCCAGAGACCC/del,Patients with the GGGG.../del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGG.../GGGG... genotype. Other genetic and clinical factors may also influence response to clonidine.
PA166135084,rs11269124,1183630679,del/del,Patients with the del/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGG.../GGGG... genotype. Other genetic and clinical factors may also influence response to clonidine.
PA166135081,rs1127687,1183614781,AA,Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135081,rs1127687,1183614782,AG,Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135081,rs1127687,1183614783,GG,Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135082,rs1127687,1183614772,AA,Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135082,rs1127687,1183614773,AG,Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135082,rs1127687,1183614774,GG,Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135233,rs1130214,1183630277,AA,"Patients with the AA genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
PA166135233,rs1130214,1183630278,AC,"Patients with the AC genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
PA166135233,rs1130214,1183630279,CC,Patients with the CC genotype and lung cancer who are treated with carboplatin or cisplatin may have a higher risk of distant disease progression as compared to patients with the AC or AA  genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
PA166135379,rs1130609,1183700233,GG,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135379,rs1130609,1183700232,GT,Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135379,rs1130609,1183700231,TT,Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166158977,rs1130864,1448100421,AA,Patients with the AA genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the AG and GG genotypes. Other factors may affect response to adalimumab.
PA166158977,rs1130864,1448100422,AG,Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.
PA166158977,rs1130864,1448100423,GG,Patients with the GG genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the AA and AG genotypes. Other factors may affect response to adalimumab.
PA166136276,rs113165732,1444700655,CC,Patients with the CC genotype and HIV may have an increased creatinine clearance when treated with tenofovir as compared to patients with the CT genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
PA166136276,rs113165732,1444700656,CT,Patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
PA166136276,rs113165732,1444700657,TT,"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance."
PA166134737,rs1126643,1446909018,CC,"Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
PA166134737,rs1126643,1446909019,CT,"Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
PA166134737,rs1126643,1446909020,TT,"Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
PA166136504,rs11313667,1447943633,C/del,Patients with the C/del genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
PA166136504,rs11313667,1447943634,CC,Patients with the CC genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
PA166136504,rs11313667,1447943635,del/del,Patients with the del/del genotype and hypertension may have increased response to hydrochlorothiazide compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
PA166136503,rs11313667,1447943617,C/del,Patients with the C/del genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.
PA166136503,rs11313667,1447943616,CC,Patients with the CC genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.
PA166136503,rs11313667,1447943618,del/del,Patients with the del/del genotype and hypertension may have increased response to atenolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to atenolol.
PA166136006,rs11313667,1447943629,C/del,Patients with the C/del genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to metoprolol
PA166136006,rs11313667,1447943628,CC,Patients with the CC genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to metoprolol.
PA166136006,rs11313667,1447943630,del/del,Patients with the del/del genotype and hypertension may have increased response to metoprolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to metoprolol.
PA166136401,rs113095083,1445594345,CC,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136401,rs113095083,1445594346,CT,Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136401,rs113095083,1445594347,TT,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166134793,rs1131882,1043858701,AA,"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134793,rs1131882,1043858700,AG,"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134793,rs1131882,1043858699,GG,Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166163792,rs1131882,1448617233,AA,"Patients with the AA genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin."
PA166163792,rs1131882,1448617234,AG,"Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin."
PA166163792,rs1131882,1448617235,GG,"Patients with the GG genotype may have decreased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to aspirin."
PA166135956,rs113288603,1446903572,CC,"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
PA166135956,rs113288603,1446903573,CT,"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
PA166135956,rs113288603,1446903574,TT,"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
PA166134056,rs1131873,982031158,AA,Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
PA166134056,rs1131873,982031159,AG,Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
PA166134056,rs1131873,982031160,GG,Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
PA166158970,rs113681054,1448106592,CC,Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.
PA166158970,rs113681054,1448106593,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
PA166158970,rs113681054,1448106594,TT,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.
PA166134644,rs1137617,982009416,AA,Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments. 
PA166134644,rs1137617,982009417,AG,Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments. 
PA166134644,rs1137617,982009418,GG,Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments. 
PA166134212,rs1136201,655385036,AA,Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134212,rs1136201,655385035,AG,Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134212,rs1136201,655385034,GG,Cardiotox was not not found in GG group in this small study. The GG genotype  (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.
PA166134238,rs1138272,655385167,CC,Patients with the CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.
PA166134238,rs1138272,655385166,CT,Patients with the CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.
PA166134238,rs1138272,655385165,TT,Patients with the TT genotype may have increased clearance of thiotepa as compared to patients with the CT or TT genotype.
PA166136396,rs1138272,1445402228,CC,"Patients with the CC genotype and cancer may have longer survival times when treated with cisplatin as compared to patients with the CT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time."
PA166136396,rs1138272,1445402229,CT,"Patients with the CT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time."
PA166136396,rs1138272,1445402230,TT,"Patients with the TT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time."
PA166134742,rs1137101,1444705470,AA,Patients with the AA genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.  
PA166134742,rs1137101,1444705471,AG,Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.  
PA166134742,rs1137101,1444705472,GG,Patients with the GG genotype and hypercholesterolemia may have a reduced response to treatment with less reduction in total cholesterol when treated with simvastatin compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.  
PA166134743,rs1137101,1444705463,AA,Patients with the AA genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134743,rs1137101,1444705464,AG,Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134743,rs1137101,1444705465,GG,Patients with the GG genotype and coronary heart disease may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166152906,rs1137101,1447979297,AA,"Female patients with the AA genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
PA166152906,rs1137101,1447979298,AG,"Female patients with the AG genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. In males, this association may be in the opposite direction. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
PA166152906,rs1137101,1447979299,GG,"Female patients with the GG genotype may have an increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AA genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
PA166135901,rs1137101,1445401391,AA,Patients with the AA genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain. 
PA166135901,rs1137101,1445401392,AG,Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain. 
PA166135901,rs1137101,1445401393,GG,Patients with the GG genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain. 
PA166151961,rs113993959,1447954385,GG,Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
PA166151961,rs113993959,1447954386,GT,"Patients with the GT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
PA166151961,rs113993959,1447954387,TT,"Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
PA166159994,rs1143623,1448256900,CC,Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
PA166159994,rs1143623,1448256901,CG,Patients with the CG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
PA166159994,rs1143623,1448256902,GG,Patients with the GG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
PA166134764,rs114202595,982045147,AA,Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134764,rs114202595,982045148,AG,Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134764,rs114202595,982045149,GG,Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134792,rs1143627,1043858694,AA,Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
PA166134792,rs1143627,1043858695,AG,Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
PA166134792,rs1143627,1043858696,GG,Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
PA166152677,rs1143634,1447960316,AA,Patients with the AA genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
PA166152677,rs1143634,1447960317,AG,Patients with the AG genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
PA166152677,rs1143634,1447960318,GG,Patients with the GG genotype and Crohn's disease may a poorer response to treatment with infliximab as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to infliximab.
PA166135920,rs1143634,1446897179,AA,Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166135920,rs1143634,1446897180,AG,Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166135920,rs1143634,1446897181,GG,Patients with the GG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166134054,rs1127354,1448108022,AA,Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134054,rs1127354,1448108023,AC,Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134054,rs1127354,1448108024,CC,Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.
PA166135960,rs1127354,1448104079,AA,Patients with chronic hepatitis C and the AA genotype may have a decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the CC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
PA166135960,rs1127354,1448104080,AC,Patients with chronic hepatitis C and the AC genotype may have a decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the CC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
PA166135960,rs1127354,1448104081,CC,"Patients with chronic hepatitis C and the CC genotype, may have an increased risk of anemia but a decreased risk of thrombocytopenia as compared to patients with the AA or AC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin."
PA166134414,rs1127354,827830328,AA,Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134414,rs1127354,827830329,AC,Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134414,rs1127354,827830330,CC,Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134586,rs1127354,1448104073,AA,"Patients with the AA genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin."
PA166134586,rs1127354,1448104074,AC,"Patients with the AC genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin."
PA166134586,rs1127354,1448104075,CC,"Patients with the CC genotype and Hepatitis C, Chronic may have an increased risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin."
PA166134603,rs1127354,982037178,AA,"Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AA genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134603,rs1127354,982037179,AC,"Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AC genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134603,rs1127354,982037180,CC,"Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166152806,rs1127354,1448106619,AA,Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of neutropenia when treated with mercaptopurine as compared to patients with the CC genotype. This may be related to the increased 6-methylmercaptopurine nucleotide metabolite concentrations in patients with the AA genotype as compared to those with the CC genotype. Other genetic and clinical factors may also influence risk of neutropenia.
PA166152806,rs1127354,1448106620,AC,"Patients with the AC genotype and acute lymphoblastic leukemia may have an increased risk of neutropenia when treated with mercaptopurine as compared to patients with the CC genotype. This may be related to the increased 6-methylmercaptopurine nucleotide metabolite concentrations in patients with the AC genotype as compared to those with the CC genotype. However, one study found a decreased risk for leukopenia for patients with the AC genotype as compared to those with the CC genotype. Other genetic and clinical factors may also influence risk of neutropenia."
PA166152806,rs1127354,1448106621,CC,"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk of neutropenia when treated with mercaptopurine as compared to patients with the AA or AC genotype. This may be related to the decreased 6-methylmercaptopurine nucleotide metabolite concentrations in patients with the CC genotype as compared to those with the AA or AC genotype. However, one study found an increased risk of leukopenia for patients with the CC genotype as compared to those with the AC genotype. Other genetic and clinical factors may also influence risk of neutropenia."
PA166134932,rs1143684,1153928104,CC,Patients with the CC genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
PA166134932,rs1143684,1153928107,CT,Patients with the CT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
PA166134932,rs1143684,1153928110,TT,Patients with the CT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
PA166159400,rs1149222,1448109600,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159400,rs1149222,1448109601,GT,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159400,rs1149222,1448109602,TT,"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166135587,rs11479,1184986818,AA,"Patients with the AA genotype and cancer may have an increased risk of drug toxicity when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer. 
"
PA166135587,rs11479,1184986819,AG,Patients with the AG genotype and cancer may have an increased risk of drug toxicity when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer. 
PA166135587,rs11479,1184986820,GG,Patients with the GG genotype and cancer may have a decreased risk of drug toxicity when administered capecitabine and/or fluorouracil as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer. 
PA166134940,rs1150226,1157230441,AA,"Patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have a decreased response as compared to patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine."
PA166134940,rs1150226,1157230442,GA,"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine."
PA166134940,rs1150226,1157230443,GG,"Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine."
PA166135515,rs1142345,1184348723,CC,Patients with the CC genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. 
PA166135515,rs1142345,1184348724,CT,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. 
PA166135515,rs1142345,1184348725,TT,Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. 
PA166134342,rs1142345,1448616406,CC,"Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134342,rs1142345,1448616407,CT,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134342,rs1142345,1448616408,TT,"Children with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166136397,rs1142345,1448275772,CC,Pediatric patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
PA166136397,rs1142345,1448275773,CT,"Pediatric patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the TT genotypes. However, they may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma."
PA166136397,rs1142345,1448275774,TT,Pediatric patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
PA166135421,rs115232898,1448097656,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and cancer who are treated with fluorouracil may have an increased risk for drug toxicity as compared to patients with the TT genotype. The CC genotype may also be associated with decreased DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135421,rs115232898,1448097657,CT,Patients with the CT genotype and cancer who are treated with fluorouracil may have an increased risk for drug toxicity as compared to patients with the TT genotype. The CT genotype is also associated with decreased DPYD activity as compared to the TT genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
PA166135421,rs115232898,1448097658,TT,"Patients with the TT genotype and cancer who are treated with fluorouracil may have a decreased risk for drug toxicity, and increased DPYD activity, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166160313,rs11543791,1448259310,CC,"Female, post-menopausal patients with the CC genotype and schizophrenia may have a decreased response to raloxifene compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to raloxifene."
PA166160313,rs11543791,1448259311,CT,"Female, post-menopausal patients with the CT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene."
PA166160313,rs11543791,1448259312,TT,"Female, post-menopausal patients with the TT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene."
PA166134062,rs11545078,637879870,AA,Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
PA166134062,rs11545078,637879871,AG,Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
PA166134062,rs11545078,637879872,GG,Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
PA166136175,rs11545078,1444666784,AA,Patients with the AA genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
PA166136175,rs11545078,1444666785,AG,"Patients with the AG genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed."
PA166136175,rs11545078,1444666786,GG,Patients with the GG genotype and lung cancer may have an increased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
PA166159815,rs11549465,1448125548,CC,"Patients with CC genotype may have increased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to axitinib and sorafenib."
PA166159815,rs11549465,1448125547,CT,"Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib."
PA166159815,rs11549465,1448125546,TT,"Patients with TT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib."
PA166136277,rs1155463,1444700664,AA,"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia. "
PA166136277,rs1155463,1444700663,AC,"Patients with the AC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia."
PA166136277,rs1155463,1444700662,CC,Patients with the CC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia. 
PA166136377,rs11563250,1445401415,AA,"Patients with the AA genotype and metastatic colorectal cancer may have increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations."
PA166136377,rs11563250,1445401416,AG,"Patients with the AG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations."
PA166136377,rs11563250,1445401417,GG,"Patients with the GG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations."
PA166136378,rs11563250,1445401422,AA,"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia."
PA166136378,rs11563250,1445401423,AG,"Patients with the AG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia."
PA166136378,rs11563250,1445401424,GG,"Patients with the GG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia."
PA166153412,rs115632870,1447989779,CC,Patients with the CC genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity. 
PA166153412,rs115632870,1447989780,CT,Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity. 
PA166153412,rs115632870,1447989781,TT,"No patients with the TT genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity. "
PA166135693,rs11568658,1444667735,AA,Patients with the AA genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
PA166135693,rs11568658,1444667736,AC,Patients with the AC genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
PA166135693,rs11568658,1444667737,CC,Patients with the CC genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
PA166159688,rs11568658,1448124592,AC,Patients with the AC genotype and kidney transplant may have increased risk of neutropenia when treated with valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.
PA166159688,rs11568658,1448124593,CC,Patients with the CC genotype and kidney transplant may have decreased risk of neutropenia when treated with valganciclovir compared to patients with the AC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.
PA166134916,rs11568695,1131245987,CC,"Patients with the CC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have a decreased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
PA166134916,rs11568695,1131245983,TC,"Patients with the TC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
PA166134916,rs11568695,1131245981,TT,"Patients with the TT genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
PA166136278,rs11568817,1444700671,AA,"Patients with the AA genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram. "
PA166136278,rs11568817,1444700670,AC,Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram. 
PA166136278,rs11568817,1444700669,CC,Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram. 
PA166136033,rs1135989,1184749285,AA,Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. 
PA166136033,rs1135989,1184749286,AG,"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. "
PA166136033,rs1135989,1184749287,GG,"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. "
PA166152815,rs11568482,1447963184,AA,Patients with the AA genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
PA166152815,rs11568482,1447963185,AT,Patients with the AT genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
PA166152815,rs11568482,1447963186,TT,Patients with the TT genotype may have increased clearance of cefotaxime as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
PA166136130,rs11572076,1444607865,CC,Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of leukopenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
PA166136130,rs11572076,1444607866,CT,Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
PA166136130,rs11572076,1444607867,TT,Patients with the TT genotype were not studied but patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
PA166134638,rs11568315,982044831,(CA)16/(CA)16,"Advanced non-small-cell lung cancer patients patients with (CA)16/(CA)16 + (CA)16/(CA)17 genotype are more likely to have better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib as compared to patients with (CA)17/(CA)17 genotype. 
NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17."
PA166134638,rs11568315,982044832,(CA)16/(CA)17,"Advanced non-small-cell lung cancer patients patients with (CA)16/(CA)16 + (CA)16/(CA)17 genotype are more likely to have better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib as compared to patients with (CA)17/(CA)17 genotype. 
NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17."
PA166134638,rs11568315,982044833,(CA)17/(CA)17,"Advanced non-small-cell lung cancer patients patients with (CA)17/(CA)17 genotype are more likely to have worse clinical response (decreased response rate (RR), decreased progression-free survival (PFS) and decreased survival time) when treated with gefitinib as compared to (CA)16/(CA)16 + (CA)16/(CA)17 genotype. 
NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17."
PA166159008,rs11568820,1448106761,CC,"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166159008,rs11568820,1448106762,CT,"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166159008,rs11568820,1448106763,TT,"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166153198,rs11580409,1447987229,AA,Patients with depressive disorder and the AA genotype may have improved response to citalopram or escitalopram as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder. 
PA166153198,rs11580409,1447987230,AC,Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder. 
PA166153198,rs11580409,1447987231,CC,Patients with depressive disorder and the CC genotype may have worse response to citalopram or escitalopram as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder. 
PA166134133,rs11572103,655384589,AA,"Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134133,rs11572103,655384590,AT,"Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134133,rs11572103,655384591,TT,"Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166135348,rs11598702,1183693451,CC,Patients with the CC genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135348,rs11598702,1183693450,CT,Patients with the CT genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135348,rs11598702,1183693449,TT,Patients with the TT genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166134024,rs11598702,1444698370,CC,Patients with the CC genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
PA166134024,rs11598702,1444698371,CT,Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
PA166134024,rs11598702,1444698372,TT,Patients with the TT genotype may have decreased clearance of gemcitabine as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect clearance of gemcitabine.
PA166134791,rs11587213,1043858681,AA,Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. 
PA166134791,rs11587213,1043858682,AG,Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. 
PA166134791,rs11587213,1043858683,GG,Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. 
PA166135393,rs11600347,1183700508,AA,Patients with the AA genotype may have  increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
PA166135393,rs11600347,1183700509,AC,Patients with the AC genotype may have  increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
PA166135393,rs11600347,1183700510,CC,Patients with the CC genotype may have  decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
PA166136280,rs1160351,1444700690,AA,"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexsual dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to fluvoxamine, milnacipran or paroxetine. "
PA166136280,rs1160351,1444700691,AC,"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexsual dysfunction as compared to patients with the CC genotype or may have a decreased, but not absent, risk of sexsual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to fluvoxamine, milnacipran or paroxetine. "
PA166136280,rs1160351,1444700692,CC,"Patients with the CC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have a decreased, but not absent, risk of sexsual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to fluvoxamine, milnacipran or paroxetine. "
PA166136448,rs11623866,1448106364,CC,"Patients with ovarian cancer and the CC genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. In a single study, the authors compared outcomes between genotypes between treatments. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes."
PA166136448,rs11623866,1448106365,CG,"Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes."
PA166136448,rs11623866,1448106366,GG,"Patients with ovarian cancer and the GG genotype may have a decreased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the CC or CG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes."
PA166134643,rs113993960,1447981027,CTT/CTT,Indication of ivacaftor in cystic fibrosis patients with the CTT/CTT genotype (no copies of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor. 
PA166134643,rs113993960,1447981028,CTT/del,Indication of ivacaftor in cystic fibrosis patients with the CTT/del genotype (one copy of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor. 
PA166134643,rs113993960,1447981029,del/del,"Ivacaftor is not recommended in cystic fibrosis patients with the del/del genotype (two copies of the F508del variant). A clinical trial of ivacaftor in patients with the del/del genotype showed ivacaftor was ineffective in these patients, though this study was not powered to examine efficacy. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166152868,rs113993960,1447964144,CTT/CTT,Patients with the CTT/CTT genotype and cystic fibrosis may not respond when treated with cysteamine as compared to patients with the CTT/del or del/del genotypes. Other genetic and clinical factors may also influence the efficacy of cysteamine.
PA166152868,rs113993960,1447964145,CTT/del,Patients with the CTT/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.
PA166152868,rs113993960,1447964146,del/del,Patients with the del/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.
PA166152934,rs113993960,1448265445,CTT/CTT,"The CTT/CTT genotype (no copies of the CFTR F508del variant) is not an indication for the combination drug of ivacaftor plus lumacaftor in patients with cystic fibrosis. 
"
PA166152934,rs113993960,1448265446,CTT/del,Patients with cystic fibrosis and the CTT/del genotype (one copy of the CFTR F508del variant) have not been shown to benefit from treatment with the combination drug of ivacaftor plus lumacaftor. This genotype is not an indication for use of the combination drug of ivacaftor plus lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence a patient's response to the combination drug of ivacaftor plus lumacaftor. 
PA166152934,rs113993960,1448265447,del/del,"Patients with the del/del genotype (two copies of the F508del variant) may benefit from treatment with the combination drug of ivacaftor plus lumacaftor, as shown by improvement in sweat chloride concentrations and/or forced expiratory volume in 1 second (FEV1) when compared to treatment with placebo. This genotype is an indication for use of the combination drug of ivacaftor plus lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence a patient's response to the combination drug of ivacaftor plus lumacaftor. "
PA166163369,rs113993960,1448604084,CTT/CTT,Patients with cystic fibrosis and the CTT/CTT genotype may not receive benefit from cavosonstat. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.
PA166163369,rs113993960,1448604085,CTT/del,Patients with cystic fibrosis and the CTT/del genotype may not receive benefit from cavosonstat. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.
PA166163369,rs113993960,1448604086,del/del,Patients with cystic fibrosis and the del/del genotype may receive benefit from cavosonstat as measured in reduction of sweat chloride content but not in change of FEV1. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.
PA166153176,rs11649514,1447986981,GG,Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
PA166153176,rs11649514,1447986982,GT,Patients with the GT genotype and essential hypertension who are administered atenolol may have a increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
PA166153176,rs11649514,1447986983,TT,Patients with the TT genotype and essential hypertension who are administered atenolol may have an increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
PA166136281,rs11628713,1444700744,CC,"Patients with the CC genotype and major depression who are treated with citalopram may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
PA166136281,rs11628713,1444700743,CT,"Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype or may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
PA166136281,rs11628713,1444700742,TT,Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
PA166135856,rs11677416,1448107342,CC,Patients with the CC genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135856,rs11677416,1448107343,CT,Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135856,rs11677416,1448107344,TT,Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134717,rs11676382,1445585322,CC,"Patients with the CC genotype may need increased dose of warfarin as compared to patients with the GG or CG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to warfarin."
PA166134717,rs11676382,1445585323,CG,"Patients with the CG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to warfarin."
PA166134717,rs11676382,1445585324,GG,"Patients with the GG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to warfarin."
PA166153453,rs11676382,1447990257,CC,"Patients with the CC genotype may need an increased dose of warfarin as compared to patients with the CG and GG genotypes, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin. 
"
PA166153453,rs11676382,1447990258,CG,"Patients with the CG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin. "
PA166153453,rs11676382,1447990259,GG,"Patients with the GG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin. "
PA166160465,rs11676382,1448262912,CC,Patients with the CC genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160465,rs11676382,1448262911,CG,Patients with the CG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160465,rs11676382,1448262910,GG,Patients with the GG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160467,rs11676382,1448262926,CC,Patients with the CC genotype may have increased time in therapeutic range when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160467,rs11676382,1448262925,CG,Patients with the CG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160467,rs11676382,1448262924,GG,Patients with the GG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166134051,rs11572080,1446908881,CC,Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134051,rs11572080,1446908882,CT,Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134051,rs11572080,1446908883,TT,Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134170,rs11572080,655384837,CC,"Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134170,rs11572080,655384836,CT,"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134170,rs11572080,655384835,TT,"Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
PA166134172,rs11572080,1448099259,CC,"Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity."
PA166134172,rs11572080,1448099260,CT,"Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity."
PA166134172,rs11572080,1448099261,TT,Patients with the TT genotype may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.
PA166134647,rs11572080,982029203,CC,"Patients with the CC genotype may have increased plasma concentrations
of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. "
PA166134647,rs11572080,982029202,CT,"Patients with the CT genotype may have reduced plasma concentrations
of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. "
PA166134647,rs11572080,982029201,TT,"Patients with the TT genotype may have reduced plasma concentrations
of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. "
PA166161459,rs11678615,1448428928,CC,Patients with the CC genotype and gout may be more likely to require 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161459,rs11678615,1448428929,CT,Patients with the CT genotype and gout may be more likely to require 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161459,rs11678615,1448428930,TT,Patients with the TT genotype and gout may be more likely to require a dose other than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161462,rs11678615,1448428953,CC,Patients with the CC genotype and gout may be more likely to require a dose other than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161462,rs11678615,1448428954,CT,Patients with the CT genotype and gout may be more likely to require a dose other than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161462,rs11678615,1448428955,TT,Patients with the TT genotype and gout may be more likely to require a dose of 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166135707,rs11692021,1447962643,CC,"Patients with the CC genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
PA166135707,rs11692021,1447962644,CT,"Patients with the CT genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
PA166135707,rs11692021,1447962645,TT,"Patients with the TT genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the CC genotype. This may be due to increased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the T allele as compared to those with the C allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
PA166135550,rs1128503,1444695586,AA,Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels. 
PA166135550,rs1128503,1444695587,AG,Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels. 
PA166135550,rs1128503,1444695588,GG,Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels. 
PA166134126,rs1128503,1447963754,AA,"Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
PA166134126,rs1128503,1447963755,AG,"Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
PA166134126,rs1128503,1447963756,GG,"Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
PA166134379,rs1128503,655387230,AA,"Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response."
PA166134379,rs1128503,655387231,AG,"Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response."
PA166134379,rs1128503,655387232,GG,"Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135080,rs1128503,1183614762,AA,Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels. 
PA166135080,rs1128503,1183614763,AG,Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels. 
PA166135080,rs1128503,1183614764,GG,Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels. 
PA166135131,rs1128503,1183615536,AA,Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
PA166135131,rs1128503,1183615537,AG,"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin."
PA166135131,rs1128503,1183615538,GG,Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
PA166134587,rs1128503,981237923,AA,Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
PA166134587,rs1128503,981237924,AG,Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
PA166134587,rs1128503,981237925,GG,Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
PA166135703,rs1128503,1448573611,AA,"Patients with the AA genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus. "
PA166135703,rs1128503,1448573612,AG,"Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus. "
PA166135703,rs1128503,1448573613,GG,"Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus. "
PA166134721,rs1128503,982034870,AA,Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134721,rs1128503,982034871,AG,Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134721,rs1128503,982034872,GG,Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134733,rs1128503,982036605,AA,"Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134733,rs1128503,982036606,AG,"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134733,rs1128503,982036607,GG,"Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166136369,rs1128503,1448612731,AA,"Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype. However, studies conflict. Other genetic and clinical factors may also influence response to imatinib. "
PA166136369,rs1128503,1448612732,AG,"Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype. However, studies conflict. Other genetic and clinical factors may also influence response to imatinib. "
PA166136369,rs1128503,1448612733,GG,"Patients with the GG genotype and chronic myeloid leukemia may have a better response to imatinib treatment as compared to patients with the AA or AG genotype. However, studies conflict. Other genetic and clinical factors may also influence response to imatinib. "
PA166136371,rs1128503,1445401255,AA,Patients with the AA genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium. 
PA166136371,rs1128503,1445401256,AG,Patients with the AG genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium. 
PA166136371,rs1128503,1445401257,GG,Patients with the GG genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium. 
PA166135907,rs1128503,1446897992,AA,"Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
PA166135907,rs1128503,1446897993,AG,"Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
PA166135907,rs1128503,1446897994,GG,"Patients with the GG genotype and acute myeloid leukemia may have a poorer response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the AA or AG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
PA166152726,rs1128503,1447960876,AA,Patients with the AA genotype and cancer may have increased exposure to tipifarnib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
PA166152726,rs1128503,1447960877,AG,Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
PA166152726,rs1128503,1447960878,GG,Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
PA166153190,rs1128503,1448266848,AA,African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153190,rs1128503,1448266849,AG,African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153190,rs1128503,1448266850,GG,African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166159002,rs1128503,1448100719,AA,Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants. 
PA166159002,rs1128503,1448100720,AG,"Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants. "
PA166159002,rs1128503,1448100721,GG,Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants. 
PA166152797,rs1128503,1447962845,AA,Patients with the AA genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.
PA166152797,rs1128503,1447962846,AG,Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.
PA166152797,rs1128503,1447962847,GG,Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.
PA166152856,rs1128503,1447963986,AA,"Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics. "
PA166152856,rs1128503,1447963987,AG,"Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics. "
PA166152856,rs1128503,1447963988,GG,"Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics. "
PA166152798,rs1128503,1447962857,AA,Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.
PA166152798,rs1128503,1447962858,AG,"Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia."
PA166152798,rs1128503,1447962859,GG,Patients with the GG genotype and hypercholesterolemia may have an increased risk for myalgia when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.
PA166152892,rs1128503,1447964544,AA,Patients with the AA genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
PA166152892,rs1128503,1447964545,AG,"Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome."
PA166152892,rs1128503,1447964546,GG,Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
PA166159992,rs1128503,1448256883,AA,Patients with the AA genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166159992,rs1128503,1448256884,AG,Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166159992,rs1128503,1448256885,GG,Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166161227,rs1128503,1448427007,AA,Patients with the AA genotype and non-small cell lung cancer may have an increased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
PA166161227,rs1128503,1448427008,AG,Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
PA166161227,rs1128503,1448427009,GG,Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
PA166136421,rs1128503,1446897682,AA,"Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of  neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
PA166136421,rs1128503,1446897683,AG,"Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of  neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
PA166136421,rs1128503,1446897684,GG,"Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of  neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
PA166136011,rs1128503,1447943746,AA,"Patients with AA genotype and HIV may have decreased concentrations of efavirenz in plasma compared to patients with AG or GG genotypes. However, this association was not significant and was not found in another study of plasma and PBMCs. Other clinical and genetic factors may affect efavirenz concentrations."
PA166136011,rs1128503,1447943747,AG,"Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and was not found in another study of plasma and PBMCs. Other clinical and genetic factors may affect efavirenz concentrations."
PA166136011,rs1128503,1447943748,GG,"Patients with GG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and was not found in another study of plasma and PBMCs.  Other clinical and genetic factors may affect efavirenz concentrations."
PA166136510,rs1128503,1447943755,AA,Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.
PA166136510,rs1128503,1447943756,AG,Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.
PA166136510,rs1128503,1447943757,GG,Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.
PA166162610,rs1128503,1448573617,AA,Patients with the AA genotype and ulcerative colitis may have a decreased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus response. 
PA166162610,rs1128503,1448573618,AG,Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response. 
PA166162610,rs1128503,1448573619,GG,Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response. 
PA166152819,rs11716445,1447963249,AA,Patients with the AA genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.
PA166152819,rs11716445,1447963250,AG,"Patients with the AG genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins."
PA166152819,rs11716445,1447963251,GG,Patients with the GG genotype with high cholesterol may have a better response when treated with pravastatin or simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.
PA166152799,rs113646094,1447962869,CC,Patients with the CC genotype may have decreased clearance of pravastatin as compared to patients with the CG genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
PA166152799,rs113646094,1447962870,CG,Patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
PA166152799,rs113646094,1447962871,GG,"No patients with the GG genotype were available for analysis, but patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin."
PA166134450,rs11739136,827864302,CC,"Patients with the CC genotype: 1) may have increased blood pressure, 2) increased risk for hypertension and 3) slower control of blood pressure when treated with verapamil as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
PA166134450,rs11739136,827864303,CT,"Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
PA166134450,rs11739136,827864304,TT,"Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
PA166134913,rs11746641,1124035502,GG,Patients with the GG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134913,rs11746641,1124035503,GT,Patients with the GT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134913,rs11746641,1124035504,TT,Patients with the TT genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134912,rs11749035,1123915620,CC,Patients with the CC genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134912,rs11749035,1123915619,CT,Patients with the CT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134912,rs11749035,1123915618,TT,Patients with the TT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166160630,rs117648444,1448265019,AA,Patients with genotype AA may have increased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
PA166160630,rs117648444,1448265020,AG,Patients with genotype AG may have increased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
PA166160630,rs117648444,1448265021,GG,Patients with genotype GG may have decreased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
PA166158877,rs117532069,1448106423,AA,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
PA166158877,rs117532069,1448106424,AG,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
PA166158877,rs117532069,1448106425,GG,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
PA166159200,rs11788456,1448103891,AA,Patients with the AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
PA166159200,rs11788456,1448103892,AG,"Patients with the AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence."
PA166159200,rs11788456,1448103893,GG,Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
PA166135532,rs116855232,1448594340,CC,"Patients with the CC genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have a reduced, but not absent risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CT or TT genotype. Patients may also tolerate higher doses of thiopurines and be less likely to discontinue thiopurine treatment as compared to patients with the CT or TT genotype, possibly due to the reduced risk for adverse effects. Other genetic and clinical factors may also influence a patient's risk for leukopenia, alopecia or treatment discontinuation. "
PA166135532,rs116855232,1448594341,CT,"Patients with the CT genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have an increased risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CC genotype. Patients may also require lower doses of thiopurines and be more likely to discontinue thiopurine treatment as compared to patients with the CC genotype, possibly due to the increased risk for adverse effects. Other genetic and clinical factors may also influence a patient's risk for leukopenia, alopecia or treatment discontinuation. "
PA166135532,rs116855232,1448594342,TT,"Patients with the TT genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have an increased risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CC genotype. Patients may also require lower doses of thiopurines and be more likely to discontinue thiopurine treatment as compared to patients with the CC genotype, possibly due to the increased risk for adverse effects. Other genetic and clinical factors may also influence a patient's risk for leukopenia, alopecia or treatment discontinuation. "
PA166152678,rs11710163,1447960329,AA,"Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152678,rs11710163,1447960330,AG,"Patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152678,rs11710163,1447960331,GG,"No patients with the GG genotype were available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166136125,rs1176744,1444607791,AA,Patients with the AA genotype and Mental Disorders who are treated with paroxetine may have an increased risk of nausea as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166136125,rs1176744,1444607792,AC,Patients with the AC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166136125,rs1176744,1444607793,CC,Patients with the CC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134934,rs11706052,1446908926,AA,"Patients with the AA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) a decreased, but not absent, risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) increased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant."
PA166134934,rs11706052,1446908927,GA,"Patients with the GA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant."
PA166134934,rs11706052,1446908928,GG ,"Patients with the GG genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant."
PA166134739,rs11706052,982037560,AA,"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166134739,rs11706052,982037559,GA,Patients with the GA genotype may have 1) an increased risk for acute rejection after kidney transplantation and 2)  decreased incidence of lymphopenia as compared to patients with the AA genotype but the GA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
PA166134739,rs11706052,982037558,GG,Patients with the GG genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the AA genotype but the GG genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
PA166136486,rs118192116,1447992118,CC,"Individuals with the CC genotype and central core myopathy may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CG or GG genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136486,rs118192116,1447992119,CG,"Individuals with the CG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136486,rs118192116,1447992120,GG,"Individuals with the GG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient of develops Malignant Hyperthermia. Please note: the G allele is thought to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with GG genotype is not known. "
PA166135875,rs118192124,1447992341,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135875,rs118192124,1447992342,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135875,rs118192124,1447992343,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. The T allele is also associated with central core myopathy. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135462,rs118192163,1447992272,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.
"
PA166135462,rs118192163,1447992273,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135462,rs118192163,1447992274,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135461,rs118192162,1447992170,AA,"Patients with the AA genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AC or CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135461,rs118192162,1447992171,AC,"Patients with the AC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135461,rs118192162,1447992172,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known."
PA166135464,rs118192170,1447992401,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135464,rs118192170,1447992402,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135464,rs118192170,1447992403,TT,"Patients with the TT genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135459,rs118192161,1447992410,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135459,rs118192161,1447992411,CT," Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135459,rs118192161,1447992412,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele confers susceptibility to MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not reported here."
PA166136354,rs118192122,1447992447,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known."
PA166136354,rs118192122,1447992448,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166136354,rs118192122,1447992449,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135465,rs118192175,1447992253,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135465,rs118192175,1447992254,CT ,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135465,rs118192175,1447992255,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known."
PA166135890,rs11615,1445401127,AA,Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
PA166135890,rs11615,1445401128,AG,Patients with the AG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
PA166135890,rs11615,1445401129,GG,Patients with the GG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
PA166134350,rs11615,1448522467,AA,"Patients with the AA genotype may have 1) an increased risk for nephrotoxicity 2) decreased survival and 3) a poorer response when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. However, some studies find no association with drug toxicity, and one study found a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
PA166134350,rs11615,1448522468,AG,"Patients with the AG genotype who are treated with platinum-based chemotherapy may have an increased risk for nephrotoxicity as compared to patients with the GG genotype. The findings for response and overall survival are inconclusive. Patients with the AG genotype may have an increased response compared to patients with the AA genotype. However, another study showed an increased response compared to patients with the GG genotype. Additionally, some studies find no association with drug toxicity or survival. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
PA166134350,rs11615,1448522469,GG,"Patients with the GG genotype may have 1) decreased but not absent risk for toxicity, 2) increased survival and 3) a better response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. However, some studies find no association with drug toxicity, and one study found a poorer response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
PA166135114,rs11615,1448522472,AA,"Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia."
PA166135114,rs11615,1448522473,AG,"Patients with the AG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia."
PA166135114,rs11615,1448522474,GG,"Patients with the GG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia."
PA166135115,rs11615,1448522462,AA,"Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
PA166135115,rs11615,1448522463,AG,"Patients with the AG genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
PA166135115,rs11615,1448522464,GG,"Patients with the GG genotype and colorectal cancer may have increased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
PA166134588,rs11615,981237931,AA,"Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result"
PA166134588,rs11615,981237932,AG,Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.
PA166134588,rs11615,981237933,GG,"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment."
PA166136387,rs11615,1445401860,AA,Patients with the AA genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
PA166136387,rs11615,1445401861,AG,Patients with the AG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
PA166136387,rs11615,1445401862,GG,Patients with the GG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
PA166135463,rs118192167,1447992376,AA,"Patients with the AA genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135463,rs118192167,1447992377,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135463,rs118192167,1447992378,GG,"Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with GG genotype is not known. "
PA166136196,rs11819745,1444667594,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136196,rs11819745,1444667595,AG,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136196,rs11819745,1444667596,GG,Patients with asthma and the GG genotype may have a increased risk of aspirin induced asthma as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135972,rs118192178,1447992462,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT, CG, GG or TT. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135972,rs118192178,1447992463,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135972,rs118192178,1447992464,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. The T allele is considered to confer MH in an autosomal dominant manner. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135972,rs118192178,1447992465,GG,"Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135972,rs118192178,1447992466,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135466,rs118192176,1447992278,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.
"
PA166135466,rs118192176,1447992279,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135466,rs118192176,1447992280,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166152679,rs11854484,1447960347,CC,Patients with the CC genotype and non-small-cell lung cancer may have a shorter median survival time and a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival time and hematologic toxicity.
PA166152679,rs11854484,1447960348,CT,Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time and an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time and hematologic toxicity.
PA166152679,rs11854484,1447960349,TT,Patients with the TT genotype and non-small-cell lung cancer may have a longer median survival time and an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time and hematologic toxicity.
PA166135903,rs11854484,1448102841,CC,"Patients with the CC genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia."
PA166135903,rs11854484,1448102842,CT,"Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia."
PA166135903,rs11854484,1448102843,TT,"Patients with the TT genotype and hepatitis C may have an increased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for anemia."
PA166153452,rs118204423,1447992421,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group."
PA166153452,rs118204423,1447992422,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group."
PA166153452,rs118204423,1447992423,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CG and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group."
PA166163251,rs11861118,1448602881,AA,Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163251,rs11861118,1448602880,AG,Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163251,rs11861118,1448602879,GG,Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166135679,rs11868547,1444666690,CC,Patients with the CC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135679,rs11868547,1444666691,CG,Patients with the CG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135679,rs11868547,1444666692,GG,Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166158878,rs11868035,1448099102,AA,Patients with the AA genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels. 
PA166158878,rs11868035,1448099103,AG,Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels. 
PA166158878,rs11868035,1448099104,GG,Patients with the GG genotype and schizophrenia may have a smaller increase or decrease in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total cholesterol levels. 
PA166135351,rs11872992,1183693537,AA,"Patients with the AA genotype and Schizophrenia may have a decreased, but not absent, risk for weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. However, the association was found as trend only and was not statistically significant. Other genetic and clinical factors may also influence a patient's risk for weight gain."
PA166135351,rs11872992,1183693538,AG,"Patients with the AG genotype and Schizophrenia may have an increased risk for weight gain when treated with clozapine or olanzapine as compared to patients with the AA genotype and a decreased, but not absent, risk for weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. However, the association was found as trend only and was not statistically significant. Other genetic and clinical factors may also influence a patient's risk for weight gain."
PA166135351,rs11872992,1183693539,GG,"Patients with the GG genotype and Schizophrenia may have an increased risk for weight gain when treated with clozapine or olanzapine as compared to patients with the AA genotype. However, the association was found as trend only and was not statistically significant. Other genetic and clinical factors may also influence a patient's risk for weight gain."
PA166135933,rs11872992,1446899014,AA,Patients with schizophrenia with the AA genotype may have a decreased likelihood of weight gain when taking clozapine or olanzapine as compared to patients the the AG or GG genotypes. Other clinical and genetic factors may also influence risk of weight gain in patients taking clozapine or olanzapine. 
PA166135933,rs11872992,1446899015,AG,Patients with schizophrenia with the AG genotype may have a decreased likelihood of weight gain when taking clozapine or olanzapine as compared to patients the the GG genotypes and an increased likelihood of weight when as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of weight gain in patients taking clozapine or olanzapine. 
PA166135933,rs11872992,1446899016,GG,Patients with schizophrenia with the GG genotype may have an increased likelihood of weight gain when taking clozapine or olanzapine as compared to patients the the AA and AG genotypes. Other clinical and genetic factors may also influence risk of weight gain in patients taking clozapine or olanzapine. 
PA166152953,rs11869731,1447980742,CC,Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to lithium treatment. 
PA166152953,rs11869731,1447980743,CG,Patients with the CG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment. 
PA166152953,rs11869731,1447980744,GG,Patients with the GG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment. 
PA166135467,rs118192177,1447992431,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT, CT, CG, or GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135467,rs118192177,1447992432,CG," Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135467,rs118192177,1447992433,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135467,rs118192177,1447992434,GG,"Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with GG genotype is not known. "
PA166135467,rs118192177,1447992435,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known."
PA166159167,rs11881222,1448102441,AA,Patients with the AA genotype and hepatitis C or HIV may have a better response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159167,rs11881222,1448102442,AG,Patients with the AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159167,rs11881222,1448102443,GG,Patients with the GG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166152993,rs11940316,1447981252,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152993,rs11940316,1447981253,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152993,rs11940316,1447981254,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166135918,rs11959113,1446766002,AA,Patients with the AA genotype and postoperative pain may require an increased dose when treated with fentanyl as compared to patients with the AG+GG genotype. Other genetic and clinical factors may also influence the required dose of fentanyl.
PA166135918,rs11959113,1446766003,AG,Patients with the AG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.
PA166135918,rs11959113,1446766004,GG,Patients with the GG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.
PA166135669,rs11942466,1444665971,AA,"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time and progression-free survival time, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166135669,rs11942466,1444665972,AC,"Patients with the AC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166135669,rs11942466,1444665973,CC,"Patients with the CC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166135889,rs11942466,1445401120,AA,Patients with the AA genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
PA166135889,rs11942466,1445401121,AC,Patients with the AC genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
PA166135889,rs11942466,1445401122,CC,Patients with the CC genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
PA166134629,rs118192172,1185023394,CC,Patients with CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins.
PA166134629,rs118192172,1185023395,CT,Patients with CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins. 
PA166134629,rs118192172,1185023396,TT,Patients with TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins. 
PA166135458,rs118192172,1447992230,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135458,rs118192172,1447992231,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135458,rs118192172,1447992232,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166153199,rs11947402,1448106382,AA,"Patients with depressive disorder and the AA genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or GG genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder."
PA166153199,rs11947402,1448106383,AG,"Patients with depressive disorder and the AG genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the GG genotypes, and smaller reductions in serotonin as compared to patients with the AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder."
PA166153199,rs11947402,1448106384,GG,"Patients with depressive disorder and the GG genotype may have smaller reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder."
PA166134957,rs11887534,1183491136,CC,"Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. This may be influenced by rs3808607 genotype, with an increased response in patients with the rs3808607 TT genotype.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. "
PA166134957,rs11887534,1183491137,CG,"Patients with the CG genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. However, this association was not observed in the majority of studies. This may be influenced by rs3808607 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. "
PA166134957,rs11887534,1183491138,GG,Patients with the GG genotype who are treated with atorvastatin may have a decreased response to treatment (measured by lower decreases in LDL-cholesterol) as compared to patients with the CC genotype. This association may be influenced by rs3808607 genotype. Several studies show no association as compared to the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166135238,rs11960832,1183631407,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
PA166135238,rs11960832,1183631406,CT,Patients with the CT genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
PA166135238,rs11960832,1183631405,TT,Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to olanzapine.
PA166136406,rs11993031,1445594507,AA,"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166136406,rs11993031,1445594508,AT,"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166136406,rs11993031,1445594509,TT,"Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166136331,rs11849538,1444704865,CC,"Patients with the CC genotype may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol."
PA166136331,rs11849538,1444704864,CG,"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype or may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol."
PA166136331,rs11849538,1444704863,GG,"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol."
PA166136137,rs12022243,1444608184,CC,"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine. "
PA166136137,rs12022243,1444608185,CT,"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine. "
PA166136137,rs12022243,1444608186,TT,"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine. "
PA166135177,rs11983225,1183619313,CC,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135177,rs11983225,1183619314,CT,"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135177,rs11983225,1183619315,TT,"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166134240,rs119774,655385181,CC,"Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
PA166134240,rs119774,655385180,CT,"Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
PA166134240,rs119774,655385182,TT,"Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
PA166135716,rs11938228,1444686971,AA,"Patients with the AA genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135716,rs11938228,1444686972,AC,"Patients with the AC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135716,rs11938228,1444686973,CC,"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135312,rs12041331,1446909067,AA,"Patients with the AA genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel."
PA166135312,rs12041331,1446909068,AG,"Patients with the AG genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel."
PA166135312,rs12041331,1446909069,GG,"Patients with the GG genotype may have 1) decreased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) increased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel."
PA166135313,rs12041331,1183681867,AA,Patients with the AA genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
PA166135313,rs12041331,1183681868,AG,Patients with the AG genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
PA166135313,rs12041331,1183681869,GG,Patients with the GG genotype may have decreased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
PA166162373,rs12041331,1448531864,AA,People with the AA genotype may have increased inhibition of platelet aggregation in response to ticagrelor compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect response to ticagrelor.
PA166162373,rs12041331,1448531865,AG,People with the AG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.
PA166162373,rs12041331,1448531866,GG,People with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.
PA166136395,rs12044852,1445402221,AA,Patients with the AA genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
PA166136395,rs12044852,1445402222,AC,Patients with the AC genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
PA166136395,rs12044852,1445402223,CC,Patients with the CC genotype and multiple sclerosis may have a poorer response to treatment with interferon beta 1a/1b as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
PA166135655,rs12046844,1444607914,AA,Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
PA166135655,rs12046844,1444607913,GA,Patients with the GA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the AA genotype and decreased risk of leukopenia as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
PA166135655,rs12046844,1444607912,GG,Patients with the GG genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
PA166159235,rs1205,1448104024,CC,Patients with the CC genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
PA166159235,rs1205,1448104025,CT,Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
PA166159235,rs1205,1448104026,TT,Patients with the TT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
PA166159033,rs12042763,1448106776,GG,Patients with the GG genotype may have a reduced risk for developing prostate cancer when treated with aspirin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
PA166159033,rs12042763,1448106777,GT,Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
PA166159033,rs12042763,1448106778,TT,Patients with the TT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
PA166134998,rs12003906,1183532530,CC,"Patients with the CC genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134998,rs12003906,1183532529,CG,"Patients with the CG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype or may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134998,rs12003906,1183532528,GG,"Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.  "
PA166136283,rs12054895,1444700764,GG,Patients with the GG genotype and major depression who are treated with citalopram or escitalopram may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
PA166136283,rs12054895,1444700763,GT,Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
PA166136283,rs12054895,1444700762,TT,Patients with the TT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
PA166152680,rs12118636,1447960354,AA,"No patients with the AA genotype are available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients."
PA166152680,rs12118636,1447960355,AG,Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
PA166152680,rs12118636,1447960356,GG,Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
PA166135079,rs12082710,1183630575,CC,Patients with the CC genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166135079,rs12082710,1183630576,CT,Patients with the CT genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166135079,rs12082710,1183630577,TT,Patients with the TT genotype and depression may be more likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166136140,rs12132152,1447989388,AA,"Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166136140,rs12132152,1447989389,AG,"Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166136140,rs12132152,1447989390,GG,"Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166135742,rs12083537,1448526088,AA,"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab."
PA166135742,rs12083537,1448526089,AG,"Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab."
PA166135742,rs12083537,1448526090,GG,Patients with the GG genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.
PA166153061,rs12143842,1447983139,CC,"Patients with the CC genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke."
PA166153061,rs12143842,1447983140,CT,"Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke."
PA166153061,rs12143842,1447983141,TT,No information were reported regarding patients with the TT genotype.
PA166135484,rs121908755,1184472568,AA,"Patients with the AA genotype (two copies of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
"
PA166135484,rs121908755,1184472569,AG,"Patients with the AG genotype (one copy of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
"
PA166135484,rs121908755,1184472570,GG,"Patients with the GG genotype (do not have a copy of the CFTR S549N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient's response to ivacaftor. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166134112,rs12050217,1447964537,AA,"Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril."
PA166134112,rs12050217,1447964538,AG,Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.
PA166134112,rs12050217,1447964539,GG,Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.
PA166136282,rs11719165,1444700755,CC,Patients with the CC genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
PA166136282,rs11719165,1444700756,CT,"Patients with the CT genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia."
PA166136282,rs11719165,1444700757,TT,"Patients with the TT genotype and neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia."
PA166135486,rs121909005,1184472589,GG,"Patients with the GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135486,rs121909005,1184472590,GT,"Patients with the GG genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135486,rs121909005,1184472591,TT,"Patients with the TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166135485,rs121908757,1184472581,AA,"Patients with the AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166135485,rs121908757,1184472582,AC,"Patients with the AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135485,rs121908757,1184472583,CC,"Patients with the CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135487,rs121909013,1184472593,AA,"Patients with the AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135487,rs121909013,1184472594,AG,"Patients with the AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135487,rs121909013,1184472595,GG,"Patients with the GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166161190,rs121909011,1448423867,CT,Patients with cystic fibrosis and a copy of the C allele resulting in residual CFTR function may respond to ivacaftor treatment. Other genetic and clinical factors may affect response to ivacaftor.
PA166161190,rs121909011,1448423868,TT,"Patients with cystic fibrosis and without residual CFTR function, such as patients with the TT genotype, may not respond to ivacaftor treatment. Other genetic and clinical factors may affect response to ivacaftor."
PA166134634,rs121434569,1448108114,CC,"Advanced non-small-cell lung cancer patients with CC genotype may less likely develop acquired resistance and more likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CT or TT genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity."
PA166134634,rs121434569,1448108115,CT,"Advanced non-small-cell lung cancer patients with CT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.
"
PA166134634,rs121434569,1448108116,TT,"Advanced non-small-cell lung cancer patients with TT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.
"
PA166135470,rs121918595,1447992381,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135470,rs121918595,1447992382,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135470,rs121918595,1447992383,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known."
PA166135471,rs121918594,1447992361,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135471,rs121918594,1447992362,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia. "
PA166135471,rs121918594,1447992363,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia. "
PA166161866,rs12191877,1448522780,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161866,rs12191877,1448522781,CT,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161866,rs12191877,1448522782,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166135468,rs121918593,1447992331,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.
"
PA166135468,rs121918593,1447992332,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135468,rs121918593,1447992333,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135460,rs121918592,1447992095,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to be inherited in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known."
PA166135460,rs121918592,1447992096,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. "
PA166135460,rs121918592,1447992097,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.  Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known."
PA166135460,rs121918592,1447992098,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. "
PA166135460,rs121918592,1447992099,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC, CG, AA or AG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. "
PA166135488,rs121909041,1184472605,CC,"Patients with the CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135488,rs121909041,1184472606,CT,"Patients with the CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135488,rs121909041,1184472607,TT,"Patients with the TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166135162,rs12208357,1183618202,CC,Patients with the CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the TT genotype. Other genetic or clinical factors may influence the response to tramadol.
PA166135162,rs12208357,1183618201,CT,Patients with the CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the CC genotype. Other genetic or clinical factors may influence the response to tramadol.
PA166135162,rs12208357,1183618200,TT,Patients with the TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the CC genotype. Other genetic or clinical factors may influence the response to tramadol.
PA166135307,rs12210538,1183680578,AA,Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135307,rs12210538,1183680577,AG,Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135307,rs12210538,1183680576,GG,Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135743,rs12221497,1444700783,AA,"Patients with the AA genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
PA166135743,rs12221497,1444700784,AG,"Patients with the AG genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype or may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
PA166135743,rs12221497,1444700785,GG,"Patients with the GG genotype and hypertension who are treated with verapamil may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
PA166134232,rs12255372,655385138,GG,Patients with the GG genotype and type II diabetes who are treated with sulfonylureas may be more likely to achieve a HbA1c level of <7% as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134232,rs12255372,655385137,GT,Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134232,rs12255372,655385136,TT,Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134344,rs12201199,1448616416,AA,"Children with the AA genotype and cancer may have a lower, but not absent, risk for hearing loss with cisplatin treatment compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134344,rs12201199,1448616417,AT,"Children with the AT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134344,rs12201199,1448616418,TT,"Children with the TT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166158971,rs12201199,1448100363,AA,Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity. 
PA166158971,rs12201199,1448100364,AT,Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity. 
PA166158971,rs12201199,1448100365,TT,"No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity. "
PA166136122,rs1229984,1444607739,CC,Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol. 
PA166136122,rs1229984,1444607740,CT,Patients with the CT genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol. 
PA166136122,rs1229984,1444607741,TT,Patients with the TT genotype may have a higher maximal rate (Vmax) of ethanol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence Vmax of ethanol. 
PA166135949,rs12346562,1446902900,AA,Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.
PA166135949,rs12346562,1446902901,AC,Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.
PA166135949,rs12346562,1446902902,CC,Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.
PA166135950,rs12346562,1446902907,AA,Patients with the AA genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135950,rs12346562,1446902908,AC,Patients with the AC genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135950,rs12346562,1446902909,CC,Patients with the CC genotype may have increased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135137,rs12407843,1183616500,AA,Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135137,rs12407843,1183616501,AG,Patients with the AG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135137,rs12407843,1183616502,GG,Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166159199,rs12364283,1448103884,AA,"Patients with the AA genotype who are given amphetamine may have decreased stop reaction time, or reduced impulsivity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence stop reaction time."
PA166159199,rs12364283,1448103885,AG,"Patients with the AG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time."
PA166159199,rs12364283,1448103886,GG,"Patients with the GG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time."
PA166135078,rs12415607,1183614736,AA,"Patients with the AA genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
PA166135078,rs12415607,1183614737,AC,"Patients with the AC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
PA166135078,rs12415607,1183614738,CC,"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the AA or AC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
PA166134331,rs12418,655386192,AA,Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134331,rs12418,655386193,AG,Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134331,rs12418,655386194,GG,Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166136515,rs12467557,1447945987,AA,Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment. 
PA166136515,rs12467557,1447945988,AG,Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment. 
PA166136515,rs12467557,1447945989,GG,Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment. 
PA166161146,rs12436663,1448423438,AA,Patients with the AA genotype and asthma may have a poorer response when treated with zileuton as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
PA166161146,rs12436663,1448423439,AG,Patients with the AG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
PA166161146,rs12436663,1448423440,GG,Patients with the GG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
PA166134241,rs12422149,1183703015,AA,No AA genotype carrier was found in the study. But patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
PA166134241,rs12422149,1183703016,AG,Patients with the AG genotype and asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
PA166134241,rs12422149,1183703017,GG,Patients with the GG genotype and Asthma treated with montelukast may have   higher plasma concentration of montelukast and better response to montelukast compared to patients with the GA genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
PA166136402,rs12505746,1445594354,AA,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136402,rs12505746,1445594355,AG,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136402,rs12505746,1445594356,GG,"Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166136229,rs12505410,1444673381,GG,Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib. 
PA166136229,rs12505410,1444673382,GT,Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib. 
PA166136229,rs12505410,1444673383,TT,Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib. 
PA166134875,rs12487736,1043880429,CC,Patients with the CC genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134875,rs12487736,1043880428,CT,Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134875,rs12487736,1043880427,TT,Patients with the TT genotype and Hypercholesterolemia may have a reduced response to simvastatin treatment as compared to patients with the the CT or CC  genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134876,rs12487736,1043880436,CC,Patients with the CC genotype who are treated with atorvastatin may have higher  expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134876,rs12487736,1043880435,CT,Patients with the CT genotype who are treated with atorvastatin may have higher  expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134876,rs12487736,1043880434,TT,Patients with the TT genotype who are treated with atorvastatin may have reduced expression of SCAP as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.  
PA166136060,rs12595985,1184987057,AA,Patients with genotype AA and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166136060,rs12595985,1184987058,AC,Patients with genotype AC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the  AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166136060,rs12595985,1184987059,CC,Patients with genotype CC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the  AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166162372,rs12566888,1448531859,GT,Patients with the GT genotype may have higher maximal platelet aggregation than patients with the TT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor. 
PA166162372,rs12566888,1448531860,TT,Patients with the TT genotype may have lower maximal platelet aggregation than patients with the GT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor. 
PA166134637,rs121434568,1446908536,GG,"Patients with an activating somatic EGFR mutation are presented in this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with erlotinib vs standard chemotherapy. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. "
PA166134637,rs121434568,1446908537,GT,"Patients with an activating somatic EGFR mutation are presented in this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with erlotinib vs standard chemotherapy. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. "
PA166134637,rs121434568,1446908538,TT,"Patients who have no activating somatic EGFR mutation were NOT included in these studies where this annotation is derived from. In this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients who have somatic mutation. Genotypes are not compared in this annotation."
PA166134633,rs121434568,1447961203,GG,"Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome. "
PA166134633,rs121434568,1447961204,GT,"Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome. "
PA166134633,rs121434568,1447961205,TT,"Patients without an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely have decreased response rate (RR) and decreased progression-free survival (PFS) time compared to patients who have activating somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568. Patients who have no mutation are presented here as TT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome."
PA166134635,rs121434568,1447961232,GG,"Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.





"
PA166134635,rs121434568,1447961233,GT,"Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome."
PA166134635,rs121434568,1447961234,TT,"Patients without an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have decreased response rate (RR) and decreased progression-free survival (PFS) time compared to patients who have activating somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568. Patients who have no mutation are presented here as TT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome."
PA166134636,rs121434568,982045115,GG,"Patients with an activating somatic EGFR mutation are presented in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time and increased response rate (RR) when treated with gefitinib vs paclitaxel plus carboplatin. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. "
PA166134636,rs121434568,982045116,GT,"Patients with an activating somatic EGFR mutation are presented in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time and increased response rate (RR) when treated with gefitinib vs paclitaxel plus carboplatin. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. "
PA166134636,rs121434568,982045117,TT,Patients who have no activating somatic EGFR mutation were NOT included in these studies where this annotation is derived from. In this annotation and effects of gefitinib vs vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. Genotypes are not compared in this annotation.
PA166153009,rs12507552,1447981492,CC,Patients with the CC genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166153009,rs12507552,1447981493,CT,Patients with the CT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166153009,rs12507552,1447981494,TT,Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166159993,rs12621220,1448256892,CC,Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166159993,rs12621220,1448256893,CT,Patients with the CT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166159993,rs12621220,1448256894,TT,Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166151930,rs1264457,1447952833,AA,"Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
PA166151930,rs1264457,1447952834,AG,"Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
PA166151930,rs1264457,1447952835,GG,"Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
PA166135381,rs1265138,1183700244,AA,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to first remission induction therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135381,rs1265138,1183700245,AG,Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135381,rs1265138,1183700246,GG,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166136447,rs12461964,1446903565,AA,"Individuals who smoke and have the AA genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the AG or GG genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
PA166136447,rs12461964,1446903566,AG,"Individuals who smoke and have the AG genotype may have decreased rates of nicotine clearance, and as a consequence may smoke less when compared to individuals who smoke and have the GG genotypes, and increased rates of metabolism as compared to patients with the AA genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
PA166136447,rs12461964,1446903567,GG,"Individuals who smoke and have the GG genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the AG or AA genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
PA166158918,rs12613732,1448102910,GG,"Patients with the GG genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy."
PA166158918,rs12613732,1448102911,GT,"Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy."
PA166158918,rs12613732,1448102912,TT,"Patients with the TT genotype and hepatocellular carcinoma may have a poorer response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy."
PA166135001,rs12654264,1183533593,AA,Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. 
PA166135001,rs12654264,1183533594,AT,Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. 
PA166135001,rs12654264,1183533595,TT,Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. 
PA166152717,rs1265112,1447960733,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152717,rs1265112,1447960734,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152717,rs1265112,1447960735,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166135235,rs12659,1183630287,AA,"Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment. "
PA166135235,rs12659,1183630288,AG,"Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment. "
PA166135235,rs12659,1183630289,GG,"Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment. "
PA166162361,rs12720066,1448531641,AA,Patients with the AA genotype and colorectal neoplasms maybe have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
PA166162361,rs12720066,1448531642,AC,Patients with the AC genotype and colorectal neoplasms maybe have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
PA166162361,rs12720066,1448531643,CC,Patients with the CC genotype and colorectal neoplasms maybe have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
PA166152836,rs12718541,1447963606,AA,Patients with the AA genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
PA166152836,rs12718541,1447963607,AG,"Patients with the AG genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction."
PA166152836,rs12718541,1447963608,GG,Patients with the GG genotype who smoke tobacco may have a decreased risk of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
PA166135766,rs12708954,1444703095,AA,"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine."
PA166135766,rs12708954,1444703096,AC,"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.. "
PA166135766,rs12708954,1444703097,CC,"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine."
PA166134487,rs12714145,1448615813,CC,"Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain."
PA166134487,rs12714145,1448615814,CT,"Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain."
PA166134487,rs12714145,1448615815,TT,"Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain."
PA166135178,rs12720067,1183619318,CC,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135178,rs12720067,1183619319,CT,"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135178,rs12720067,1183619320,TT,"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166134362,rs12248560,1448102392,CC,"Patients with the CC genotype (*1/*1): 1) may have decreased activation of clopidogrel 2) may have a decreased, but not absent, risk for bleeding with clopidogrel as compared to patients with the CT or TT genotype 3) may have an increased risk for adverse cardiovascular events as compared to patients with a CT or TT genotype. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events."
PA166134362,rs12248560,1448102393,CT,"Patients with the CT (*1/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with the CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *1/*17 genotype as of yet. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events."
PA166134362,rs12248560,1448102394,TT,"Patients with the TT (*17/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with a CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *17/*17 genotype as of yet. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events."
PA166134388,rs12248560,982030635,CC,"Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles  *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134388,rs12248560,982030636,CT,"Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134388,rs12248560,982030637,TT,"Patients with the TT genotype who are treated with escitalopram may require an increased dose as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134389,rs12248560,655387768,CC,"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134389,rs12248560,655387769,CT,"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166134389,rs12248560,655387770,TT,"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
PA166135144,rs12248560,1183631927,CC,"Patients with the CC genotype (CYP2C19*1/*1) and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the CT or TT genotype (CYP2C19*1/*17 or *17/*17). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. "
PA166135144,rs12248560,1183631928,CT,"Patients with the CT genotype (CYP2C19*1/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. "
PA166135144,rs12248560,1183631929,TT,"Patients with the TT genotype (CYP2C19*17/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. "
PA166135744,rs12248560,1444700792,CC,"Patients with the CC genotype and acute coronary syndrome who are treated with prasugrel may have an decreased, but not absent, risk for bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding."
PA166135744,rs12248560,1444700791,CT,Patients with the CT genotype and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
PA166135744,rs12248560,1444700790,TT,Patients with the TT genotype and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
PA166134746,rs12248560,1448260921,CC,"Patients with the CC genotype may have decreased metabolism of amitriptyline as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.  "
PA166134746,rs12248560,1448260922,TC,"Patients with the TC genotype may have decreased metabolism of amitriptyline as compared to patients with the TT genotype or may have increased metabolism of amitriptyline as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. "
PA166134746,rs12248560,1448260923,TT,"Patients with the TT genotype may have increased metabolism of amitriptyline levels as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. "
PA166134816,rs12248560,1444701085,CC,"Patients with the CC genotype may have decreased metabolism of citalopram or escitalopram as compared to patients with the TT or CT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's citalopram or escitalopram metabolism. "
PA166134816,rs12248560,1444701086,CT,"Patients with the CT genotype (CYP2C19*1/*17) may have an increased metabolism of citalopram or escitalopram as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's citalopram or escitalopram metabolism. "
PA166134816,rs12248560,1444701087,TT,"Patients with the TT genotype (CYP2C19*17/*17) may have an increased metabolism of citalopram or escitalopram as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's citalopram or escitalopram metabolism. "
PA166136234,rs12248560,1444686773,CC,"Patients with the CC genotype (CYP2C19 *1/*1) undergoing transplantation may have decreased metabolism of busulfan as compared to patients with the CT (*1/*17) or TT (*17/*17) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan."
PA166136234,rs12248560,1444686774,CT,"Patients with the CT (CYP2C19 *1/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan."
PA166136234,rs12248560,1444686775,TT,"Patients with the TT (CYP2C19 *17/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan."
PA166134923,rs12721226,1143918645,AA,Patients with the AA genotype may have a decreased affinity to losartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to losartan.
PA166134923,rs12721226,1143918648,AG,The AG genotype was not studied in association with affinity to losartan.
PA166134923,rs12721226,1143918651,GG,Patients with the GG genotype may have an increased affinity to losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to losartan.
PA166134134,rs12721627,655384594,CC,Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.
PA166134134,rs12721627,655384595,CG,Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.
PA166134134,rs12721627,655384596,GG,Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.
PA166134290,rs12721627,982035393,CC,The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.
PA166134290,rs12721627,982035394,CG,"While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is."
PA166134290,rs12721627,982035395,GG,The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.
PA166134861,rs12720462,1043880304,AA,Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166134861,rs12720462,1043880305,AC,Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166134861,rs12720462,1043880306,CC,Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166135651,rs12721646,1448107215,CC,Patients with the CC genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
PA166135651,rs12721646,1448107216,TC,Patients with the TC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
PA166135651,rs12721646,1448107217,TT,Patients with the TT genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
PA166136475,rs12746200,1446908676,AA,"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
PA166136475,rs12746200,1446908675,AG,"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
PA166136475,rs12746200,1446908674,GG,"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
PA166134860,rs12721655,1043880301,AA,"Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution ""the relevance of these data is uncertain, given the low number of rare alleles"". Other clinical or genetic factors may also influence a patient's response."
PA166134860,rs12721655,1043880300,AG,"Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution ""the relevance of these data is uncertain, given the low number of rare alleles"". Other clinical or genetic factors may also influence a patient's response."
PA166134860,rs12721655,1043880299,GG,"Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution ""the relevance of these data is uncertain, given the low number of rare alleles"". Other clinical or genetic factors may also influence a patient's response."
PA166136117,rs12762549,1444607701,CC,Patients with the CC genotype who are treated with docetaxel may have an increased clearance and decreased risk of leukopenia as compared to patients with the GG genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
PA166136117,rs12762549,1444607700,CG,Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
PA166136117,rs12762549,1444607699,GG,Patients with the GG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
PA166134046,rs12720441,619523390,AA,Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134046,rs12720441,619523391,AG,Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134046,rs12720441,619523392,GG,Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134655,rs12777823,1447949441,AA,Patients with the AA genotype may require a lower dose of warfarin (may require a dose reduction of 934 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134655,rs12777823,1447949442,AG,Patients with the AG genotype may require a lower dose of warfarin (may require a dose reduction of 692 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134655,rs12777823,1447949443,GG,Patients with the GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166136284,rs12768009,1444700798,AA,Patients with the AA genotype and HIV who are treated with nevirapine  may have decreased clearance of nevirapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
PA166136284,rs12768009,1444700799,AG,Patients with the AG genotype and HIV who are treated with nevirapine  may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
PA166136284,rs12768009,1444700800,GG,Patients with the GG genotype and HIV who are treated with nevirapine  may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
PA166134839,rs12795437,1043873024,CC,Patients with the CC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
PA166134839,rs12795437,1043873025,CG,Patients with the CG genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
PA166134839,rs12795437,1043873026,GG,Patients with the GG genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CC genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
PA166136513,rs12817819,1447945960,CC,Patients with the CC genotype who are treated with antihypertensives may have a lower risk for resistant hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension. 
PA166136513,rs12817819,1447945961,CT,Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension. 
PA166136513,rs12817819,1447945962,TT,Patients with the TT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension. 
PA166135306,rs12819210,1183680573,CC,Patients with the CC genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
PA166135306,rs12819210,1183680572,CT,Patients with the CT genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
PA166135306,rs12819210,1183680571,TT,Patients with the TT genotype may have increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
PA166134837,rs12903202,1183679872,AA,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates. 
PA166134837,rs12903202,1183679873,AG,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates. 
PA166134837,rs12903202,1183679874,GG,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates. 
PA166136285,rs12806698,1444700810,AA,Patients with the AA genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
PA166136285,rs12806698,1444700811,AC,Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
PA166136285,rs12806698,1444700812,CC,Patients with the CC genotype who are treated gemcitabine and platinum compounds may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
PA166153448,rs12806698,1447990226,AA,"Patients with the AA genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in one study. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer. "
PA166153448,rs12806698,1447990227,AC,"Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in one study. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer. "
PA166153448,rs12806698,1447990228,CC,"Patients with the CC genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in one study. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer. "
PA166135677,rs12819505,1444666676,AA,Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135677,rs12819505,1444666677,AG,Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135677,rs12819505,1444666678,GG,Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135303,rs12946454,1184514151,AA,Patients with the AA genotype may have decreased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem. 
PA166135303,rs12946454,1184514150,AT,Patients with the AT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem. 
PA166135303,rs12946454,1184514149,TT,Patients with the TT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem. 
PA166134838,rs12800734,1043873021,AA,Patients with the AA genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
PA166134838,rs12800734,1043873020,AG,Patients with the AG genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
PA166134838,rs12800734,1043873019,GG,Patients with the GG genotype may have increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with AA or AG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
PA166136023,rs1295686,1447946100,CC,"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine. "
PA166136023,rs1295686,1447946101,CT,"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine. "
PA166136023,rs1295686,1447946102,TT,"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine. "
PA166135060,rs12948783,1183614548,AA,Patients with the AA genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.
PA166135060,rs12948783,1183614549,AG,Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.
PA166135060,rs12948783,1183614550,GG,Patients with the GG genotype may have better pain relief to opioids in cancer patients as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to opioids.
PA166135304,rs12943590,1183680561,AA,"Patients with the AA genotype may have 1) decreased response to metformin in people with Diabetes Mellitus, 2)  increased renal and secretory clearance of metformin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin. "
PA166135304,rs12943590,1183680562,AG,"Patients with the AG genotype may have 1) increased response to metformin in people with Diabetes Mellitus, 2)  decreased renal and secretory clearance of metformin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin. "
PA166135304,rs12943590,1183680563,GG,"Patients with the GG genotype may have 1) increased response to metformin in people with Diabetes Mellitus, 2)  decreased renal and secretory clearance of metformin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin. "
PA166135305,rs12943590,1448594871,AA,"Individuals with the AA genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin. "
PA166135305,rs12943590,1448594872,AG,"Individuals with the AG genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin. "
PA166135305,rs12943590,1448594873,GG,"Individuals with the GG genotype may have decreased renal and secretory clearance of metformin as compared to individuals with the AA genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin. "
PA166134840,rs12782374,1043873033,AA,Patients with the AA genotype may require decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.
PA166134840,rs12782374,1043873034,AG,"Patients with the AG genotype may 1) require decreased dose of phenytoin, 2) have increase metabolism of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin."
PA166134840,rs12782374,1043873035,GG,"Patients with the GG genotype may 1) require increased dose of phenytoin, 2) have decrease metabolism of phenytoin in people with Epilepsy as compared to patients with genotype AA or AG. Other clinical or genetic factors may also influence a patient's dose of phenytoin."
PA166134330,rs12960,655386187,AA,Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134330,rs12960,655386188,AG,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
PA166134330,rs12960,655386189,GG,Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
PA166136147,rs13104811,1444665941,AA,"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166136147,rs13104811,1444665942,AG,"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166136147,rs13104811,1444665943,GG,"Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166135871,rs12980275,1448105886,AA,"Patients with the AA genotype may have increased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy. "
PA166135871,rs12980275,1448105887,AG,"Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy. "
PA166135871,rs12980275,1448105888,GG,"Patients with the GG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy. "
PA166152719,rs130072,1447960747,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152719,rs130072,1447960748,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152719,rs130072,1447960749,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166136287,rs13064411,1444700826,AA,Patients with the AA genotype may have increased response to hmg coa reductase inhibitors as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166136287,rs13064411,1444700825,AG,Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166136287,rs13064411,1444700824,GG,Patients with the GG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166163508,rs13144136,1448612778,GG,Patients with the GG genotype and hypertension may have an increased response to antihypertensives compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect response to antihypertensive therapy.
PA166163508,rs13144136,1448612779,GT,Patients with the GT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.
PA166163508,rs13144136,1448612780,TT,Patients with the TT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.
PA166135207,rs130058,1183624422,AA,"Patients with the AA genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation. "
PA166135207,rs130058,1183624423,AT,"Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation. "
PA166135207,rs130058,1183624424,TT,"Patients with the TT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation. "
PA166135147,rs130058,1183617566,AA,Patients with the AA genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation. 
PA166135147,rs130058,1183617567,AT,Patients with the AT genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype or may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation. 
PA166135147,rs130058,1183617568,TT,Patients with the TT genotype and depression who are treated with paroxetine may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation. 
PA166136227,rs13207351,1444673204,AA,Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136227,rs13207351,1444673205,AG,Patients with the AG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136227,rs13207351,1444673206,GG,Patients with the GG genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135538,rs13242038,1184514465,CC,Patients with the CC genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence. 
PA166135538,rs13242038,1184514466,CT,Patients with the CT genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence. 
PA166135538,rs13242038,1184514467,TT,Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence. 
PA166136230,rs13120400,1444673393,CC,Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
PA166136230,rs13120400,1444673394,CT,Patients with the CT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
PA166136230,rs13120400,1444673395,TT,Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to imatinib.
PA166134253,rs13120400,655385288,CC,Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134253,rs13120400,655385289,CT,Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134253,rs13120400,655385290,TT,Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166159061,rs13120400,1448101438,CC,"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have an improved response to, and increased concentrations of deferasirox as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia."
PA166159061,rs13120400,1448101439,CT,"Patients with the CT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to, and decreased concentrations of deferasirox as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia."
PA166159061,rs13120400,1448101440,TT,"Patients with the TT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to, and decreased concentrations of deferasirox as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia."
PA166136012,rs13250975,1447943762,AA,Patients with AA genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AG and GG genotype. Other clinical and genetic factors may affect response to antipsychotics.
PA166136012,rs13250975,1447943763,AG,Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.
PA166136012,rs13250975,1447943764,GG,Patients with GG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.
PA166135893,rs13253389,1445401188,AA,Patients with the AA genotype may have decreased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
PA166135893,rs13253389,1445401189,AG,Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
PA166135893,rs13253389,1445401190,GG,Patients with the GG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
PA166135392,rs13273672,1183700494,CC,Patients with the CC genotype may have decreased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
PA166135392,rs13273672,1183700495,CT,Patients with the CT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
PA166135392,rs13273672,1183700496,TT,Patients with the TT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
PA166134297,rs13058338,1448099374,AA,"Cancer patients with the AA genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166134297,rs13058338,1448099375,AT,Cancer patients with the AT genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166134297,rs13058338,1448099376,TT,Cancer patients with the TT genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166135300,rs13306278,1448105734,CC,Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135300,rs13306278,1448105735,CT,Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135300,rs13306278,1448105736,TT,Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166159662,rs1330344,1448124220,CC,Patients with the CC genotype may have decreased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166159662,rs1330344,1448124219,CT,Patients with the CT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166159662,rs1330344,1448124218,TT,Patients with the TT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166161294,rs1334802,1448428110,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms. "
PA166161294,rs1334802,1448428111,CT,Patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms. 
PA166161294,rs1334802,1448428112,TT,Patients with the TT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms. 
PA166134020,rs13429709,1184348868,CC,Patients with the CC genotype and Schizophrenia who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the CT or TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics. 
PA166134020,rs13429709,1184348869,CT,Patients with the CT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype or may have greater weight gain as compared to patients with the TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics. 
PA166134020,rs13429709,1184348870,TT,Patients with the TT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics. 
PA166151973,rs13431554,1447954529,AA,"Patients with the AA genotype may have lower platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the efficacy of clopidogrel."
PA166151973,rs13431554,1447954528,AG,"Patients with the AG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel."
PA166151973,rs13431554,1447954527,GG,"Patients with the GG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel."
PA166135074,rs1344706,1183630579,AA,Patients with the AA genotype and schizophrenia may have a poorer response when treated with antipsychotics as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antipsychotics. 
PA166135074,rs1344706,1183630580,AC,Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics. 
PA166135074,rs1344706,1183630581,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics. 
PA166135076,rs13432159,1183619609,GG,Patients with the GG genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline. 
PA166135076,rs13432159,1183619610,GT,"Patients with the GT genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype, or a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline. "
PA166135076,rs13432159,1183619611,TT,Patients with the TT genotype and major depressive disorder may experience a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline. 
PA166135301,rs13266634,1183680534,CC,"Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
PA166135301,rs13266634,1183680533,CT,"Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
PA166135301,rs13266634,1183680532,TT,"Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
PA166136207,rs13266634,1444668484,CC,Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate. 
PA166136207,rs13266634,1444668485,CT,Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate. 
PA166136207,rs13266634,1444668486,TT,Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate. 
PA166136145,rs1353295,1444608493,AA,"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment. "
PA166136145,rs1353295,1444608494,AG,"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment. "
PA166136145,rs1353295,1444608495,GG,"Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment. "
PA166152880,rs1355368,1447964280,AA,Patients with the AA genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152880,rs1355368,1447964281,AG,Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152880,rs1355368,1447964282,GG,Patients with the GG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166136288,rs1353411,1444700834,AA,"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166136288,rs1353411,1444700833,AG,"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166136288,rs1353411,1444700832,GG,Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134834,rs135543,1043873000,CC,Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
PA166134834,rs135543,1043873001,CT,Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
PA166134834,rs135543,1043872999,TT,Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
PA166135299,rs13306673,1183680522,CC,Patients with the CC genotype may have increased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to  patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
PA166135299,rs13306673,1183680523,CT,Patients with the CT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to  patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
PA166135299,rs13306673,1183680524,TT,Patients with the TT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to  patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
PA166134835,rs135550,1043873006,CC,Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
PA166134835,rs135550,1043873005,CT,Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
PA166134835,rs135550,1043873004,TT,Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
PA166135277,rs1346268,1183679140,CC,Patients with the CC genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
PA166135277,rs1346268,1183679141,CT,"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."
PA166135277,rs1346268,1183679142,TT,Patients with the TT genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
PA166158976,rs13393173,1448100459,AA,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
PA166158976,rs13393173,1448100460,AG,"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared with patients with genotype GG, or more likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response."
PA166158976,rs13393173,1448100461,GG,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
PA166136416,rs1364805,1446897504,GG,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
PA166136416,rs1364805,1446897505,GT,Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotypes and an increased response as compared to patients with a GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
PA166136416,rs1364805,1446897506,TT,Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GG and GT genotypes genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
PA166134836,rs1364043,1043873011,GG,"Patients with the GG genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine."
PA166134836,rs1364043,1043873010,GT,"Patients with the GT genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine."
PA166134836,rs1364043,1043873009,TT,"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine."
PA166136013,rs1367094,1447943774,CC,Patients with genotype CC and hypertension have increased response to atenolol compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect patient response to atenolol. 
PA166136013,rs1367094,1447943775,CT,Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol. 
PA166136013,rs1367094,1447943776,TT,Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol. 
PA166134337,rs1382368,655386325,CC,Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134337,rs1382368,655386326,CT,"Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance."
PA166134337,rs1382368,655386327,TT,Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166136511,rs138335,1447944808,CC,Patients with the CC genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
PA166136511,rs138335,1447944809,CG,Patients with the CG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
PA166136511,rs138335,1447944810,GG,Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
PA166134348,rs13181,655386617,GG,Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.
PA166134348,rs13181,655386618,GT,Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.
PA166134348,rs13181,655386619,TT,Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.
PA166134590,rs13181,981237960,GG,"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin."
PA166134590,rs13181,981237961,GT,"Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin."
PA166134590,rs13181,981237962,TT,"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin."
PA166136384,rs13181,1448263867,GG,"Patients with the GG genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia."
PA166136384,rs13181,1448263868,GT,"Patients with the GT genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia."
PA166136384,rs13181,1448263869,TT,"Patients with the TT genotype and breast cancer may have an increased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for neutropenia."
PA166136168,rs13181,1444666624,GG,Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
PA166136168,rs13181,1444666625,GT,Patients with the GT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
PA166136168,rs13181,1444666626,TT,Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
PA166153038,rs138417770,1447982815,CC,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153038,rs138417770,1447982814,CT,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153038,rs138417770,1447982813,TT,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166135302,rs12979860,1448105740,CC,"Patients with the CC genotype may have better response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135302,rs12979860,1448105741,CT,"Patients with the CT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135302,rs12979860,1448105742,TT,"Patients with the TT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134444,rs12979860,1448107058,CC,"Patients with the CC genotype and Hepatitis C genotype 1 may have increased response (sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have higher spontaneous clearance in acute HCV infections than patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to peg interferon and ribavirin."
PA166134444,rs12979860,1448107059,CT,"Patients with the CT genotype and Hepatitis C genotype 1 may have decreased response (sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to peg interferon and ribavirin."
PA166134444,rs12979860,1448107060,TT,"Patients with the TT genotype and Hepatitis C genotype 1 may have decreased response (sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to peg interferon and ribavirin."
PA166135481,rs12979860,1448105801,CC,"Patients with the CC genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CT or TT genotype. Patients with the CC genotype may also more likely to be eligible for shortened therapy (24 weeks instead of standard 48 weeks). The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy."
PA166135481,rs12979860,1448105802,CT,"Patients with the CT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy."
PA166135481,rs12979860,1448105803,TT,"Patients with the TT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy."
PA166136349,rs12979860,1444876861,CC,Patients with the CC genotype may have increased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
PA166136349,rs12979860,1444876862,CT,Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
PA166136349,rs12979860,1444876863,TT,Patients with the TT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
PA166135872,rs12979860,1444930644,CC,Patients with genotype CC may have increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
PA166135872,rs12979860,1444930645,CT,Patients with genotype CT may have decreased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
PA166135872,rs12979860,1444930646,TT,Patients with genotype TT may have decreased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
PA166135873,rs12979860,1444930910,CC,"Patients with genotype CC may have increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all IL28B genotypes (CC, CT, or TT) regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
PA166135873,rs12979860,1444930911,CT,"Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all IL28B genotypes (CC, CT, or TT) regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
PA166135873,rs12979860,1444930912,TT,"Patients with genotype TT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all IL28B genotypes (CC, CT, or TT) regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
PA166136350,rs12979860,1444930852,CC,"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for each of the CC, CT, and TT genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
PA166136350,rs12979860,1444930853,CT,"Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for each of the CC, CT, and TT genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
PA166136350,rs12979860,1444930854,TT,"Patients with TT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for each of the CC, CT, and TT genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
PA166162412,rs12979860,1448532317,CC,"Patients with genotype CC may have decreased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype TT. Other genetic and clinical factors may also influences response to  ledipasvir/sofosbuvir therapy."
PA166162412,rs12979860,1448532316,CT,"Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to  ledipasvir/sofosbuvir therapy."
PA166162412,rs12979860,1448532315,TT,"Patients with genotype TT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to  ledipasvir/sofosbuvir therapy."
PA166134263,rs1367117,655385371,AA,Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166134263,rs1367117,655385372,AG,Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166134263,rs1367117,655385373,GG,Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166135249,rs139887,1183631560,CC,"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135249,rs139887,1183631561,CG,"Patients with the CG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135249,rs139887,1183631562,GG,"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135746,rs140471703,1444700849,CC,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135746,rs140471703,1444700848,CT,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135746,rs140471703,1444700847,TT,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166153057,rs1409314,1448106545,AA,"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153057,rs1409314,1448106546,AG,"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153057,rs1409314,1448106547,GG,"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166134329,rs1402467,655386182,CC,Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134329,rs1402467,655386183,CG,Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166134329,rs1402467,655386184,GG,Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166158975,rs1415744,1448100391,CC,"Patients with the CC genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CT and TT genotypes. Other factors may affect response to these drugs."
PA166158975,rs1415744,1448100392,CT,"Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs."
PA166158975,rs1415744,1448100393,TT,"Patients with the TT genotype and schizophrenia may have decreased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CC and CT genotypes. Other factors may affect response to these drugs."
PA166135103,rs1414334,1183615138,CC,Women with the CC genotype and mental disorders (excluding schizophrenia) may have smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.
PA166135103,rs1414334,1183615137,CG,"Women with the CG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype, or smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain."
PA166135103,rs1414334,1183615136,GG,Women with the GG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype. Other genetic and clinical factors may also influence weight gain.
PA166134285,rs1414334,1446906313,CC,Patients with the CC genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
PA166134285,rs1414334,1446906314,CG,Patients with the CG genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
PA166134285,rs1414334,1446906315,GG,"Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome."
PA166158882,rs141059755,1448106435,AA,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166158882,rs141059755,1448106436,AG,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166158882,rs141059755,1448106437,GG,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166135073,rs1417938,1183614707,AA,Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135073,rs1417938,1183614708,AT,Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135073,rs1417938,1183614709,TT,Patients with the TT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135862,rs1387923,1448107354,AA,Patients with the AA genotype and Bipolar disorder may have increased response to lithium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166135862,rs1387923,1448107355,AG,Patients with the AG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166135862,rs1387923,1448107356,GG,Patients with the GG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166159242,rs14158,1448104138,AA,"Patients with the AA genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response. "
PA166159242,rs14158,1448104139,AG,"Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response. "
PA166159242,rs14158,1448104140,GG,"Patients with the GG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have an increased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response. "
PA166136015,rs138337,1447944815,AA,Patients with the AA genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
PA166136015,rs138337,1447944816,AG,Patients with the AG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
PA166136015,rs138337,1447944817,GG,Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
PA166152756,rs1419555,1447961124,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152756,rs1419555,1447961125,CT,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152756,rs1419555,1447961126,TT,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166135346,rs1429376,1183693439,AA,Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135346,rs1429376,1183693440,AC,Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135346,rs1429376,1183693441,CC,Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166134129,rs1360780,1446908909,CC,"Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased, but not absent, risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134129,rs1360780,1446908910,CT,"Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134129,rs1360780,1446908911,TT,"Patients with the TT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134596,rs1360780,1183629912,CC,"Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone."
PA166134596,rs1360780,1183629913,CT,"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone."
PA166134596,rs1360780,1183629914,TT,"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone."
PA166135732,rs1360780,1444700386,CC,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135732,rs1360780,1444700385,CT,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135732,rs1360780,1444700384,TT,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135298,rs1423515,1183680517,AA,Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
PA166135298,rs1423515,1183680518,AG,Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
PA166135298,rs1423515,1183680519,GG,Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
PA166158956,rs1433099,1448100231,CC,Patients with the CC genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pravastatin response. 
PA166158956,rs1433099,1448100232,CT,"Patients with the CT genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response. "
PA166158956,rs1433099,1448100233,TT,Patients with the TT genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response. 
PA166152638,rs1448673,1447959728,AA,Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152638,rs1448673,1447959727,AG,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype, or a decreased response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152638,rs1448673,1447959726,GG,Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166135747,rs143690364,1444700857,CC,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135747,rs143690364,1444700856,CT,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135747,rs143690364,1444700855,TT,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166136225,rs144854329,1444673181,GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA,Patients with the GGTC.../GGTC... genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136225,rs144854329,1444673180,GGTCCCACTCTTCCCACA/del,Current literature evidence finds no significant effect of the GGTC.../del genotype on progression-free survival time in patients taking docetaxel.
PA166136225,rs144854329,1444673179,del/del,Patients with the del/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GGTC.../GGTC... genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166161281,rs1439050,1448427974,GG,Patients with the GG genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
PA166161281,rs1439050,1448427975,GT,Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
PA166161281,rs1439050,1448427976,TT,Patients with the TT genotype and depression may have decreased risk of suicidal thoughts when taking antidepressants compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
PA166136434,rs145489027,1446899731,AA,Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166136434,rs145489027,1446899732,AG,Patients with the AG genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the GG genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166136434,rs145489027,1446899733,GG,Patients with the GG genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166136514,rs1468412,1447945980,AA,"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory. "
PA166136514,rs1468412,1447945981,AT,"Patients with the AT genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory. "
PA166136514,rs1468412,1447945982,TT,Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have an increased risk for worsening of working memory as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory. 
PA166136016,rs1449683,1447944821,CC,Patients with the CC genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
PA166136016,rs1449683,1447944822,CT,Patients with the CT genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
PA166136016,rs1449683,1447944823,TT,Patients with the TT genotype and depressive disorder may have an increased response to fluvoxamine compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
PA166136027,rs1476413,1184748870,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136027,rs1476413,1184748871,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136027,rs1476413,1184748872,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134239,rs1487278,982030522,CC,"Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)"
PA166134239,rs1487278,982030523,CT,Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.
PA166134239,rs1487278,982030524,TT,Patients with the TT genotype may be less likely to respond to antidepressant treatments as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.
PA166159208,rs1470579,1448103975,AA,Patients with the AA genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166159208,rs1470579,1448103976,AC,Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166159208,rs1470579,1448103977,CC,Patients with the CC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166162393,rs149104283,1448532006,CC,Patients with the CC genotype may have decreased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to clozapine.
PA166162393,rs149104283,1448532005,CT,Patients with the CT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.
PA166162393,rs149104283,1448532004,TT,Patients with the TT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.
PA166134699,rs1491850,982032307,CC,Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134699,rs1491850,982032308,CT,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134699,rs1491850,982032309,TT,Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166135695,rs149711321,1444668308,CC,"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166135695,rs149711321,1444668309,CT,"In healthy volunteers as well as patients with diabetes mellitus the CT genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the TT genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
"
PA166135695,rs149711321,1444668310,TT,"In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166136286,rs1495741,1444700817,AA,"Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease, abnormal liver-function tests and decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease. "
PA166136286,rs1495741,1444700819,AG ,"Patients with the AG genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease, abnormal liver-function tests and decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with GG genotype or may have decreased risk for toxic liver disease, abnormal liver-function tests and increased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease. "
PA166136286,rs1495741,1444700818,GG,"Patients with the GG genotype who are treated with drugs for treatment of tuberculosis may have decreased risk for toxic liver disease, abnormal liver-function tests and increased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease. "
PA166135942,rs1495509,1446899738,CC,"Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
"
PA166135942,rs1495509,1446899739,CT,Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166135942,rs1495509,1446899740,TT,Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166135297,rs1517114,1183680512,CC,Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135297,rs1517114,1183680513,CG,Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135297,rs1517114,1183680514,GG,Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135296,rs1522113,1183680507,AA,Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
PA166135296,rs1522113,1183680508,AG,Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
PA166135296,rs1522113,1183680509,GG,Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
PA166135241,rs1523130,1183631463,CC,Patients with the CC genotype and dementia may have increased clearance of memantine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of memantine.
PA166135241,rs1523130,1183631461,CT,Patients with the CT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.
PA166135241,rs1523130,1183631462,TT,Patients with the TT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.
PA166160777,rs1523130,1448266415,CC,Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.
PA166160777,rs1523130,1448266416,CT,Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.
PA166160777,rs1523130,1448266417,TT,Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.
PA166158793,rs1536475,1448098356,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158793,rs1536475,1448098357,AG,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166135391,rs1532624,1183700489,AA,Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166135391,rs1532624,1183700490,AC,Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166135391,rs1532624,1183700491,CC,Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166134392,rs1544105,655387826,CC,Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134392,rs1544105,655387827,CT,Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134392,rs1544105,655387828,TT,Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166136210,rs1529927,1448106082,CC,Patients with the CC genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype. Other genetic and clinical factors may also influence response to loop diuretics. 
PA166136210,rs1529927,1448106083,CG,"Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics. "
PA166136210,rs1529927,1448106084,GG,Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics. 
PA166135071,rs153560,1183619590,AA,"Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. "
PA166135071,rs153560,1183619591,AG,"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. "
PA166135071,rs153560,1183619592,GG,"Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. "
PA166136017,rs1544938,1447944857,CC,Patients with the CC genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
PA166136017,rs1544938,1447944858,CG,Patients with the CG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
PA166136017,rs1544938,1447944859,GG,Patients with the GG genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the CC or CG genotypes. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
PA166160833,rs15524,1448266840,AA,Patients with the AA genotype and epilepsy may have increased concentrations of carbamazepine compared to patients with the AG and GG genotypes when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine. 
PA166160833,rs15524,1448266841,AG,Patients with the AG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine. 
PA166160833,rs15524,1448266842,GG,Patients with the GG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine. 
PA166135383,rs1561876,1183700256,AA,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135383,rs1561876,1183700255,AG,Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135383,rs1561876,1183700254,GG,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer response to treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166151815,rs1540339,1447949634,CC,Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
PA166151815,rs1540339,1447949635,CT,Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
PA166151815,rs1540339,1447949636,TT,Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
PA166135888,rs1563828,1448102817,AA,Patients with the AA genotype and breast cancer may have a better response when treated with docetaxel and epirubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
PA166135888,rs1563828,1448102818,AG,Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
PA166135888,rs1563828,1448102819,GG,Patients with the GG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
PA166136228,rs1570360,1445402445,AA,"Patients with the AA genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel."
PA166136228,rs1570360,1445402446,AG,"Patients with the AG genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel."
PA166136228,rs1570360,1445402447,GG,"Patients with the GG genotype and breast cancer may have a poorer response to docetaxel treatment as compared to patients with the AA or AG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel."
PA166135892,rs1570360,1448102835,AA,Patients with the AA genotype and prostate cancer may have shorter progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135892,rs1570360,1448102836,AG,Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135892,rs1570360,1448102837,GG,Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135999,rs1570360,1447814167,AA,"Patients with the AA genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166135999,rs1570360,1447814168,AG,"Patients with the AG genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166135999,rs1570360,1447814169,GG,"Patients with the GG genotype may have more favorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166135605,rs1611115,1184987585,CC,"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135605,rs1611115,1184987586,CT,"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135605,rs1611115,1184987587,TT,"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166136289,rs1611115,1444700878,CC,Patients with the CC genotype may have a decreased response to levodopa in people with cocaine-related disorders as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
PA166136289,rs1611115,1444700877,CT,Patients with the CT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
PA166136289,rs1611115,1444700876,TT,Patients with the TT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
PA166135880,rs1611115,1445400919,CC,Patients with the CC genotype who are alcohol-dependent may have a poorer response to treatment with naltrexone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to naltrexone. 
PA166135880,rs1611115,1445400920,CT,Patients with the CT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.
PA166135880,rs1611115,1445400921,TT,Patients with the TT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.
PA166135345,rs1594160,1183693434,AA,Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135345,rs1594160,1183693435,AC,Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166135345,rs1594160,1183693436,CC,Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
PA166134790,rs1613662,1043858676,AA ,Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134790,rs1613662,1043858677,AG,Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134790,rs1613662,1043858678,GG,"Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166135565,rs1643650,1184748890,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135565,rs1643650,1184748891,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135565,rs1643650,1184748892,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135682,rs1650697,1444666772,AA,Patients with the AA genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity. 
PA166135682,rs1650697,1444666773,AG,Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity. 
PA166135682,rs1650697,1444666774,GG,Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity. 
PA166136526,rs1650723,1447946228,CC,"Patients with the CC genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate."
PA166136526,rs1650723,1447946229,CT,"Patients with the CT genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype, or increased severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate."
PA166136526,rs1650723,1447946230,TT,"Patients with the TT genotype and osteosarcoma may have increased severity of mucositis when receiving methotrexate, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate."
PA166152758,rs1663330,1447961138,AA,Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152758,rs1663330,1447961139,AG,"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152758,rs1663330,1447961140,GG,Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152759,rs1663332,1447961146,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152759,rs1663332,1447961147,CT,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152759,rs1663332,1447961148,TT,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166135293,rs1678387,1183679866,CC,Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135293,rs1678387,1183679865,CT,Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135293,rs1678387,1183679864,TT,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166134471,rs151264360,1448423056,TTAAAG/TTAAAG,"Patients with the  TTAAAG/TTAAAG genotype who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity and may develop less severe oral mucositis as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity."
PA166134471,rs151264360,1448423057,TTAAAG/del,"Patients with the  TTAAAG/del genotype who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity and may develop less severe oral mucositis as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity."
PA166134471,rs151264360,1448423058,del/del,Patients with the del/del genotype who are treated with methotrexate may have an increased risk of hepatotoxicity and may develop more severe oral mucositis as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.
PA166134472,rs151264360,1448423050,TTAAAG/TTAAAG,Patients with the TTAAAG/TTAAAG genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the del/del genotype and the 3/3 genotype at rs151264360. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134472,rs151264360,1448423051,TTAAAG/del,Patients with the TTAAAG/del genotype and the 3/3 genotype at rs151264360 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAG/TTAAAG genotype. Patients with the TTAAAG/del genotype may have a lower response to treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134472,rs151264360,1448423052,del/del,Patients with the del/del genotype and the 3/3 genotype at rs151264360 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134497,rs151264360,1448568538,TTAAAG/TTAAAG,"Patients with the TTAAAG/TTAAAG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have decreased survival time, and decreased risk of toxicity, as compared to patients with the TTAAAG/del or del/del genotypes. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134497,rs151264360,1448568539,TTAAAG/del,"Patients with the TTAAAG/del genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have increased survival time as compared to those with the TTAAAG/TTAAAG genotyoe, and decreased risk of toxicity as compared to those with the del/del genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134497,rs151264360,1448568540,del/del,"Patients with the del/del genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have increased survival time, and increased risk of drug toxicity, as compared to patients with the TTAAAG/TTAAAG or TTAAAG/del genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134498,rs151264360,1448423070,TTAAAG/TTAAAG,Patients with the TTAAAG/TTAAAG genotype and Colorectal Cancer who are treated with fluorouracil-based adjuvant therapy may have a better response as compared to patients with the TTAAAG/del or del/del genotype who also have rs45445694 genotype 2R/2R. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134498,rs151264360,1448423071,TTAAAG/del,Patients with the TTAAAG/del genotype who also have rs45445694 genotype 2R/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134498,rs151264360,1448423072,del/del,Patients with the del/del genotype who also have rs45445694 genotype 2R/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166136370,rs151264360,1448106246,TTAAAG/TTAAAG,Patients with the TTAAAG/TTAAAG genotype and mesothelioma may have shorter progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAG/del or del/del genotype. Other genetic and clinical factors may also influence response to pemetrexed. 
PA166136370,rs151264360,1448106247,TTAAAG/del,Patients with the TTAAAG/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence response to pemetrexed. 
PA166136370,rs151264360,1448106248,del/del,Patients with the del/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence response to pemetrexed. 
PA166134271,rs165599,1448108785,AA,Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134271,rs165599,1448108786,AG,Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134271,rs165599,1448108787,GG,Patients with the GG genotype may have a decreased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134220,rs165599,655385074,AA,Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134220,rs165599,655385075,AG,Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134220,rs165599,655385076,GG,Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166136029,rs16853826,1184748880,AA,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
PA166136029,rs16853826,1184748881,AG,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
PA166136029,rs16853826,1184748882,GG,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
PA166134789,rs16851030,1448107080,CC,"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134789,rs16851030,1448107081,CT,"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134789,rs16851030,1448107082,TT,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166134395,rs167771,655387877,AA,Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134395,rs167771,655387878,AG,Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134395,rs167771,655387879,GG,Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166136433,rs16870989,1446899724,AA,Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and TT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166136433,rs16870989,1446899725,AT,Patients with the AT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166136433,rs16870989,1446899726,TT,Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166135206,rs167770,1183624334,AA,Patients with the AA genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166135206,rs167770,1183624335,AG,Patients with the AG genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166135206,rs167770,1183624336,GG,Patients with the GG genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166158944,rs16873129,1448106557,CC,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158944,rs16873129,1448106558,CT,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158944,rs16873129,1448106559,TT,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
PA166135722,rs1554973,1444687034,CC,Patients with the CC genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135722,rs1554973,1444687035,CT,Patients with the CT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135722,rs1554973,1444687036,TT,Patients with the TT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166152682,rs16886403,1447960373,CC,"Patients with the CC genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152682,rs16886403,1447960374,CT,"Patients with the CT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152682,rs16886403,1447960375,TT,"Patients with the TT genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166135750,rs16947,1444700883,AA,Patients with the AA genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
PA166135750,rs16947,1444700884,AG,Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
PA166135750,rs16947,1444700885,GG,Patients with the GG genotype and open-angle glaucoma who are treated with timolol may have a decreased risk for bradycardia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
PA166152952,rs16909440,1447980726,CC,Patients with the CC genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment. 
PA166152952,rs16909440,1447980727,CT,"Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the TT genotype, and a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment. "
PA166152952,rs16909440,1447980728,TT,Patients with the TT genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to lithium treatment. 
PA166135292,rs16950650,1183679861,CC,Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.
PA166135292,rs16950650,1183679860,CT,Patients with the CT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.
PA166135292,rs16950650,1183679859,TT,Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.
PA166135259,rs16960228,1183634103,AA,Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135259,rs16960228,1183634104,AG,Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the GG genotype and decreased reduction of diastolic blood pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135259,rs16960228,1183634105,GG,Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166158798,rs16935279,1448098378,CC,Patients with the CC genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.
PA166158798,rs16935279,1448098379,CT,Patients with the CT genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.
PA166158798,rs16935279,1448098380,TT,Patients with the TT genotype and schizophrenia or psychotic disorder may have increased metabolism of antiepileptics compared to patients with the CC or CT genotype. Other factor may affect metabolism of antiepileptics.
PA166135070,rs16965962,1183630673,AA,Patients with the AA genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence general side-effect burden.
PA166135070,rs16965962,1183630674,AC,"Patients with the AC genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype, or a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden."
PA166135070,rs16965962,1183630675,CC,Patients with the CC genotype and major depressive disorder may have a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.
PA166134359,rs1544410,655386870,CC,Patients with the CC genotype who are treated with bisphosphonates may have greater improvement in bone mineral density as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bisphosphonates.
PA166134359,rs1544410,655386871,CT,The response of patients with the CT genotype who are treated with bisphosphonates is not clear compared to that of patients with the CC or the TT genotype.
PA166134359,rs1544410,655386872,TT,Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bisphosphonates.
PA166135749,rs1544410,1444700871,CC,"Patients with the CC genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
PA166135749,rs1544410,1444700870,CT,"Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
PA166135749,rs1544410,1444700869,TT,Patients with the TT genotype and Hepatitis C may have an increased risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
PA166159004,rs1544410,1448100779,CC,"Patients with the CC genotype may have increased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166159004,rs1544410,1448100780,CT,"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the TT genotype, and decreased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166159004,rs1544410,1448100781,TT,"Patients with the TT genotype may have decreased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166152781,rs1544410,1447962622,CC,Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence changes in bone mineral density. 
PA166152781,rs1544410,1447962623,CT,"Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density. "
PA166152781,rs1544410,1447962624,TT,Patients with the TT genotype may have a greater increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density. 
PA166158752,rs16973225,1448097824,AA,Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
PA166158752,rs16973225,1448097825,AC,Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
PA166158752,rs16973225,1448097826,CC,Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
PA166134909,rs16944,1444705346,AA,"Patients with the AA genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134909,rs16944,1444705347,AG,"Patients with the AG genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134909,rs16944,1444705348,GG,"Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166135294,rs16944,1183680430,AA,"Patients with the AA genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori."
PA166135294,rs16944,1183680431,AG,"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori."
PA166135294,rs16944,1183680432,GG,"Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori."
PA166134361,rs16944,655386889,AA,"Patients with the AA genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates."
PA166134361,rs16944,655386890,AG,"Patients with the AG genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates."
PA166134361,rs16944,655386891,GG,Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.
PA166135884,rs16944,1446897173,AA,Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166135884,rs16944,1446897174,AG,Patients with the AG genotype and schizophrenia may have higher weight gain when treated with antipsychotics as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166135884,rs16944,1446897175,GG,Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166158844,rs17021408,1448098795,CC,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients. "
PA166158844,rs17021408,1448098796,CT,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients. "
PA166158844,rs17021408,1448098797,TT,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients. "
PA166135767,rs1703794,1444703104,CC,Patients with the CC genotype and Rheumatoid Arthritis may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135767,rs1703794,1444703103,CT,Patients with the CT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype or may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135767,rs1703794,1444703102,TT,Patients with the TT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135291,rs17024608,1183679854,AA,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to  patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166135291,rs17024608,1183679855,AG,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to  patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166135291,rs17024608,1183679856,GG,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to  patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166135768,rs1705772,1444703109,AA,"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166135768,rs1705772,1444703110,AG,"Patients with the AG genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166135768,rs1705772,1444703111,GG,Patients with the GG genotype who are treated with gemcitabine may have an increased risk for toxicity as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135290,rs17060812,1183679849,CC,Patients with the CC genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
PA166135290,rs17060812,1183679850,CT,Patients with the CT genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
PA166135290,rs17060812,1183679851,TT,Patients with the TT genotype may have decreased response to nortriptyline in people with Depression as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
PA166152955,rs16973410,1447980755,CC,Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment. 
PA166152955,rs16973410,1447980756,CT,Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
PA166152955,rs16973410,1447980757,TT,Patients with the TT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
PA166135289,rs17091162,1183679846,AA,Patients with the AA genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AC or CC. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166135289,rs17091162,1183679845,AC,Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166135289,rs17091162,1183679844,CC,Patients with the CC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166136444,rs17109924,1446903312,CC,Patients with the CC genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil. 
PA166136444,rs17109924,1446903313,CT,Patients with the CT genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil. 
PA166136444,rs17109924,1446903314,TT,Patients with the TT genotype and colon cancer may have a shorter time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluorouracil. 
PA166135476,rs16964189,1183863782,CC,Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135476,rs16964189,1183863783,CT,Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135476,rs16964189,1183863781,TT,Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135069,rs17135437,1183614692,CC,Patients with the CC genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.
PA166135069,rs17135437,1183614693,CT,"Patients with the CT genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype, or increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence hearing and vision-related side-effects."
PA166135069,rs17135437,1183614694,TT,Patients with the TT genotype and major depressive disorder may have increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.
PA166160030,rs17126068,1448257267,AA,Patients with the AA genotype may require increased dose of warfarin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of warfarin.
PA166160030,rs17126068,1448257266,AG,Patients with the AG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
PA166160030,rs17126068,1448257265,GG,Patients with the GG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
PA166136394,rs17143212,1445402203,CC,Patients with the CC genotype and psychotic illnesses may be at a lower risk for haloperidol-induced toxicities as compared to patients with the CT genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
PA166136394,rs17143212,1445402204,CT,Patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
PA166136394,rs17143212,1445402205,TT,"No patients with the TT genotype were present, but patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities."
PA166135686,rs17160359,1444667317,GG,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166135686,rs17160359,1444667318,GT,"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model.
"
PA166135686,rs17160359,1444667319,TT,"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166134962,rs17161788,1183491190,CC,Patients with the CC genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134962,rs17161788,1183491191,CT,Patients with the CT genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134962,rs17161788,1183491192,TT,Patients with the TT genotype and Hypercholesterolemia may have a reduced response to atorvastatin treatment as compared to patients with the CT or CC  genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166159975,rs17180299,1448256736,AA,Patients with the AA genotype and heroin-dependence who are treated with methadone maintenance therapy may have decreased plasma concentrations of R-methadone compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect concentrations of R-methadone.
PA166159975,rs17180299,1448256737,AG,Patients with the AG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.
PA166159975,rs17180299,1448256738,GG,Patients with the GG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.
PA166136491,rs17179108,1447680047,CC,Patients with colorectal cancer and the CC genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the CT genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166136491,rs17179108,1447680048,CT,Patients with colorectal cancer and the CT genotype may have a better response to capecitabine or fluorouracil as compared to patients with the CC genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166134568,rs16969968,1448107595,AA,"Patients with AA genotype may have an increased likelihood of addiction to nicotine as compared to patients with the GG genotype. No significant results have been seen for an association with likelihood of smoking cessation. Additionally, some negative or contradictory findings exist. Other genetic and clinical factors may influence a patient's likelihood of nicotine addiction. "
PA166134568,rs16969968,1448107596,AG,"Patients with AG genotype may have an increased likelihood of addiction to nicotine as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the AA genotype. No significant results have been seen for an association with likelihood of smoking cessation. Additionally, some negative or contradictory findings exist. Other genetic and clinical factors may influence a patient's likelihood of nicotine addiction. "
PA166134568,rs16969968,1448107597,GG,"Patients with GG genotype may have a decreased likelihood of addiction to nicotine as compared to patients with the AA genotype. No significant results have been seen for an association with likelihood of smoking cessation. Additionally, some negative or contradictory findings exist. Other genetic and clinical factors may influence a patient's likelihood of nicotine addiction. "
PA166134570,rs16969968,981204903,AA,"Patients with AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency."
PA166134570,rs16969968,981204904,AG,"Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency."
PA166134570,rs16969968,981204905,GG,"Patients with GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG and AA genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency."
PA166153169,rs16969968,1448101128,AA,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
PA166153169,rs16969968,1448101129,AG,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
PA166153169,rs16969968,1448101130,GG,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
PA166159035,rs16969968,1448101158,AA,Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
PA166159035,rs16969968,1448101159,AG,"Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype, or decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction."
PA166159035,rs16969968,1448101160,GG,Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
PA166159193,rs16969968,1448106823,AA,Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
PA166159193,rs16969968,1448106824,AG,"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism."
PA166159193,rs16969968,1448106825,GG,Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
PA166135276,rs1719247,1183679127,CC,Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
PA166135276,rs1719247,1183679128,CT,"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."
PA166135276,rs1719247,1183679129,TT,Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
PA166135061,rs17183814,1184999870,AA,Patients with the AA genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics. 
PA166135061,rs17183814,1184999871,AG,Patients with the AG genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics. 
PA166135061,rs17183814,1184999872,GG,Patients with the GG genotype and epilepsy may be more likely to respond to antiepileptic drugs as compared to patients with the AG or AA genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics. 
PA166161199,rs17268282,1448424041,GG,Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.
PA166161199,rs17268282,1448424042,GT,"Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide."
PA166161199,rs17268282,1448424043,TT,Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.
PA166134580,rs17222723,981237696,AA,Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
PA166134580,rs17222723,981237697,AT,Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
PA166134580,rs17222723,981237698,TT,Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
PA166134298,rs17222723,655385974,AA,Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166134298,rs17222723,655385975,AT,"Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166134298,rs17222723,655385976,TT,"Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166135288,rs1736557,1448109547,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166135288,rs1736557,1448109548,AG,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166135288,rs1736557,1448109549,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166136299,rs1736557,1444703117,AA,Patients with the AA genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
PA166136299,rs1736557,1444703118,AG,Patients with the AG genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
PA166136299,rs1736557,1444703119,GG,Patients with the GG genotype who are treated with rosuvastatin may have increased LDL-C reduction as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
PA166134138,rs17244841,1446905263,AA,Patients with the AA genotype who are treated with statins may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
PA166134138,rs17244841,1446905264,AT,Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
PA166134138,rs17244841,1446905265,TT,Patients with the TT genotype are too infrequent to have been assessed for this response.
PA166134982,rs17244841,1183491742,AA,Patients with the AA genotype may have a better response to simvastatin treatment (a higher reduction in LDL-cholesterol) as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134982,rs17244841,1183491743,AT,Patients with the AT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134982,rs17244841,1183491744,TT,Patients with the TT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134983,rs17244841,1183491763,AA,Patients with the AA genotype may have a better response (a higher reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134983,rs17244841,1183491764,AT,Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134983,rs17244841,1183491765,TT,Patients with the TT genotype were not studied. Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166152683,rs17309872,1447960381,AA,"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152683,rs17309872,1447960382,AT,"Patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152683,rs17309872,1447960383,TT,"No patients with the TT genotype were available for analysis, but patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166136237,rs1741981,1444686798,CC,"Patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
PA166136237,rs1741981,1444686799,CT,"Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
PA166136237,rs1741981,1444686800,TT,"Patients with the TT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
PA166136028,rs17421511,1184748875,AA,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136028,rs17421511,1184748876,AG,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136028,rs17421511,1184748877,GG,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136188,rs17431184,1444667341,CC,"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166136188,rs17431184,1444667342,CT,"Patients with metastasized cancer and the CT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CC genotype and improved response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166136188,rs17431184,1444667343,TT,"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166135286,rs17574269,1183679830,AA,Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
PA166135286,rs17574269,1183679829,AG,Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
PA166135286,rs17574269,1183679831,GG,Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
PA166135287,rs17376848,1448263017,AA,"Patients with the AA genotype and cancer may have a decreased risk of drug toxicities when treated with fluoropyrimidine-based chemotherapy as compared to patients with the AG genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135287,rs17376848,1448263018,AG,"Patients with the AG genotype and cancer may have an increased risk of drug toxicities when treated with fluoropyrimidine-based chemotherapy as compared to patients with AA or GG genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135287,rs17376848,1448263019,GG,"Patients with the GG genotype and cancer may have a decreased risk of drug toxicities when treated with fluoropyrimidine-based chemotherapy as compared to patients with the AG genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166152755,rs17495520,1447961117,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152755,rs17495520,1447961118,CT,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152755,rs17495520,1447961119,TT,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166162363,rs17501331,1448531663,AA,Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
PA166162363,rs17501331,1448531664,AG,Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
PA166162363,rs17501331,1448531665,GG,Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
PA166134237,rs1751034,655385161,CC,"The CC genotype carriers had lower tenofovir renal clearance, and higher  AUC than TT genotype."
PA166134237,rs1751034,655385162,CT,"The TC  genotype carriers had lower tenofovir renal clearance, and higher  AUC than TT genotype."
PA166134237,rs1751034,655385163,TT,"The TT genotype is associated with higher tenofovir renal clearance, and lower AUC compared to TC and CC cariers."
PA166135285,rs17583889,1448109553,AA,"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166135285,rs17583889,1448109554,AC,"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166135285,rs17583889,1448109555,CC,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166135284,rs1760217,1183679819,AA,Patients with the AA genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166135284,rs1760217,1183679820,AG,Patients with the AG genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166135284,rs1760217,1183679821,GG,Patients with the GG genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
PA166158954,rs17587100,1448106751,AA,"Patients with the AA genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
PA166158954,rs17587100,1448106752,AC,"Patients with the AC genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
PA166158954,rs17587100,1448106753,CC,"Patients with the CC genotype and schizophrenia may have an increased risk for weight gain when treated with antipsychotics as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
PA166135283,rs17626122,1183679816,CC,Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166135283,rs17626122,1183679815,CT,Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166135283,rs17626122,1183679814,TT,Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134545,rs17602729,981204211,AA,Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134545,rs17602729,981204212,AG,Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.
PA166134545,rs17602729,981204213,GG,Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166136524,rs17602729,1447946214,AA,Patients with the AA genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
PA166136524,rs17602729,1447946215,AG,Patients with the AG genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
PA166136524,rs17602729,1447946216,GG,Patients with the GG genotype may have a lower elevation in systolic blood pressure and a lower incidence of side effects when given regadenoson as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
PA166136517,rs17671591,1447946006,CC,Patients with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a smaller drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
PA166136517,rs17671591,1447946007,CT,Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
PA166136517,rs17671591,1447946008,TT,Patients with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
PA166159396,rs17645700,1448109560,CC,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
"
PA166159396,rs17645700,1448109561,CT,"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
"
PA166159396,rs17645700,1448109562,TT,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
"
PA166152684,rs17661089,1447960398,AA,"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152684,rs17661089,1447960399,AG,"Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152684,rs17661089,1447960400,GG,"Patients with the GG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166134139,rs17238540,1183491626,GG,Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
PA166134139,rs17238540,1183491627,GT,Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
PA166134139,rs17238540,1183491628,TT,Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
PA166134979,rs17238540,1183491552,GG,"Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134979,rs17238540,1183491553,GT,Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134979,rs17238540,1183491554,TT,Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134980,rs17238540,1183491622,GG,Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134980,rs17238540,1183491623,GT,Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134980,rs17238540,1183491624,TT,Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134019,rs17655,1184348750,CC,"Patients the CC genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. "
PA166134019,rs17655,1184348751,CG,"Patients the CG genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. "
PA166134019,rs17655,1184348752,GG,"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. "
PA166152754,rs17701271,1447961110,AA,Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152754,rs17701271,1447961111,AC,"Patients with the AC genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152754,rs17701271,1447961112,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166136018,rs17716295,1447944884,AA,Patients with genotype AA and schizophrenia may have decreased response to antipsychotics compared to patients with AC or CC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
PA166136018,rs17716295,1447944885,AC,Patients with genotype AC and schizophrenia may have increased response to antipsychotics compared to patients with AA genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
PA166136018,rs17716295,1447944886,CC,Patients with genotype CC and schizophrenia may have increased response to antipsychotics compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
PA166134996,rs17655652,1183492245,CC,Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134996,rs17655652,1183492246,CT,Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134996,rs17655652,1183492247,TT,Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166135731,rs1778929,1444700375,CC,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135731,rs1778929,1444700374,CT,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135731,rs1778929,1444700373,TT,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166134251,rs17731538,655385276,AA,"Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134251,rs17731538,655385275,AG,Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134251,rs17731538,655385274,GG,Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166158973,rs17839843,1448100372,AA,"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity. "
PA166158973,rs17839843,1448100373,AG,Patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity. 
PA166158973,rs17839843,1448100374,GG,Patients with the GG genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence TPMT activity. 
PA166134157,rs17708472,1184996838,AA,"Patients with the AA genotype (homozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin."
PA166134157,rs17708472,1184996839,AG,"Patients with the AG genotype (heterozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin."
PA166134157,rs17708472,1184996840,GG,"Patients with the GG genotype may require a lower dose of warfarin as compared to patients with the AG and AA genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin."
PA166135282,rs17751934,1183679809,CC,Patients with the CC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135282,rs17751934,1183679810,CT,Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135282,rs17751934,1183679811,TT,Patients with the TT genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166158741,rs17863778,1448106406,AA,"Patients with HIV and the AA genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166158741,rs17863778,1448106407,AC,"Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166158741,rs17863778,1448106408,CC,"Patients with HIV and the CC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166136142,rs1786929,1444608286,AA,"Patients with the AA genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
PA166136142,rs1786929,1444608287,AG,"Patients with the AG genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
PA166136142,rs1786929,1444608288,GG,"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
PA166158738,rs17868323,1448106400,GG,"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166158738,rs17868323,1448106401,GT,"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166158738,rs17868323,1448106402,TT,"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28.Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166135068,rs17782313,1446899061,CC,"Patients with the CC genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain."
PA166135068,rs17782313,1446899062,CT,"Patients with the CT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain."
PA166135068,rs17782313,1446899063,TT,"Patients with the TT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have a decreased risk of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of weight gain."
PA166136097,rs17878544,1185002371,CC,Patients with the CC genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136097,rs17878544,1185002372,CT,Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136097,rs17878544,1185002373,TT,Patients with the TT genotype may require decreased dose of acenocoumarol as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136429,rs17885382,1446899682,AA,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma. 
PA166136429,rs17885382,1446899683,AT,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma. 
PA166136429,rs17885382,1446899684,TT,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma. 
PA166134726,rs17880887,982035485,GG,Patients with the GG genotype may require lower dose of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
PA166134726,rs17880887,982035484,GT,Patients with the GT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
PA166134726,rs17880887,982035483,TT,Patients with the TT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
PA166136521,rs179008,1447946116,A,Males with basal cell carcinoma who are hemizygous for the A allele may have a better response to treatment with imiquimod as compared to males hemizygous for the T allele. Other genetic and clinical factors may also influence response to imiquimod treatment. 
PA166136521,rs179008,1447946117,T,Males with basal cell carcinoma who are hemizygous for the T allele may have a poorer response to treatment with imiquimod as compared to males hemizygous for the A allele. Other genetic and clinical factors may also influence response to imiquimod treatment. 
PA166134869,rs17886199,1043880384,AA,Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134869,rs17886199,1043880385,AG,Patients with the AG genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134869,rs17886199,1043880386,GG,Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166159398,rs17863783,1448109580,GG,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159398,rs17863783,1448109581,GT,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159398,rs17863783,1448109582,TT,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166135281,rs17868320,1183679804,CC,Patients with the CC genotype may have decreased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
PA166135281,rs17868320,1183679805,CT,Patients with the CT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
PA166135281,rs17868320,1183679806,TT,Patients with the TT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
PA166134755,rs17868320,982040686,CC,"Patients with the CC genotype who are treated with mycophenolate mofetil may have 1) no changes in mycophenolic acid exposure-related parameters and 2) a decreased, but not absent, risk of acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. "
PA166134755,rs17868320,982040687,TC,"Patients with the TC genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. "
PA166134755,rs17868320,982040688,TT,"Patients with the TT genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. "
PA166135329,rs1799724,1448099769,CC,"Patients with the CC genotype and inflammatory diseases may be more likely to respond to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors. "
PA166135329,rs1799724,1448099770,CT,"Patients with the CT genotype and inflammatory diseases may be less likely to respond to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors. "
PA166135329,rs1799724,1448099771,TT,"Patients with the TT genotype and inflammatory diseases may be less likely to respond to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors. "
PA166134081,rs1695,1448568518,AA,"Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AG or GG genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AA might have a decreased, but not absent, risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment."
PA166134081,rs1695,1448568519,AG,"Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment."
PA166134081,rs1695,1448568520,GG,"Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment."
PA166134082,rs1695,1448519738,AA,Patients with the AA genotype and cancer who are treated with platinum-based drugs may have the highest risk of toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for  toxicity.
PA166134082,rs1695,1448519739,AG,Patients with the AG genotype and cancer who are treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134082,rs1695,1448519740,GG,"Patients with the GG genotype and cancer who are treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134083,rs1695,1448568523,AA,"Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with cancer as compared to patients with the GG genotype, but some studies found increased survival or no association with survival. Other genetic and clinical factors may also influence a patient's response."
PA166134083,rs1695,1448568524,AG,Patients with the AG genotype may have an average risk for progression with platinum-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134083,rs1695,1448568525,GG,Patients with the GG genotype may have decreased risk for progression with platinum-based treatments as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134598,rs1695,1448602251,AA,"Patients with the AA genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil."
PA166134598,rs1695,1448602252,AG,"Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil."
PA166134598,rs1695,1448602253,GG,"Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil."
PA166134411,rs1695,769171388,AA,Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.
PA166134411,rs1695,769171389,AG,"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil."
PA166134411,rs1695,769171390,GG,"Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil."
PA166134428,rs1695,1448568528,AA,"Patients with the AA genotype and cancer who are treated with fluorouracil and oxaliplatin may have poorer treatment outcome (reduced responsiveness, lower overall survival time, increased risk of death) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment."
PA166134428,rs1695,1448568529,AG,"Patients with the AG genotype and cancer who are treated with fluorouracil and oxaliplatin may have better treatment outcome as compared to patients with the AA genotype, or may have poorer treatment outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment."
PA166134428,rs1695,1448568530,GG,"Patients with the GG genotype and cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment."
PA166134589,rs1695,981237951,AA,"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment."
PA166134589,rs1695,981237952,AG,"Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment."
PA166134589,rs1695,981237953,GG,"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment."
PA166134602,rs1695,981238398,AA,Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
PA166134602,rs1695,981238399,AG,Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
PA166134602,rs1695,981238400,GG,Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
PA166153179,rs1695,1448616392,AA,Pediatric patients with the AA genotype and medulloblastoma may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.
PA166153179,rs1695,1448616393,AG,Pediatric patients with the AG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.
PA166153179,rs1695,1448616394,GG,Pediatric patients with the GG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.
PA166159049,rs1695,1448101291,AA,"Patients with tuberculosis and the AA genotype who are treated with isoniazid and rifampin may have an increased likelihood of drug-induced liver injury as compared to patients with the AG or GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury."
PA166159049,rs1695,1448101292,AG,"Patients with tuberculosis and the AG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in one study. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury."
PA166159049,rs1695,1448101293,GG,"Patients with tuberculosis and the GG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in one study. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury."
PA166153041,rs1695,1447982836,AA,Patients with the AA genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.
PA166153041,rs1695,1447982835,AG,Patients with the AG genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.
PA166153041,rs1695,1447982834,GG ,Patients with the GG genotype and psoriasis who are treated with fumaric acid esters may have a decreased response as patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's drug response.
PA166135758,rs1799722,1444701003,CC,Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.
PA166135758,rs1799722,1444701002,CT,Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.
PA166135758,rs1799722,1444701001,TT,Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.
PA166136292,rs1799722,1444701011,CC,"Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
PA166136292,rs1799722,1444701010,CT,"Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
PA166136292,rs1799722,1444701009,TT,"Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
PA166134162,rs1799722,1000539641,CC,"Patients with the CC genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
PA166134162,rs1799722,1000539642,CT,Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
PA166134162,rs1799722,1000539643,TT,Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
PA166136124,rs1799782,1444607763,AA,"Patients with the AA genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG  genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy."
PA166136124,rs1799782,1444607764,AG,"Patients with the AG genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG  genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy."
PA166136124,rs1799782,1444607765,GG,"Patients with the GG genotype and non-small-cell lung cancer may be less likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the AA or AG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy."
PA166134351,rs1799735,982031643,CCT/CCT,"Patients with the CCT/CCT genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the del/del or del/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events."
PA166134351,rs1799735,982031644,CCT/del,"Patients with the CCT/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events."
PA166134351,rs1799735,982031645,del/del,"Patients with the del/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events."
PA166136112,rs1799735,1444607429,CCT/CCT,Individuals with the CCT/CCT genotype may have increased clearance of olanzapine as compared to individuals with the CCT/del or del/del genotype. Other genetic and clinical factors may also influence clearance of olanzapine.
PA166136112,rs1799735,1444607430,CCT/del,Individuals with the CCT/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.
PA166136112,rs1799735,1444607431,del/del,Individuals with the del/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.
PA166152686,rs1799808,1447960413,CC,Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon. 
PA166152686,rs1799808,1447960414,CT,Patients with the CT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon. 
PA166152686,rs1799808,1447960415,TT,Patients with the TT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon. 
PA166158957,rs1799852,1448100237,CC,Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
PA166158957,rs1799852,1448100238,CT,Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
PA166158957,rs1799852,1448100239,TT,Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
PA166134027,rs1799807,1444698442,CC,Patients with the CC genotype have an increased risk of post anesthesia apnea  when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166134027,rs1799807,1444698443,CT,Patients with the CT genotype have an increased risk of post anesthesia apnea  when treated with succinylcholine as compared to patients with the TT genotype and a decreased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166134027,rs1799807,1444698444,TT,Patients with the TT genotype have a decreased risk of post anesthesia apnea as compared to patients with the CC genotype when treated with succinylcholine. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135672,rs1799801,1444666610,CC,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135672,rs1799801,1444666611,CT,Patients with the CT genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135672,rs1799801,1444666612,TT,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166134357,rs1799889,655386853,AA,Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs2227631. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
PA166134357,rs1799889,655386854,AG,Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
PA166134357,rs1799889,655386855,GG,Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
PA166152862,rs1799930,1447964079,AA,Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. They also may have decreased clearance of isoniazid as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.
PA166152862,rs1799930,1447964080,AG,"Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA genotype, and decreased clearance as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid."
PA166152862,rs1799930,1447964081,GG,Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.
PA166134401,rs1799732,1448099738,G/G,"Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
PA166134401,rs1799732,1448099739,G/del,"Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
PA166134401,rs1799732,1448099740,del/del,"Patients with the del/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
PA166158912,rs1799732,1448099748,G/del,"Patients with the G/del genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del/del genotype, or a decreased risk as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects."
PA166158912,rs1799732,1448099747,GG,"Patients with the GG genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects."
PA166158912,rs1799732,1448099749,del/del,"Patients with the del/del genotype and psychotic disorders may have a decreased risk for side effects when treated with antipsychotics as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects."
PA166152732,rs1799732,1447960933,G/del,Patients with the G/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
PA166152732,rs1799732,1447960932,GG,Patients with the GG genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with bupropion as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.
PA166152732,rs1799732,1447960934,del/del,Patients with the del/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
PA166152733,rs1799732,1447960940,G/del,Patients with the G/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
PA166152733,rs1799732,1447960939,GG,Patients with the GG genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.
PA166152733,rs1799732,1447960941,del/del,Patients with the del/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
PA166161879,rs1799732,1448525461,G/del,Patients with the G/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
PA166161879,rs1799732,1448525460,GG,Patients with the GG genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
PA166161879,rs1799732,1448525462,del/del,Patients with the del/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
PA166134576,rs1799793,1448568550,CC,Patients with the CC genotype and cancer who are treated with cisplatin may have shorter survival times as compared to patients with the CT or TT genotype. This has been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166134576,rs1799793,1448568551,CT,Patients with the CT genotype and cancer who are treated with cisplatin may have longer survival times as compared to patients with the CC genotype. This has been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166134576,rs1799793,1448568552,TT,Patients with the TT genotype and cancer who are treated with cisplatin may have longer survival times as compared to patients with the CC genotype. This has been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166136169,rs1799793,1448256859,CC,Patients with the CC genotype and non-small-cell lung cancer may have 1) a decreased risk for pneumonitis and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis. 
PA166136169,rs1799793,1448256860,CT,Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis. 
PA166136169,rs1799793,1448256861,TT,Patients with the TT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis and 2) a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis. 
PA166152745,rs1799929,1447961030,CC,"Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
PA166152745,rs1799929,1447961031,CT,"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
PA166152745,rs1799929,1447961032,TT,"Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
PA166135698,rs1799963,1444672768,AA,No evidence available.
PA166135698,rs1799963,1444672769,AG,"Patients with the AG genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the GG genotype who are not taking oral contraceptives. Current evidence suggests that patients with the AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives."
PA166135698,rs1799963,1444672770,GG,"Patients with the GG genotype who are not taking oral contraceptives (OCs) may have a decreased risk for deep vein thrombosis (DVT), as compared to patients with the AG genotype who are taking oral contraceptives. Current evidence suggests that patients with the AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives."
PA166136296,rs1799964,1444702766,CC,Patients with the CC genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors. 
PA166136296,rs1799964,1444702767,CT,Patients with the CT genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors. 
PA166136296,rs1799964,1444702768,TT,Patients with the TT genotype and ankylosing spondylitis may have a better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors. 
PA166159044,rs1799964,1448101240,CC,Patients with the CC genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence neuropathy risk.
PA166159044,rs1799964,1448101241,CT,"Patients with the CT genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk."
PA166159044,rs1799964,1448101242,TT,Patients with the TT genotype and HIV may have a decreased risk for neuropathy when treated with stavudine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.
PA166134328,rs1799931,655386177,AA,Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134328,rs1799931,655386178,AG,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
PA166134328,rs1799931,655386179,GG,Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
PA166152863,rs1799931,1447964086,AA,"Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity."
PA166152863,rs1799931,1447964087,AG,"Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity."
PA166152863,rs1799931,1447964088,GG,"Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA or AG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity."
PA166134383,rs1799978,655387653,CC,Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.
PA166134383,rs1799978,655387654,CT,Patients with the TC genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134383,rs1799978,655387655,TT,Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134384,rs1799978,655387673,CC,Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134384,rs1799978,655387674,CT,Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134384,rs1799978,655387675,TT,"Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166135770,rs1799978,1444703133,CC,Patients with the CC genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
PA166135770,rs1799978,1444703134,CT,Patients with the CT genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
PA166135770,rs1799978,1444703135,TT,Patients with the TT genotype and Schizophrenia who are treated with olanzapine or risperidone may have increased time until response as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
PA166152946,rs1799978,1447980679,CC,Patients with the CC genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose.
PA166152946,rs1799978,1447980680,CT,"Patients with the CT genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype, or an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose."
PA166152946,rs1799978,1447980681,TT,Patients with the TT genotype who are heroin dependent may require an increased dose of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.
PA166134678,rs1799983,1446909012,GG,"Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
PA166134678,rs1799983,1446909013,TG,"Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
PA166134678,rs1799983,1446909014,TT,"Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
PA166134372,rs1799983,655387010,GG,"Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival."
PA166134372,rs1799983,655387011,GT,"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival."
PA166134372,rs1799983,655387012,TT,"Patients with the TT genotype 
1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival."
PA166135756,rs1799983,1444700987,GG,"Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients."
PA166135756,rs1799983,1444700986,GT,"Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients."
PA166135756,rs1799983,1444700985,TT,"Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients."
PA166136360,rs1799983,1445400875,GG,Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.
PA166136360,rs1799983,1445400876,GT,Patients with acute myeloid leukemia and the GT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.
PA166136360,rs1799983,1445400877,TT,Patients with acute myeloid leukemia and the TT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.
PA166135883,rs1799983,1445400947,GG,Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.
PA166135883,rs1799983,1445400948,GT,Patients with the GT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.
PA166135883,rs1799983,1445400949,TT,Patients with the TT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.
PA166135917,rs1799983,1445737076,GG,"Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens."
PA166135917,rs1799983,1445737077,GT,"Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens."
PA166135917,rs1799983,1445737078,TT,"Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens."
PA166152927,rs1799983,1447979516,GG,Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152927,rs1799983,1447979517,GT,Patients with the GT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152927,rs1799983,1447979518,TT,Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
PA166135063,rs1799998,1183630649,AA,Patients with the AA genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.
PA166135063,rs1799998,1183630650,AG,Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.
PA166135063,rs1799998,1183630651,GG,Patients with the GG genotype and hypertension may be more likely to respond to treatment with candesartan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to candesartan.
PA166135064,rs1799998,1183630603,AA,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
PA166135064,rs1799998,1183630604,AG,Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
PA166135064,rs1799998,1183630605,GG,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
PA166134856,rs1799752,1043880272,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the insert/insert genotype and Coronary Artery Disease may be less  responsive to fluvastatin treatment as compared to patients with the del/del or del/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134856,rs1799752,1043880273,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,"Patients with the del/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del/del genotype, or may have a better response to fluvastatin treatment as compared to patients with the insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. "
PA166134856,rs1799752,1043880274,del/del,Patients with the del/del genotype and Coronary Artery Disease may have a better response to fluvastatin treatment as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134857,rs1799752,1043880260,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC ,Patients with the insert/insert genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134857,rs1799752,1043880261,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the insert/del genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134857,rs1799752,1043880262,del/del,Patients with the del/del genotype may be more likely to benefit from pravastatin treatment as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134858,rs1799752,1043880289,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the insert/insert genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due to an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134858,rs1799752,1043880290,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the insert/del genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134858,rs1799752,1043880291,del/del,Patients with the del/del genotype and Coronary Artery Disease may benefit less from atorvastatin and quinapril treatment (due to less of a reduction in the fibrinolytic marker D-dimer) as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135065,rs1799752,1183614617,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Healthy males with the ATAC.../ATAC... genotype may have a decreased response when given bumetanide, furosemide or torasemide as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide. "
PA166135065,rs1799752,1183614616,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,"Healthy males with the ATAC.../del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATAC.../ATAC... genotype, or a decreased response as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide. "
PA166135065,rs1799752,1183614615,del/del,"Healthy males with the del/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATAC.../ATAC... genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide. "
PA166135510,rs1799752,1184233185,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the insert/insert genotype and Migraine with Aura or Chronic Migraine may be less likely to use pharmacological prophylaxis as compared to patients with the ins/del or del/del genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis. 
PA166135510,rs1799752,1184233186,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the insert/del genotype and Migraine with Aura or Chronic Migraine  may be more likely to use pharmacological prophylaxis as compared to patients with the ins/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis. 
PA166135510,rs1799752,1184233187,del/del,Patients with the del/del genotype and Migraine with Aura or Chronic Migraine may be more likely to use pharmacological prophylaxis as compared to patients with the ins/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis. 
PA166135066,rs1799752,1183631288,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the ATAC.../ATAC... genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril. 
PA166135066,rs1799752,1183631289,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the ATAC.../del genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril. 
PA166135066,rs1799752,1183631290,del/del,Patients with the del/del genotype and diabetes or hypertension may have a better response when treated with benazepril or perindopril as compared to patients with the ATAC.../del or ATAC.../ATAC... genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril. 
PA166135112,rs1799752,1445402428,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Patients with the ATAC.../ATAC... genotype may have an increased response when treated with lisinopril as compared to patients with the del/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril."
PA166135112,rs1799752,1445402429,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,"Patients with the ATAC.../del genotype may have an increased response when treated with lisinopril as compared to patients with the del/del genotype, or a decreased response when treated with lisinopril as compared to patients with the ATAC.../ATAC... genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril."
PA166135112,rs1799752,1445402430,del/del,"Patients with the del/del genotype may have a decreased response when treated with lisinopril as compared to patients with the ATAC.../ATAC... genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril."
PA166134561,rs1799752,981204550,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. The opposite association is found for females in some studies where female patients carrying the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased reduction in blood pressure as compared to female patients with the del/del   genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166134561,rs1799752,981204551,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166134561,rs1799752,981204552,del/del,Patients with the del/del genotype and essential hypertension who are treated with hydrochlorothiazide may have an increased reduction in blood pressure as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. The opposite association is found for females in some studies where female patients carrying the del/del genotype may have a decreased reduction in blood pressure as compared to female patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC  genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166135697,rs1799752,1444668816,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC ,Hypertensive patients with the ATAC.../ATAC... genotype may have a greater reduction in diastolic blood pressure when treated with irbesartan as compared to patients with the ATAC.../del or del/del genotype. Other genetic and clinical factors may also influence diastolic blood pressure response. 
PA166135697,rs1799752,1444668817,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Hypertensive patients with the ATAC.../del genotype may have a smaller reduction in diastolic blood pressure when treated with irbesartan as compared to patients with the ATAC.../ATAC... genotype. Other genetic and clinical factors may also influence diastolic blood pressure response. 
PA166135697,rs1799752,1444668815, del/del,Hypertensive patients with the del/del genotype may have a smaller reduction in diastolic blood pressure when treated with irbesartan as compared to patients with the ATAC.../ATAC... genotype. Other genetic and clinical factors may also influence diastolic blood pressure response. 
PA166134722,rs1799752,982034930,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with acetylcholine as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.
PA166134722,rs1799752,982034931,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may experience greater vasodilation as compared to patients with the del/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with acetylcholine. Other genetic and clinical factors may also influence a patient's response to acetylcholine.
PA166134722,rs1799752,982034932,del/del,Patients with the del/del genotype may experience less vasodilation when treated with acetylcholine as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.
PA166134723,rs1799752,982034920,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with nitroprusside as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.
PA166134723,rs1799752,982034921,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may experience greater vasodilation as compared to patients with the del/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with nitroprusside. Other genetic and clinical factors may also influence a patient's response to nitroprusside.
PA166134723,rs1799752,982034922,del/del,Patients with the del/del genotype may experience less vasodilation when treated with nitroprusside as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.
PA166134730,rs1799752,982036349,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134730,rs1799752,982036350,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134730,rs1799752,982036351,del/del,"Patients with the del/del genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134777,rs1799752,1444667074,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Patients with the ATAC.../ATAC... genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have an increased response when treated with captopril as compared to patients with the del/del genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient's response to captopril."
PA166134777,rs1799752,1444667075,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,"Patients with the ATAC.../del genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have an increased response when treated with captopril as compared to patients with the del/del genotype, or a decreased response compared to patients with the ATAC.../ATAC... genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient's response to captopril."
PA166134777,rs1799752,1444667076,del/del,"Patients with the del/del genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the ATAC.../del or ATAC.../ATAC... genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient's response to captopril."
PA166134778,rs1799752,1183615230,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Patients with the ATAC.../ATAC... genotype and conditions such as kidney disease, heart disease, hypertension and arteriosclerosis may have an increased response when treated with enalapril as compared to patients with the del/del or ATAC.../del genotype. However, evidence is highly contradictory, with almost half the studies showing a decreased response to enalapril for this genotype. Some patients were also treated with losartan or atenolol. One study found an increased risk of kidney failure for this genotype (compared to the del/del or ATAC.../del genotypes), and another a decreased response in bone mineral density (compared to the del/del genotype). Other genetic and clinical factors may also influence a patient's response to enalapril, risk of kidney failure or response in bone mineral density."
PA166134778,rs1799752,1183615231,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del,"Patients with the ATAC.../del genotype and conditions such as kidney disease, heart disease, hypertension and arteriosclerosis may have an increased response when treated with enalapril as compared to patients with the del/del genotype. However, evidence is highly contradictory, with one study showing a decreased response for this genotype compared to the del/del genotype, one showing an increased response compared to the ATAC.../ATAC... genotype, and another a decreased response compared to the ATAC.../ATAC... genotype. Some patients were also treated with losartan or atenolol. One study found a decreased risk of kidney failure for this genotype compared to ATAC.../ATAC..., and another a decreased response in bone mineral density compared to del/del. Other genetic and clinical factors may also influence a patient's response to enalapril, risk of kidney failure or response in bone mineral density."
PA166134778,rs1799752,1183615232,del/del,"Patients with the del/del genotype and conditions such as kidney disease, heart disease, hypertension and arteriosclerosis may have a decreased response when treated with enalapril as compared to patients with the ATAC.../del or ATAC.../ATAC... genotype. However, evidence is highly contradictory, with almost half the studies showing an increased response to enalapril for this genotype. Some patients were also treated with losartan or atenolol. One study found a decreased risk of kidney failure for this genotype, and another an increased response in bone mineral density, both compared to the ATAC.../ATAC... genotype. Other genetic and clinical factors may also influence a patient's response to enalapril, risk of kidney failure or response in bone mineral density."
PA166135769,rs1799752,1444703127,ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors."
PA166135769,rs1799752,1444703126,del/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC,"Patients with the del/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype or may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors."
PA166135769,rs1799752,1444703125,del/del,Patients with the del/del genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.
PA166159165,rs1799752,1448102426,ATTTGTTCATGCCT/ATTTGTTCATGCCT,Patients with depressive disorder and the ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.
PA166159165,rs1799752,1448102425,del/ATTTGTTCATGCCT,Patients with depressive disorder and the del/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.
PA166159165,rs1799752,1448102424,del/del,Patients with depressive disorder and the del/del genotype may have an improved response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.
PA166135771,rs1800469,1448107294,AA,Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
PA166135771,rs1800469,1448107295,AG,Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
PA166135771,rs1800469,1448107296,GG,Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
PA166161128,rs1800469,1448422841,AA,Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. 
PA166161128,rs1800469,1448422842,AG,Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. 
PA166161128,rs1800469,1448422843,GG,Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. 
PA166134345,rs1800460,1448616411,CC,"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134345,rs1800460,1448616412,CT,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134345,rs1800460,1448616413,TT,"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166135120,rs1800471,1183630761,CC,"No patients with the CC genotype were present in this study. However, patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab."
PA166135120,rs1800471,1183630762,CG,Patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.
PA166135120,rs1800471,1183630763,GG,Patients with the GG genotype and rheumatoid arthritis may be less likely to respond to rituximab treatment as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to rituximab.
PA166136215,rs1800470,1444673067,AA,Patients with the AA genotype and rheumatoid arthritis may have a poorer response when treated with rituximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to rituximab.
PA166136215,rs1800470,1444673068,AG,Patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.
PA166136215,rs1800470,1444673069,GG,"No patients with the GG genotype were present in the population. However, patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab."
PA166153062,rs1800012,1447983146,AA,Patients with the AA genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
PA166153062,rs1800012,1447983147,AC,Patients with the AC genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
PA166153062,rs1800012,1447983148,CC,Patients with the CC genotype and epilepsy who are treated with valproic acid may have increased bone density as compared to patients with the AA + AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
PA166152956,rs1800012,1447980769,AA,Patients with the AA genotype and growth hormone deficiency who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant may require a decreased dose of recombinant human growth hormone (somatropin) as compared to patients with the CC genotype who are also homozygotes of the full length GHR gene. Other genetic and clinical factors may also influence dose of somatropin.
PA166152956,rs1800012,1447980771,AC,This genotype was not analyzed in this study.
PA166152956,rs1800012,1447980770,CC,Patients with the CC genotype and growth hormone deficiency who are also homozygotes of the full length GHR gene may require an increased dose of recombinant human growth hormone (somatropin) as compared to patients with the AA genotype who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant. Other genetic and clinical factors may also influence dose of somatropin.
PA166134945,rs1800544,1183490965,CC,Patients with the CC genotype may have an increased sedative response to dexmedetomidine as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
PA166134945,rs1800544,1183490964,GC,Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
PA166134945,rs1800544,1183490963,GG,Patients with the GG genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
PA166135417,rs1800544,1448100283,CC,"Pediatric patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to methylphenidate treatment as compared to pediatric patients with the CG or GG genotype. However, patients with the CC genotype and autism spectrum disorder (ASD) were found to have a better response to methylphenidate, though this was a non-significant result after correction for multiple testing. Other genetic and clinical factors may also influence response to methylphenidate."
PA166135417,rs1800544,1448100284,CG,"Pediatric patients with the CG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to pediatric patients with the CC genotype. However, patients with the CG genotype and autism spectrum disorder (ASD) were found to have a poorer response to methylphenidate, though this was a non-significant result after correction for multiple testing. Other genetic and clinical factors may also influence response to methylphenidate."
PA166135417,rs1800544,1448100285,GG,"Pediatric patients with the GG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to pediatric patients with the CC genotype. However, patients with the GG genotype and autism spectrum disorder (ASD) were found to have a poorer response to methylphenidate, though this was a non-significant result after correction for multiple testing. Other genetic and clinical factors may also influence response to methylphenidate."
PA166151946,rs1800544,1448612789,CC,Patients with the CC genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.
PA166151946,rs1800544,1448612790,CG,Patients with the CG genotype and major depressive disorder may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the CC and GG genotypes. Other genetic and clinical factors may also influence a patient's response to SSRIs.
PA166151946,rs1800544,1448612791,GG,Patients with the GG genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.
PA166151947,rs1800544,1447953201,CC,Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
PA166151947,rs1800544,1447953202,CG,Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
PA166151947,rs1800544,1447953203,GG,Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
PA166135772,rs1800477,1444703158,CC,"Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin."
PA166135772,rs1800477,1444703157,CT,"Patients with the CT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype or may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin."
PA166135772,rs1800477,1444703156,TT,Patients with the TT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.
PA166134715,rs1800532,982032766,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166134715,rs1800532,982032765,GT,Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166134715,rs1800532,982032764,TT,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166134783,rs1800532,1043858635,GG,"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. "
PA166134783,rs1800532,1043858634,GT,"Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. "
PA166134783,rs1800532,1043858633,TT,"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. "
PA166136365,rs1800559,1445401010,CC,"Patients with the CC genotype may have decreased risk of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT. Please note: this clinical annotation is based on two case studies and there were no individuals who were genotype TT. Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia."
PA166136365,rs1800559,1445401011,CT,"Patients with the CT genotype may have increased risk of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC.  Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia."
PA166136365,rs1800559,1445401012,TT,"Patients with the TT genotype may have increased risk of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: this clinical annotation is based on two case studies and there were no individuals who were genotype TT.  Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia."
PA166135604,rs1799971,1184987580,AA,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics. "
PA166135604,rs1799971,1184987581,AG,"Patients with the AG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics. "
PA166135604,rs1799971,1184987582,GG,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics. "
PA166134563,rs1799971,982037101,AA,"Patients with the AA genotype may have a decreased , but not absent, severity of intoxication and a decreased response when exposed to ethanol as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's ethanol response."
PA166134563,rs1799971,982037102,AG,Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.
PA166134563,rs1799971,982037103,GG,Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.
PA166134564,rs1799971,981204696,AA,"Patients with the AA genotype who are treated with naltrexone may have a decreased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AG or GG genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone."
PA166134564,rs1799971,981204697,AG,"Patients with the AG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone."
PA166134564,rs1799971,981204698,GG,"Patients with the GG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone."
PA166134565,rs1799971,982037129,AA,"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to AG and GG genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
PA166134565,rs1799971,982037130,AG,"Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
PA166134565,rs1799971,982037131,GG,"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
PA166136120,rs1799971,1444607725,AA,"Patients with the AA genotype who are receiving hydrocodone may have a decreased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone."
PA166136120,rs1799971,1444607726,AG,"Patients with the AG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone."
PA166136120,rs1799971,1444607727,GG,"Patients with the GG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone."
PA166134718,rs1799971,1446899228,AA,"Individuals with the AA genotype may experience increased efficacy of opioids for pain and opioid related drugs to treat addiction, and may require a decreased dose of opioids as compared to individuals with the AG and GG genotypes. However this has been contradicted in some studies. In some studies, the AA and AG genotypes were found to have a increased efficacy, and to require a decreased dose as compared to the GG genotype.  Other genetic and clinical factors may also influence a patient's response to opioid drugs. "
PA166134718,rs1799971,1446899229,AG,"Individuals with the AG genotype may experience decreased efficacy of opioids for pain and opioid related drugs to treat addiction, and may require an increased dose of opioids as compared to individuals with the AA genotype. However this has been contradicted in some studies. In some studies, the AA and AG genotypes were found to have a increased efficacy, and to require a decreased dose as compared to the GG genotype.  Other genetic and clinical factors may also influence a patient's dependence on opioid drugs. "
PA166134718,rs1799971,1446899230,GG,"Individuals with the GG genotype may experience decreased efficacy of opioids for pain and opioid related drugs to treat addiction, and may require an increased dose of opioids as compared to individuals with the AA genotype. However this has been contradicted in some studies. In some studies, the AA and AG genotypes were found to have a increased efficacy, and to require a decreased dose as compared to the GG genotype. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's dependence on opioid drugs. "
PA166134242,rs1799971,1448612986,AA,Patients with the AA genotype who are treated with morphine: 1) may require a lower dose as compared to patients with the AG or GG genotype 2) may be more likely to have an increased pain relief as compared to patients with the AG or GG genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.
PA166134242,rs1799971,1448612987,AG,Patients with the AG genotype who are treated with morphine: 1) may require a higher dose as compared to patients with the AA genotype 2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.
PA166134242,rs1799971,1448612988,GG,Patients with the GG genotype who are treated with morphine: 1) may require the highest dose as compared to patients with the AG and AA genotype  2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.
PA166134246,rs1799971,655385244,AA,Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.
PA166134246,rs1799971,655385243,AG,Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.
PA166134246,rs1799971,655385242,GG,Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.
PA166151951,rs1799971,1447953272,AA,Patients with the AA genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.
PA166151951,rs1799971,1447953273,AG,Patients with the AG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.
PA166151951,rs1799971,1447953274,GG,Patients with the GG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.
PA166135059,rs1800545,1183614512,AA,Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.
PA166135059,rs1800545,1183614511,AG,Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.
PA166135059,rs1800545,1183614510,GG,Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.
PA166152789,rs1800588,1447962718,CC,Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
PA166152789,rs1800588,1447962719,CT,Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
PA166152789,rs1800588,1447962720,TT,Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
PA166152790,rs1800588,1447962725,CC,"Patients with the CC genotype may have a smaller increase in HDL cholesterol when treated with pravastatin as compared to patients with the CT or TT genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response."
PA166152790,rs1800588,1447962726,CT,"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response."
PA166152790,rs1800588,1447962727,TT,"Patients with the TT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response."
PA166134910,rs1800591,1050579068,GG,Patients with the GG genotype who are treated with pravastatin may be less likely to benefit from treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134910,rs1800591,1050579071,GT,Patients with the GT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134910,rs1800591,1050579074,TT,Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134911,rs1800591,1051394397,GG,Men with the GG genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134911,rs1800591,1051394401,GT,Men with the GT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134911,rs1800591,1051394404,TT,Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134870,rs1800566,1447749019,AA,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134870,rs1800566,1447749020,AG,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134870,rs1800566,1447749021,GG,Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose.
PA166134950,rs1800566,1446906858,AA,"Patients with the AA genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have worse outcome (overall survival and progression-free survival) as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome."
PA166134950,rs1800566,1446906859,AG,"Patients with the AG genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype and a worse outcome as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome."
PA166134950,rs1800566,1446906860,GG,"Patients with the GG genotype and Breast Neoplasms and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome."
PA166135993,rs1800566,1447749026,AA,"Patients with the AA genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
"
PA166135993,rs1800566,1447749027,AG,"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
"
PA166135993,rs1800566,1447749028,GG,"Patients with the GG genotype may require an increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
"
PA166134055,rs1799853,1448112404,CC,Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134055,rs1799853,1448112405,CT,Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134055,rs1799853,1448112406,TT,Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166135117,rs1799853,1183615297,CC,Patients with the CC genotype who are taking acenocoumarol may have a decreased risk of a gastrointestinal hemorrhage as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.
PA166135117,rs1799853,1183615298,CT,Patients with the CT genotype who are taking acenocoumarol may have an increased risk of a gastrointestinal hemorrhage as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.
PA166135117,rs1799853,1183615299,TT,Patients with the TT genotype who are taking acenocoumarol may have an increased risk of a gastrointestinal hemorrhage as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.
PA166134578,rs1799853,1448615596,CC,"Patients with the CC genotype and Epilepsy who are treated with phenytoin may have an increased metabolism of phenytoin, decreased plasma free phenytoin concentration, and a decreased, but not absent, risk of drug toxicity as compared to patients with the CT and TT genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin."
PA166134578,rs1799853,1448615597,CT,"Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin."
PA166134578,rs1799853,1448615598,TT,"Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin."
PA166134579,rs1799853,1183690927,CC,Patients with the CC genotype who are treated with celecoxib may have an increased metabolism of celecoxib and as compared to patients with the CT and TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.
PA166134579,rs1799853,1183690928,CT,Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.
PA166134579,rs1799853,1183690929,TT,Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.
PA166134754,rs1799853,1446909043,CC,"Patients with the CC genotype may have 1) increased exposure to clopidogrel active metabolite and 2) decreased, but not absent, risk of poor responder status as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134754,rs1799853,1446909044,CT,"Patients with the CT genotype may have 1) decreased exposure to clopidogrel active metabolite and 2) an increased risk of poor responder status as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134754,rs1799853,1446909045,TT,"Patients with the TT genotype may have 1) decreased exposure to clopidogrel active metabolite and 2) an increased risk of poor responder status as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134289,rs1799853,655385722,CC,Patients with the CC genotype and type II diabetes who are treated with sulfonylureas: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the TT genotype 2) May be more likely to experience treatment failure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.
PA166134289,rs1799853,655385723,CT,Results from patients with the CT genotype were not statistically significant.
PA166134289,rs1799853,655385724,TT,Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.
PA166136235,rs1799853,1444686785,CC,Patients with the CC (CYP2C9 *1/*1) genotype undergoing hemopoietic stem cell transplant may have increased metabolism of busulfan as compared to patients with the CT (*1/*2) or TT (*2/*2) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
PA166136235,rs1799853,1444686786,CT,Patients with the CT (CYP2C9 *1/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
PA166136235,rs1799853,1444686787,TT,Patients with the TT (CYP2C9 *2/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
PA166153429,rs1799853,1447990046,CT,Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.
PA166153429,rs1799853,1447990047,TT,Patients with the TT genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.
PA166136241,rs1800871,1444686838,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have a greater chance of achieving target concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus."
PA166136241,rs1800871,1444686839,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus."
PA166136241,rs1800871,1444686840,GG,"Patients with the GG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus."
PA166136256,rs1800871,1444694576,AA,"Patients undergoing liver transplantation who receive a donor liver with the AA genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166136256,rs1800871,1444694577,AG,"Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166136256,rs1800871,1444694578,GG,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166134217,rs1800497,1448099299,AA,Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134217,rs1800497,1448099300,AG,Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134217,rs1800497,1448099301,GG,Patients with the GG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134385,rs1800497,982035403,AA,Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
PA166134385,rs1800497,982035404,AG,Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
PA166134385,rs1800497,982035405,GG,"Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride."
PA166134947,rs1800497,1183490979,AA,"Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.
"
PA166134947,rs1800497,1183490980,AG,Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.
PA166134947,rs1800497,1183490981,GG,Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.
PA166134566,rs1800497,1448104251,AA,"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
PA166134566,rs1800497,1448104252,AG,"Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
PA166134566,rs1800497,1448104253,GG,"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
PA166134569,rs1800497,981204891,AA,Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.
PA166134569,rs1800497,981204892,AG,Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.
PA166134569,rs1800497,981204893,GG,"Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency."
PA166134272,rs1800497,1446898315,AA,"Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence a patient's chance for quitting smoking."
PA166134272,rs1800497,1446898316,AG,"Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence a patient's chance for quitting smoking."
PA166134272,rs1800497,1446898317,GG,"Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes, although this has been contradicted in one study. Other genetic and clinical factors may also influence a patient's chance for quitting smoking."
PA166134281,rs1800497,1448255889,AA,"Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects."
PA166134281,rs1800497,1448255890,AG,"Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's risk for side effects."
PA166134281,rs1800497,1448255891,GG,"Patients with the GG genotype may have decreased but not non-existant risk of side effects including hyperprolactinemia and weight gain, but increased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects."
PA166152807,rs1800497,1448106626,AA,Patients with the AA genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
PA166152807,rs1800497,1448106627,AG,Patients with the AG genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
PA166152807,rs1800497,1448106628,GG,Patients with the GG genotype and schizophrenia may have a poorer response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
PA166135902,rs1800497,1445401401,AA,Patients with the AA genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain.
PA166135902,rs1800497,1445401402,AG,Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.
PA166135902,rs1800497,1445401403,GG,Patients with the GG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.
PA166136113,rs1800497,1444607461,AA,Individuals with the AA genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
PA166136113,rs1800497,1444607462,AG,Individuals with the AG genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
PA166136113,rs1800497,1444607463,GG,Individuals with the GG genotype may have decreased area under the curve (AUC) of olanzapine as compared to individuals with the AA or AG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
PA166134844,rs1800872,1043880069,GG,Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
PA166134844,rs1800872,1043880068,GT,Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
PA166134844,rs1800872,1043880067,TT,Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
PA166135727,rs1800872,1444694569,GG,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166135727,rs1800872,1444694570,GT,"Patients undergoing liver transplantation who receive a donor liver with the GT genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166135727,rs1800872,1444694571,TT,"Patients undergoing liver transplantation who receive a donor liver with the TT genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the GG or GT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166135373,rs1800795,1183698832,CC,Patients with the CC genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
PA166135373,rs1800795,1183698833,CG,Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
PA166135373,rs1800795,1183698834,GG,Patients with the GG genotype who have a high risk of cardiovascular disease may have a poorer anti-inflammatory response when treated with fenofibrate as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
PA166135773,rs1800795,1444703175,CC,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
PA166135773,rs1800795,1444703174,CG,"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
PA166135773,rs1800795,1444703173,GG,"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
PA166135774,rs1800795,1444703182,CC,Patients with the CC genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135774,rs1800795,1444703181,CG,Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have decreased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135774,rs1800795,1444703180,GG,Patients with the GG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166158960,rs1800795,1448102904,CC,Patients with the CC genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
PA166158960,rs1800795,1448102905,CG,Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
PA166158960,rs1800795,1448102906,GG,Patients with the GG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
PA166136255,rs1800896,1444694557,CC,"No patients with the CC genotype were present in the population. However, patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus. "
PA166136255,rs1800896,1444694558,CT,"Patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus. "
PA166136255,rs1800896,1444694559,TT,"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may require a decreased dose of tacrolimus as compared to patients who receive a donor liver with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus. "
PA166136464,rs1800896,1446906450,CC,Patients with genotype CC may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections  as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
PA166136464,rs1800896,1446906449,CT,Patients with genotype CT may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections  as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
PA166136464,rs1800896,1446906448,TT,Patients with genotype TT may have increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections  as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
PA166162495,rs1800896,1448567995,CC,Patients with the CC genotype who underwent kidney transplantation may have increased dose-adjusted trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations. 
PA166162495,rs1800896,1448567996,CT,Patients with the CT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations. 
PA166162495,rs1800896,1448567997,TT,Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations. 
PA166163325,rs1800896,1448603627,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations."
PA166163325,rs1800896,1448603628,CT,"Patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations."
PA166163325,rs1800896,1448603629,TT,"Patients with the TT genotype who are undergoing lung transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations."
PA166135948,rs1800925,1446901313,CC,Patients with renal cell carcinoma and the CC genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib. 
PA166135948,rs1800925,1446901314,CT,Patients with renal cell carcinoma and the CT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib. 
PA166135948,rs1800925,1446901315,TT,Patients with renal cell carcinoma and the TT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib. 
PA166134278,rs1800909,655385480,AA,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have less improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
PA166134278,rs1800909,655385481,AG,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
PA166134278,rs1800909,655385482,GG,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
PA166136166,rs1800975,1444666603,CC,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166136166,rs1800975,1444666604,CT,Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166136166,rs1800975,1444666605,TT,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135058,rs1801020,1183614505,AA,Patients with the AA genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
PA166135058,rs1801020,1183614506,AG,Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
PA166135058,rs1801020,1183614507,GG,Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
PA166152849,rs1801058,1447963805,CC,Women with the CC genotype and hypertensive nephrosclerosis may have a better response to treatment with metoprolol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to metoprolol. 
PA166152849,rs1801058,1447963806,CT,Women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype.  No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol. 
PA166152849,rs1801058,1447963807,TT,"No women with the TT genotype were available for analysis, but women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype.  No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol. "
PA166158924,rs1801157,1448099830,CC,Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.
PA166158924,rs1801157,1448099831,CT,Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.
PA166158924,rs1801157,1448099832,TT,Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.
PA166134573,rs1801019,1448104907,CC,"Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CG and GG genotype. One study found no association between the CC genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence response to leucovorin, tegafur, capecitabine and fluorouracil."
PA166134573,rs1801019,1448104908,CG,"Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype. Another study found no association between the CG genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence response to leucovorin, tegafur, capecitabine and fluorouracil."
PA166134573,rs1801019,1448104909,GG,"Patients with GG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. One study found no association between the GG genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence response to leucovorin, tegafur, capecitabine and fluorouracil."
PA166135876,rs1801086,1447992059,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135876,rs1801086,1447992060,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135876,rs1801086,1447992061,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135876,rs1801086,1447992062,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135876,rs1801086,1447992063,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA, AG, CC, CG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166134845,rs1800629,1448107094,AA,"Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
"
PA166134845,rs1800629,1448107095,AG,"Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
"
PA166134845,rs1800629,1448107096,GG,Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
PA166134987,rs1800629,1183491818,AA,Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134987,rs1800629,1183491819,AG,Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134987,rs1800629,1183491820,GG,Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134163,rs1800629,1448099213,AA,Patients with the AA genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.
PA166134163,rs1800629,1448099214,AG,Patients with the AG genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.
PA166134163,rs1800629,1448099215,GG,Patients with the GG genotype and inflammatory diseases who are treated with anti-TNF therapies may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.
PA166134293,rs1800629,1448107918,AA,Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
PA166134293,rs1800629,1448107919,AG,There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.
PA166134293,rs1800629,1448107920,GG,Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
PA166135757,rs1800629,1444700993,AA,"Patients with the AA genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs."
PA166135757,rs1800629,1444700994,AG,"Patients with the AG genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs."
PA166135757,rs1800629,1444700995,GG,"Patients with the GG genotype may have decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs."
PA166159946,rs1800629,1448255943,AA,"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166159946,rs1800629,1448255942,AG,"Patients with genotype AG may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166159946,rs1800629,1448255941,GG,"Patients with genotype GG may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype AG or AA. Other genetic and clinical factors may also influence the response to sorafenib."
PA166134488,rs1801158,1448568508,CC,"Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased but not absent risk of toxicity and 2) increased DPYD activity as compared to patients with the CT genotype (DPYD *1/*4). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134488,rs1801158,1448568509,CT,"Patients with the CT genotype (DPYD *1/*4) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of toxicity and 2) decreased DPYD activity as compared to patients with the CC genotype (DPYD *1/*1). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134488,rs1801158,1448568510,TT,"No patients with the TT genotype (DPYD *4/*4) were available for analysis, but patients with the CT genotype (DPYD *1/*4) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of toxicity and 2) decreased DPYD activity as compared to patients with the CC genotype (DPYD *1/*1). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166136441,rs1801249,1446899907,AA,"Women with ovarian cancer and the AA genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136441,rs1801249,1446899908,AG,"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
"
PA166136441,rs1801249,1446899909,GG,"Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
"
PA166135904,rs1801160,1448263011,CC,"Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased metabolism of fluorouracil and 2) decreased risk for drug toxicities as compared to patients with the CT or TT genotype (DPYD *1/*6 or *6/*6). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135904,rs1801160,1448263012,CT,"Patients with the CT genotype (DPYD *1/*6) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased metabolism of fluorouracil and 2) increased risk for drug toxicities as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135904,rs1801160,1448263013,TT,"Patients with the TT genotype (DPYD *6/*6) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased metabolism of fluorouracil and 2) increased risk for drug toxicities when treated with as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166136300,rs1801252,1444703189,AA,Patients with the AA genotype who are treated with timolol may have increased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
PA166136300,rs1801252,1444703190,AG,Patients with the AG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
PA166136300,rs1801252,1444703191,GG,Patients with the GG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
PA166134270,rs1801252,982030723,AA,"Patients with the AA genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253)."
PA166134270,rs1801252,982030724,AG,"Patients with the AG genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253)."
PA166134270,rs1801252,982030725,GG,"People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253)."
PA166134489,rs1801159,1448522482,CC,"Patients with the CC genotype (DPYD *5/*5) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased likelihood of nausea, vomiting, and leukopenia, 2) decreased response and 3) decreased clearance of fluorouracil as compared to patients with the TT genotype (DPYD *1/*1). However, other studies find no associations or contradictory associations with fluoropyrimidine-induced drug toxicity or response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134489,rs1801159,1448522483,CT,"Patients with the CT genotype (DPYD *1/*5) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased response and 2) an increased likelihood of hyperammonemia as compared to patients with the TT genotype (DPYD *1/*1). However, the vast majority of studies find no association between this diplotype and fluoropyrimidine-induced drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134489,rs1801159,1448522484,TT,"Patients with the TT genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased likelihood of nausea, vomiting, and leukopenia, 2) increased response and 3) increased clearance of fluorouracil as compared to patients with the CT or CC genotype (DPYD *1/*5 or *5/*5). However, other studies find no associations or contradictory associations with fluoropyrimidine-induced drug toxicity or response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135358,rs1801131,1447945919,GG,"Cancer patients with the GG genotype may have decreased event-free survival when treated with methotrexate as compared to patients with the TT genotype. However, some conflicting or non-significant evidence exists. Other genetic and clinical factors may also influence event-free survival."
PA166135358,rs1801131,1447945920,GT,"Cancer patients with the GT genotype may have decreased event-free survival when treated with methotrexate as compared to patients with the TT genotype. However, some conflicting or non-significant evidence exists. Other genetic and clinical factors may also influence event-free survival."
PA166135358,rs1801131,1447945921,TT,"Cancer patients with the TT genotype may have increased event-free survival when treated with methotrexate as compared to patients with the GG or GT genotype. However, some conflicting or non-significant evidence exists. Other genetic and clinical factors may also influence event-free survival."
PA166134339,rs1801131,1448099623,GG,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
PA166134339,rs1801131,1448099624,GT,"Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment."
PA166134339,rs1801131,1448099625,TT,"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment."
PA166134394,rs1801131,982035724,GG,Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
PA166134394,rs1801131,982035725,GT,Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
PA166134394,rs1801131,982035726,TT,Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
PA166134404,rs1801131,1447964591,GG,"Patients with the GG genotype and ALL or lymphoma who are treated with methotrexate may have 1) a reduced risk of myelosuppression and decreased likelihood of red blood cell transfusion 2) may have an increased risk of mucositis 3) may require a lower dose, as compared to patients with the TT genotype. The majority of studies find no association with methotrexate concentrations or toxicity and genotypes of this variant. Other genetic and clinical factors may also influence a patient's dosage and risk of methotrexate-induced toxicity."
PA166134404,rs1801131,1447964592,GT,"Patients with the GT genotype and ALL or lymphoma who are treated with methotrexate may have 1) an increased risk of myelosuppression 2) may have a reduced risk of mucositis as compared to  patients with the GG genotype, and 3) may require a lower dose as compared to patients with the TT genotype. The majority of studies find no association with methotrexate concentrations or toxicity and genotypes of this variant. Other genetic and clinical factors may also influence a patient's dosage and risk of methotrexate-induced toxicity."
PA166134404,rs1801131,1447964593,TT,"Patients with the TT genotype and ALL or lymphoma who are treated with methotrexate may have 1) an increased risk of myelosuppression and an increased likelihood of red blood cell transfusion 2) may have a reduced risk of mucositis 3) may require a higher dose, as compared to  patients with the GG genotype. The majority of studies find no association with methotrexate concentrations or toxicity and genotypes of this variant. Other genetic and clinical factors may also influence a patient's dosage and risk of methotrexate-induced toxicity."
PA166134405,rs1801131,1448108282,GG,"Patients with the GG genotype who are treated with methotrexate may have a decreased likelihood of methotrexate response as compared to patients with the GT and TT genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment."
PA166134405,rs1801131,1448108283,GT,"Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GG genotype, but decreased response as compared to patients with the TT genotype. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment."
PA166134405,rs1801131,1448108284,TT,"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GT and GG genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment."
PA166134560,rs1801131,981204526,GG,"Genotype GG may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed."
PA166134560,rs1801131,981204527,GT,"Genotype GT may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed."
PA166134560,rs1801131,981204528,TT,"Genotype TT may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed."
PA166134567,rs1801131,1448522589,GG,"Patients with the GG genotype who have cancer and are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of drug toxicities and 2) decreased survival times as compared to patients with the GT or TT genotype.  However, multiple studies find conflicting or negative results for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134567,rs1801131,1448522590,GT,"Patients with the GT genotype who have cancer and are treated with fluoropyrimidine-based chemotherapy may have decreased survival times as compared to patients with the GG genotype. Evidence regarding the GT genotype and drug toxicities is conflicted. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134567,rs1801131,1448522591,TT,"Patients with the TT genotype who have cancer and are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased risk of drug toxicities and 2) increased survival times as compared to patients with the GG genotype. However, multiple studies find conflicting or negative results for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135882,rs1801131,1445400941,GG,Patients with the GG genotype and schizophrenia or schizoaffective disorder may have greater weight gain when treated with clozapine or olanzapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
PA166135882,rs1801131,1445400942,GT,Patients with the GT genotype and schizophrenia or schizoaffective disorder may have less weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
PA166134763,rs1801262,982045140,CC,Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134763,rs1801262,982045139,CT,Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134763,rs1801262,982045138,TT,Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166153407,rs1801266,1448123177,AA,Patients with the AA genotype (DPYD *8/*8) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153407,rs1801266,1448123178,AG,Patients with the AG genotype (DPYD *1/*8) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153407,rs1801266,1448123179,GG,Patients with the GG genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AA or AG genotype (DPYD *8/*8 or *1/*8). Other genetic and clinical factors may also affect DPYD activity. 
PA166134448,rs1801272,827864180,AA,Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
PA166134448,rs1801272,827864181,AT,Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
PA166134448,rs1801272,827864182,TT,Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
PA166153409,rs1801268,1447989725,AA,Patients with the AA genotype (DPYD *10/*10) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153409,rs1801268,1447989726,AC,Patients with the AC genotype (DPYD *1/*10) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153409,rs1801268,1447989727,CC,Patients with the CC genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AC or AA genotype (DPYD *1/*10 or *10/*10). Other genetic and clinical factors may also affect DPYD activity. 
PA166135222,rs1801274,1447945754,AA,Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
PA166135222,rs1801274,1447945755,GA,Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
PA166135222,rs1801274,1447945756,GG,Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
PA166136098,rs1801274,1185003578,AA,Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.
PA166136098,rs1801274,1185003579,AG,Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.
PA166136098,rs1801274,1185003580,GG,Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.
PA166136221,rs1801274,1448426978,AA,Patients with the AA genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136221,rs1801274,1448426979,AG,Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136221,rs1801274,1448426980,GG,Patients with the GG genotype and psoriasis may have a higher psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166134419,rs1801253,1444667359,CC,"Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents."
PA166134419,rs1801253,1444667360,CG,"Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents."
PA166134419,rs1801253,1444667361,GG,"Patients with the GG genotype may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents."
PA166135056,rs1801253,1183614487,CC,"Healthy males with the CC genotype may have a greater increase in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CG or GG genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure."
PA166135056,rs1801253,1183614488,CG,"Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure."
PA166135056,rs1801253,1183614489,GG,"Healthy males with the GG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure."
PA166134166,rs1801253,982033836,CC,"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment."
PA166134166,rs1801253,982033837,CG,Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
PA166134166,rs1801253,982033838,GG,Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
PA166134254,rs1801253,655385296,CC,Patients with the  CC (Arg389) genotype may have a stronger DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele. Other genetic and clinical factors may also influence the patient's response to metoprolol.
PA166134254,rs1801253,655385297,CG,Patients with the CG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.
PA166134254,rs1801253,655385298,GG,Patients with the GG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.
PA166152687,rs1801253,1447960438,CC,Patients with the CC genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
PA166152687,rs1801253,1447960439,CG,"Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines."
PA166152687,rs1801253,1447960440,GG,Patients with the GG genotype and coronary artery disease may require an increased dose of catecholamines as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
PA166152688,rs1801253,1447960450,CC,Patients with the GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
PA166152688,rs1801253,1447960451,CG,Patients with the CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
PA166152688,rs1801253,1447960452,GG,Patients with the CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
PA166135516,rs1801280,1184348732,CC,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135516,rs1801280,1184348733,CT,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166135516,rs1801280,1184348734,TT,"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 2-4 anemia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. "
PA166134966,rs1801368,1183491301,CC,"Patients with the CC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have  higher biochemical response, optimal cytoreduction, and sensitivity to the treatment as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel."
PA166134966,rs1801368,1183491300,TC,"Patients with the TC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel."
PA166134966,rs1801368,1183491299,TT,"Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel."
PA166135055,rs1801701,1183614482,CC,Patients with the CC genotype and left ventricular hypertrophy may have an increased response when treated with irbesartan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to irbesartan.
PA166135055,rs1801701,1183614483,CT,Patients with the CT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.
PA166135055,rs1801701,1183614484,TT,Patients with the TT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.
PA166152858,rs1801282,1447964004,CC,Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain. 
PA166152858,rs1801282,1447964005,CG,Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain. 
PA166152858,rs1801282,1447964006,GG,"No patients with the GG genotype were available for analysis, but patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain. "
PA166134714,rs1801260,982032759,AA,"Patients with the AA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium."
PA166134714,rs1801260,982032758,GA,"Patients with the GA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium."
PA166134714,rs1801260,982032757,GG,Patients with the GG genotype and Bipolar Disorder may have an increased risk for sleep disturbances when treated with lithium as compared to patients with the AA genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166134491,rs1801265,1448522487,AA,"Patients with the AA genotype (DPYD *1/*1) and cancer who are treated with fluorouracil may have 1) a decreased but not absent risk for drug toxicities, 2) increased response, 3) increased clearance of fluorouracil and 4) decreased DPYD activity as compared to patients with the AG or GG genotypes (DPYD *1/*9A or *9A/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134491,rs1801265,1448522488,AG,"Patients with the AG genotype (DPYD *1/*9A) and cancer who are treated with fluorouracil may have 1) an increased risk for drug toxicities, 2) decreased response and 3) increased DPYD activity as compared to patients with the AA genotype (DPYD *1/*1). Patients with the AG genotype were also found to have increased clearance of fluorouracil as compared to those with the GG genotype (DPYD *9A/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance, and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134491,rs1801265,1448522489,GG,"Patients with the GG genotype (DPYD *9A/*9A) and cancer who are treated with fluorouracil may have 1) an increased risk for drug toxicities, 2) decreased response, 3) decreased clearance of fluorouracil and 4) increased DPYD activity as compared to patients with the AA or AG genotype (DPYD *1/*1 or *1/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance, and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135054,rs1805010,1183630748,AA,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135054,rs1805010,1183630749,AG,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135054,rs1805010,1183630750,GG,Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166136476,rs1805034,1446908681,CC,"Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema."
PA166136476,rs1805034,1446908682,CT,"Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema."
PA166136476,rs1805034,1446908683,TT,"Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema."
PA166136520,rs1805015,1447946109,CC,"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
PA166136520,rs1805015,1447946110,CT,"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
PA166136520,rs1805015,1447946111,TT,"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
PA166135530,rs1803274,1444698449,CC,Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135530,rs1803274,1444698450,CT,Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135530,rs1803274,1444698451,TT,Patients with the TT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166153430,rs1803274,1447990056,CC,"Patients with the CC genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, and as compared to patients with the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease."
PA166153430,rs1803274,1447990057,CT,"Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease."
PA166153430,rs1803274,1447990058,TT,"Patients with the TT genotype and Lewy Body disease or Alzheimer's disease may have worse response to rivastigmine as compared to patients with the CC genotype, as well as the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease."
PA166158753,rs1803274,1448097839,CC,Patients with the CC genotype may be less likely to develop an addiction to cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to cocaine.
PA166158753,rs1803274,1448097840,CT,Patients with the CT genotype may be less likely to develop an addiction to cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to cocaine.
PA166158753,rs1803274,1448097841,TT,Patients with the TT genotype may be less likely to develop an addiction to cocaine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also be associated with addiction to cocaine.
PA166152689,rs1805054,1447960460,CC,Patients with the CC genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
PA166152689,rs1805054,1447960461,CT,Patients with the CT genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
PA166152689,rs1805054,1447960462,TT,Patients with the TT genotype and schizophrenia may have lower weight gain when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
PA166134953,rs1801394,1183491040,AA,Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
PA166134953,rs1801394,1183491041,AG,Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
PA166134953,rs1801394,1183491042,GG,Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have increased severity of pain as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
PA166134504,rs1801394,1448106021,AA,Pediatric ALL patients with AA genotypes may have  decreased likelihood of methotrexate induced toxicity (oral mucositis) and decreased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the GG and AG genotype. Other genetic and clinical factors may also influence response to methotrexate.
PA166134504,rs1801394,1448106022,AG,"Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate."
PA166134504,rs1801394,1448106023,GG,Pediatric ALL patients with GG genotypes may have  increased likelihood of methotrexate induced toxicity (oral mucositis) and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.
PA166152808,rs1805094,1447963051,CC,Patients with the CC genotype were not studied. Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
PA166152808,rs1805094,1447963052,CG,Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
PA166152808,rs1805094,1447963053,GG,Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
PA166135715,rs1816702,1444686960,CC,"Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135715,rs1816702,1444686961,CT,"Patients with the CT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135715,rs1816702,1444686962,TT,"Patients with the TT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166158997,rs1804645,1448100652,CC,Female patients with the CC genotype may have less of a decrease in bone mineral density when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen. 
PA166158997,rs1804645,1448100653,CT,Female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen. 
PA166158997,rs1804645,1448100654,TT,"No patients with the TT genotype were available for analysis, but female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen. "
PA166159159,rs1805128,1448102348,CC,"Patients with the CC genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of torsades de pointes. 
"
PA166159159,rs1805128,1448102349,CT,"Patients with the CT genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes. "
PA166159159,rs1805128,1448102350,TT,Patients with the TT genotype may have an increased risk of drug-induced torsades de pointes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes. 
PA166163555,rs181781,1448613250,AA,Patients with the AA genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
PA166163555,rs181781,1448613251,AG,Patients with the AG genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
PA166163555,rs181781,1448613252,GG,Patients with the GG genotype and kidney transplantation may have decreased exposure (Concentration/Dose) to tacrolimus compared to patients with the AG and AA genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
PA166135219,rs1806201,1183629476,AA,Patients with the AA genotype who are treated with quetiapine may have an increased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
PA166135219,rs1806201,1183629477,AG,Patients with the AG genotype who are treated with quetiapine may have a decreased  likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
PA166135219,rs1806201,1183629478,GG,Patients with the GG genotype who are treated with quetiapine may have a decreased  likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
PA166135220,rs1806201,1183629485,AA,Patients with the AA genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG  genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone. 
PA166135220,rs1806201,1183629486,AG,Patients with the AG genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG  genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone. 
PA166135220,rs1806201,1183629487,GG,Patients with the GG genotype who are treated with risperidone may have an increased likelihood of adverse reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone. 
PA166151937,rs183205964,1447953074,CC,"Patients with the CC genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients."
PA166151937,rs183205964,1447953075,CG,"Patients with the CG genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients."
PA166151937,rs183205964,1447953076,GG,"Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients."
PA166152690,rs183484,1447960475,AA,Patients with the AA genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine. 
PA166152690,rs183484,1447960476,AC,Patients with the AC genotype and cancer may have shorter progression-free survival times when treated with gemcitabine as compared to patients with the AA or CC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine. 
PA166152690,rs183484,1447960477,CC,Patients with the CC genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine. 
PA166135955,rs1872328,1446903529,AA,Pediatric patients with brain tumors and the AA genotype may have an increased risk of experiencing hearing loss when treated with regimens containing cisplatin as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hearing-loss in pediatric patients exposed to cisplatin. 
PA166135955,rs1872328,1446903530,AG,Pediatric patients with brain tumors and the AG genotype may have an increased risk of experiencing hearing loss when treated with regimens containing cisplatin as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hearing-loss in pediatric patients exposed to cisplatin. 
PA166135955,rs1872328,1446903531,GG,Pediatric patients with brain tumors and the GG genotype may have a decreased risk of experiencing hearing loss when treated with regimens containing cisplatin as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of hearing-loss in pediatric patients exposed to cisplatin. 
PA166151956,rs1875705,1447953313,AA,Patients with the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166151956,rs1875705,1447953314,AG,Patients with the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166151956,rs1875705,1447953315,GG,Patients with the GG genotype may have an increased response to risperidone as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166159864,rs1870377,1448126024,AA,"Patients with genotype AA may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib."
PA166159864,rs1870377,1448126023,AT,"Patients with genotype AT may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib."
PA166159864,rs1870377,1448126022,TT,"Patients with genotype TT may have increased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to sorafenib."
PA166160287,rs1870377,1448259029,AA,Patients with the AA genotype may have decreased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype TT.
PA166160287,rs1870377,1448259028,AT,Patients with the AT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.
PA166160287,rs1870377,1448259027,TT,Patients with the TT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.
PA166134327,rs1871450,1000539652,AA,Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134327,rs1871450,1000539653,AG,Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134327,rs1871450,1000539654,GG,Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166135053,rs1805087,1183614471,AA,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
PA166135053,rs1805087,1183614472,AG,Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
PA166135053,rs1805087,1183614473,GG,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
PA166134581,rs1805087,981237705,AA,"Patients with the AA genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134581,rs1805087,981237706,AG,"Patients with the AG genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134581,rs1805087,981237707,GG,"Patients with the GG genotype may have: 1) increased likelihood of Drug Toxicity, 2) decreased response when treated with methotrexate as compared to patients with genotypes AA or AG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134582,rs1805087,1183679790,AA,"Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine."
PA166134582,rs1805087,1183679791,AG,"Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine."
PA166134582,rs1805087,1183679792,GG,"Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine."
PA166159157,rs187238,1448102871,CC,"Patients with the CC genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy. 
"
PA166159157,rs187238,1448102872,CG,"Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy. 
"
PA166159157,rs187238,1448102873,GG,"Patients with the GG genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy. 
"
PA166135775,rs1877724,1444703210,CC,Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166135775,rs1877724,1444703211,CT,Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166135775,rs1877724,1444703209,TT,Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166136341,rs1880676,1444706863,AA,Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166136341,rs1880676,1444706864,AG,Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype.or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166136341,rs1880676,1444706865,GG,Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134449,rs1876828,1447961357,CC,Patients with the CC genotype may have 1) decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) increased endogenous cortisol compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.
PA166134449,rs1876828,1447961358,CT,Patients with the CT genotype may have decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment). Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.
PA166134449,rs1876828,1447961359,TT,Patients with the TT genotype may have 1) increased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) altered hypothalamic pituitary adrenal axis and decreased endogenous cortisol compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.
PA166151932,rs1884613,1448106507,CC,Patients with the CC genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
PA166151932,rs1884613,1448106508,CG,Patients with the CG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
PA166151932,rs1884613,1448106509,GG,Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
PA166136293,rs1886629,1444701021,CC,Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
PA166136293,rs1886629,1444701020,CT,Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
PA166136293,rs1886629,1444701019,TT,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
PA166158874,rs1891059,1448099061,AA,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166158874,rs1891059,1448099062,AG,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166158874,rs1891059,1448099063,GG,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166135776,rs1901440,1444703219,AA,"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
PA166135776,rs1901440,1444703218,AC,"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
PA166135776,rs1901440,1444703217,CC,Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
PA166135777,rs1901633,1444703227,AA,Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135777,rs1901633,1444703226,AG,Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135777,rs1901633,1444703225,GG,Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134326,rs1883322,655386167,CC,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134326,rs1883322,655386168,CT,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134326,rs1883322,655386169,TT,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134973,rs1922242,1183491381,AA,Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134973,rs1922242,1183491382,AT,Patients with the AT genotype and Hypercholesterolemia may have a reduced  response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134973,rs1922242,1183491383,TT,"Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. "
PA166135593,rs1927907,1184986573,CC,Organ transplant patients with the CC genotype who are administered tacrolimus may have increased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and TT genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients. 
PA166135593,rs1927907,1184986574,CT,Organ transplant patients with the CT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CC genotype. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients. 
PA166135593,rs1927907,1184986575,TT,Organ transplant patients with the TT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and CC genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients. 
PA166135927,rs1933437,1446897668,AA,"Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have an increased risk of experiencing adverse events such as neutropenia, and leukopenia, as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence risk of leukopenia, neutropenia, or other toxicities in patients with renal cell carcinoma who are administered sunitinib."
PA166135927,rs1933437,1446897669,AG,"Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have a decreased risk of experiencing adverse events such as neutropenia, and leukopenia, as compared to patients with the AA genotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence risk of leukopenia, neutropenia, or other toxicities in patients with renal cell carcinoma who are administered sunitinib."
PA166135927,rs1933437,1446897670,GG,"Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have a decreased risk of experiencing adverse events such as neutropenia, and leukopenia, as compared to patients with the AA genotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence risk of leukopenia, neutropenia, or other toxicities in patients with renal cell carcinoma who are administered sunitinib."
PA166134135,rs1934951,655384601,CC,Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
PA166134135,rs1934951,655384600,CT,Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
PA166134135,rs1934951,655384599,TT,Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
PA166136382,rs1934951,1448263857,CC,"Patients with the CC genotype and breast cancer may have a decreased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for anemia."
PA166136382,rs1934951,1448263858,CT,"Patients with the CT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia."
PA166136382,rs1934951,1448263859,TT,"Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia."
PA166134299,rs1883112,1448099381,AA,Cancer patients with the AA genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166134299,rs1883112,1448099382,AG,"Cancer patients with the AG genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166134299,rs1883112,1448099383,GG,"Cancer patients with the GG genotype who are treated with doxorubcin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166135352,rs1934969,1185235061,AA,"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism."
PA166135352,rs1934969,1185235062,AT,"Patients with the AT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results.  Other genetic and clinical factors may also influence a patient's losartan metabolism."
PA166135352,rs1934969,1185235063,TT,"Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism."
PA166136379,rs1934969,1445401441,AA,Patients with the AA genotype and epilepsy may have decreased dose-adjusted trough concentrations of phenytoin as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
PA166136379,rs1934969,1445401442,AT,Patients with the AT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
PA166136379,rs1934969,1445401443,TT,Patients with the TT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
PA166134758,rs1937840,982043294,CC,"Breast cancer patients with GC + CC genotypes have decreased progression-free survival (PFS), overall survival (OS) and, increased absolute leucocyte and neutrophil counts when treated with docetaxel and doxorubicin when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy."
PA166134758,rs1937840,982043295,GC,"Breast cancer patients with GC + CC genotypes have decreased progression-free survival (PFS), overall survival (OS) and, increased absolute leucocyte and neutrophil counts when treated with docetaxel and doxorubicin when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy."
PA166134758,rs1937840,982043296,GG,"Breast cancer patients with GG genotypes have increased progression-free survival (PFS), overall survival (OS) and, decreased absolute leucocyte and neutrophil counts when treated with docetaxel and doxorubicin when compared to patients with CC + GC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy."
PA166135489,rs193922525,1184472609,AA,"Patients with the AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135489,rs193922525,1184472610,AG,"Patients with the AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135489,rs193922525,1184472611,GG,"Patients with the GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166134273,rs1935349,655385428,CC,"Patients with the CC genotype may have decreased but not non-existent, risk for statin-related myalgia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins."
PA166134273,rs1935349,655385429,CT,"Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins."
PA166134273,rs1935349,655385430,TT,Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.
PA166134390,rs1902023,1447963593,AA,Subjects with the AA genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.
PA166134390,rs1902023,1447963594,AC,"Subjects with the AC genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam."
PA166134390,rs1902023,1447963595,CC,Subjects with the CC genotype may have increased clearance of oxazepam or lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam. 
PA166136485,rs193922753,1447992023,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GT and TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166136485,rs193922753,1447992024,GT,"Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166136485,rs193922753,1447992025,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the T allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135879,rs193922747,1447992405,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135879,rs193922747,1447992406,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135879,rs193922747,1447992407,TT,"Patients with the TT genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135975,rs193922807,1447992321,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the C allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135975,rs193922807,1447992322,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166135975,rs193922807,1447992323,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166151936,rs193922770,1447992193,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166151936,rs193922770,1447992194,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166151936,rs193922770,1447992195,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known."
PA166135971,rs193922809,1447992326,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to cause MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135971,rs193922809,1447992327,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. The A allele is considered to confer MH in an autosomal dominant manner. Based on the classification as Malignant Hyperthermia susceptible the use of desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane or succinylcholine is contraindicated. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135971,rs193922809,1447992328,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136353,rs193922803,1448615845,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166136353,rs193922803,1448615846,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  "
PA166136353,rs193922803,1448615847,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known."
PA166136356,rs193922802,1447992305,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.  Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known."
PA166136356,rs193922802,1447992306,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166136356,rs193922802,1447992307,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166136355,rs193922772,1447992240,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GT. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136355,rs193922772,1447992241,GT,"Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136355,rs193922772,1447992242,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166136351,rs193922876,1447992473,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. "
PA166136351,rs193922876,1447992474,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the  the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. "
PA166136351,rs193922876,1447992475,TT,"Patients with the TT genotype may develop of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known."
PA166134571,rs1801133,1448568563,AA,"Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs."
PA166134571,rs1801133,1448568564,AG,"Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs."
PA166134571,rs1801133,1448568565,GG,"Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs."
PA166134341,rs1801133,655386551,AA,Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134341,rs1801133,655386552,AG,Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134341,rs1801133,655386553,GG,"Has average risk for metabolic syndrome when treated with antipsychotics.
Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134393,rs1801133,655387836,AA,Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
PA166134393,rs1801133,655387837,AG,Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
PA166134393,rs1801133,655387838,GG,Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
PA166134429,rs1801133,1448124407,AA,"Patients with the AA genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the AG or GG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment."
PA166134429,rs1801133,1448124408,AG,"Patients with the AG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the GG genotype, or 1) may have better response to treatment 2) may be at decreased risk of toxicity, and 3) may require a higher dose of methotrexate as compared to patients with the AA genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment."
PA166134429,rs1801133,1448124409,GG,"Patients with the GG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have better response to treatment 2) may be at decreased risk of toxicity 3) may require a higher dose of methotrexate, and 4) may be at lower risk of folate deficiency as compared to patients with the AA or AG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment."
PA166134972,rs1801133,1183491367,AA,Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
PA166134972,rs1801133,1183491366,AG,Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
PA166134972,rs1801133,1183491365,GG,Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
PA166134984,rs1801133,1183491784,AA,Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134984,rs1801133,1183491785,AG,Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease  as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134984,rs1801133,1183491786,GG,Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease  as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166135057,rs1801133,1183614500,AA,Patients with the AA genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.
PA166135057,rs1801133,1183614501,AG,Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.
PA166135057,rs1801133,1183614502,GG,Patients with the GG genotype and cocaine dependence may have a decreased response when treated with disulfiram as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to disulfiram.
PA166135111,rs1801133,1445402423,AA,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
PA166135111,rs1801133,1445402424,AG,Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
PA166135111,rs1801133,1445402425,GG,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
PA166134572,rs1801133,981204930,AA,Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.
PA166134572,rs1801133,981204931,AG,Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.
PA166134572,rs1801133,981204932,GG,Patients with the GG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.
PA166134574,rs1801133,981204976,AA,"Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine."
PA166134574,rs1801133,981204977,AG,"Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine."
PA166134574,rs1801133,981204978,GG,"Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine."
PA166134575,rs1801133,981204986,AA,"Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patient's response to cisplatin."
PA166134575,rs1801133,981204987,AG,"Patients with the AG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin."
PA166134575,rs1801133,981204988,GG,"Patients with the GG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin."
PA166134577,rs1801133,982031653,AA,Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's response to carboplatin.
PA166134577,rs1801133,982031654,AG,Patients with AG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.
PA166134577,rs1801133,982031655,GG,Patients with GG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.
PA166135681,rs1801133,1444666765,AA,Patients with the AA genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.
PA166135681,rs1801133,1444666766,AG,Patients with the AG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.
PA166135681,rs1801133,1444666767,GG,Patients with the GG genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall survival time.
PA166134454,rs1801133,978608465,AA,Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.
PA166134454,rs1801133,978608466,AG,Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.
PA166134454,rs1801133,978608467,GG,Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.
PA166134256,rs1801133,1448108634,AA,Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
PA166134256,rs1801133,1448108635,AG,"Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment."
PA166134256,rs1801133,1448108636,GG,"Patients with the GG genotype and Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events and toxicity as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment."
PA166136496,rs1801133,1448106501,AA,"Patients with genotype AA and colonic neoplasms may have decreased response to  fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with genotypes AG and GG. However, other studies showed as increased response to oxaliplatin. Studies also conflict as to whether patients with AA genotype are at increased risk of toxicity, such as developing neutropenia, when taking oxaliplatin, compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin."
PA166136496,rs1801133,1448106502,AG,"Patients with genotype AG and colonic neoplasms may have decreased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with genotypes GG. However, other studies showed an increased response to oxaliplatin. Studies also conflict as to whether patients with AG genotype are at increased risk of toxicity, such as developing neutropenia, when taking oxaliplatin, compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin."
PA166136496,rs1801133,1448106503,GG,"Patients with genotype GG and colonic neoplasms may have increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with genotypes AA and AG. However, other studies showed decreased response to oxaliplatin. Studies also conflict as to whether patients with AA genotype are at increased risk of toxicity, such as developing neutropenia, when taking oxaliplatin, compared to patients with AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin."
PA166136198,rs1946518,1448603642,GG,"Patients with the GG genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.
"
PA166136198,rs1946518,1448603643,GT,"Patients with the GT genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.
"
PA166136198,rs1946518,1448603644,TT,"Patients with the TT genotype and kidney or lung transplantation may experience increased metabolism of tacrolimus resulting in decreased exposure as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence metabolism of tacrolimus.
"
PA166159158,rs1946518,1448102865,GG,"Patients with the GG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy. 
"
PA166159158,rs1946518,1448102866,GT,"Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy. 
"
PA166159158,rs1946518,1448102867,TT,"Patients with the TT genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy. 
"
PA166136357,rs193922816,1447992346,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166136357,rs193922816,1447992347,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166136357,rs193922816,1447992348,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia."
PA166134703,rs1948308,982032480,AA,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134703,rs1948308,982032479,AG,Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134703,rs1948308,982032478,GG,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166152876,rs1947275,1447964252,CC,Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152876,rs1947275,1447964253,CT,Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152876,rs1947275,1447964254,TT,Patients with the TT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166135974,rs193922878,1447992486,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CG or GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135974,rs193922878,1447992487,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135974,rs193922878,1447992488,GG,"Patients with the GG genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135052,rs1969624,1183613867,CC,Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135052,rs1969624,1183613868,CT,"Patients with the CT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135052,rs1969624,1183613869,TT,Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166134665,rs1992647,982030868,AA,Patients with the AA genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134665,rs1992647,982030869,AG,Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134665,rs1992647,982030870,GG,Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166136001,rs1967309,1448126004,AA,Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo. 
PA166136001,rs1967309,1448126005,AG,"Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo. "
PA166136001,rs1967309,1448126006,GG,Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo. 
PA166135973,rs193922818,1447992371,AA,"Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135973,rs193922818,1447992372,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. The A allele is considered to confer MH in an autosomal dominant manner. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166135973,rs193922818,1447992373,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia."
PA166153070,rs199695765,1447983221,CC,Patients with the CC genotype may have decreased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
PA166153070,rs199695765,1447983220,CT,Patients with the CT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
PA166153070,rs199695765,1447983219,TT,Patients with the TT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
PA166153039,rs201045130,1447982822,AA,"Patients with the AA genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
PA166153039,rs201045130,1447982821,AG,"No information are available for the AG genotype. However, patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
PA166153039,rs201045130,1447982820,GG ,"Patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
PA166135537,rs1990040,1184514459,AA,Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135537,rs1990040,1184514460,AG,Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135537,rs1990040,1184514461,GG,Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135641,rs2003569,1296666991,AA,Patients with the AA genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
PA166135641,rs2003569,1296666992,AG,Patients with the AG genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
PA166135641,rs2003569,1296666993,GG,Patients with the GG genotype may have decreased response to simvastatin (higher LDL lowering effect) as compared to patients withe the AA or AG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
PA166153063,rs200148,1447983158,AA,Patients with the AA genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
PA166153063,rs200148,1447983159,AG,Patients with the AG genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
PA166153063,rs200148,1447983160,GG ,No information were reported regarding patients with the GG genotype.
PA166134757,rs2010851,982042113,AA,Colon cancer patients with  AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the  tumor recurrence time.
PA166134757,rs2010851,982042112,CA,Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the  tumor recurrence time.
PA166134757,rs2010851,982042111,CC,Colon cancer patients with CC genotype may have shorter time to tumor recurrence when treated 5-fluorouracil compared to patients with CA + AA genotypes. Other genetic and clinical factors may also influence the  tumor recurrence time.
PA166134903,rs1979277,1043880842,AA,"Patients with the AA genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin."
PA166134903,rs1979277,1043880843,AG,"Patients with the AG genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin."
PA166134903,rs1979277,1043880844,GG,"Patients with the GG genotype and Colorectal Neoplasms may have 1) decreased response, 2) decreased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin."
PA166134600,rs1979277,1448107640,AA,Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134600,rs1979277,1448107641,AG,Patients with the AG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype or may have decreased red blood cell folate as compared to patients with the AA genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134600,rs1979277,1448107642,GG,Patients with the GG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have decreased red blood cell folate as compared to patients with the AA genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134601,rs1979277,981481601,AA,"Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134601,rs1979277,981481602,AG,"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134601,rs1979277,981481603,GG,"Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166136002,rs201279313,1447814393,TTA/TTA,"Patients with the TTA/TTA genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/del genotype. Other genetic and clinical factors may also influence a patient's response."
PA166136002,rs201279313,1447814394,TTA/del,"Patients with the TTA/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/TTA genotype. Other genetic and clinical factors may also influence a patient's response."
PA166136002,rs201279313,1447814395,del/del,"No patients with del/del were studied. However, patients with the del/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/TTA genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134406,rs2016848,699639344,AA,Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.
PA166134406,rs2016848,699639345,AG,Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.
PA166134406,rs2016848,699639346,GG,"Patients with the GG genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment."
PA166135414,rs2010963,1183703001,CC,Patients with the CC genotype and prostate cancer may have shorter progression-free survival time when treated with cyclophosphamide as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence length of progression-free survival.
PA166135414,rs2010963,1183703002,CG,Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.
PA166135414,rs2010963,1183703003,GG,Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.
PA166136135,rs2010963,1444608134,CC,"Patients with the CC genotype and choroidal neovascularization may have a poorer response to anti-VEGF treatment, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment. "
PA166136135,rs2010963,1444608135,CG,"Patients with the CG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment. "
PA166136135,rs2010963,1444608136,GG,"Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment. "
PA166152924,rs2010963,1447979497,CC,Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152924,rs2010963,1447979496,CG,Patients with the CG genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152924,rs2010963,1447979495,GG,Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to sorafenib.
PA166159249,rs2010963,1448104355,CC,Patients with the CC genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
PA166159249,rs2010963,1448104356,CG,Patients with the CG genotype and colorectal cancer may have a poorer response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
PA166159249,rs2010963,1448104357,GG,Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
PA166136000,rs2010963,1447814182,CC,"Patients with the CC genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166136000,rs2010963,1447814181,CG,"Patients with the CG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166136000,rs2010963,1447814180,GG,"Patients with the GG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166134325,rs2016520,655386162,CC,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134325,rs2016520,655386163,CT,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134325,rs2016520,655386164,TT,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134656,rs1954787,1448099858,CC,Patients with the CC genotype and Depressive Disorder or Depression may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants. 
PA166134656,rs1954787,1448099859,CT,Patients with the CT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants. 
PA166134656,rs1954787,1448099860,TT,Patients with the TT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants. 
PA166136054,rs2011425,1447980838,GG,"Patients with the GG genotype and epilepsy who are administered lamotrigine may have decreased serum concentrations of lamotrigine, as well as a worse response to lamotrigine, and may need a lower dose as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism, response, and dose of lamotrigine.  "
PA166136054,rs2011425,1447980839,GT,"Patients with the GT genotype and epilepsy who are administered lamotrigine may have decreased serum concentrations of lamotrigine, as well as worse response to lamotrigine, and may need a lower dose as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism, response, and dose of lamotrigine.  "
PA166136054,rs2011425,1447980840,TT,"Patients with the TT genotype and epilepsy who are administered lamotrigine may have increased serum concentrations of lamotrigine, as well as improved response to lamotrigine, and may need a higher dose as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism, response, and dose of lamotrigine.  "
PA166159472,rs2011425,1448112198,GG,Patients with the GG genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.
PA166159472,rs2011425,1448112199,GT,Patients with the GT genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.
PA166159472,rs2011425,1448112200,TT,Patients with the TT genotype and breast cancer may have decreased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the GG and GT genotypes. Other clinical and genetic factors may affect the metabolism of tamoxifen.
PA166152842,rs2036657,1447963676,AA,Patients with the AA genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
PA166152842,rs2036657,1447963677,AG,"Patients with the AG genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction."
PA166152842,rs2036657,1447963678,GG,Patients with the GG genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
PA166159420,rs2019604,1448109804,GG,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159420,rs2019604,1448109805,GT,"Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159420,rs2019604,1448109806,TT,"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166134049,rs2032583,1448276546,AA,"Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects."
PA166134049,rs2032583,1448276547,AG,"Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects."
PA166134049,rs2032583,1448276548,GG,"Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects."
PA166136212,rs2054675,1444673034,CC,"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
PA166136212,rs2054675,1444673035,CT,"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
PA166136212,rs2054675,1444673036,TT,"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
PA166152867,rs2031920,1447964151,CC,"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity."
PA166152867,rs2031920,1447964152,CT,"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity."
PA166152867,rs2031920,1447964153,TT,"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity."
PA166134148,rs20417,655384681,CC,Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
PA166134148,rs20417,655384682,CG,Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
PA166134148,rs20417,655384683,GG,Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
PA166134420,rs20417,827836552,CC,Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
PA166134420,rs20417,827836553,CG,Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
PA166134420,rs20417,827836554,GG,Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
PA166134542,rs20417,981204108,CC,"Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
PA166134542,rs20417,981204109,CG,"Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
PA166134542,rs20417,981204110,GG,"Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
PA166152776,rs2056527,1447961396,CC,Smokers with the CC genotype who are treated with nicotine gum or nicotine patches may have a greater likelihood of abstinence as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
PA166152776,rs2056527,1447961397,CT,Smokers with the CT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
PA166152776,rs2056527,1447961398,TT,Smokers with the TT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
PA166136216,rs20575,1444673074,CC,Patients with the CC genotype and rheumatoid or psoriatic arthritis may have a better response when treated with anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies. 
PA166136216,rs20575,1444673075,CG,Patients with the CG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies. 
PA166136216,rs20575,1444673076,GG,Patients with the GG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies. 
PA166134311,rs20572,1448105706,CC,Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
PA166134311,rs20572,1448105707,CT,Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
PA166134311,rs20572,1448105708,TT,Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
PA166136064,rs2058878,1184988862,AA,Patients with the AA genotype and alcoholism may have an increased response to acamprosate as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism. 
PA166136064,rs2058878,1184988863,AT,Patients with the AT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the TT genotype and a decreased response as compared to patients with the AT genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism. 
PA166136064,rs2058878,1184988864,TT,Patients with the TT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism. 
PA166135122,rs2066844,1183615431,CC,Patients with the CC genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
PA166135122,rs2066844,1183615432,CT,Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
PA166135122,rs2066844,1183615433,TT,Patients with the TT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
PA166135265,rs2061051,1183632161,AA,Patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166135265,rs2061051,1183632162,AG,Patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166135265,rs2061051,1183632163,GG,Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166151959,rs2069062,1447953349,CC,Patients with the CC genotype may have increased response to risperidone as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166151959,rs2069062,1447953350,CG,Patients with the CG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166151959,rs2069062,1447953351,GG,Patients with the GG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134766,rs2069502,1448105567,CC,Patient with CC genotype may have decreased IGH-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CT + TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. 
PA166134766,rs2069502,1448105568,CT,Patient with CT + TT genotypes may have increased IGH-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. 
PA166134766,rs2069502,1448105569,TT,Patient with CT + TT genotypes may have increased IGH-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. 
PA166134482,rs2046934,1448601688,AA,"Patients with the AA genotype may have increased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the GG or AG genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel."
PA166134482,rs2046934,1448601689,AG,"Patients with the AG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel."
PA166134482,rs2046934,1448601690,GG,"Patients with the GG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel."
PA166159665,rs2046934,1448124244,AA,Patients with the AA genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166159665,rs2046934,1448124245,AG,Patients with the AG genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166159665,rs2046934,1448124246,GG,Patients with the GG genotype may have decreased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166135199,rs2069521,1183622528,AA,Patients with the AA genotype and major depressive disorder who are treated with escitalopram may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135199,rs2069521,1183622529,AG,Patients with the AG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype or may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135199,rs2069521,1183622530,GG,Patients with the GG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135200,rs2069526,1183622562,GG,Patients with the GG genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram. 
PA166135200,rs2069526,1183622563,GT,Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced  metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram. 
PA166135200,rs2069526,1183622564,TT,Patients with the TT genotype and major depressive disorder may have reduced  metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram. 
PA166153064,rs2070296,1447983167,CC,Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166153064,rs2070296,1447983166,CT,Patients with the CT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166153064,rs2070296,1447983165,TT,Patients with the TT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134928,rs2070676,1148508970,CC,"Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis."
PA166134928,rs2070676,1148508971,CG,"Female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis."
PA166134928,rs2070676,1148508972,GG,"Patients with the GG genotype were not studied but female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis."
PA166135318,rs2070673,1183684145,AA,"Patients with the AA genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135318,rs2070673,1183684146,AT,"Patients with the AT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype and an increased likelihood of toxic liver disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135318,rs2070673,1183684147,TT,"Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166134484,rs2069514,981201889,AA,Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
PA166134484,rs2069514,981201890,AG,Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
PA166134484,rs2069514,981201891,GG,Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
PA166134465,rs2070744,981201444,CC,Patients with the CC genotype may have increased risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
PA166134465,rs2070744,981201445,CT,Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
PA166134465,rs2070744,981201446,TT,Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
PA166134373,rs2070744,655387015,CC,Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.
PA166134373,rs2070744,655387016,CT,Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.
PA166134373,rs2070744,655387017,TT,Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.
PA166134282,rs2070744,655385580,CC,Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.
PA166134282,rs2070744,655385581,CT,"Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance."
PA166134282,rs2070744,655385582,TT,"Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance."
PA166136294,rs2070744,1444701026,CC,Patients with the CC genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.
PA166136294,rs2070744,1444701027,CT,Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.
PA166136294,rs2070744,1444701028,TT,Patients with the TT genotype may have decreased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to sildenafil.
PA166152692,rs2070744,1447960486,CC,Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
PA166152692,rs2070744,1447960487,CT,Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
PA166152692,rs2070744,1447960488,TT,Patients with the TT genotype and hypertension may have a lesser reduction in blood pressure when treated with enalapril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
PA166152926,rs2070744,1447979511,CC,Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152926,rs2070744,1447979510,CT,Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152926,rs2070744,1447979509,TT,Patients with the TT genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to sorafenib.
PA166134332,rs2070995,1448103922,CC,"Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CC genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone. "
PA166134332,rs2070995,1448103923,CT,"Patients with the CT genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CT genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone. "
PA166134332,rs2070995,1448103924,TT,"Patients with the TT genotype and post-operative pain may be more likely to require rescue analgesic administration as compared to patients with the CT or CC genotype.  Additionally, patients with the TT genotype who are addicted to heroin may require an increased dose of methadone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone. "
PA166159201,rs2070995,1448103912,CC,Patients with the CC genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
PA166159201,rs2070995,1448103913,CT,Patients with the CT genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
PA166159201,rs2070995,1448103914,TT,Patients with the TT genotype who are addicted to heroin may have decreased withdrawal symptoms when treated with methadone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
PA166135780,rs2071197,1444703254,AA,Patients with the AA genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
PA166135780,rs2071197,1444703253,AG,Patients with the AG genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
PA166135780,rs2071197,1444703252,GG,Patients with the GG genotype and Epilepsy who are treated with carbamazepine may have  increased concentration-to-dose ratios as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
PA166158986,rs2071197,1448263590,AA,"Patients with the AA genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AG and GG genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other factors may affect concentration of lamotrigine."
PA166158986,rs2071197,1448263591,AG,"Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotype. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine."
PA166158986,rs2071197,1448263592,GG,"Patients with the GG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine."
PA166158955,rs2071303,1448100224,CC,Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
PA166158955,rs2071303,1448100225,CT,Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
PA166158955,rs2071303,1448100226,TT,Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
PA166134458,rs2070959,981188354,AA,Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.
PA166134458,rs2070959,981188355,AG,Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.
PA166134458,rs2070959,981188356,GG,Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.
PA166136217,rs2070959,1444673117,AA,"Patients with the AA genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
PA166136217,rs2070959,1444673118,AG,"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
PA166136217,rs2070959,1444673119,GG,"Patients with the GG genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
PA166134711,rs2071427,1043818287,CC,"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium. "
PA166134711,rs2071427,1043818288,CT,"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium. "
PA166134711,rs2071427,1043818289,TT,"Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium. "
PA166159041,rs2072658,1448101215,AA,"No patients with the AA genotype were available for analysis, but patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking."
PA166159041,rs2072658,1448101216,AG,Patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
PA166159041,rs2072658,1448101217,GG,Patients with the GG genotype who are smokers may have decreased physical responses to smoking as compared to patients with the AG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
PA166159814,rs2071559,1448126028,AA,"Patients with AA genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166159814,rs2071559,1448126029,AG,"Patients with AG genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
PA166159814,rs2071559,1448126030,GG,"Patients with GG genotype may have increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib."
PA166136263,rs2071888,1444700470,CC,Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166136263,rs2071888,1444700469,CG,Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. 
PA166136263,rs2071888,1444700468,GG,Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. 
PA166159037,rs2072660,1448101177,CC,Patients with the CC genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166159037,rs2072660,1448101178,CT,"Patients with the CT genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
PA166159037,rs2072660,1448101179,TT,Patients with the TT genotype may have an increased risk for smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166135925,rs2073618,1446897548,CC,"Patients with breast cancer and the CC genotype may have an increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CG and GG. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases who are taking anastrozole or letrozole."
PA166135925,rs2073618,1446897549,CG,"Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole."
PA166135925,rs2073618,1446897550,GG,"Patients with breast cancer and the GG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CC. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole."
PA166134140,rs20455,1043737552,AA,"Patients with the AA genotype may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the AG or GG genotype. Patients with the AA genotype may have a poorer response to statin treatment than patients with the GG or AG genotype. However, contradictory results have also been reported. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events."
PA166134140,rs20455,1043737553,AG,"Patients with the AG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Statin treatments (Pravastatin or atorvastatin) substantially reduced that risk. Patients with the AG genotype may have a better statin response than patients with the AA genotype.  However, contradictory results have also been reported. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events."
PA166134140,rs20455,1043737554,GG,"Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Statin treatment (Pravastatin or atorvastatin)  substantially reduced that risk. Patients with the GG genotype may have a better statin response than patients with the AA genotype.  However, contradictory results have also been reported. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events."
PA166134977,rs20455,1183491459,AA,Patients with the AA genotype may have a lower risk of coronary disease and may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134977,rs20455,1183491460,AG,Patients with the AG genotype may have a higher risk of coronary disease and may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134977,rs20455,1183491461,GG,Patients with the GG genotype may have a higher risk of coronary disease and may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134978,rs20455,1183491451,AA,Patients with the AA genotype may have a lower risk of coronary disease and may be less likely to benefit from atorvastatin treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134978,rs20455,1183491452,AG,Patients with the AG genotype may have a higher risk of coronary disease and may be more likely to benefit from atorvastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134978,rs20455,1183491453,GG,Patients with the GG genotype may have a higher risk of coronary disease and may be more likely to benefit from atorvastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134079,rs2075252,1448098963,CC,Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.
PA166134079,rs2075252,1448098964,CT,Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.
PA166134079,rs2075252,1448098965,TT,Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.
PA166152722,rs2073724,1447960777,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152722,rs2073724,1447960778,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152722,rs2073724,1447960779,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166151950,rs2075572,1447953265,CC,Patients with the CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's severity of sleep disorders when treated with methadone.
PA166151950,rs2075572,1447953266,CG,Patients with the CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's severity of sleep disorders when treated with methadone.
PA166151950,rs2075572,1447953267,GG,"No data is available for patients with GG genotype, but one might expect patients with the GG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's severity of sleep disorders when treated with methadone."
PA166135781,rs2075797,1444703343,CC,Patients with the CC genotype and asthma who are treated with aspirin may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135781,rs2075797,1444703342,CG,Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135781,rs2075797,1444703341,GG,Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166159038,rs2072661,1448101189,AA,"Patients with the AA genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."
PA166159038,rs2072661,1448101190,AG,"Patients with the AG genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."
PA166159038,rs2072661,1448101191,GG,"Patients with the GG genotype may have a decreased risk for smoking addiction, and have an increased likelihood of smoking cessation, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."
PA166134188,rs2076369,655384921,GG,"Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse."
PA166134188,rs2076369,655384920,GT,Patients with this genotype were not studied.
PA166134188,rs2076369,655384919,TT,Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.
PA166136408,rs2076828,1445624607,CC,Patients with the CC genotype may have a decreased response to metformin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to metformin.
PA166136408,rs2076828,1445624608,CG,Patients with the CG genotype may have a decreased response to metformin as compared to patients with the GG genotype and an increased response to metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to metformin.
PA166136408,rs2076828,1445624609,GG,Patients with the GG genotype may have a decreased response to metformin as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to metformin.
PA166159421,rs2108623,1448109814,AA,"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159421,rs2108623,1448109815,AG,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159421,rs2108623,1448109816,GG,"Patients with the GG genotype may have a dcreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or AA genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166135051,rs2106809,1183612734,AA,Women with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
PA166135051,rs2106809,1183612733,AG,Women with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
PA166135051,rs2106809,1183612732,GG,Women with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with captopril as compared to women with the AA or AG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
PA166158950,rs2112460,1448100189,AA,Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AG and GG genotypes. Other factors may affect response to antidepressants.
PA166158950,rs2112460,1448100190,AG,Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158950,rs2112460,1448100191,GG,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
PA166134374,rs2072671,1448099675,AA,"Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
PA166134374,rs2072671,1448099676,AC,Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
PA166134374,rs2072671,1448099677,CC,Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
PA166134459,rs2072671,1447960497,AA,"Patients with cancer and the AA genotype who are treated with gemcitabine may have 1) decreased expression of CDA leading to decreased clearance of gemcitabine and 2) a higher incidence of toxicity events, such as neutropenia and GI toxicity as compared to patients with the CC genotype. However current evidence is contradictory. Other genetic and clinical factors may also influence gemcitabine's risk of inducing toxicity."
PA166134459,rs2072671,1447960498,AC,"Patients with cancer and the AC genotype who are treated with gemcitabine may have 1) decreased expression of CDA leading to decreased clearance of gemcitabine and 2) a higher incidence of toxicity events, such as neutropenia and GI toxicity as compared to patients with the CC genotype. However current evidence is contradictory. Other genetic and clinical factors may also influence gemcitabine's risk of inducing toxicity."
PA166134459,rs2072671,1447960499,CC,"Patients with the CC genotype who are treated with gemcitabine may have 1) increased expression of CDA leading to increased clearance of gemcitabine and  2) a lower incidence of toxicity events, including neutropenia and GI toxicity as compared to patients with the CC genotype. However current evidence is contradictory. Other genetic and clinical factors may also influence gemcitabine's risk of inducing toxicity."
PA166163764,rs2072671,1448616851,AA,"Patients with cancer and the AA genotype who are treated with capecitabine may have an increased incidence of adverse events, including hand-foot syndrome, as compared to patients with the AC or CC genotypes, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine. "
PA166163764,rs2072671,1448616852,AG,"Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine. "
PA166163764,rs2072671,1448616853,CC,"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine. "
PA166134700,rs2120266,982032353,AA,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134700,rs2120266,982032354,AG,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134700,rs2120266,982032355,GG,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134191,rs2115819,655384931,AA,"Patients with the AA genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
PA166134191,rs2115819,655384932,AG,"Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
PA166134191,rs2115819,655384933,GG,"Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment,  compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
PA166136219,rs212091,1444673137,CC,Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.
PA166136219,rs212091,1444673138,CT,Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.
PA166136219,rs212091,1444673139,TT,Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.
PA166152715,rs2125739,1447960718,CC,Patients with the CC genotype and HIV may have decreased concentrations of nevirapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
PA166152715,rs2125739,1447960719,CT,Patients with the CT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
PA166152715,rs2125739,1447960720,TT,Patients with the TT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
PA166135596,rs2144300,1184987036,CC,Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
PA166135596,rs2144300,1184987037,CT,Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
PA166135596,rs2144300,1184987038,TT,Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
PA166136059,rs2144297,1184987025,CC,Patients with genotype CC and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with genotype CT and TT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension. 
PA166136059,rs2144297,1184987026,CT,Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension. 
PA166136059,rs2144297,1184987027,TT,Patients with genotype TT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC and CT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension. 
PA166134905,rs2168631,1043880873,AA,Patients with the AA genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134905,rs2168631,1043880874,AG,Patients with the AG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166134905,rs2168631,1043880875,GG,Patients with the GG genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
PA166135540,rs2189814,1184514475,CC,Patients with the CC genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135540,rs2189814,1184514476,CT,Patients with the CT genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135540,rs2189814,1184514477,TT,Patients with the TT genotype may have an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166136304,rs2189784,1448107565,AA,"Patients with the AA genotype who are treated with warfarin may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin."
PA166136304,rs2189784,1448107566,AG,"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin."
PA166136304,rs2189784,1448107567,GG,"Patients with the GG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin."
PA166151862,rs2199939,1448105918,CC,Patients with the CC genotype may have decreased response (decreased LDL-C reduction) to rosuvastatin as compared to patients who have genotype TT or CT. Other Genetic and clinical factors may also influence the response to rosuvastatin.
PA166151862,rs2199939,1448105919,CT,Patients with the CT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.
PA166151862,rs2199939,1448105920,TT,Patients with the TT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.
PA166136305,rs2216711,1444703395,AA,Female patients with the AA genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166136305,rs2216711,1444703396,AG,Female patients with the AG genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166136305,rs2216711,1444703397,GG,Female patients with the GG genotype and major depression may have increased response to paroxetine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166136008,rs2177370,1447943660,AA,Patients with the AA genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine .
PA166136008,rs2177370,1447943661,AG,Patients with the AG genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.
PA166136008,rs2177370,1447943662,GG,Patients with the GG genotype and Alzheimer's disease may have decreased response to galantamine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.
PA166136007,rs2177370,1447943667,AA,Patients with the AA genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
PA166136007,rs2177370,1447943668,AG,Patients with the AG genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
PA166136007,rs2177370,1447943669,GG,Patients with the GG genotype and Alzheimer's disease may have decreased response to donepezil compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
PA166136505,rs2177370,1447943655,AA,Patients with the AA genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
PA166136505,rs2177370,1447943656,AG,Patients with the AG genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
PA166136505,rs2177370,1447943657,GG,Patients with the GG genotype and Alzheimer's disease may have decreased response to rivastigmine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
PA166134324,rs2227291,655386157,CC,Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134324,rs2227291,655386158,CG,Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166134324,rs2227291,655386159,GG,Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166135050,rs2227310,1183612433,CC,"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence overall survival time."
PA166135050,rs2227310,1183612434,CG,"Patients with the CG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time."
PA166135050,rs2227310,1183612435,GG,"Patients with the GG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time."
PA166134889,rs2207396,1043880660,AA,Patients with the AA genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
PA166134889,rs2207396,1043880661,AG,Patients with the AG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
PA166134889,rs2207396,1043880662,GG,"Patients with the GG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have a decreased, but not absent, risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment."
PA166134358,rs2227631,655386857,AA,Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
PA166134358,rs2227631,655386858,AG,Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
PA166134358,rs2227631,655386859,GG,Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
PA166134038,rs2227956,1448108727,AA,Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
PA166134038,rs2227956,1448108728,AG,Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
PA166134038,rs2227956,1448108729,GG,Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
PA166134460,rs2227983,1444608449,AA,"Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134460,rs2227983,1444608450,AG,"Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes.  No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134460,rs2227983,1444608451,GG,"Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes.  No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166162516,rs2227983,1448568210,AA,Patients with the AA genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.
PA166162516,rs2227983,1448568211,AG,Patients with the AG genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.
PA166162516,rs2227983,1448568212,GG,Patients with the GG genotype may have increased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to cetuximab.
PA166159031,rs2228075,1448101081,CC,Pediatric patients undergoing heart transplantation who have the CC genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance. 
PA166159031,rs2228075,1448101082,CT,"Pediatric patients undergoing heart transplantation who have the CT genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance. "
PA166159031,rs2228075,1448101083,TT,Pediatric patients undergoing heart transplantation who have the TT genotype may have an increased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance. 
PA166161521,rs2228014,1448432219,AA,Patients with the AA genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time. 
PA166161521,rs2228014,1448432220,AG,Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time. 
PA166161521,rs2228014,1448432221,GG,Patients with the GG genotype and colorectal cancer may have longer progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time. 
PA166136477,rs2228246,1446908690,AA,"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema."
PA166136477,rs2228246,1446908689,AG,"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema."
PA166136477,rs2228246,1446908688,GG,"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema."
PA166134788,rs2228079,1043858671,GG,"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134788,rs2228079,1043858672,GT,"Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134788,rs2228079,1043858673,TT,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166158864,rs2228171,1448098977,AA,Pediatric cancer patients with the AA genotype may have a decreased risk for ototoxicity when treated with cisplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
PA166158864,rs2228171,1448098978,AG,Pediatric cancer patients with the AG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
PA166158864,rs2228171,1448098979,GG,Pediatric cancer patients with the GG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
PA166134827,rs2228478,1043859383,AA,Patients with the AA genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
PA166134827,rs2228478,1043859382,AG,Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
PA166134827,rs2228478,1043859381,GG,Patients with the GG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
PA166134826,rs2228479,1043859375,AA,Patients with the AA genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
PA166134826,rs2228479,1043859376,AG,Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
PA166134826,rs2228479,1043859377,GG,Patients with the GG genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
PA166134347,rs2228001,1448616401,GG,"Patients with the GG genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134347,rs2228001,1448616402,GT,"Patients with the GT genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134347,rs2228001,1448616403,TT,Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166159175,rs2228570,1448602956,AA,Patients with the AA genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
PA166159175,rs2228570,1448602957,AG,Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
PA166159175,rs2228570,1448602958,GG,Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
PA166135135,rs2229437,1183615622,GG,Patients with the GG genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.
PA166135135,rs2229437,1183615623,GT,Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.
PA166135135,rs2229437,1183615624,TT,Patients with the TT genotype and hypertension may have an increased response when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to benazepril.
PA166159042,rs2229959,1448101222,AA,Patients with the AA genotype who are smokers may have decreased physical responses to smoking as compared to patients with the CC genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
PA166159042,rs2229959,1448101223,AC,"Patients with the AC genotype who are smokers may have increased physical responses to smoking as compared to patients with the CC genotype, or decreased physical responses as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking."
PA166159042,rs2229959,1448101224,CC,Patients with the CC genotype who are smokers may have increased physical responses to smoking as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
PA166135704,rs2230345,1444673027,AA,Patients with the AA genotype and heart conditions may have a poorer response to treatment with beta-blockers or antihypertensives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
PA166135704,rs2230345,1444673028,AT,Patients with the AT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
PA166135704,rs2230345,1444673029,TT,Patients with the TT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
PA166134451,rs2230345,827864514,AA,Patients with the AA genotype and heart failure may have an elevated risk for death as compared to patients with the TT genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
PA166134451,rs2230345,827864515,AT,"Patients with the AT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events."
PA166134451,rs2230345,827864516,TT,"Patients with the TT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype regardless of beta blocker.
treatment. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events."
PA166134995,rs2230806,1183492240,CC,Patients with the CC genotype and Coronary Disease who are treated with pravastatin may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134995,rs2230806,1183492241,CT,Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134995,rs2230806,1183492242,TT,Patients with the TT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166135049,rs2230806,1183607902,CC,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135049,rs2230806,1183607903,CT,Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135049,rs2230806,1183607904,TT,Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166136409,rs2229774,1446846515,AA,Patients with the AA genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
PA166136409,rs2229774,1446846516,AG,Patients with the AG genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
PA166136409,rs2229774,1446846517,GG,Patients with the GG genotype may have decreased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with genotype AG or AA. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
PA166135048,rs2230808,1183607657,CC,Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135048,rs2230808,1183607658,CT,"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype, or a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate."
PA166135048,rs2230808,1183607659,TT,Patients with the TT genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166136525,rs2231135,1447946221,AA,"Patients with the AA genotype and osteosarcoma may be at decreased risk for mucositis when receiving methotrexate, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate."
PA166136525,rs2231135,1447946222,AG,"Patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate."
PA166136525,rs2231135,1447946223,GG,"No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate."
PA166135047,rs2231137,1183607420,CC,Patients with the CC genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
PA166135047,rs2231137,1183607421,CT,Patients with the CT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
PA166135047,rs2231137,1183607422,TT,Patients with the TT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
PA166135738,rs2231137,1444700526,CC,"Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166135738,rs2231137,1444700525,CT,"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
PA166135738,rs2231137,1444700524,TT,"Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166135420,rs2232228,1183703761,AA,Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
PA166135420,rs2232228,1183703762,AG,Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
PA166135420,rs2232228,1183703763,GG,Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
PA166134091,rs2229109,637880447,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134091,rs2229109,637880448,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134091,rs2229109,637880449,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134092,rs2229109,637880452,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
PA166134092,rs2229109,637880453,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
PA166134092,rs2229109,637880454,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
PA166134093,rs2229109,637880456,CC,Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
PA166134093,rs2229109,637880457,CT,Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes (inferred).
PA166134093,rs2229109,637880458,TT,Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
PA166134094,rs2229109,637880460,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  prazosin compared to cells with other genotypes.
PA166134094,rs2229109,637880461,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  prazosin compared to cells with other genotypes.
PA166134094,rs2229109,637880462,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  prazosin compared to cells with other genotypes.
PA166134095,rs2229109,637880464,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  verapamil compared to cells with other genotypes.
PA166134095,rs2229109,637880465,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  verapamil compared to cells with other genotypes.
PA166134095,rs2229109,637880466,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  verapamil compared to cells with other genotypes.
PA166134096,rs2229109,637880468,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  vinblastine compared to cells with other genotypes.
PA166134096,rs2229109,637880469,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  vinblastine compared to cells with other genotypes.
PA166134096,rs2229109,637880470,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  vinblastine compared to cells with other genotypes.
PA166134097,rs2229109,637880472,CC,Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.
PA166134097,rs2229109,637880473,CT,Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
PA166134097,rs2229109,637880474,TT,Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
PA166136391,rs2229109,1448102847,CC,"Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse."
PA166136391,rs2229109,1448102848,CT,"Patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse."
PA166136391,rs2229109,1448102849,TT,"No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse."
PA166159690,rs2229109,1448124606,CC,Patients with the CC genotype and kidney transplantation may have reduced risk of neutropenia when taking valganciclovir compared to patients with the CT genotype. Other genetic and clinical factors may affect response to valganciclovir.
PA166159690,rs2229109,1448124607,CT,Patients with the CT genotype and kidney transplantation may have increased risk of neutropenia when taking valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect response to valganciclovir.
PA166136512,rs2229109,1448102859,CC,"Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens."
PA166136512,rs2229109,1448102860,CT,"Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens."
PA166136512,rs2229109,1448102861,TT,"No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens."
PA166135551,rs2234693,1184472742,CC,Patients with cancer and the CC genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
PA166135551,rs2234693,1184472743,CT,Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
PA166135551,rs2234693,1184472744,TT,Patients with cancer and the TT genotype may have a decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
PA166159198,rs2234693,1448103877,CC,Patients with the CC genotype and who are addicted to methamphetamines may have an increased risk for methamphetamine-induced psychosis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
PA166159198,rs2234693,1448103878,CT,Patients with the CT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
PA166159198,rs2234693,1448103879,TT,Patients with the TT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
PA166152904,rs2234693,1447979274,CC,Female patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to leflunomide.
PA166152904,rs2234693,1447979275,CT,"Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide."
PA166152904,rs2234693,1447979276,TT,Female patients with the TT genotype and rheumatoid arthritis may have a better response when treated with leflunomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.
PA166135524,rs2108622,1444698406,CC,Patients with the CC genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
PA166135524,rs2108622,1444698407,CT,"Patients with the CT genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the TT genotypes, and increased steady-state levels as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements."
PA166135524,rs2108622,1444698408,TT, Patients with the TT genotype may have increased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
PA166135544,rs2108622,1448099681,CC,"Patients with the CC genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CT or TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dose."
PA166135544,rs2108622,1448099682,CT,"Patients with the CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dose."
PA166135544,rs2108622,1448099683,TT,"Patients with the TT genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dose."
PA166135545,rs2108622,1184661224,CC,Patients with the CC genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
PA166135545,rs2108622,1184661225,CT,Patients with the CT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype or a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
PA166135545,rs2108622,1184661226,TT,Patients with the TT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
PA166135782,rs2108622,1446909079,CC,Patients with the CC genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
PA166135782,rs2108622,1446909080,CT,Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
PA166135782,rs2108622,1446909081,TT,Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
PA166134268,rs2108622,1448615833,CC,"Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or TT genotype. Some studies have not found an association between genotypes of this SNP and warfarin dose, or report finding a trend that was not statistically significant. This SNP is not currently associated with time to INR, risk of hemorrhage, or risk of over-coagulation. Other genetic and clinical factors may also influence a patient's required warfarin dose."
PA166134268,rs2108622,1448615834,CT,"Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Some studies have not found an association between genotypes of this SNP and warfarin dose, or report finding a trend that was not statistically significant. This SNP is not currently associated with time to INR, risk of hemorrhage, or risk of over-coagulation. Other genetic and clinical factors may also influence a patient's required warfarin dose."
PA166134268,rs2108622,1448615835,TT,"Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype. Some studies have not found an association between genotypes of this SNP and warfarin dose, or report finding a trend that was not statistically significant. This SNP is not currently associated with time to INR, risk of hemorrhage, or risk of over-coagulation. Other genetic and clinical factors may also influence a patient's required warfarin dose."
PA166160464,rs2108622,1448262905,CC,Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT or CT in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160464,rs2108622,1448262904,CT,Patients with the CT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160464,rs2108622,1448262903,TT,Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166158891,rs2234753,1448099325,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
PA166158891,rs2234753,1448099326,AG,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel  may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
PA166158792,rs2234753,1448098351,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158792,rs2234753,1448098352,AG,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166135148,rs2235040,1183617619,CC,Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects. 
PA166135148,rs2235040,1183617620,CT,Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased  risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects. 
PA166135148,rs2235040,1183617621,TT,Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects. 
PA166135179,rs2235040,1183619323,CC,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135179,rs2235040,1183619324,CT,"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135179,rs2235040,1183619325,TT,"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166134036,rs2234922,1447679540,AA,"Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."
PA166134036,rs2234922,1447679541,AG,"Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."
PA166134036,rs2234922,1447679542,GG,"Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."
PA166134336,rs2234922,655386321,AA,Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134336,rs2234922,655386322,AG,Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134336,rs2234922,655386323,GG,Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134303,rs2234922,655385994,AA,"Patients with the AA genotype who are exposed to phenytoin during the first trimester of pregnancy may have a decreased, but not absent, risk for having a child with a craniofacial abnormality as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a person's risk for having a child with a craniofacial abnormality after phenytoin exposure."
PA166134303,rs2234922,655385995,AG,Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134303,rs2234922,655385996,GG,Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134050,rs2235015,1448276533,AA,"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission."
PA166134050,rs2235015,1448276534,AC,"Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission."
PA166134050,rs2235015,1448276535,CC,"Patients with the CC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission."
PA166135216,rs2235067,1183629318,CC,"Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135216,rs2235067,1183629317,CT,"Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135216,rs2235067,1183629316,TT,"Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166159402,rs2235047,1448109614,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159402,rs2235047,1448109615,AC,"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA and decreased likelihood as compared to patients with the CC genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159402,rs2235047,1448109616,CC,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166136189,rs2236722,1444667353,AA,"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166136189,rs2236722,1444667354,AG,"Patients with metastasized cancer and the AG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AA genotype and improved response as compared to people with the GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166136189,rs2236722,1444667355,GG,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166134039,rs2236196,982033815,AA,Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166134039,rs2236196,982033816,AG,Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166134039,rs2236196,982033817,GG,"Patients with the GG genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence."
PA166134045,rs2236196,982033808,AA,"Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence."
PA166134045,rs2236196,982033809,AG,Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166134045,rs2236196,982033810,GG,Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
PA166136057,rs2236861,1184986746,AA,Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids. 
PA166136057,rs2236861,1184986747,AG,Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype and an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids. 
PA166136057,rs2236861,1184986748,GG,Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids. 
PA166134367,rs2236624,655386986,CC,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for an adverse event."
PA166134367,rs2236624,655386987,CT,"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for an adverse event."
PA166134367,rs2236624,655386988,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype.
PA166135046,rs2237892,1183607143,CC,Patients with the CC genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166135046,rs2237892,1183607144,CT,Patients with the CT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166135046,rs2237892,1183607145,TT,Patients with the TT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166134461,rs2236225,1448617089,AA,Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.
PA166134461,rs2236225,1448617090,AG,Patients with the AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.
PA166134461,rs2236225,1448617091,GG,Patients with the GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.
PA166134249,rs2238476,655385266,AA,"Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity."
PA166134249,rs2238476,655385265,AG,"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity."
PA166134249,rs2238476,655385264,GG,Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.
PA166135044,rs2238032,1183630631,GG,"Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers."
PA166135044,rs2238032,1183630632,GT,"Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers."
PA166135044,rs2238032,1183630633,TT,"Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers."
PA166135045,rs2237895,1183607014,AA,Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166135045,rs2237895,1183607015,AC,Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166135045,rs2237895,1183607016,CC,Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166136253,rs2237895,1444694508,AA,Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
PA166136253,rs2237895,1444694507,AC,"Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation."
PA166136253,rs2237895,1444694506,CC,Patients with the CC genotype who are undergoing kidney transplantation may have an increased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
PA166134078,rs2032582,637880016,AC,Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
PA166134078,rs2032582,637880015,CC,"Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens."
PA166134078,rs2032582,637880017,CT,Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
PA166134929,rs2032582,1447953237,AA,Patients with the AA genotype who are treated with atorvastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134929,rs2032582,1447953238,AC,Patients with the AC genotype who are treated with atorvastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134929,rs2032582,1447953239,AT,Patients with the AT genotype who are treated with atorvastatin may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134929,rs2032582,1447953240,CC,Patients with the CC genotype who are treated with atorvastatin may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134929,rs2032582,1447953241,TT,Patients with the TT genotype who are treated with atorvastatin may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166135322,rs2032582,1446897985,AA,"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment. "
PA166135322,rs2032582,1446897986,AC,"Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment. "
PA166135322,rs2032582,1446897987,AT,"Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment. "
PA166135322,rs2032582,1446897988,CC,"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment. "
PA166135322,rs2032582,1446897989,TT,"Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment. "
PA166136119,rs2032582,1447990219,AA,Patients with the AA genotype who are treated with ritonavir may have a decreased intracellular/plasma trough concentration as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
PA166136119,rs2032582,1447990220,AC,Patients with the AC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
PA166136119,rs2032582,1447990221,CC,Patients with the CC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
PA166134125,rs2032582,655384544,AA,Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
PA166134125,rs2032582,655384543,AC,Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
PA166134125,rs2032582,655384545,CC,Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
PA166134119,rs2032582,655384478,AA,Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
PA166134119,rs2032582,655384480,AT,"Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy."
PA166134119,rs2032582,655384476,TT,Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
PA166134418,rs2032582,1447963747,AA,"Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
PA166134418,rs2032582,1447963748,AC,"Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
PA166134418,rs2032582,1447963749,CC,"Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
PA166134418,rs2032582,1447963750,CT,"Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
PA166134924,rs2032582,1145764730,AA,Patients with the AA genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134924,rs2032582,1145764731,AC,"Patients with the AC genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients who do not have the C allele. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134924,rs2032582,1145764733,AT,"Patients with the AT genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients who do not have the C allele. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134924,rs2032582,1145764732,CC,Patients with the CC genotype and Acute Coronary Syndrome who are treated with pravastatin may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or TT genotype. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134924,rs2032582,1145764734,TT,Patients with the TT genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134930,rs2032582,1151460691,AA,Patients with the AA genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134930,rs2032582,1151460697,AC,Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134930,rs2032582,1151460701,AT,Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134930,rs2032582,1151460707,CC,"Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. "
PA166134930,rs2032582,1151460708,TT,Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134931,rs2032582,1152935194,AA,Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions. 
PA166134931,rs2032582,1152935195,AC,Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions. 
PA166134931,rs2032582,1152935196,AT,Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions. 
PA166134931,rs2032582,1152935201,CC,Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions. 
PA166134931,rs2032582,1152935207,TT,Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions. 
PA166134544,rs2032582,981204138,AA,"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
PA166134544,rs2032582,981204139,AC,"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
PA166134544,rs2032582,981204140,CC,"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
PA166134591,rs2032582,981238028,CC,Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
PA166134591,rs2032582,981238027,CT,Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
PA166134591,rs2032582,981238026,TT,Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
PA166134592,rs2032582,981238042,AA,"Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
PA166134592,rs2032582,981238043,AC,"Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
PA166134592,rs2032582,981238044,CC,"Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
PA166134593,rs2032582,981238058,AA,Patients with the  AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
PA166134593,rs2032582,981238059,AC,Patients with the  AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
PA166134593,rs2032582,981238060,CC,Patients with the  CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
PA166134594,rs2032582,1447963974,AA,"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
PA166134594,rs2032582,1447963975,AC,"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
PA166134594,rs2032582,1447963976,CC,"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
PA166134595,rs2032582,981238111,AA,Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.
PA166134595,rs2032582,981238110,AC,Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.
PA166134595,rs2032582,981238109,CC,Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.
PA166134597,rs2032582,1448106070,AA,Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.
PA166134597,rs2032582,1448106071,AC,Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.
PA166134597,rs2032582,1448106072,CC,Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz
PA166135778,rs2032582,1444703232,AA,Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166135778,rs2032582,1444703233,AC,Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166135778,rs2032582,1444703234,CC,Patients with the CC genotype and Depressive Disorder may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166135779,rs2032582,1444703247,CC,"Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to  carbamazepine, phenytoin or valproic acid."
PA166135779,rs2032582,1444703246,CT,"Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to  carbamazepine, phenytoin or valproic acid."
PA166135779,rs2032582,1444703245,TT ,"Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to  carbamazepine, phenytoin or valproic acid."
PA166134543,rs2032582,1448573629,AA,"Patients with AA genotype may have higher success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with AC or CC genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
PA166134543,rs2032582,1448573630,AC,"Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
PA166134543,rs2032582,1448573631,CC,"Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
PA166134713,rs2032582,1043818283,AA,"Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine. "
PA166134713,rs2032582,1043818284,AC,"Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine. "
PA166134713,rs2032582,1043818285,CC,"Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine. "
PA166134729,rs2032582,1043737360,AA,Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
PA166134729,rs2032582,1043737361,AC,Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
PA166134729,rs2032582,1043737362,CC,Patients with the CC genotype may have decreased metabolism of verapamil as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
PA166134753,rs2032582,982040644,AA,Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. 
PA166134753,rs2032582,982040645,AC,Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. 
PA166134753,rs2032582,982040646,CC,"Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. "
PA166134294,rs2032582,1444705446,AA,"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp."
PA166134294,rs2032582,1444705447,AT,"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp."
PA166134294,rs2032582,1444705450,CA,"Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp."
PA166134294,rs2032582,1444705451,CC,Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
PA166134294,rs2032582,1444705449,CT,"Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp."
PA166134294,rs2032582,1444705448,TT,"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp."
PA166134295,rs2032582,655385861,AA,"Patients with the AA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
PA166134295,rs2032582,655385862,AC,"Patients with the CA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
PA166134295,rs2032582,655385863,CC,"Patients with the CC, CT or TT genotype and cancer who are treated with anthracyclines 1) may have an increased risk of resistance as compared to patients with the AC and AA genotype 2) may have decreased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
PA166136254,rs2032582,1448573622,AA,"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
PA166136254,rs2032582,1448573623,AC,"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
PA166136254,rs2032582,1448573624,CC,"Patients with the CC genotype who are undergoing organ transplantation may have increased metabolism and dose requirements of tacrolimus, as compared to patients with the AA, AC, CT or TT genotypes. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
PA166136254,rs2032582,1448573625,CT,"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
PA166136254,rs2032582,1448573626,TT,"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
PA166135928,rs2032582,1446897758,AA,"Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of neutropenia when treated with sunitinib as compared to patients with any of the following genotypes: CC, CT, TT . Other clinical and genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are treated with sunitinib."
PA166135928,rs2032582,1446897759,AC,"Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of neutropenia when treated with sunitinib as compared to patients with any of the following genotypes: CC, CT, TT . Other clinical and genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are treated with sunitinib."
PA166135928,rs2032582,1446897760,AT,"Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of neutropenia when treated with sunitinib as compared to patients with any of the following genotypes: CC, CT, TT . Other clinical and genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are treated with sunitinib."
PA166135928,rs2032582,1446897761,CC,"Patients with renal cell carcinoma and the CC genotypes may have an increased risk of neutropenia when treated with sunitinib as compared to patients with any of the following genotypes: AA, AC, AT . Other clinical and genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are treated with sunitinib."
PA166135928,rs2032582,1446897762,CT,"Patients with renal cell carcinoma and the CT genotypes may have an increased risk of neutropenia when treated with sunitinib as compared to patients with any of the following genotypes: AA, AC, AT . Other clinical and genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are treated with sunitinib."
PA166135928,rs2032582,1446897763,TT,"Patients with renal cell carcinoma and the TT genotypes may have an increased risk of neutropenia when treated with sunitinib as compared to patients with any of the following genotypes: AA, AC, AT . Other clinical and genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are treated with sunitinib."
PA166136422,rs2032582,1446897725,AA,"Patients with renal cell carcinoma and the AA genotype may have a decreased response to sunitinib as compared to patients with the AC, AT, CC, CT, or TT genotypes. There is no association between this SNP and overall or progression free survival.  Response here refers to stable disease or partial response and non-response to progressive disease. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma. "
PA166136422,rs2032582,1446897726,AC,Patients with renal cell carcinoma and the AC genotype may have an incresed response to sunitinib as compared to patients with the AA genotypes. There is no association between this SNP and overall or progression free survival.  Response here refers to stable disease or partial response and non-response to progressive disease. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma. 
PA166136422,rs2032582,1446897727,AT,Patients with renal cell carcinoma and the AT genotype may have an incresed response to sunitinib as compared to patients with the AA genotypes. There is no association between this SNP and overall or progression free survival.   Response here refers to stable disease or partial response and non-response to progressive disease. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma. 
PA166136422,rs2032582,1446897728,CC,Patients with renal cell carcinoma and the CC genotype may have an incresed response to sunitinib as compared to patients with the AA genotypes. There is no association between this SNP and overall or progression free survival.   Response here refers to stable disease or partial response and non-response to progressive disease. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma. 
PA166136422,rs2032582,1446897729,CT,Patients with renal cell carcinoma and the CT genotype may have an incresed response to sunitinib as compared to patients with the AA genotypes. There is no association between this SNP and overall or progression free survival.  Response here refers to stable disease or partial response and non-response to progressive disease. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma. 
PA166136422,rs2032582,1446897730,TT,Patients with renal cell carcinoma and the TT genotype may have an incresed response to sunitinib as compared to patients with the AA genotypes. There is no association between this SNP and overall or progression free survival.  Response here refers to stable disease or partial response and non-response to progressive disease. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma. 
PA166151949,rs2032582,1447953253,AC,Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.
PA166151949,rs2032582,1447953252,CC,Patients with the CC genotype and narcolepsy may have a decreased response to modafinil as compared to patients with the AC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to modafinil.
PA166151949,rs2032582,1447953254,CT,Patients with the CT genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.
PA166153106,rs2032582,1447984148,AA,Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
PA166153106,rs2032582,1447984149,AC,"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics."
PA166153106,rs2032582,1447984150,CC,Patients with the CC genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
PA166158883,rs2032582,1448099151,AA,Patients with the AA genotype and bone fractures may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to tramadol. 
PA166158883,rs2032582,1448099152,AC,"Patients with the AC genotype and bone fractures may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. Other genetic and clinical factors may also influence response to tramadol. "
PA166158883,rs2032582,1448099153,CC,Patients with the CC genotype and bone fractures may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tramadol. 
PA166159258,rs2032582,1448104374,CC,Patients with the CC genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.
PA166159258,rs2032582,1448104375,CT,Patients with the CT genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.
PA166159258,rs2032582,1448104376,TT,Patients with the TT genotype may have decreased risk of drug-induced liver injury compared to patients with the CC genotype. Other factors may affect liver toxicity when treated with atorvastatin.
PA166152805,rs2032582,1448102934,AA,"Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
PA166152805,rs2032582,1448102935,AC,"Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
PA166152805,rs2032582,1448102936,CC,"Patients with the CC genotype and cystic fibrosis may have increased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
PA166135273,rs2032582,1446896679,AA,Patients with genotype AA may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135273,rs2032582,1446896680,AC,Patients with genotype AC may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135273,rs2032582,1446896681,AT,Patients with genotype AT may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135273,rs2032582,1446896682,CC,Patients with genotype CC may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166135273,rs2032582,1446896683,TT,Patients with genotype TT may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
PA166136463,rs2032582,1446906443,AA,Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.
PA166136463,rs2032582,1446906442,AC,Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.
PA166136463,rs2032582,1446906441,CC,Patients with genotype CC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.
PA166162406,rs2032582,1448532206,AA,People with the AA genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran. 
PA166162406,rs2032582,1448532205,AC,People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran. 
PA166162406,rs2032582,1448532204,CC,"People with the CC genotype may have decreased exposure to dabigatran compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran. "
PA166162406,rs2032582,1448532207,CT,People with the CT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran. 
PA166162406,rs2032582,1448532208,TT,People with the TT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran. 
PA166162407,rs2032582,1448532215,AA,"People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
PA166162407,rs2032582,1448532214,AC,"People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
PA166162407,rs2032582,1448532213,CC,"People with the CC genotype may have decreased exposure to rivaroxaban compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
PA166162407,rs2032582,1448532216,CT,"People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
PA166162407,rs2032582,1448532217,TT,"People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
PA166163392,rs2032582,1448604253,AA,"People with opioid addiction and the AA genotype may have decreased concentrations of methadone compared to people with the AC genotypes, but may not require different doses, and reports conflict as to the direction of the association between genotype and methadone concentration and clearance. Other clinical and genetic factors may affect methadone dose and clearance.  "
PA166163392,rs2032582,1448604254,AC,"People with opioid addiction and the AC genotype may have increased concentrations of methadone compared to people with the AA and CC genotypes, but may not require different doses, and reports conflict as to the direction of the association between genotype and methadone concentration and clearance. Other clinical and genetic factors may affect methadone dose and clearance.  "
PA166163392,rs2032582,1448604255,CC,"People with opioid addiction and the CC genotype may have decreased concentrations of methadone compared to people with the AC genotypes, but may not require different doses, and reports conflict as to the direction of the association between genotype and methadone concentration and clearance. Other clinical and genetic factors may affect methadone dose and clearance.  "
PA166163644,rs2032582,1448615149,AA,Postmenopausal women with HR+ breast cancer and the AA genotype may have increased plasma concentrations of anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
PA166163644,rs2032582,1448615150,AC,Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
PA166163644,rs2032582,1448615151,CC,Postmenopausal women with HR+ breast cancer and the CC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
PA166163786,rs2032582,1448617156,AA,Patients with the AA genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir. 
PA166163786,rs2032582,1448617157,AC,Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir. 
PA166163786,rs2032582,1448617158,AT,Patients with the AT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir. 
PA166163786,rs2032582,1448617159,CC,"Patients with the CC genotype who are administered atazanavir may have decreased risk of hyperbilirubinemia as compared to patients with the AA, AT, TT, AC, or CT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir. "
PA166163786,rs2032582,1448617160,CT,Patients with the CT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir. 
PA166163786,rs2032582,1448617161,TT,Patients with the TT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir. 
PA166134323,rs2238472,655386152,CC,Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134323,rs2238472,655386153,CT,Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134323,rs2238472,655386154,TT,Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166151816,rs2239179,1447949641,CC,Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
PA166151816,rs2239179,1447949642,CT,Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
PA166151816,rs2239179,1447949643,TT,Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
PA166134709,rs2239622,982032673,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
PA166134709,rs2239622,982032674,AG,Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
PA166134709,rs2239622,982032675,GG,Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
PA166135041,rs2239347,1183630752,AA,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135041,rs2239347,1183630753,AC,Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135041,rs2239347,1183630754,CC,Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135043,rs2239050,1183630635,CC,"Patients with the CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
PA166135043,rs2239050,1183630636,CG,"Patients with the CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
PA166135043,rs2239050,1183630637,GG,"Patients with the GG genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response."
PA166152693,rs2242046,1447960504,AA,Patients with the AA genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity. 
PA166152693,rs2242046,1447960505,AG,Patients with the AG genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity. 
PA166152693,rs2242046,1447960506,GG,Patients with the GG genotype and non-small-cell lung cancer may have a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity. 
PA166135042,rs2239128,1183630643,CC,"Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
PA166135042,rs2239128,1183630644,CT,"Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response."
PA166135042,rs2239128,1183630645,TT,"Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
PA166135694,rs2241766,1444667904,GG,Patients with the GG genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
PA166135694,rs2241766,1444667905,GT,Patients with the GT genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
PA166135694,rs2241766,1444667906,TT,Patients with the TT genotype and diabetes mellitus may have a decreased response to pioglitazone as compared to patients with the GT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
PA166152830,rs2240017,1447963460,CC,Pediatric patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to corticosteroids.
PA166152830,rs2240017,1447963461,CG,Pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.
PA166152830,rs2240017,1447963462,GG,"No patients with the GG genotype were available for analysis, but pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids."
PA166163158,rs2242446,1448601912,CC,Patients with the CC genotype and major depressive disorder may have an increased response to venlafaxine compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect response to venlafaxine. 
PA166163158,rs2242446,1448601913,CT,Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine. 
PA166163158,rs2242446,1448601914,TT,Patients with the TT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine. 
PA166134787,rs2243250,1043858659,CC,Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134787,rs2243250,1043858658,CT,Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134787,rs2243250,1043858657,TT,Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135012,rs2241883,1183604886,CC,"Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate."
PA166135012,rs2241883,1183604887,CT,"Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate."
PA166135012,rs2241883,1183604888,TT,"Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate."
PA166134943,rs2244613,1448100950,GG,"Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding."
PA166134943,rs2244613,1448100951,GT,"Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding."
PA166134943,rs2244613,1448100952,TT,Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
PA166163250,rs2244613,1448602873,GG,Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163250,rs2244613,1448602874,GT,Patients with the GT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163250,rs2244613,1448602875,TT,Patients with the TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163249,rs2244614,1448602869,AA,Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163249,rs2244614,1448602868,AG,Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163249,rs2244614,1448602867,GG,Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166136497,rs2239702,1447814173,CC,"Patients with the CC genotype may have more favorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib."
PA166136497,rs2239702,1447814174,CT,"Patients with the CT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib."
PA166136497,rs2239702,1447814175,TT,"Patients with the TT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib."
PA166135040,rs2245705,1183604794,CC,Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135040,rs2245705,1183604795,CT,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135040,rs2245705,1183604796,TT,Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135039,rs2251954,1183604440,CC,Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135039,rs2251954,1183604441,CT,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135039,rs2251954,1183604442,TT,Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166136128,rs2252281,1444607829,CC,"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence patient's response to metformin."
PA166136128,rs2252281,1444607830,CT,"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to metformin."
PA166136128,rs2252281,1444607831,TT,"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to metformin."
PA166136157,rs2250242,1444666349,AA,Patients with the AA genotype and prostate cancer may have increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
PA166136157,rs2250242,1444666350,AG,Patients with the AG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
PA166136157,rs2250242,1444666351,GG,Patients with the GG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
PA166136471,rs225440,1446908598,CC,"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
PA166136471,rs225440,1446908597,CT,"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
PA166136471,rs225440,1446908596,TT,"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
PA166159809,rs2257212,1448125501,CC,Patients with genotype CC have shorter progression-free survival time when treated with sorafenib as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence the response to sorafenib.
PA166159809,rs2257212,1448125502,CT,Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.
PA166159809,rs2257212,1448125503,TT,Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.
PA166134933,rs2231142,1448612863,GG,Patients with the GG genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.
PA166134933,rs2231142,1448612864,GT,"Patients with the GT genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype, or 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics."
PA166134933,rs2231142,1448612865,TT,Patients with the TT genotype and who are treated with rosuvastatin 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.
PA166134935,rs2231142,1155598161,GG,Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.
PA166134935,rs2231142,1155598164,GT,Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.
PA166134935,rs2231142,1155598167,TT,Patients with the TT genotype may have higher plasma concentrations of atorvastatin as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.
PA166134937,rs2231142,1156228668,GG,Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. 
PA166134937,rs2231142,1156228673,GT,Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. 
PA166134937,rs2231142,1156228679,TT,Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. 
PA166134939,rs2231142,1156738777,GG,Patients with the GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin. 
PA166134939,rs2231142,1156738780,GT,Patients with the GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin. 
PA166134939,rs2231142,1156738792,TT,Patients with the TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin. 
PA166135075,rs2231142,1183614748,GG,Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
PA166135075,rs2231142,1183614749,GT,Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
PA166135075,rs2231142,1183614750,TT,Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
PA166136151,rs2231142,1446903235,GG,"Patients with the GG genotype and cancer may have decreased exposure to sunitinib and a decreased risk for experiencing drug toxicities, as compared to patients with the TT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence exposure to sunitinib and risk for drug toxicities. "
PA166136151,rs2231142,1446903236,GT,"Patients with the GT genotype and renal cell carcinoma may have decreased exposure to sunitinib and a decreased risk for experiencing drug toxicities, as compared to patients with the TT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence risk for drug toxicities when receiving sunitinib."
PA166136151,rs2231142,1446903237,TT,"Patients with the TT genotype and renal cell carcinoma may have increased exposure to sunitinib and an increased risk for experiencing drug toxicities, as compared to patients with the GG or GT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence risk for drug toxicities when receiving sunitinib."
PA166136238,rs2231142,1448522437,GG,Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
PA166136238,rs2231142,1448522438,GT,Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
PA166136238,rs2231142,1448522439,TT,Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
PA166136240,rs2231142,1444686831,GG,Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
PA166136240,rs2231142,1444686832,GT,Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
PA166136240,rs2231142,1444686833,TT,Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
PA166136267,rs2231142,1444700516,GG,"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166136267,rs2231142,1444700517,GT,"Patients with the GT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype. Patients with the GT genotype are not studied for sensitivity to imatinib, but based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
PA166136267,rs2231142,1444700518,TT,"Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166158984,rs2231142,1448263568,GG,"Patients with the GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations."
PA166158984,rs2231142,1448263569,GT,"Patients with the GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype.  However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations."
PA166158984,rs2231142,1448263570,TT,"Patients with the TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype.  However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations."
PA166152841,rs2231142,1447963669,GG,"Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea."
PA166152841,rs2231142,1447963670,GT,"Patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea."
PA166152841,rs2231142,1447963671,TT,"No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea."
PA166153014,rs2231142,1447982584,GG,Patients with the GG genotype and gout may have improved response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to allopurinol.
PA166153014,rs2231142,1447982585,GT,Patients with the GT genotype and gout may have worse response when treated with allopurinol as compared to patients with the GG genotype and improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to allopurinol.
PA166153014,rs2231142,1447982586,TT,Patients with the TT genotype and gout may have worse response when treated with allopurinol as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to allopurinol.
PA166135937,rs2231142,1448612858,GG,Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
PA166135937,rs2231142,1448612859,GT,Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
PA166135937,rs2231142,1448612860,TT,Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
PA166134862,rs2266780,1043880311,AA,Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166134862,rs2266780,1043880310,AG,Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166134862,rs2266780,1043880309,GG,Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166135611,rs2266780,1184987920,AA,Patients with the AA genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
PA166135611,rs2266780,1184987921,AG,The AG genotype has not been evaluated.
PA166135611,rs2266780,1184987922,GG,Patients with the GG genotype may have a decreased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
PA166163527,rs2266780,1448613040,AA,People with the AA genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
PA166163527,rs2266780,1448613041,AG,People with the AG genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
PA166163527,rs2266780,1448613042,GG,People with the GG genotype may have increased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.
PA166134366,rs2267076,655386982,CC,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134366,rs2267076,655386983,CT,"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134366,rs2267076,655386984,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
PA166135610,rs2266782,1184987913,AA,Patients with the AA genotype may have a decreased metabolism of itopride as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of itopride. 
PA166135610,rs2266782,1184987914,AG,The AG genotype has not been evaluated. 
PA166135610,rs2266782,1184987915,GG,Patients with the GG genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride. 
PA166163526,rs2266782,1448613034,AA,People with the AA genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
PA166163526,rs2266782,1448613035,AG,People with the AG genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
PA166163526,rs2266782,1448613036,GG,People with the GG genotype may have decreased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.
PA166134227,rs2267715,655385114,AA,"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response."
PA166134227,rs2267715,655385113,AG,"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response."
PA166134227,rs2267715,655385112,GG,"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response."
PA166135649,rs2269577,1444607643,CC,"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for nausea or vomiting and be more likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy."
PA166135649,rs2269577,1444607644,CG,No significant findings available. 
PA166135649,rs2269577,1444607645,GG,"Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for nausea or vomiting and be less likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy."
PA166159003,rs2269879,1448100764,CC,"Patients with the CC genotype and hypertension may have poorer blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CT or TT genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide. "
PA166159003,rs2269879,1448100765,CT,"Patients with the CT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide. "
PA166159003,rs2269879,1448100766,TT,"Patients with the TT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide. "
PA166134767,rs2270777,1184764358,CC,Patient with CC + CT genotypes may have a decreased IGH-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. 
PA166134767,rs2270777,1184764359,CT,Patient with CT + CC genotypes may have a decreased IGH-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. 
PA166134767,rs2270777,1184764360,TT,Patient with TT genotypes may have an increased IGH-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. 
PA166158884,rs2273618,1448099158,CT,Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158884,rs2273618,1448099159,TT,Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166135843,rs2270007,1444705208,CC,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135843,rs2270007,1444705209,CG,Patients with the CG genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135843,rs2270007,1444705210,GG,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135519,rs2268639,1184348875,AA,Patients with the rs2268639 AA genotype and Schizophrenia and genotype TT at SNP rs13429709 who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the rs2268639 TT genotype and at least one C allele at SNP rs13429709. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics. 
PA166135519,rs2268639,1184348874,AT,Patients with the rs2268639 AT genotype and Schizophrenia and genotype TT at SNP rs13429709 who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the rs2268639 TT genotype and at least one C allele at SNP rs13429709. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics. 
PA166135519,rs2268639,1184348873,TT,Patients with the rs2268639 TT genotype and Schizophrenia who also have at least one allele C at SNP rs13429709 who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the rs2268639 AA genotype who also have genotype rs13429709 TT. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics. 
PA166135113,rs2276302,1183630697,AA,Patients with the AA genotype and schizophrenia may may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135113,rs2276302,1183630698,AG,"Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine."
PA166135113,rs2276302,1183630699,GG,Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166136249,rs2275913,1444686992,AA,"Patients with the AA genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136249,rs2275913,1444686993,AG,"Patients with the AG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136249,rs2275913,1444686994,GG,"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166134740,rs2242480,1446909025,CC,"Patients with the CC genotype may be less likely to respond to clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. "
PA166134740,rs2242480,1446909026,TC,"Patients with the TC genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. "
PA166134740,rs2242480,1446909027,TT,"Patients with the TT genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. "
PA166135906,rs2242480,1448266823,CC,"Patients with the CC genotype (CYP3A4 *1/*1) and epilepsy may have increased concentrations of carbamazepine as compared to patients with the CT (*1/*1G) or TT (*1G/*1G) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine."
PA166135906,rs2242480,1448266824,CT,"Patients with the CT (CYP3A4 *1/*1G) genotype and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine."
PA166135906,rs2242480,1448266825,TT,"Patients with the TT genotype (CYP3A4 *1G/*1G) and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine."
PA166136462,rs2242480,1446906428,CC,Patients with genotype CC may have decreased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to methadone.
PA166136462,rs2242480,1446906429,CT,Patients with genotype CT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.
PA166136462,rs2242480,1446906430,TT,Patients with genotype TT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.
PA166163557,rs2242480,1448613256,CC,"People with the CC genotype and kidney transplantation may have increased exposure to tacrolimus, as measured by the concentration/dose ratio, compared to people with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to tacrolimus."
PA166163557,rs2242480,1448613257,CT,"People with the CT genotype and kidney transplantation may have decreased exposure to tacrolimus, as measured by the concentration/dose ratio, compared to people with the CC genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
PA166163557,rs2242480,1448613258,TT,"People with the TT genotype and kidney transplantation may have decreased exposure to tacrolimus, as measured by the concentration/dose ratio, compared to people with the CC genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
PA166136220,rs2274567,1444673144,AA,Patients with the AA genotype and paroxysmal nocturnal hemoglobinuria may have a better response to treatment with eculizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to eculizumab.
PA166136220,rs2274567,1444673145,AG,Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.
PA166136220,rs2274567,1444673146,GG,Patients with the GG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.
PA166136055,rs2276706,1184986672,AA,Patients with the AA genotype may have increased metabolism of repaglinide as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of repaglinide. 
PA166136055,rs2276706,1184986673,AG,The AG genotype did not differ significantly in metabolism of repaglinide as compared to patients with the GG or AA genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide. 
PA166136055,rs2276706,1184986674,GG,Patients with the GG genotype may have decreased metabolism of repaglinide as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of repaglinide. 
PA166163397,rs2277984,1448604318,CC,"Patients with the CC genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
PA166163397,rs2277984,1448604319,CT,"Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
PA166163397,rs2277984,1448604320,TT,"Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
PA166134264,rs2276307,655385381,AA,"Patients with the AA genotype and Hypercholesterolemia may have a decreased, but not absent, risk of statin-related myalgia as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia."
PA166134264,rs2276307,655385382,AG,"Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia."
PA166134264,rs2276307,655385383,GG,Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.
PA166136244,rs2276707,1444686916,CC,Patients with the CC genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
PA166136244,rs2276707,1444686917,CT,Patients with the CT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
PA166136244,rs2276707,1444686918,TT,Patients with the TT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
PA166160779,rs2276707,1448266431,CC,Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.
PA166160779,rs2276707,1448266432,CT,Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.
PA166160779,rs2276707,1448266433,TT,Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.
PA166135011,rs2246709,1183604504,AA,"Patients with the AA genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine."
PA166135011,rs2246709,1183604505,AG,"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine."
PA166135011,rs2246709,1183604506,GG,"Patients with the GG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine."
PA166152950,rs2246709,1447980715,AA,Patients with the AA genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
PA166152950,rs2246709,1447980716,AG,"Patients with the AG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or more severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone."
PA166152950,rs2246709,1447980717,GG,Patients with the GG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
PA166134990,rs2279020,1183492033,AA,"Patients with the AA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have a decreased, but not absent, risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
PA166134990,rs2279020,1183492032,GA,"Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
PA166134990,rs2279020,1183492031,GG,"Patients with the GG genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
PA166134245,rs2278293,1448103897,CC,Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
PA166134245,rs2278293,1448103898,CT,"Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype  but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation."
PA166134245,rs2278293,1448103899,TT,"Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation."
PA166135809,rs2279238,1444704016,CC,"Patients with the CC genotype and hypertension and coronary artery disease who are treated with verapamil may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
PA166135809,rs2279238,1444704015,CT,"Patients with the CT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype or may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
PA166135809,rs2279238,1444704014,TT,"Patients with the TT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
PA166134463,rs2278294,982032340,CC,"Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134463,rs2278294,982032341,CT,"Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134463,rs2278294,982032342,TT,"Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134464,rs2278294,982032405,CC,Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134464,rs2278294,982032406,CT,Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134464,rs2278294,982032407,TT,Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166135365,rs2282143,1448594866,CC,Patients with the CC genotype may have increased clearance of metformin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of metformin. 
PA166135365,rs2282143,1448594867,CT,Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin. 
PA166135365,rs2282143,1448594868,TT,Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin. 
PA166134891,rs2281617,1043880670,CC,Patients with the CC genotype may have increased Euphoric and Energetic after amphetamine exposure as compared to patients with the CT or TT genotype.
PA166134891,rs2281617,1043880671,CT,Patients with the CT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.
PA166134891,rs2281617,1043880672,TT,Patients with the TT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.
PA166135453,rs2279345,1446906129,CC,Patients with the CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.
PA166135453,rs2279345,1446906130,CT,Patients with the CT genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.
PA166135453,rs2279345,1446906131,TT,Patients with the TT genotype and HIV may have decreased metabolism of efavirenz resulting in higher efavirenz plasma levels as compared to patients with the CC or CT  genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.
PA166134946,rs2283265,1183490972,AA,Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.
PA166134946,rs2283265,1183490973,AC,Patients with the AC genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.
PA166134946,rs2283265,1183490974,CC,Patients with the CC genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AC or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.
PA166134707,rs2283265,982032639,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134707,rs2283265,982032640,AC,Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134707,rs2283265,982032641,CC,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166152817,rs2283265,1447963229,AA,Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
PA166152817,rs2283265,1447963230,AC,"Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death."
PA166152817,rs2283265,1447963231,CC,Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
PA166158982,rs2283265,1448100466,AA,Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
PA166158982,rs2283265,1448100467,AC,Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
PA166158982,rs2283265,1448100468,CC,Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.
PA166134688,rs2284018,982031410,CC,Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166134688,rs2284018,982031409,CT,Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134688,rs2284018,982031408,TT,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166158746,rs2284449,1448097720,CC,"Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer."
PA166158746,rs2284449,1448097721,CT,"Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer."
PA166158746,rs2284449,1448097722,TT,"Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer."
PA166160031,rs2288344,1448257272,GG,Patients with the GG genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.
PA166160031,rs2288344,1448257273,GT,Patients with the GT genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.
PA166160031,rs2288344,1448257274,TT,Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.
PA166136187,rs2289310,1444667324,GG,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166136187,rs2289310,1444667325,GT,"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166136187,rs2289310,1444667326,TT,"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166134847,rs2273697,1448100559,AA,"Patients with the AA genotype were not studied. However, patients with AG genotype and Kidney Transplantation may have a decreased metabolism of mycophenolic acid as compared to patients with the GG genotype. However, no association is reported regarding increased risk of adverse drug reactions and this has been contradicted in at least one study. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166134847,rs2273697,1448100560,AG,"Patients with AG genotype and Kidney Transplantation may have a decreased metabolism of mycophenolic acid as compared to patients with the GG genotype. However, no association is reported regarding increased risk of adverse drug reactions and this has been contradicted in at least one study. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166134847,rs2273697,1448100561,GG,"Patients with GG genotype and Kidney Transplantation may have an increased metabolism of mycophenolic acid as comapred to patients with the AG genotype. However, no association is reported regarding increased risk of adverse drug reactions and this has been contradicted in at least one study. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166135118,rs2273697,1183615318,AA,Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
PA166135118,rs2273697,1183615319,AG,Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
PA166135118,rs2273697,1183615320,GG,Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
PA166136162,rs2273697,1444666552,AA,"No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox."
PA166136162,rs2273697,1444666553,AG,Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136162,rs2273697,1444666554,GG,Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166134462,rs2273697,1447813528,AA,"Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134462,rs2273697,1447813529,AG,"Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134462,rs2273697,1447813530,GG,"Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134234,rs2273697,655385146,AA,People with the AA genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.
PA166134234,rs2273697,655385147,AG,People with the AG genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with the GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.
PA166134234,rs2273697,655385148,GG,People with the GG genotype may have higher bioavailablilty of orally administered talinolol as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.
PA166134292,rs2273697,1444666865,AA,"Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134292,rs2273697,1444666866,AG,"Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134292,rs2273697,1444666867,GG,"Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166136084,rs2273697,1185000099,AA,Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions. 
PA166136084,rs2273697,1185000100,AG,Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions. 
PA166136084,rs2273697,1185000101,GG,"Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions. "
PA166135986,rs2289105,1447681840,CC,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135986,rs2289105,1447681841,CT,"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the TT genotypes and decreased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole in combination with a statin."
PA166135986,rs2289105,1447681842,TT,"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CT or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135985,rs2289105,1447681833,CC,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166135985,rs2289105,1447681834,CT,"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166135985,rs2289105,1447681835,TT,"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166134701,rs2289658,982032397,CC,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134701,rs2289658,982032398,CT,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134701,rs2289658,982032399,TT,Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166135832,rs2289669,1448105851,AA,"Patients with the genotype AA may have better response to metformin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AG or GG, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin."
PA166135832,rs2289669,1448105852,AG,"Patients with genotype AG may have decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin."
PA166135832,rs2289669,1448105853,GG,"Patients with genotype GG may have decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin."
PA166134228,rs2284220,655385119,AA,No conclusive results regarding the association between this variant and bronchodilator response.
PA166134228,rs2284220,655385118,AG,No conclusive results regarding the association between this variant and bronchodilator response.
PA166134228,rs2284220,655385117,GG,No conclusive results regarding the association between this variant and bronchodilator response.
PA166135010,rs2290732,1183604229,AA,Patients with the AA genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
PA166135010,rs2290732,1183604230,AG,Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
PA166135010,rs2290732,1183604231,GG,Patients with the GG genotype and epilepsy may have decreased retention rates when treated with carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
PA166136324,rs2290271,1448109738,AA,"Patients with genotype AA may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or AC, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166136324,rs2290271,1448109739,AC,"Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166136324,rs2290271,1448109740,CC,"Patients with genotype CC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166152828,rs2290573,1447963444,AA,Patients with the AA genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
PA166152828,rs2290573,1447963445,AG,Patients with the AG genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
PA166152828,rs2290573,1447963446,GG,Patients with the GG genotype and chronic myeloid leukemia may have a lower rate of major cytogenetic response when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
PA166158903,rs2291075,1448099572,CC,"Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
PA166158903,rs2291075,1448099571,CT,"Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
PA166158903,rs2291075,1448099570,TT,"Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
PA166158904,rs2291075,1448099578,CC,"Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
PA166158904,rs2291075,1448099577,CT,"Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
PA166158904,rs2291075,1448099576,TT,"Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
PA166135899,rs2291767,1445401312,CC,Cancer patients with the CC genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for ototoxicity.
PA166135899,rs2291767,1445401313,CT,Cancer patients with the CT genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for ototoxicity.
PA166135899,rs2291767,1445401314,TT,Cancer patients with the TT genotype may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for ototoxicity.
PA166134466,rs2284017,982030587,CC,Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134466,rs2284017,982030588,CT,Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134466,rs2284017,982030589,TT,Patients with the TT genotype may have decreased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166152640,rs2291858,1448106274,AA,Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152640,rs2291858,1448106275,AG,"Patients with the AG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype, or an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152640,rs2291858,1448106276,GG,Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166136470,rs2292997,1446908589,AA,"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
PA166136470,rs2292997,1446908590,AG,"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
PA166136470,rs2292997,1446908591,GG,"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
PA166136339,rs2291073,1444706168,GG,Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.
PA166136339,rs2291073,1444706167,TG,Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.
PA166136339,rs2291073,1444706166,TT,Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.
PA166135666,rs2293347,1444608398,CC,"Patients with the CC genotype and gastric cancer may have a poorer response when treated with fluorouracil, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fluorouracil. "
PA166135666,rs2293347,1444608399,CT,"Patients with the CT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil. "
PA166135666,rs2293347,1444608400,TT,"Patients with the TT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil. "
PA166152762,rs2293347,1447961168,CC,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with gefitinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to gefitinib.
PA166152762,rs2293347,1447961169,CT,Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.
PA166152762,rs2293347,1447961170,TT,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.
PA166136185,rs2291078,1444667251,AA,Patients with metastasized cancer and the AA genotype may have worse response to capecitabine or fluorouracil as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction. 
PA166136185,rs2291078,1444667252,AT,Patients with metastasized cancer and the AT genotype may have worse response to capecitabine or fluorouracil as compared to patients with the TT genotype and improved response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction. 
PA166136185,rs2291078,1444667253,TT,Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction. 
PA166134047,rs2297480,1448106218,GG,Patients with the GG genotype may have a decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134047,rs2297480,1448106219,GT,Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134047,rs2297480,1448106220,TT,"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Patients with the TT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response."
PA166134660,rs2297480,982030766,GG,Patients with genotype GG may have decreased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patient's chance of response.
PA166134660,rs2297480,982030767,TG,Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's chance of response.
PA166134660,rs2297480,982030768,TT,Patients with genotype TT may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's chance of response.
PA166136456,rs2297480,1446905763,GG,Patients with the GG genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
PA166136456,rs2297480,1446905762,GT,Patients with the GT genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
PA166136456,rs2297480,1446905761,TT,Patients with the TT genotype may have increased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
PA166134322,rs2292954,655386147,AA,Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134322,rs2292954,655386148,AG,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134322,rs2292954,655386149,GG,Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166135062,rs2298771,1447679802,CC,Patients with the CC genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response within a 15 month treatment period as compared to patients with the TT genotype. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment. 
PA166135062,rs2298771,1447679803,CT,Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response within a 15 month treatment period as compared to patients with the TT genotype. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment. 
PA166135062,rs2298771,1447679804,TT,Patients with the TT genotype and epilepsy who are treated with carbamazepine may have an increased likelihood of a good response within a 15 month treatment period  as compared to patients with the CC genotype. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment. 
PA166136500,rs2298805,1447814484,AA,Patients with genotype AA and urticaria may have increased response to desloratadine and mizolastine compared to patients with genotypes AG or GG. Other clinical and genetic factors also may affect response to desloratadine and mizolastine. 
PA166136500,rs2298805,1447814485,AG,Patients with genotype AG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine. 
PA166136500,rs2298805,1447814486,GG,Patients with genotype GG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine. 
PA166135240,rs2279343,1447953012,AA,Patients with the AA genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166135240,rs2279343,1447953013,AG,Patients with the AG genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166135240,rs2279343,1447953014,GG,Patients with the GG genotype and HIV may have decreased clearance and increased plasma concentration of efavirenz as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134368,rs2279343,655386991,AA,"Patients with the AA genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis."
PA166134368,rs2279343,655386992,AG,Patients with the AG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
PA166134368,rs2279343,655386993,GG,Patients with the GG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
PA166135413,rs2279343,1445402473,AA,"Patients with the AA genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the GG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone."
PA166135413,rs2279343,1445402474,AG,"Patients with the AG genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the GG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone."
PA166135413,rs2279343,1445402475,GG,"Patients with the GG genotype who are being treated with methadone for heroin addiction may require a decreased dose of the drug as compared to patients with the AA or AG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone."
PA166136423,rs2279343,1446898326,AA,Individuals with tobacco use disorder and the AA genotype may have an improved response to bupropion as compared to individuals with the AG and GG genotypes. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder. 
PA166136423,rs2279343,1446898327,AG,Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder. 
PA166136423,rs2279343,1446898328,GG,Individuals with tobacco use disorder and the GG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder. 
PA166135810,rs2279343,1444704029,AA,Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of nicotine.
PA166135810,rs2279343,1444704028,AG,Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype or may have decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of nicotine.
PA166135810,rs2279343,1444704027,GG,Patients with the GG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of nicotine.
PA166162743,rs2279343,1448594291,AA,"Patients with the AA genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance."
PA166162743,rs2279343,1448594292,AG,"Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance."
PA166162743,rs2279343,1448594293,GG,"Patients with the GG genotype who undergo anesthesia with propofol may have increased clearance of the drug as compared to patients with the AA or AG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance."
PA166134970,rs2298826,1183491355,AA,Patients with the AA genotype and Schizophrenia who are treated with haloperidol may have an increased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
PA166134970,rs2298826,1183491356,AG,Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
PA166134970,rs2298826,1183491357,GG,Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
PA166158945,rs2299267,1448100153,AA,Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158945,rs2299267,1448100154,AG,Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158945,rs2299267,1448100155,GG,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
PA166159177,rs2299939,1448102661,AA,Patients with the AA genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166159177,rs2299939,1448102662,AC,Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166159177,rs2299939,1448102663,CC,Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166134321,rs2301159,655386142,AA,Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134321,rs2301159,655386143,AG,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134321,rs2301159,655386144,GG,Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166160813,rs2302489,1448266601,AA,Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.
PA166160813,rs2302489,1448266602,AT,Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.
PA166160813,rs2302489,1448266603,TT,Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.
PA166134719,rs2301149,982034443,CC,"Patients with the CC genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
PA166134719,rs2301149,982034444,CG,"Patients with the CG genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
PA166134719,rs2301149,982034445,GG,"Patients with the GG genotype and hypertensive coronary artery disease may have an increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
PA166135811,rs2302821,1444704036,AA,"Patients with the AA genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
PA166135811,rs2302821,1444704035,AC,"Patients with the AC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype or may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
PA166135811,rs2302821,1444704034,CC,Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
PA166134364,rs2298383,655386962,CC,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134364,rs2298383,655386963,CT,"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134364,rs2298383,655386964,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
PA166134468,rs2298383,981201550,CC,Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.
PA166134468,rs2298383,981201551,CT,Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.
PA166134468,rs2298383,981201552,TT,Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.
PA166159675,rs2298383,1448124428,AA,Children with the AA genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
PA166159675,rs2298383,1448124429,AG,Children with the AG genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
PA166159675,rs2298383,1448124430,GG,Children with the GG genotype and acute lymphoblastic leukemia may have increased risk of neurotoxicity when taking methotrexate compared to children with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
PA166135367,rs2304016,1184999882,AA,"Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs (such as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate) may have an increased risk of drug resistance as compared to patients with the GG genotype. Another study found no association. Other genetic and clinical factors may also influence a patient's response to antiepileptic drugs."
PA166135367,rs2304016,1184999883,AG,"Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs (such as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate) may have an increased risk of drug resistance as compared to patients with the GG genotype.  Another study found no association. Other genetic and clinical factors may also influence a patient's response to antiepileptic drugs."
PA166135367,rs2304016,1184999884,GG,"Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs (such as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate) may have a decreased,but not absent, risk of drug resistance as compared to patients with the AG or AA genotype.  Another study found no association. Other genetic and clinical factors may also influence a patient's response to antiepileptic drugs."
PA166136374,rs2295632,1448603287,GG,Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for respiratory depression when treated with opioids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
PA166136374,rs2295632,1448603288,GT,Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
PA166136374,rs2295632,1448603289,TT,Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
PA166163294,rs2295632,1448603293,GG,Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of PONV. 
PA166163294,rs2295632,1448603294,GT,Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV. 
PA166163294,rs2295632,1448603295,TT,Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV. 
PA166160874,rs2304429,1448267399,CC,Patients with the CC genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.
PA166160874,rs2304429,1448267400,CT,Patients with the CT genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.
PA166160874,rs2304429,1448267401,TT,Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.
PA166135009,rs2301339,1183630587,AA,"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol. "
PA166135009,rs2301339,1183630588,AG,Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence systolic blood pressure response to atenolol. 
PA166135009,rs2301339,1183630589,GG,"Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol. "
PA166135008,rs2305089,1183630719,CC,Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.
PA166135008,rs2305089,1183630720,CT,Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.
PA166135008,rs2305089,1183630721,TT,Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide.
PA166135319,rs2302948,1183684156,CC,"Patients with the CC genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135319,rs2302948,1183684155,CT,"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135319,rs2302948,1183684154,TT,"Patients with the TT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166136320,rs2306719,1444703980,CC,"Patients with the CC genotype were not studied. However, patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide."
PA166136320,rs2306719,1444703979,CT,Patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
PA166136320,rs2306719,1444703978,TT,Patients with the TT genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
PA166135522,rs2306744,1184472893,CC,Patients with acute myeloid leukemia and the CC genotype may have an increased response to cytarabine and idarubicin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin. 
PA166135522,rs2306744,1184472892,CT,"Patients with acute myeloid leukemia and the CT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin. "
PA166135522,rs2306744,1184472891,TT,Patients with acute myeloid leukemia and the TT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin. 
PA166159416,rs2305364,1448109790,CC,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159416,rs2305364,1448109791,CT,"Patients with the CT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159416,rs2305364,1448109792,TT,"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166135812,rs2306168,1444704044,CC,Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
PA166135812,rs2306168,1444704043,CT,Patients with the CT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
PA166135812,rs2306168,1444704042,TT,Patients with the TT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
PA166153180,rs2307424,1447987012,AA,"Patients with the AA genotype and HIV who do not have the rs3745274 TT genotype may have decreased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
PA166153180,rs2307424,1447987013,AG,"Patients with the AG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
PA166153180,rs2307424,1447987014,GG,"Patients with the GG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
PA166158940,rs231775,1448100112,AA,Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth. 
PA166158940,rs231775,1448100113,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth. "
PA166158940,rs231775,1448100114,GG,Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth. 
PA166134467,rs2297595,1448267801,CC,"Patients with the CC genotype may have 1) increased risk of severe toxicity when treated with fluoropyrimidines and 2) decreased metabolism of fluorouracil as compared to patients with the TT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
"
PA166134467,rs2297595,1448267802,CT,"Patients with the CT genotype may have 1) increased risk of severe toxicity when treated with fluoropyrimidines and 2) decreased metabolism of fluorouracil as compared to patients with the TT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
"
PA166134467,rs2297595,1448267803,TT,"Patients with the TT genotype may have 1) decreased but not absent risk of severe toxicity when treated with fluoropyrimidines and 2) increased metabolism of fluorouracil as compared to patients with the CC or CT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
"
PA166134687,rs2314339,982032323,CC,Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134687,rs2314339,982032324,TC,Patients with the TC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134687,rs2314339,982032325,TT,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166158748,rs232043,1448097785,AA,Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer. 
PA166158748,rs232043,1448097786,AG,Patients with non-small cell lung cancer and the AG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer. 
PA166158748,rs232043,1448097787,GG,Patients with non-small cell lung cancer and the GG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer. 
PA166134244,rs2368564,1043737604,CC,Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.
PA166134244,rs2368564,1043737605,CT,"No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar."
PA166134244,rs2368564,1043737606,TT,"Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar."
PA166134255,rs2372536,655385302,CC,Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.
PA166134255,rs2372536,655385301,CG,Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.
PA166134255,rs2372536,655385300,GG,Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have symptom improvement  as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134704,rs2378676,982032496,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134704,rs2378676,982032497,AC,Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134704,rs2378676,982032498,CC,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166135256,rs238,1183634050,AA,Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have slightly decreased reduction of systolic blood pressure as compared to patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135256,rs238,1183634051,AG,"Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA genotype, and slightly decreased reduction of systolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment."
PA166135256,rs238,1183634052,GG,Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure  as compared to patients with the AA or the AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166153065,rs2396185,1447983174,AA,Patients with the AA genotype may have a decreased response to topiramate as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166153065,rs2396185,1447983173,AC,Patients with the AC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166153065,rs2396185,1447983172,CC,Patients with the CC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166135793,rs2412459,1444703533,CC,"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
PA166135793,rs2412459,1444703531,CT,"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
PA166135793,rs2412459,1444703532,TT,"Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
PA166135794,rs2412459,1444703541,CC,"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
PA166135794,rs2412459,1444703540,CT,Patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
PA166135794,rs2412459,1444703539,TT,Patients with the TT genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
PA166134841,rs242941,1043876907,AA,Patients with the AA genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166134841,rs242941,1043876906,AC,Patients with the AC genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166134841,rs242941,1043876905,CC,Patients with the CC genotype and major depression and high anxiety may have an increased response to fluoxetine treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166159010,rs2413739,1448102889,CC,Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity. 
PA166159010,rs2413739,1448102890,CT,"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity."
PA166159010,rs2413739,1448102891,TT,Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.
PA166159957,rs2413739,1448256102,CC,Patients with the CC genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT.
PA166159957,rs2413739,1448256101,CT,Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT.
PA166159957,rs2413739,1448256100,TT,Patients with the TT genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC or CT.
PA166135724,rs2430561,1444687048,AA,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135724,rs2430561,1444687049,AT,"Patients with the AT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135724,rs2430561,1444687050,TT,"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135965,rs2429427,1446906416,AA,Patients with genotype AA may have decreased response to calcium channel blockers in people with Hypertension as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to calcium channel blockers.
PA166135965,rs2429427,1446906415,AG,Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.
PA166135965,rs2429427,1446906414,GG,Patients with genotype GG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.
PA166135038,rs2440390,1183603973,CC,Patients with the CC genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.
PA166135038,rs2440390,1183603972,CT,"Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain."
PA166135038,rs2440390,1183603971,TT,Patients with the TT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.
PA166135264,rs2445142,1183632156,CC,Patients with the CC genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166135264,rs2445142,1183632157,CG,Patients with the CG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics..
PA166135264,rs2445142,1183632158,GG,Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166135808,rs2433320,1444704009,AA,Patients with the AA genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166135808,rs2433320,1444704008,AG,Patients with the AG genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166135808,rs2433320,1444704007,GG,Patients with the GG genotype and major depression who are treated with fluoxetine may have increased response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166153184,rs2461817,1447987054,AA,Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166153184,rs2461817,1447987055,AC,"Patients with the AC genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
PA166153184,rs2461817,1447987056,CC,Patients with the CC genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166159504,rs244898,1448112616,CC,Patients with the CC genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
PA166159504,rs244898,1448112617,CT,Patients with the CT genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
PA166159504,rs244898,1448112618,TT,Patients with the TT genotype and bladder cancer may have an increased response to cisplatin-based therapies compared to patients with the CC and CT genotypes. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
PA166135815,rs2472297,1448107336,CC,Patients with the CC genotype may have decreased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
PA166135815,rs2472297,1448107337,CT,Patients with the CT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
PA166135815,rs2472297,1448107338,TT,Patients with the TT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
PA166134252,rs246240,655385279,AA,Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.
PA166134252,rs246240,655385280,AG,"Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate."
PA166134252,rs246240,655385281,GG,"Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate."
PA166135868,rs246240,1444843393,AA,"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate."
PA166135868,rs246240,1444843392,AG,"Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
PA166135868,rs246240,1444843391,GG,"Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
PA166135149,rs2470890,1183617624,CC,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. 
PA166135149,rs2470890,1183617625,CT,Patients with the CT genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype or may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. 
PA166135149,rs2470890,1183617626,TT,Patients with the TT genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. 
PA166136165,rs2470890,1448101444,CC,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136165,rs2470890,1448101445,CT,Patients with the CT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136165,rs2470890,1448101446,TT,"Patients with the TT genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox."
PA166134883,rs2306283,1043880596,AA,"Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
"
PA166134883,rs2306283,1043880597,AG,"Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
"
PA166134883,rs2306283,1043880598,GG,Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
PA166134884,rs2306283,1447953140,AA,"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels and another found increased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. "
PA166134884,rs2306283,1447953141,AG,"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. "
PA166134884,rs2306283,1447953142,GG,"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may a larger reduction in LDL as compared to patients with the AA or AG genotype. However, one study found no association with LDL levels and another found decreased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. "
PA166134906,rs2306283,1446908946,AA,"Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of intolerance to treatment as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment."
PA166134906,rs2306283,1446908947,AG,"Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have  increased creatine kinase levels, and higher a higher risk of intolerance to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134906,rs2306283,1446908948,GG,"Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of intolerance to treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166135355,rs2306283,1183697545,AA,"Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
PA166135355,rs2306283,1183697546,AG,"Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
PA166135355,rs2306283,1183697547,GG,"Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
PA166135359,rs2306283,1444667974,AA,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate. 
PA166135359,rs2306283,1444667975,AG,Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate. 
PA166135359,rs2306283,1444667976,GG,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence clearance of methotrexate. 
PA166134168,rs2306283,655384824,AA,Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134168,rs2306283,655384823,AG,"While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype."
PA166134168,rs2306283,655384822,GG,Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134214,rs2306283,1043880586,AA,Patients with the AA genotype may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics. 
PA166134214,rs2306283,1043880587,AG,"Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics. "
PA166134214,rs2306283,1043880588,GG,Patients with the GG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics. 
PA166135895,rs2306283,1445401262,AA,Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.
PA166135895,rs2306283,1445401263,AG,Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
PA166135895,rs2306283,1445401264,GG,Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
PA166153465,rs2306283,1448100575,AA,Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
PA166153465,rs2306283,1448100576,AG,Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
PA166153465,rs2306283,1448100577,GG,Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
PA166158881,rs2306283,1448099127,AA,Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance. 
PA166158881,rs2306283,1448099128,AG,Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance. 
PA166158881,rs2306283,1448099129,GG,Patients with the GG genotype may have decreased clearance of rifampin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence rifampin clearance. 
PA166160272,rs2306283,1448258738,AA,Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.
PA166160272,rs2306283,1448258737,AG,Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
PA166160272,rs2306283,1448258736,GG,Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
PA166161285,rs2306283,1448428032,AA,"Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
PA166161285,rs2306283,1448428033,AG,"Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
PA166161285,rs2306283,1448428034,GG,"Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
PA166135150,rs2472304,1183617645,AA,Patients with the AA genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. 
PA166135150,rs2472304,1183617646,AG,Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. 
PA166135150,rs2472304,1183617647,GG,Patients with the GG genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. 
PA166136410,rs2472304,1446896598,AA,Patients with the AA genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
PA166136410,rs2472304,1446896599,AG,Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
PA166136410,rs2472304,1446896600,GG,Patients with the GG genotype may have decreased concentrations of erlotinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
PA166160819,rs247616,1448266667,CC,Patients with the CC genotype may have a worse response to statin therapy compared to patients with the TT genotype. Other clinical and genetic factors may affect response to statins.
PA166160819,rs247616,1448266666,CT,Patients with the CT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.
PA166160819,rs247616,1448266665,TT,Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.
PA166135377,rs2494752,1183699231,AA,Patients with the AA genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
PA166135377,rs2494752,1183699232,AG,Patients with the AG genotype who are treated with carboplatin or cisplatin may have increased risk of progression of disease as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
PA166135377,rs2494752,1183699233,GG,Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
PA166134218,rs2494732,655385066,CC,Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134218,rs2494732,655385065,CT,Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134218,rs2494732,655385064,TT,Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have an improvement in symptoms as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166159178,rs2498804,1448102668,AA,Patients with the AA genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.
PA166159178,rs2498804,1448102669,AC,Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.
PA166159178,rs2498804,1448102670,CC,Patients with the CC genotype and non-small-cell lung cancer may have an increased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for disease progression.
PA166135037,rs2497538,1183603767,AA,Women with the AA genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to women with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain.
PA166135037,rs2497538,1183603766,AC,"Women with the AC genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to women with the AA genotype, or decreased weight gain when treated with olanzapine as compared to women with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain."
PA166135037,rs2497538,1183603765,CC,Women with the CC genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to women with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain.
PA166134686,rs2499984,982031352,AA,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134686,rs2499984,982031353,AG,Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134686,rs2499984,982031354,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166158783,rs2501873,1448099219,CC,Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
PA166158783,rs2501873,1448099220,CT,Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
PA166158783,rs2501873,1448099221,TT,Patients with nasopharyngeal cancer and the TT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
PA166136080,rs2501873,1184997929,CC,Patients with the CC genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166136080,rs2501873,1184997928,CT,Patients with the CT genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166136080,rs2501873,1184997927,TT,Patients with the TT genotype and rs3212198 T allele who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype in combination with any allele of rs3212198. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166158781,rs2502815,1448099202,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel  may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158781,rs2502815,1448099203,AG,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel  may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158781,rs2502815,1448099204,GG,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel  may have a increased severity of anemia as compared to patients with the AA or AG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166134215,rs2472677,655385049,CC,Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.
PA166134215,rs2472677,655385048,CT,"Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects."
PA166134215,rs2472677,655385047,TT,"Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects."
PA166136093,rs2472677,1447987146,CC,Patients with the CC genotype and HIV may have decreased metabolism of atazanavir as compared to patients with the CT and TT genotypes but the genotype is not associated with drug discontinuation. Other clinical and genetic factors may also influence metabolism of atazanavir in patients with HIV.
PA166136093,rs2472677,1447987147,CT,Patients with the CT genotype and HIV may have decreased metabolism of atazanavir as compared to patients with the TT genotype and an increased metabolism of atazanavir as compared to patients with the CC genotype but the genotype is not associated with drug discontinuation. Other clinical and genetic factors may also influence metabolism of atazanavir in patients with HIV.
PA166136093,rs2472677,1447987148,TT,Patients with the TT genotype and HIV may have increased  metabolism of atazanavir as compared to patients with the CT and TT genotypes but the genotype is not associated with drug discontinuation. Other clinical and genetic factors may also influence metabolism of atazanavir in patients with HIV.
PA166135320,rs2515641,1183684165,CC,"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135320,rs2515641,1183684164,CT,"Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135320,rs2515641,1183684163,TT,"Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166151943,rs2513265,1447953164,AA,Patients with the AA genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166151943,rs2513265,1447953165,AT,Patients with the AT genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166151943,rs2513265,1447953166,TT,Patients with the TT genotype and schizophrenia may have a decreased response to antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166159308,rs2523864,1448107481,CC,Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease. 
PA166159308,rs2523864,1448107482,CT,Patients with retinal disease and the CT genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the TT genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease. 
PA166159308,rs2523864,1448107483,TT,Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease. 
PA166158948,rs2532560,1448106574,AA,Patients with the AA genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants. 
PA166158948,rs2532560,1448106575,AG,Patients with the AG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants. 
PA166158948,rs2532560,1448106576,GG,Patients with the GG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants. 
PA166134914,rs2500535,1127092673,AA,Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
PA166134914,rs2500535,1127092677,AG,Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
PA166134914,rs2500535,1127092680,GG,Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
PA166159631,rs2535629,1448123836,AA,"Patients with the AA genotype and schizophrenia may have increased response to clozapine compared to patients with the AG and GG genotypes. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine."
PA166159631,rs2535629,1448123837,AG,"Patients with the AG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine."
PA166159631,rs2535629,1448123838,GG,"Patients with the GG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine."
PA166161864,rs2546890,1448522768,AA,Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161864,rs2546890,1448522769,AG,Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161864,rs2546890,1448522770,GG,Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166134229,rs255100,655385122,AA,No conclusive results regarding the association between this variant and bronchodilator response.
PA166134229,rs255100,655385123,AT,No conclusive results regarding the association between this variant and bronchodilator response.
PA166134229,rs255100,655385124,TT,No conclusive results regarding the association between this variant and bronchodilator response.
PA166134210,rs2359612,1448276196,AA,Patients with the AA genotype who are treated with warfarin may require the lowest dose as compared to patients with the AG or GG genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134210,rs2359612,1448276197,AG,Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134210,rs2359612,1448276198,GG,Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166135401,rs25648,1183700858,CC,Patients with the CC genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135401,rs25648,1183700859,CT,Patients with the CT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135401,rs25648,1183700860,TT,Patients with the TT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166158988,rs2514036,1448100516,CC,Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.
PA166158988,rs2514036,1448100517,CT,Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.
PA166158988,rs2514036,1448100518,TT,Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.
PA166152723,rs2562519,1447960797,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152723,rs2562519,1447960798,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152723,rs2562519,1447960799,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166135718,rs2569190,1444686985,AA,Patients with the AA genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135718,rs2569190,1444686986,AG,Patients with the AG genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135718,rs2569190,1444686987,GG,Patients with the GG genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166158983,rs2585428,1448100473,CC,Patients with the CC genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the CT and TT genotypes. Other factors may affect trough concentrations of telaprevir.
PA166158983,rs2585428,1448100474,CT,Patients with the CT genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the TT genotype. Other factors may affect trough concentrations of telaprevir.
PA166158983,rs2585428,1448100475,TT,Patients with the TT genotype and Hepatitis C may have increased trough concentrations of telaprevir compared to patients with the CC and CT genotypes. Other factors may affect trough concentrations of telaprevir.
PA166153446,rs2571598,1447990194,CC,Patient with the CC genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
PA166153446,rs2571598,1447990195,CT,Patient with the CT genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
PA166153446,rs2571598,1447990196,TT,Patient with the TT genotype and Alzheimer's Disease may have an increased response to rivastigmine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
PA166136233,rs2592551,1444680140,AA,"Patients with the AA genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin."
PA166136233,rs2592551,1444680141,AG,"Patients with the AG genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin."
PA166136233,rs2592551,1444680142,GG,"Patients with the GG genotype and atrial fibrillation may require a lower dose of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin."
PA166136138,rs2612091,1448568543,CC,"Patients with the CC genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166136138,rs2612091,1448568544,CT,"Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166136138,rs2612091,1448568545,TT,"Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166135705,rs2631367,1444673086,CC,Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
PA166135705,rs2631367,1444673087,CG,Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
PA166135705,rs2631367,1444673088,GG,Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
PA166134053,rs25531,1446908895,CC,Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patient's response.
PA166134053,rs25531,1446908896,CT,Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patient's response.
PA166134053,rs25531,1446908897,TT,Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT .  Other genetic and clinical factors may also influence a patient's response.
PA166135844,rs25531,1444705216,CC,Patients with the CC genotype may have increased likelihood of side effects when treated with citalopram as compared to patients with the TT genotype. No association was found with response or remission. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135844,rs25531,1444705217,CT,Patients with the CT genotype may have increased likelihood of side effects when treated with citalopram as compared to patients with the TT genotype or may have decreased likelihood of side effects when treated with citalopram as compared to patients with the CC genotype. No association was found with response or remission. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135844,rs25531,1444705218,TT,Patients with the TT genotype may have decreased likelihood of side effects when treated with citalopram as compared to patients with the CC genotype. No association was found with response or remission. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166134029,rs264588,1184514254,AA,Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166134029,rs264588,1184514255,AC,"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. "
PA166134029,rs264588,1184514256,CC,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166159234,rs2606345,1448424088,AA,Female patients with the AA genotype and epilepsy may have a poorer response when treated with antiepileptic drugs as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antiepileptics.
PA166159234,rs2606345,1448424089,AC,Female patients with the AC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.
PA166159234,rs2606345,1448424090,CC,Female patients with the CC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.
PA166136163,rs2606345,1448101450,AA,"Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox."
PA166136163,rs2606345,1448101451,AC,Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136163,rs2606345,1448101452,CC,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166135536,rs264631,1184514263,CC,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135536,rs264631,1184514262,CG,"Patients with the CG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. "
PA166135536,rs264631,1184514261,GG,Patients with the  GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166134190,rs2619538,655384927,AA,"Patients with the AA genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note that in the study reporting this association there were no subjects with the AA genotype, but the A allele was found to be associated with increased risk. Please note the associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis."
PA166134190,rs2619538,655384928,AT,"Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis."
PA166134190,rs2619538,655384929,TT,"Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis."
PA166135535,rs264651,1184514251,AA,Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135535,rs264651,1184514250,AG,"Patients with the AG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
PA166135535,rs264651,1184514249,GG,Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166134028,rs264663,1184514243,CC,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166134028,rs264663,1184514242,CT,"Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. "
PA166134028,rs264663,1184514241,TT,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135613,rs2647087,1184989692,AA,"Patients with the AA genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have a reduced, but not absent, risk of pancreatitis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis. "
PA166135613,rs2647087,1184989693,AC,Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis. 
PA166135613,rs2647087,1184989694,CC,Patients with the CC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis. 
PA166135375,rs2631372,1183698847,CC,"Patients with the CC genotype and gastrointestinal stromal tumours may have a shorter time to progression when treated with imatinib, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression."
PA166135375,rs2631372,1183698848,CG,"Patients with the CG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression."
PA166135375,rs2631372,1183698849,GG,"Patients with the GG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression."
PA166135797,rs2650972,1444703582,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135797,rs2650972,1444703581,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype or may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135797,rs2650972,1444703580,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134216,rs2661319,1448099292,CC,Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134216,rs2661319,1448099293,CT,Patients with the CT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype or may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134216,rs2661319,1448099294,TT,Patients with the TT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166163225,rs2669429,1448602691,AA,Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
PA166163225,rs2669429,1448602692,AG,Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
PA166163225,rs2669429,1448602693,GG,Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
PA166135490,rs267606723,1184472597,AA,"Patients with the AA genotype (two copies of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135490,rs267606723,1184472598,AG,"Patients with the AG genotype (one copy of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135490,rs267606723,1184472599,GG,"Patients with the GG genotype (do not have a copy of the CFTR G1244E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166136201,rs2683511,1444668294,CC,"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
"
PA166136201,rs2683511,1444668295,CT,"Patients with the CT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the CC genotype and a lower secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
"
PA166136201,rs2683511,1444668296,TT,"Patients with the TT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166134192,rs2660845,655384937,AA,"Patients with the AA genotype and asthma who are treated with montelukast  may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
PA166134192,rs2660845,655384936,AG,Patients with the AG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
PA166134192,rs2660845,655384935,GG,Patients with the GG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
PA166136262,rs267606618,1444843901,C,Patients with the 1095C allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss
PA166136262,rs267606618,1444843902,T,"Patients with the 1095T allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095C allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."
PA166159176,rs2699887,1448102635,CC,Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166159176,rs2699887,1448102636,CT,No significant results have been seen for patients with the CT genotype.
PA166159176,rs2699887,1448102637,TT,Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166136261,rs267606619,1448256033,C,"Patients with the 1494C allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."
PA166136261,rs267606619,1448256034,T,"Patients with the 1494T allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494C allele. In the majority of studies, every individual who carried the 1494T allele developed hearing loss after receiving aminoglycoside antibiotics. Almost all individuals studied were homoplasmic for the T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."
PA166158999,rs2717162,1448100689,CC,Patients with the CC genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment. 
PA166158999,rs2717162,1448100690,CT,Patients with the CT genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment. 
PA166158999,rs2717162,1448100691,TT,Patients with the TT genotype who are addicted to smoking may have a better response to treatment with bupropion as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bupropion treatment. 
PA166159000,rs2717162,1448100697,CC,Patients with the CC genotype who are addicted to smoking and are trying to quit may have a reduced cravings for nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence nicotine cravings. 
PA166159000,rs2717162,1448100698,CT,Patients with the CT genotype who are addicted to smoking and are trying to quit may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings. 
PA166159000,rs2717162,1448100699,TT,Patients with the TT genotype who are addicted to smoking and are trying to quite may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings. 
PA166135708,rs2725252,1444673414,AA,Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.
PA166135708,rs2725252,1444673415,AC,Patients with the AC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.
PA166135708,rs2725252,1444673416,CC,Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.
PA166152840,rs265976,1447963651,GG,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166152840,rs265976,1447963652,GT,Patients with the GT genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166152840,rs265976,1447963653,TT,Patients with the TT genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166136321,rs2734833,1444703989,AA,Patients with the AA genotype and major depression may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166136321,rs2734833,1444703988,AG,Patients with the AG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype or may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166136321,rs2734833,1444703987,GG,Patients with the GG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135857,rs2734841,1444706871,AA,Female patients with the AA genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135857,rs2734841,1444706872,AC,Female patients with the AC genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135857,rs2734841,1444706873,CC,Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135858,rs2734842,1444706880,CC,Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135858,rs2734842,1444706879,CG,Female patients with the CG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166135858,rs2734842,1444706878,GG,Female patients with the GG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166152850,rs2727786,1447963823,CC,Patients with the CC genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166152850,rs2727786,1447963824,CG,Patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166152850,rs2727786,1447963825,GG,"No patients with the GG genotype were available for analysis, but patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. "
PA166158958,rs2738466,1448100244,AA,Patients with the AA genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence pravastatin response. 
PA166158958,rs2738466,1448100245,AG,"Patients with the AG genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response. "
PA166158958,rs2738466,1448100246,GG,Patients with the GG genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response. 
PA166135714,rs2741049,1444686888,CC,"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the CT or TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
PA166135714,rs2741049,1444686889,CT,"In human liver microsomes, the CT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
PA166135714,rs2741049,1444686890,TT,"In human liver microsomes, the TT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
PA166163496,rs2741049,1448612664,CC,Patients with the CC genotype and seizures may have increased response to oxcarbazepine compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
PA166163496,rs2741049,1448612665,CT,Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
PA166163496,rs2741049,1448612666,TT,Patients with the TT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
PA166136139,rs2741171,1444608203,CC,"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166136139,rs2741171,1444608204,CT,"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166136139,rs2741171,1444608205,TT,"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
PA166135036,rs2742390,1183603159,AA,Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135036,rs2742390,1183603160,AG,"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135036,rs2742390,1183603161,GG,Patients with the GG genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135034,rs2742421,1183602850,GG,Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135034,rs2742421,1183602851,GT,"Patients with the GT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135034,rs2742421,1183602852,TT,Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135033,rs2742423,1183602694,AA,Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135033,rs2742423,1183602695,AG,"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135033,rs2742423,1183602696,GG,Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135035,rs2742417,1183603019,CC,Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135035,rs2742417,1183603018,CT,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135035,rs2742417,1183603017,TT,Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166136144,rs267606617,1448256020,A,"Patients with the 1555A allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555G allele.  Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."
PA166136144,rs267606617,1448256021,G,"Patients with the 1555G allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555A allele. In the majority of studies, every individual who carried the 1555G allele developed hearing loss after receiving aminoglycoside antibiotics. Most individuals studied were homoplasmic for the G allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. Other genetic and clinical factors may also influence risk of hearing loss."
PA166135032,rs2742435,1183602563,AA,Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166135032,rs2742435,1183602562,AG,"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects."
PA166135032,rs2742435,1183602561,GG,Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
PA166153011,rs274713,1447981476,GG,Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166153011,rs274713,1447981477,GT,Patients with the GT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166153011,rs274713,1447981478,TT,Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166136297,rs2760118,1444702773,CC,Patients with the CC genotype who are opioid-dependent may have a better response when treated with methadone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to methadone.
PA166136297,rs2760118,1444702774,CT,Patients with the CT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.
PA166136297,rs2760118,1444702775,TT,Patients with the TT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.
PA166134113,rs275651,1447964503,AA,Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
PA166134113,rs275651,1447964504,AT,Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
PA166134113,rs275651,1447964505,TT,"Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril."
PA166136358,rs2770150,1445400674,AG,Patients with the AG genotype may have a better response to the pertussis vaccine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine. 
PA166136358,rs2770150,1445400675,GG,Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine. 
PA166134795,rs2768759,1043858725,AA,Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134795,rs2768759,1043858724,AC,No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134795,rs2768759,1043858723,CC,Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134710,rs2769605,982032722,CC,Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium or valproic acid as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134710,rs2769605,982032723,CT,Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134710,rs2769605,982032724,TT,Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166135257,rs2776546,1183634264,AA,Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have  greater reduction of diastolic blood pressure as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135257,rs2776546,1183634265,AC,"Patients with the AC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA genotype, and greater reduction of diastolic blood pressure as compared to patients with the  CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment."
PA166135257,rs2776546,1183634266,CC,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135940,rs2789047,1446899697,AA,Patients with the AA genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AC and CC genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin. 
PA166135940,rs2789047,1446899698,AG,Patients with the AG genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the CC genotype and a lower likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin. 
PA166135940,rs2789047,1446899699,CC,Patients with the CC genotype may have a lower likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AA genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin. 
PA166159236,rs2808630,1448104031,CC,Patients with the CC genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
PA166159236,rs2808630,1448104032,CT,Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
PA166159236,rs2808630,1448104033,TT,Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
PA166153455,rs274622,1447990278,CC,Patients with the CC genotype may have an increased risk of addiction to heroin when using heroin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin. 
PA166153455,rs274622,1447990279,CT,Patients with the CT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CC genotype and an increased risk of heroin addiction as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin. 
PA166153455,rs274622,1447990280,TT,Patients with the TT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin. 
PA166134164,rs2781659,1448108737,AA,Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
PA166134164,rs2781659,1448108738,AG,Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
PA166134164,rs2781659,1448108739,GG,Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
PA166134632,rs2819742,981419551,AA,Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. 
PA166134632,rs2819742,981419552,AG,Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. 
PA166134632,rs2819742,981419553,GG,Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. 
PA166153193,rs2819742,1447987130,AA,Patients with the AA genotype and cardiovascular disease who are taking atorvastatin or simvastatin may have an increased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin.
PA166153193,rs2819742,1447987131,AG,Patients with the AG genotype and cardiovascular disease who are taking atorvastatin or simvastatin may have an increased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin.
PA166153193,rs2819742,1447987132,GG,Patients with the GG genotype and cardiovascular disease who are taking atorvastatin or simvastatin may have an decreased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin.
PA166151952,rs2813543,1447953279,AA,Patients with the AA genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
PA166151952,rs2813543,1447953280,AG,Patients with the AG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
PA166151952,rs2813543,1447953281,GG,Patients with the GG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
PA166134064,rs2814707,637879933,CC,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
PA166134064,rs2814707,637879934,CT,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
PA166134064,rs2814707,637879935,TT,Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
PA166136156,rs2832407,1444666310,AA,"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate. "
PA166136156,rs2832407,1444666311,AC,"Patients with the AC genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate. "
PA166136156,rs2832407,1444666312,CC,"Patients with the CC genotype and who are heavy drinkers or have an alcohol-use disorder may have lower concentrations of topiramate, and a better response to treatment with the drug, as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate. "
PA166135922,rs2835859,1446897344,CC,Patients with the CC genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
PA166135922,rs2835859,1446897345,CT,Patients with the CT genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
PA166135922,rs2835859,1446897346,TT,Patients with the TT genotype and post-operative pain may require an increased dose of fentanyl as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
PA166134352,rs25487,1448617094,CC,"Patients with the CC genotype may have 1) increased survival and response and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. However, one study found decreased survival and response for patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based regimens."
PA166134352,rs25487,1448617095,CT,"Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CC genotype. However, one study found increased survival as compared to patients with the CC genotype. Conflicting results exist for the relationship between the CT genotype and response to platinum-based treatment. Other genetic and clinical factors may also influence response to platinum-based regimens."
PA166134352,rs25487,1448617096,TT,"Patients with the TT genotype may have 1) decreased survival and response and 2) decreased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CC genotype. However, one study found increased survival and response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based regimens."
PA166134618,rs25487,1448522457,CC,"Patients with the CC genotype and cancer may have increased response to fluorouracil-containing chemotherapy regimens, as well as a decreased risk for and a later onset of sensory neuropathy, as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
PA166134618,rs25487,1448522458,CT,"Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
PA166134618,rs25487,1448522459,TT,"Patients with the TT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
PA166134619,rs25487,981345286,CC,"Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
PA166134619,rs25487,981345287,CT,"Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
PA166134619,rs25487,981345288,TT,"Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
PA166134685,rs2826494,982031341,CC,Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134685,rs2826494,982031342,GC,Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134685,rs2826494,982031343,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166158951,rs2831440,1448100196,GG,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GT and TT genotypes. Other factors may affect response to antidepressants.
PA166158951,rs2831440,1448100197,GT,Patients with the GT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158951,rs2831440,1448100198,TT,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG and GT genotypes. Other factors may affect response to antidepressants.
PA166135555,rs274618,1184514454,AA,Patients with the AA genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135555,rs274618,1184514455,AT,Patients with the AT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166135555,rs274618,1184514456,TT,Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
PA166136184,rs28360521,1444667177,CC,Patients with the CC genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CT and TT genotypes.  Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
PA166136184,rs28360521,1444667178,CT,Patients with the CT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
PA166136184,rs28360521,1444667179,TT,Patients with the TT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
PA166134304,rs2784917,655385998,AA,Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134304,rs2784917,655385999,AG,Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134304,rs2784917,655386000,GG,Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134248,rs28364006,655385261,AA,"Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134248,rs28364006,655385260,AG,Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134248,rs28364006,655385259,GG,Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166153010,rs274717,1447981498,AA,Patients with the AA genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166153010,rs274717,1447981499,AG,Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166153010,rs274717,1447981500,GG,Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer. 
PA166152963,rs28371706,1447980877,AA,Pediatric patients with the AA genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
PA166152963,rs28371706,1447980878,AG,Pediatric patients with the AG genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
PA166152963,rs28371706,1447980879,GG,Pediatric patients with the GG genotype and HIV may have increased clearance of nevirapine as compared to pediatric patients with the AA or AG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
PA166153186,rs28365063,1447987068,AA,Patients with the AA genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153186,rs28365063,1447987069,AG,Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153186,rs28365063,1447987070,GG,Patients with the GG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166158964,rs28365063,1448100315,AA,"Patients with the AA genotype and epilepsy may have decreased clearance of lamotrigine compared to patients with the GG genotype, though studies conflict. Other factors may affect clearance of lamotrigine. "
PA166158964,rs28365063,1448100316,AG,"Patients with the AG genotype and epilepsy may have decreased clearance of lamotrigine compared to patients with the GG genotype, though studies conflict. Other factors may affect clearance of lamotrigine. "
PA166158964,rs28365063,1448100317,GG,"Patients with the GG genotype and epilepsy may have increased clearance of lamotrigine compared to patients with the AA and AG genotypes, though studies conflict. Other factors may affect clearance of lamotrigine. "
PA166134058,rs28371686,1183702165,CC,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134058,rs28371686,1183702166,CG,Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134058,rs28371686,1183702167,GG,Patients with the GG genotype who are treated with warfarin may require the lowest does as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166135368,rs28371759,1447946673,AA,"Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG genotype (*1/*18B). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus."
PA166135368,rs28371759,1447946674,AG,"Patients with the AG genotype (CYP3A4 *1/*18B) who underwent kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype (*1/*1). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus."
PA166135368,rs28371759,1447946675,GG,"No patients with this genotype were included in the analysis. However, patients with the AG genotype (CYP3A4 *1/*18B) who underwent kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype (*1/*1). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus."
PA166135369,rs28371759,1183698800,AA,Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
PA166135369,rs28371759,1183698801,AG,Patients with the AG genotype (CYP3A4 *1/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
PA166135369,rs28371759,1183698802,GG,Patients with the GG genotype (CYP3A4 *18B/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1/*1 or *1/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
PA166151945,rs2839698,1447953180,AA,Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151945,rs2839698,1447953181,AG,Patients with the AG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151945,rs2839698,1447953182,GG,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166134479,rs28399468,981201828,AA,"Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked."
PA166134479,rs28399468,981201829,AC,"Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked."
PA166134479,rs28399468,981201830,CC,"Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked."
PA166134057,rs28371685,1183703153,CC,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134057,rs28371685,1183703154,CT,Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134057,rs28371685,1183703155,TT,Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166136173,rs28364032,1444666733,CC,Patients with the CC genotype and major depressive disorder may have a poorer response to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166136173,rs28364032,1444666734,CT,Patients with the CT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166136173,rs28364032,1444666735,TT,Patients with the TT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166134915,rs28365062,1127557410,AA,Patients with the AA genotype may have a dereased metabolism of zidovudine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
PA166134915,rs28365062,1127557436,GA,Patients with the GA genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
PA166134915,rs28365062,1127557441,GG,Patients with the GG genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
PA166153181,rs28365062,1447987025,AA,"Patients with the AA genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
PA166153181,rs28365062,1447987026,AG,"Patients with the AG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
PA166153181,rs28365062,1447987027,GG,"Patients with the GG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have decreased metabolism of efavirenz as compared to patients with the AA or AG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
PA166134478,rs28399454,1447953055,CC,"Patients with the CC genotype may have decreased plasma drug concentration when treated with efavirenz as compared to patients with the CT or TT genotypes. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked."
PA166134478,rs28399454,1447953056,CT,"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked."
PA166134478,rs28399454,1447953057,TT,"Patients with the TT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked."
PA166135336,rs2740574,1183689996,CC,"Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of sirolimus  as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
PA166135336,rs2740574,1183689997,CT,"Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of sirolimus  as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
PA166135336,rs2740574,1183689998,TT,"Transplant recipients with the TT (CYP3A4 *1/*1) genotype may require a decreased dose of sirolimus  as compared to patients with the CC (*1B/*1B) or CT (*1B/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
PA166134131,rs2740574,1448263849,CC,"Patients with the CC genotype may have increased clearance of docetaxel and an increased risk of infusion-related reaction as compared to patients with the TT genotype. These patients may experience an increased risk of neurotoxicity with docetaxel treatment, though reports conflict.  Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
PA166134131,rs2740574,1448263850,CT,"Patients with the CT genotype may have increased clearance of docetaxel as compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Patients with the CT genotype may have an increased risk of an infusion-related reaction as compared to patients with the TT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
PA166134131,rs2740574,1448263851,TT,"Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
PA166134369,rs2740574,655386996,CC,Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
PA166134369,rs2740574,655386997,CT,Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
PA166134369,rs2740574,655386998,TT,Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
PA166134377,rs2740574,1448285947,CC,"Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of tacrolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
PA166134377,rs2740574,1448285948,CT,"Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of tacrolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
PA166134377,rs2740574,1448285949,TT,"Transplant recipients with the TT (CYP3A4 (*1/*1) genotype may require a decreased dose of tacrolimus as compared to patients with the CT (*1B/*1) or CC (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
PA166135007,rs2740574,1183603319,CC,"Women with the CC genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CT or TT genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
PA166135007,rs2740574,1183603320,CT,"Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
PA166135007,rs2740574,1183603321,TT,"Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
PA166134475,rs2740574,981201789,CC,Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134475,rs2740574,981201790,CT,Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134475,rs2740574,981201791,TT,Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134175,rs2740574,1448099247,CC,Patients with the CC genotype and HIV infection may have decreased metabolism of indinavir compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence indinavir metabolism.
PA166134175,rs2740574,1448099248,CT,Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.
PA166134175,rs2740574,1448099249,TT,Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.
PA166153191,rs2740574,1447987108,CC,Patients with the CC genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153191,rs2740574,1447987109,CT,Patients with the CT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153191,rs2740574,1447987110,TT,Patients with the TT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166152846,rs2740574,1447963708,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer."
PA166152846,rs2740574,1447963709,CT,Patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
PA166152846,rs2740574,1447963710,TT,Patients with the TT genotype and breast cancer may have a decreased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
PA166152864,rs2740574,1447964093,CC,"Patients with the CC genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug."
PA166152864,rs2740574,1447964094,CT,"Patients with the CT genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug."
PA166152864,rs2740574,1447964095,TT,"Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug."
PA166135332,rs28401781,1183689586,CC,Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment. 
PA166135332,rs28401781,1183689587,CT,Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment. 
PA166135332,rs28401781,1183689588,TT,Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment. 
PA166136045,rs2844665,1184764190,CC,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. 
PA166136045,rs2844665,1184764191,CT,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166136045,rs2844665,1184764192,TT,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166134646,rs28399504,1446908970,AA,"Patients with the AA genotype 1) may have increased metabolism of clopidogrel and 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG and AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel."
PA166134646,rs28399504,1446908971,AG,Patients with the AG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
PA166134646,rs28399504,1446908972,GG,Patients with the GG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
PA166153066,rs28399504,1447983181,AA,Patients with the AA genotype may have a decreased metabolism of mephenytoin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166153066,rs28399504,1447983180,AG,Patients with the AG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166153066,rs28399504,1447983179,GG ,Patients with the GG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166153415,rs2847153,1447989805,AA,Patients with the AA genotype and pancreatic cancer may have an increased chance of survival when treated with fluorouracil as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
PA166153415,rs2847153,1447989806,AG,Patients with the AG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
PA166153415,rs2847153,1447989807,GG,Patients with the GG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
PA166135248,rs2849380,1183631555,CC,"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135248,rs2849380,1183631556,CT,"Patients with the CT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135248,rs2849380,1183631557,TT,"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166134202,rs2842030,655384978,GG,"Patients with the GG genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
PA166134202,rs2842030,655384977,GT,"Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
PA166134202,rs2842030,655384976,TT,"Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
PA166134203,rs2842030,655384982,GG,"Patients with the GG genotype is associated with better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134203,rs2842030,655384981,GT,"Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134203,rs2842030,655384980,TT,"Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134391,rs2853539,655387822,AA,Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have improvement in disease activity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134391,rs2853539,655387823,AG,Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134391,rs2853539,655387824,GG,Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134480,rs28399499,1447952990,CC,Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134480,rs28399499,1447952991,CT,Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134480,rs28399499,1447952992,TT,Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134481,rs28399499,1444666901,CC,Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134481,rs28399499,1444666902,CT,Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134481,rs28399499,1444666903,TT,Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166136159,rs28399499,1444666388,CC,Patients with the CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
PA166136159,rs28399499,1444666389,CT,Patients with the CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
PA166136159,rs28399499,1444666390,TT,Patients with the TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
PA166135760,rs2857657,1444702782,CC,Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135760,rs2857657,1444702781,CG,Patients with the CG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135760,rs2857657,1444702780,GG,Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166152809,rs2853826,1447963059,A,Patients with the A allele and HIV may have a lesser decline in adiponectin when treated with antiretroviral therapy as compared to patients with the G allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy. 
PA166152809,rs2853826,1447963060,G,Patients with the G allele and HIV may have a greater decline in adiponectin when treated with antiretroviral therapy as compared to patients with the A allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy. 
PA166134223,rs2854116,1448104320,CC,Patients with the CC genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166134223,rs2854116,1448104321,CT,Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166134223,rs2854116,1448104322,TT,Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166135274,rs28399433,1444667556,AA,Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
PA166135274,rs28399433,1444667557,AC,Patients with the AC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
PA166135274,rs28399433,1444667558,CC,Patients with the CC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
PA166134476,rs28399433,981201798,AA,Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134476,rs28399433,981201799,AC,Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134476,rs28399433,981201800,CC,Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134477,rs28399433,981201806,AA,Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134477,rs28399433,981201807,AC,Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166134477,rs28399433,981201808,CC,Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
PA166152931,rs28399433,1447979550,AA,"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AC or CC genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152931,rs28399433,1447979551,AC,"Hepatic cells with the AC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152931,rs28399433,1447979552,CC,"Hepatic cells with the CC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152811,rs2869950,1448106632,CC,Patients with the CC genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype. Other genetic and clinical factors may also influence body mass index.
PA166152811,rs2869950,1448106633,CT,"Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index."
PA166152811,rs2869950,1448106634,TT,Patients with the TT genotype who smoke tobacco may have a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.
PA166158782,rs28738963,1448099208,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have an increased severity of neutropenia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158782,rs28738963,1448099209,AG,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166152884,rs2854744,1447964338,GG,Patients with the GG genotype and stomach cancer may have a poorer survival outcomes when treated with fluorouracil as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival outcome.
PA166152884,rs2854744,1447964339,GT,Patients with the GT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
PA166152884,rs2854744,1447964340,TT,Patients with the TT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
PA166134222,rs2854117,1448104341,CC,Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166134222,rs2854117,1448104342,CT,Patients with the TC genotype and HIV who are treated with ritonavir may have higher triglyceride (increased risk of Hypertriglyceridemia) levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134222,rs2854117,1448104343,TT,Patients with the TT genotype and HIV who are treated with ritonavir may have higher triglyceride levels (increased risk of Hypertriglyceridemia) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135531,rs28933389,1444698455,AA,Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135531,rs28933389,1444698456,AG,Patients with the AG genotype have an decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135531,rs28933389,1444698457,GG,Patients with the GG genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the A genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135553,rs28933390,1444698461,AA,Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135553,rs28933390,1444698462,AC,Patients with the AC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166135553,rs28933390,1444698463,CC,Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the T genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
PA166136363,rs28933396,1447992336,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166136363,rs28933396,1447992337,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166136363,rs28933396,1447992338,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135382,rs2898950,1183700249,AA,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to the first course of remission induction therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135382,rs2898950,1183700250,AC,Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135382,rs2898950,1183700251,CC,Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166159171,rs28416813,1448102485,CC,Patients with the CC genotype and chronic hepatitis C or HIV may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159171,rs28416813,1448102486,CG,Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159171,rs28416813,1448102487,GG,Patients with the GG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166135469,rs28933397,1447992356,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135469,rs28933397,1447992357,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166135469,rs28933397,1447992358,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. "
PA166134727,rs2884737,1184986372,AA,Patients with the AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's warfarin dose. 
PA166134727,rs2884737,1184986373,AC,Patients with the AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's warfarin dose. 
PA166134727,rs2884737,1184986374,CC,Patients with the CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's warfarin dose. 
PA166161861,rs2916205,1448522750,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161861,rs2916205,1448522751,CT,Patients with the CT genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161861,rs2916205,1448522752,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166152816,rs292449,1447963221,CC,Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response. 
PA166152816,rs292449,1447963222,CG,Patients with the CG genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response. 
PA166152816,rs292449,1447963223,GG,Patients with the GG genotype and hypertension may have a smaller reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response. 
PA166136205,rs2900478,1444668459,AA,Patients with the AA genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. 
PA166136205,rs2900478,1444668460,AT,Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. 
PA166136205,rs2900478,1444668461,TT,Patients with the TT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. 
PA166163183,rs2942857,1448602110,AA,People who smoke and have the AA genotype may have increased clearance and decreased exposure to cotinine compared to people with the AC and CC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
PA166163183,rs2942857,1448602111,AC,People who smoke and have the AC genotype may have increased clearance and decreased exposure to cotinine compared to people with the CC genotype. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
PA166163183,rs2942857,1448602112,CC,People who smoke and have the CC genotype may have decreased clearance and increased exposure to cotinine compared to people with the AA and AC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
PA166135813,rs2973049,1444704052,CC,Patients with the CC genotype and major depression may have increased response to paroxetine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166135813,rs2973049,1444704050,CT,Patients with the CT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166135813,rs2973049,1444704051,TT,Patients with the TT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134291,rs290487,655385764,CC,"Patients with the CC genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
PA166134291,rs290487,655385765,CT,"Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
PA166134291,rs290487,655385766,TT,"Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
PA166135817,rs296766,1444704093,CC,"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones."
PA166135817,rs296766,1444704092,CT,"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype or may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones."
PA166135817,rs296766,1444704091,TT,"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones."
PA166153182,rs3003596,1447987032,AA,"Patients with the AA genotype and HIV may have increased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
PA166153182,rs3003596,1447987033,AG,"Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
PA166153182,rs3003596,1447987034,GG,"Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
PA166135025,rs2952768,1446905840,CC,Patients with the CC genotype may have increased opioid analgesic requirements after surgery as compared to patients with the CT or TT genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.
PA166135025,rs2952768,1446905841,CT,Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.
PA166135025,rs2952768,1446905842,TT,Patients with the TT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.
PA166135026,rs2952768,1183574181,CC,"Patients with the CC genotype may have less vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to opioids."
PA166135026,rs2952768,1183574182,CT,"Patients with the CT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids."
PA166135026,rs2952768,1183574183,TT,"Patients with the TT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids."
PA166135853,rs301434,1444706814,CC,Patients with the CC genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135853,rs301434,1444706813,CT,Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135853,rs301434,1444706812,TT,Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135006,rs3024530,1183630744,AA,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135006,rs3024530,1183630745,AG,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135006,rs3024530,1183630746,GG,Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
PA166135854,rs301435,1444706820,CC,Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135854,rs301435,1444706821,CT,Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135854,rs301435,1444706822,TT,Patients with the TT genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166159973,rs3025040,1448256720,CC,"Patients with the CC genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166159973,rs3025040,1448256721,CT,"Patients with the CT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166159973,rs3025040,1448256722,TT,"Patients with the TT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166159233,rs2975226,1448104007,AA,Patients with the AA genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166159233,rs2975226,1448104008,AT,"Patients with the AT genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype, or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine."
PA166159233,rs2975226,1448104009,TT,Patients with the TT genotype and schizophrenia may have a decreased response to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166136025,rs3077,1447949092,AA,Patients with AA genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
PA166136025,rs3077,1447949091,AG,Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
PA166136025,rs3077,1447949090,GG,Patients with GG genotype may have increased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
PA166152885,rs2960436,1447964348,AA,Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
PA166152885,rs2960436,1447964349,AG,Patients with the AG genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
PA166152885,rs2960436,1447964350,GG,Patients with the GG genotype and stomach cancer may have better poorer survival outcomes when treated with fluorouracil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival outcome.
PA166135805,rs307821,1444703852,AA,"Patients with the AA genotype were not studied. However, patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
PA166135805,rs307821,1444703850,AC,Patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
PA166135805,rs307821,1444703851,CC,Patients with the CC genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
PA166135005,rs3025000,1183630627,CC,Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
PA166135005,rs3025000,1183630628,CT,Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
PA166135005,rs3025000,1183630629,TT,Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
PA166135804,rs307826,1444703844,CC,"Patients with the CC genotype were not studied. However, patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
PA166135804,rs307826,1444703842,CT,Patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
PA166135804,rs307826,1444703843,TT,Patients with the TT genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
PA166163499,rs308395,1448612684,CC,Patients with the CC genotype and multiple myeloma may have increased response to lenalidomide and thalidomide treatment compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect progression of multiple myeloma.
PA166163499,rs308395,1448612685,CG,Patients with the CG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.
PA166163499,rs308395,1448612686,GG,Patients with the GG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.
PA166161170,rs3087243,1448423691,AA,"Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
"
PA166161170,rs3087243,1448423692,AG,Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161170,rs3087243,1448423693,GG,Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161232,rs3025039,1448427407,CC,Patients with the CC genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166161232,rs3025039,1448427408,CT,Patients with the CT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166161232,rs3025039,1448427409,TT,Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166136415,rs3025039,1446909105,CC,"Patients with colorectal cancer and the CC genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, oxaliplatin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin."
PA166136415,rs3025039,1446909106,CT,"Patients with colorectal cancer and the CT genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, oxaliplatin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin."
PA166136415,rs3025039,1446909107,TT,"Patients with colorectal cancer and the TT genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, oxaliplatin as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence a patient's response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin."
PA166161129,rs3087465,1448422848,AA,Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. 
PA166161129,rs3087465,1448422849,AG,Patients with the AG genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. 
PA166161129,rs3087465,1448422850,GG,Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. 
PA166151960,rs3087403,1447953356,CC,Patients with the CC genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166151960,rs3087403,1447953357,CT,Patients with the CT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166151960,rs3087403,1447953358,TT,Patients with the TT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166153482,rs2965667,1447990848,AA,Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin. 
PA166153482,rs2965667,1447990849,AT,Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin. 
PA166153482,rs2965667,1447990850,TT,Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin. 
PA166135031,rs3091244,1183601917,AA,"Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate."
PA166135031,rs3091244,1183601915,AG,Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135031,rs3091244,1183601918,AT,"Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate."
PA166135031,rs3091244,1183601916,GG,Patients with the GG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135031,rs3091244,1183601919,GT,Patients with the GT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135855,rs3087879,1444706832,CC,Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135855,rs3087879,1444706833,CG,Patients with the CG genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166135855,rs3087879,1444706834,GG,Patients with the GG genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166158743,rs3093105,1448097683,AA,The AA genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
PA166158743,rs3093105,1448097684,AC,The AC genotype may be associated with increased CYP4F2 activity and decreased vitamin e metabolism as compared to the AA genotype and decreased metabolism as compared to the CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
PA166158743,rs3093105,1448097685,CC,The CC genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or AA genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
PA166135911,rs3087374,1446897480,AA,Patients with the AA genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity. 
PA166135911,rs3087374,1446897481,AC,"Patients with the AC genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype, or a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity. "
PA166135911,rs3087374,1446897482,CC,Patients with the CC genotype who are treated with valproic acid may have a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity. 
PA166136046,rs3094188,1184764195,AA,Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. 
PA166136046,rs3094188,1184764196,AC,"Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166136046,rs3094188,1184764197,CC,"Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166136109,rs310786,1444607368,CC,"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
PA166136109,rs310786,1444607369,CT,"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
PA166136109,rs310786,1444607370,TT,"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
PA166136107,rs310786,1444607375,CC,Women with the CC genotype and breast cancer may have increased lumbar bone loss when treated with tamoxifen as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
PA166136107,rs310786,1444607376,CT,Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
PA166136107,rs310786,1444607377,TT,Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
PA166136190,rs3097671,1444667501,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136190,rs3097671,1444667502,CG,Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136190,rs3097671,1444667503,GG,Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166158985,rs3114020,1448100496,CC,Patients with the CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. Other factors may affect concentrations of lamotrigine.
PA166158985,rs3114020,1448100497,CT,Patients with the CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. Other factors may affect concentrations of lamotrigine.
PA166158985,rs3114020,1448100498,TT,Patients with the TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. Other factors may affect concentrations of lamotrigine.
PA166134483,rs3093726,1448108949,CC,"Patients with the CC genotype may have Increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134483,rs3093726,1448108950,CT,"Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166134483,rs3093726,1448108951,TT,"Patients with the TT genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events."
PA166136048,rs3099844,1184986498,AA,Female patients with the AA genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine. 
PA166136048,rs3099844,1184986499,AC,Female patients with the AC genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype and a decreased risk of Stevens-Johnson syndrome as compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine. 
PA166136048,rs3099844,1184986500,CC,Female patients with the CC genotype and acquired immunodeficiency syndrome (AIDS) may have a decreased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine. 
PA166135689,rs3130100,1448106306,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135689,rs3130100,1448106307,CT,Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT  genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135689,rs3130100,1448106308,TT,Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136193,rs3129294,1444667551,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136193,rs3129294,1444667552,AC,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136193,rs3129294,1444667553,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135583,rs3130931,1184764209,CC,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. 
PA166135583,rs3130931,1184764210,CT,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
PA166135583,rs3130931,1184764211,TT,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166135582,rs3130501,1184764202,AA,"Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166135582,rs3130501,1184764201,AG,"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166135582,rs3130501,1184764200,GG,Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. 
PA166152642,rs3133084,1447959754,AA,Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152642,rs3133084,1447959755,AG,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152642,rs3133084,1447959756,GG,Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166160701,rs319952,1448265600,AA,Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160701,rs319952,1448265601,AG,Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160701,rs319952,1448265602,GG,Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160699,rs320003,1448265583,AA,Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160699,rs320003,1448265584,AG,Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160699,rs320003,1448265585,GG,Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166134854,rs3025058,1043880216,A/del,Patients with the A/del genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134854,rs3025058,1043880215,AA,Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134854,rs3025058,1043880217,del/del,Patients with the del/del genotype and Coronary Artery Disease may be less likely to benefit from pravastatin treatment as compared to patients with the AA or A/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134855,rs3025058,1043880472,A/del,Patients with the A/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke. 
PA166134855,rs3025058,1043880473,AA,Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke. 
PA166134855,rs3025058,1043880474,del/del,Patients with the del/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke. 
PA166135702,rs3135506,1444672988,CC,Patients with the CC genotype and hypertriglyceridemia may have a poorer response to treatment with fenofibrate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135702,rs3135506,1444672989,CG,Patients with the CG genotype and hypertriglyceridemia may have a better response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135702,rs3135506,1444672990,GG,Patients with the GG genotype and hypertriglyceridemia may have a better response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166152851,rs320,1447963831,GG,Patients with the GG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166152851,rs320,1447963832,GT,Patients with the GT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166152851,rs320,1447963833,TT,Patients with the TT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166135814,rs3212198,1444704062,CC,Patients with the CC genotype and rs2501873 TT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166135814,rs3212198,1444704063,CT,Patients with the CT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype or may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166135814,rs3212198,1444704064,TT,Patients with the TT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166160670,rs3213094,1448265268,CC,Patients with the CC genotype and Psoriasis may have decreased response to ustekinumab compared to patients with the CT genotype. Other clinical and genetic factors may affect response to ustekinumab.
PA166160670,rs3213094,1448265269,CT,Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.
PA166160670,rs3213094,1448265270,TT,Patients with the TT genotype and Psoriasis were not found to have different response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.
PA166136167,rs3213239,1444666617,CCGG/CCGG,Patients with the CCGG/CCGG genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
PA166136167,rs3213239,1444666618,CCGG/del,Patients with the CCGG/del genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
PA166136167,rs3213239,1444666619,del/del,Patients with the del/del genotype and non-small-cell lung cancer may have longer overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the CCGG/CCGG or CCGG/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
PA166134859,rs3211371,1043880296,CC,Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
PA166134859,rs3211371,1043880295,TC,Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
PA166134859,rs3211371,1043880294,TT,Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
PA166136398,rs3211371,1446898336,CC,"Patients with the CC genotype who are smokers may have a lower chance of smoking cessation when treated with bupropion as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
PA166136398,rs3211371,1446898337,CT,"Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
PA166136398,rs3211371,1446898338,TT,"Patients with the TT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
PA166134185,rs3213422,1448107933,AA,Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166134185,rs3213422,1448107934,AC,It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.
PA166134185,rs3213422,1448107935,CC,Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166135598,rs3213619,1184987043,AA,Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135598,rs3213619,1184987044,AG,Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135598,rs3213619,1184987045,GG,Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135685,rs3218592,1444667294,CC,"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166135685,rs3218592,1444667295,CT,"Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166135685,rs3218592,1444667296,TT,"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
PA166163248,rs3217164,1448602862,G/del,Patients with the G/del genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163248,rs3217164,1448602861,GG,Patients with the GG genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163248,rs3217164,1448602863,del/del,Patients with the del/del genotype may have decreased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the G/G genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166134080,rs316019,637880088,AA,Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134080,rs316019,637880089,AC,Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134080,rs316019,637880090,CC,Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135239,rs316019,1183631423,AA,Patients with the AA genotype may have decreased clearance of L-tryptophan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response.
PA166135239,rs316019,1183631424,AC,"Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135239,rs316019,1183631425,CC,Patients with the CC genotype may have increased clearance of L-tryptophan as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.
PA166135366,rs316019,1446898178,AA,"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin. "
PA166135366,rs316019,1446898179,AC,"Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin. "
PA166135366,rs316019,1446898180,CC,"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the AC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin. "
PA166135734,rs316019,1448616421,AA,Patients with the AA genotype may have decreased risk of cisplatin-induced ototoxicity as compared to patients with AC or CC genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.
PA166135734,rs316019,1448616422,AC,Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.
PA166135734,rs316019,1448616423,CC,Patients with the CC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.
PA166159399,rs316019,1448109593,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159399,rs316019,1448109594,AC,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159399,rs316019,1448109595,CC,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or AA, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166160844,rs316019,1448266988,AA,"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity."
PA166160844,rs316019,1448266989,AC,"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity."
PA166160844,rs316019,1448266990,CC,"Patients with the CC genotype and non-small cell lung cancer may have decreased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the AA and AC genotypes. Other clinical and genetic factors may affect risk of toxicity."
PA166134017,rs3219484,1184348727,CC,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. 
PA166134017,rs3219484,1184348728,CT,"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. "
PA166134017,rs3219484,1184348729,TT,"Patients with the TT genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy. "
PA166135204,rs324026,1183624307,CC,Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166135204,rs324026,1183624308,CT,Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166135204,rs324026,1183624309,TT,Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166159011,rs324650,1448100882,AA,Patients with the AA genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
PA166159011,rs324650,1448100883,AT,"Patients with the AT genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction."
PA166159011,rs324650,1448100884,TT,Patients with the TT genotype may have an increased risk of becoming addicted to nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
PA166135205,rs324023,1183624314,CC,Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166135205,rs324023,1183624315,CT,Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166135205,rs324023,1183624316,TT,Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine. 
PA166134189,rs3213207,655384923,CC,Patients with this genotype were not studied.
PA166134189,rs3213207,655384924,CT,Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype.  Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.
PA166134189,rs3213207,655384925,TT,"Patients with the TT genotype who are exposed to methamphetamine may have a decreased, but not absent, risk for psychosis as compared to patients with the TC genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure."
PA166135002,rs328,1183533885,CC,Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166135002,rs328,1183533884,CG,Patients with the CG genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166135002,rs328,1183533883,GG,Patients with the GG genotype who are treated with pravastatin may have a better response (higher decreases in total cholesterol) as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166136385,rs3212986,1448106256,AA,Patients with the AA genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.
PA166136385,rs3212986,1448106257,AC,Patients with the AC genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.
PA166136385,rs3212986,1448106258,CC,Patients with the CC genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for mucositis.
PA166134353,rs3212986,655386662,AA,Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
PA166134353,rs3212986,655386663,AC,Patients with the AC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
PA166134353,rs3212986,655386664,CC,Patients with the CC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
PA166134354,rs3212986,655386666,AA,Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
PA166134354,rs3212986,655386667,AC,Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
PA166134354,rs3212986,655386668,CC,Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
PA166134417,rs3212986,1183491961,AA,"Patients with the AA genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma or esophageal cancer or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds."
PA166134417,rs3212986,1183491962,AC,"Patients with the AC genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma or esophageal cancer or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds."
PA166134417,rs3212986,1183491963,CC,"Patients with the CC genotype may have worse overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma or esophageal cancer or Ovarian Neoplasms as compared to patients with AA and AC genotypes. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds."
PA166136386,rs3212986,1445401849,AA,Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
PA166136386,rs3212986,1445401850,AC,Patients with the AC genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
PA166136386,rs3212986,1445401851,CC,Patients with the CC genotype and breast cancer may have an decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
PA166134895,rs324420,1446898818,AA,"Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain."
PA166134895,rs324420,1446898819,AC,"Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain."
PA166134895,rs324420,1446898820,CC,"Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain."
PA166134649,rs324420,982029688,AA,Men with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects. 
PA166134649,rs324420,982029689,AC,"Men with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects. "
PA166134649,rs324420,982029690,CC,Men with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects. 
PA166152844,rs324420,1447963690,AA,Patients with the AA genotype may be less likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence THC dependency. 
PA166152844,rs324420,1447963691,AC,Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency. 
PA166152844,rs324420,1447963692,CC,Patients with the CC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency. 
PA166163297,rs324420,1448603311,AA,Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166163297,rs324420,1448603312,AC,Children with the AC genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166163297,rs324420,1448603313,CC,Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166135824,rs3397,1444704330,CC,Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135824,rs3397,1444704331,CT,Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166135824,rs3397,1444704332,TT,Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
PA166152780,rs340874,1447962615,CC,Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
PA166152780,rs340874,1447962616,CT,"Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels."
PA166152780,rs340874,1447962617,TT,Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
PA166136301,rs342293,1444703202,CC,Patients with the CC genotype and Coronary Artery Disease may have  decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel. 
PA166136301,rs342293,1444703203,CG,Patients with the CG genotype and Coronary Artery Disease may have  increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype or may have  decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel. 
PA166136301,rs342293,1444703204,GG,Patients with the GG genotype and Coronary Artery Disease may have  increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel. 
PA166135163,rs34130495,1183618205,AA,Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
PA166135163,rs34130495,1183618206,AG,Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
PA166135163,rs34130495,1183618207,GG,Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
PA166135713,rs34231037,1444686876,AA,"Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib. "
PA166135713,rs34231037,1444686877,AG,"Patients with the AG genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the GG genotypes. Conversely, patients with the AG genotype may have decreased steady state levels of KDR, and an increased response to pazopanib as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism and response to pazopanib. "
PA166135713,rs34231037,1444686878,GG,"Patients with the GG genotype and Kidney Neoplasms may have decreased steady state levels of KDR, possibly leading to decreased metabolism of and increased response to pazopanib as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib. "
PA166134469,rs3215400,982033498,C/del,Patients with the C/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
PA166134469,rs3215400,982033499,CC,"Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
PA166134469,rs3215400,982033500,del/del,Patients with the del/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
PA166134470,rs3215400,1448099930,C/del,Patients with the C/del genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
PA166134470,rs3215400,1448099931,CC,Patients with the C/C genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
PA166134470,rs3215400,1448099932,del/del,Patients with the del/del genotype and cancer who are treated with capecitabine may have an increased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the CC or C/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
PA166136445,rs34548976,1446903544,CC,"In pediatric patients with asthma and the CC genotype may have an increased response to beta-adrenergic inhalants as compared to patients with the CT and TT genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma. "
PA166136445,rs34548976,1446903543,CT,"In pediatric patients with asthma and the CT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CC genotypes and an increased response to beta-adrenergic inhalants as compared to patients with the TT genotype. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma. "
PA166136445,rs34548976,1446903542,TT,"In pediatric patients with asthma and the TT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CT and CC genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma. "
PA166134063,rs339097,1184986331,AA,Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166134063,rs339097,1184986332,AG,Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166134063,rs339097,1184986333,GG,Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166161458,rs34650714,1448428922,CC,Patients with the CC genotype and gout may require a dose of 300 mg/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
PA166161458,rs34650714,1448428921,CT,Patients with the CT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
PA166161458,rs34650714,1448428920,TT,Patients with the TT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
PA166136315,rs34834489,1444703795,AA,Patients with the AA genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136315,rs34834489,1444703794,AG,Patients with the AG genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the GG genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136315,rs34834489,1444703793,GG,Patients with the GG genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136247,rs352139,1444686937,CC,"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136247,rs352139,1444686938,CT,"Patients with the CT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136247,rs352139,1444686939,TT,"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166134689,rs352428,982031518,AA,Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. 
PA166134689,rs352428,982031519,AG,Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. 
PA166134689,rs352428,982031520,GG,Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
PA166152783,rs34993780,1447962668,GG,Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
PA166152783,rs34993780,1447962669,GT,"Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38."
PA166152783,rs34993780,1447962670,TT,Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
PA166135164,rs35167514,1183618211,A/del,Patients with the A/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
PA166135164,rs35167514,1183618212,AA,Patients with the AA genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the del/del genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
PA166135164,rs35167514,1183618210,del/del,Patients with the del/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
PA166152837,rs351855,1448102939,AA,"Patients with the AA genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time."
PA166152837,rs351855,1448102940,AG,"Patients with the AG genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time."
PA166152837,rs351855,1448102941,GG,"Patients with the GG genotype and node-positive breast cancer may have longer disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence disease-free survival time."
PA166134684,rs334558,982031324,AA,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134684,rs334558,982031325,AG,Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134684,rs334558,982031326,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
PA166134412,rs334558,982030581,AA,Patients with the AA genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
PA166134412,rs334558,982030582,AG,Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
PA166134412,rs334558,982030583,GG,Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
PA166136099,rs35303484,1447953001,AA,Patients with the AA genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. Evidence is conflicting as to this association.
PA166136099,rs35303484,1447953002,AG,Patients with the AG genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype or may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. 
PA166136099,rs35303484,1447953003,GG,Patients with the GG genotype and HIV who are treated with efavirenz may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. 
PA166134250,rs35592,655385271,CC,Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134250,rs35592,655385270,CT,Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134250,rs35592,655385269,TT,Patients with the TT genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134986,rs352046,1183491805,CC,Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134986,rs352046,1183491806,CG,Patients with the CG genotype and Acute coronary syndrome who are treated with statins may have a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134986,rs352046,1183491807,GG,Patients with the GG genotype and Acute coronary syndrome who are treated with statins may have a deceased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166162364,rs35621,1448531676,CC,Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.
PA166162364,rs35621,1448531677,CT,Patients with the CT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.
PA166162364,rs35621,1448531678,TT,Patients with the TT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.
PA166153008,rs35687416,1447981486,GG,Patients with the GG genotype and pancreatic cancer may have a longer time to progression and overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer. 
PA166153008,rs35687416,1447981487,GT,Patients with the GT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer. 
PA166153008,rs35687416,1447981488,TT,Patients with the TT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer. 
PA166136316,rs36056065,1444703805,GTAAGTTG/GTAAGTTG,"Patients with the GTAAGTTG/GTAAGTTG genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype. Other genetic and clinical factors may also influence a patient's response to metformin."
PA166136316,rs36056065,1444703806,GTAAGTTG/del,"Patients with the GTAAGTTG/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype or may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin."
PA166136316,rs36056065,1444703807,del/del,"Patients with the del/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin."
PA166136226,rs35864111,1444673187,G/del,Current literature evidence finds no significant effect of the G/del genotype on progression-free survival time in patients taking docetaxel.
PA166136226,rs35864111,1444673186,GG,Patients with the GG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136226,rs35864111,1444673188,del/del,Patients with the del/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136440,rs3594,1446899892,AA,"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
"
PA166136440,rs3594,1446899893,AC,"Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
"
PA166136440,rs3594,1446899894,CC,"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
"
PA166152785,rs35350960,1447962676,AA,Cells with the AA genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
PA166152785,rs35350960,1447962677,AC,"Cells with the AC genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype, or increased activity as compared to those with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38."
PA166152785,rs35350960,1447962678,CC,Cells with the CC genotype may have increased enzymatic activity toward SN-38 as compared to cells with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
PA166153068,rs367543000,1447983194,AA,Patients with the AA genotype were not studied.
PA166153068,rs367543000,1447983193,AG,Patients with the AG genotype and depression who are treated with venlafaxine may experience agitation and dysphoria. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166153068,rs367543000,1447983195,GG ,Patients with the GG genotype were not studied.
PA166152859,rs36118214,1447964017,AA,"Patients with the AA genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels."
PA166152859,rs36118214,1447964018,AG,"Patients with the AG genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the GG genotype, and increased plasma levels as compared to those with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels."
PA166152859,rs36118214,1447964019,GG,"Patients with the GG genotype and HIV may have increased plasma levels of efavirenz as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels."
PA166153067,rs370457585,1447983188,CC,"Patients with the CC genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the TT genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166153067,rs370457585,1447983187,CT,"No information are available for patients with the CT genotype. However, patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166153067,rs370457585,1447983186,TT,"Patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166135980,rs371194629,1447680032,ATTTGTTCATGCCT/ATTTGTTCATGCCT,Patients with colorectal cancer and the HLA-G ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166135980,rs371194629,1447680031,del/ATTTGTTCATGCCT,Patients with colorectal cancer and the HLA-G del/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166135980,rs371194629,1447680030,del/del,Patients with colorectal cancer and the HLA-G del/del genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the HLA-G del/ATTTGTTCATGCCT or ATTTGTTCATGCCT/ATTTGTTCATGCCT genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166153037,rs371793722,1447982808,AA,Patients with the AA genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153037,rs371793722,1447982807,AG,"No information are available for the AG genotype. However, patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153037,rs371793722,1447982806,GG ,Patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166161461,rs3731722,1448428946,AA,Patients with the AA genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161461,rs3731722,1448428947,AG,Patients with the AG genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161461,rs3731722,1448428948,GG,Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166136522,rs361525,1447946146,AA,"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab."
PA166136522,rs361525,1447946147,AG,Patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
PA166136522,rs361525,1447946148,GG,Patients with the GG genotype may have a better response to treatment with infliximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to infliximab.
PA166161295,rs363341,1448428119,CC,Patients with the CC genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166161295,rs363341,1448428120,CT,Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166161295,rs363341,1448428121,TT,Patients with the TT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166135416,rs3732218,1445402368,AA,"Patients with the AA genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
PA166135416,rs3732218,1445402369,AG,"Patients with the AG genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
PA166135416,rs3732218,1445402370,GG,"Patients with the GG genotype may have increased glucuronidation of anastrozole as compared to patients with the AA or AG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
PA166135415,rs3732219,1445402362,CC,"Patients with the CC genotype may have increased glucuronidation of anastrozole as compared to patients with the CT or TT genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole. "
PA166135415,rs3732219,1445402363,CT,"Patients with the CT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole. "
PA166135415,rs3732219,1445402364,TT,"Patients with the TT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole. "
PA166135696,rs368234815,1444668640,G/TT,"Patients with the G/TT genotype may have faster viral clearance and increased drug efficacy  in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin."
PA166135696,rs368234815,1444668639,GG,"Patients with the GG genotype may have slower viral clearance and decreased drug efficacy  in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin as compared to patients with genotype G/TT + TT/TT. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin."
PA166135696,rs368234815,1444668641,TT/TT,"Patients with the TT/TT genotype may have faster viral clearance and increased drug efficacy  in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin."
PA166135501,rs368234815,1446906828,G/TT,Patients with the G/TT genotype may have decreased response or treatment failure with pegIFN-alpha/ribavirin treatment (with and without telaprevir) in people with chronic Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to pegIFN-alpha based therapy.
PA166135501,rs368234815,1446906829,GG,Patients with the GG genotype may have decreased response or treatment failure with pegIFN-alpha/ribavirin treatment (with and without telaprevir) in people with chronic Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to pegIFN-alpha based therapy.
PA166135501,rs368234815,1446906830,TT/TT,Patients with the TT/TT genotype may have increased response or treatment failure with pegIFN-alpha/ribavirin treatment (with and without telaprevir) in people with chronic Hepatitis C as compared to patients with genotype GG or G/TT. Other genetic and clinical factors may also influence the response to pegIFN-alpha based therapy.
PA166160626,rs368234815,1448264445,G/TT,Patients with genotype G/TT may have decreased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
PA166160626,rs368234815,1448264446,GG,Patients with genotype GG may have decreased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
PA166160626,rs368234815,1448264444,TT/TT,Patients with genotype TT/TT may have increased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype G/TT or  GG. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
PA166163136,rs3732759,1448601694,AA,Patients with the AA genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.
PA166163136,rs3732759,1448601695,AG,Patients with the AG genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.
PA166163136,rs3732759,1448601696,GG,Patients with the GG genotype and coronary disease may have decreased response to clopidogrel treatment compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect clopidogrel response.
PA166158786,rs3732359,1448099236,AA,Patients with nasopharyngeal cancer and the AA genotype may have more severe anemia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158786,rs3732359,1448099237,AG,Patients with nasopharyngeal cancer and the AG genotype may have less severe anemia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158787,rs3732360,1448098317,CT,Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158787,rs3732360,1448098318,TT,Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia who are treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166135195,rs3737224,1183622266,CC,Patients with the CC genotype who are treated with prasugrel may have higher  levels of platelet aggregation inhibition as compared to patients with the TT  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135195,rs3737224,1183622265,CT,Patients with the CT genotype who are treated with prasugrel may have higher  levels of platelet aggregation inhibition as compared to patients with the TT  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135195,rs3737224,1183622264,TT,Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166134320,rs3734254,655386137,CC,Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134320,rs3734254,655386138,CT,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166134320,rs3734254,655386139,TT,Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166135675,rs3738948,1444666596,AA,Patients with the AA genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135675,rs3738948,1444666597,AG,"Patients with the AG genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype, and an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy."
PA166135675,rs3738948,1444666598,GG,Patients with the GG genotype and non-small-cell lung cancer may have an increased response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135798,rs3740065,1444703623,AA,"Patients with the AA genotype and leukemia who are treated with methotrexate may have decreased plasma level and decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166135798,rs3740065,1444703622,AG,Patients with the AG genotype and leukemia who are treated with methotrexate may have increased plasma level and increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135798,rs3740065,1444703621,GG,Patients with the GG genotype and leukemia who are treated with methotrexate may have increased plasma level and increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166152694,rs3740065,1447960516,AA,Patients with the AA genotype and breast cancer may have an increased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
PA166152694,rs3740065,1447960517,AG,No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype. 
PA166152694,rs3740065,1447960518,GG,Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
PA166135121,rs3740556,1183630669,AA,Patients with the AA genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135121,rs3740556,1183630670,AG,Patients with the AG genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166135121,rs3740556,1183630671,GG,Patients with the GG genotype and lung cancer may have a poorer response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
PA166153040,rs374150125,1447982827,AA,"Patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
PA166153040,rs374150125,1447982828,AG,"No information are available for the AG genotype. However, patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
PA166153040,rs374150125,1447982829,GG ,"Patients with the GG genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
PA166162366,rs3743527,1448531804,CC,Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia when taking irinotecan compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
PA166162366,rs3743527,1448531805,CT,Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
PA166162366,rs3743527,1448531806,TT,Patients with the TT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
PA166159046,rs3743078,1448101262,CC,Patients with the CC genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166159046,rs3743078,1448101263,CG,"Patients with the CG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
PA166159046,rs3743078,1448101264,GG,Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166152947,rs3735451,1447980693,CC,Patients with the CC genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
PA166152947,rs3735451,1447980694,CT,"Patients with the CT genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype, or less severe effects and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone."
PA166152947,rs3735451,1447980695,TT,Patients with the TT genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
PA166136303,rs3742106,1444703277,AA,Patients with genotype AA may have decreased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype CC or AC. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
PA166136303,rs3742106,1444703276,AC,Patients with genotype AC may have increased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype AA. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
PA166136303,rs3742106,1444703275,CC,Patients with genotype CC may have increased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype AA. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
PA166134206,rs3745009,982035276,AA,Patients with the AA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
PA166134206,rs3745009,982035277,AG,Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
PA166134206,rs3745009,982035278,GG,Patients with the GG genotype who are treated with nifedipine may have larger mean changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
PA166158885,rs3746574,1448099164,CT,"Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
"
PA166158885,rs3746574,1448099165,TT,"Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
"
PA166153005,rs3750117,1447981393,AA,"Patients with the AA genotype and cancer may have increased clearance of gemcitabine, and decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance."
PA166153005,rs3750117,1447981394,AG,"Patients with the AG genotype and cancer may have increased clearance of gemcitabine as compared to patients with the GG genotype, or decreased clearance as compared to patients with the AA genotype. Patients may also have decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to those with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance."
PA166153005,rs3750117,1447981395,GG,"Patients with the GG genotype and cancer may have decreased clearance of gemcitabine as compared to patients with the AA genotype, and increased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence gemcitabine clearance."
PA166136318,rs3750117,1444703940,AA,"Patients with the AA genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin."
PA166136318,rs3750117,1444703939,AG,"Patients with the AG genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin."
PA166136318,rs3750117,1444703938,GG,Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.
PA166136474,rs3749438,1446908624,AA,"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea."
PA166136474,rs3749438,1446908625,AG,"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea."
PA166136474,rs3749438,1446908626,GG,"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 34 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea."
PA166135004,rs3740066,1183598054,CC,Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
PA166135004,rs3740066,1183598055,CT,Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
PA166135004,rs3740066,1183598056,TT,Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
PA166134499,rs3740066,1185000116,CC,Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
PA166134499,rs3740066,1185000117,CT,Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
PA166134499,rs3740066,1185000118,TT,Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
PA166135834,rs3740066,1444704925,CC,Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
PA166135834,rs3740066,1444704924,CT,Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
PA166135834,rs3740066,1444704923,TT,Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
PA166158992,rs3740066,1448100569,CC,"Patients with the CC genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation."
PA166158992,rs3740066,1448100570,CT,"Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation."
PA166158992,rs3740066,1448100571,TT,"Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation."
PA166153028,rs3750920,1447982725,CC,Patients with the CC genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine. 
PA166153028,rs3750920,1447982726,CT,Patients with the CT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine. 
PA166153028,rs3750920,1447982727,TT,Patients with the TT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect response to N-acetylcysteine. 
PA166152813,rs3754446,1448106647,AA,Patients with the AA genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of busulfan.
PA166152813,rs3754446,1448106648,AC,"Patients with the AC genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan."
PA166152813,rs3754446,1448106649,CC,Patients with the CC genotype and acute myeloid leukemia may have increased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.
PA166134503,rs3758149,981202367,AA,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
PA166134503,rs3758149,981202368,AG,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates as compared to the AA genotype 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
PA166134503,rs3758149,981202369,GG,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates 2) may have increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
PA166134679,rs35599367,1447674062,AA,"Patients with the AA genotype were not studied, however they may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam. "
PA166134679,rs35599367,1447674063,AG,Patients with the AG genotype and tumors may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam. 
PA166134679,rs35599367,1447674064,GG,Patients with the GG genotype and tumors may have increased metabolism of midazolam as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of midazolam. 
PA166134680,rs35599367,1448108126,AA,"Patients with the AA genotype were not studied, however they may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. "
PA166134680,rs35599367,1448108127,AG,Patients with the AG genotype and tumors may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin. 
PA166134680,rs35599367,1448108128,GG,Patients with the GG genotype and tumors may have increased metabolism of erythromycin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
PA166135323,rs35599367,1448602367,AA,"Transplant recipients with the AA genotype (also known as CYP3A4 *22/*22) may have decreased metabolism of tacrolimus, resulting in increased exposure and a lower dose requirement (among other pharmacokinetic parameters), as compared to patients with the GG genotype (CYP3A4 *1/*1). Around half of studies report an association, and half report no association. One study found an association with liver transplant donor genotype but not recipient genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence metabolism of tacrolimus."
PA166135323,rs35599367,1448602368,AG,"Transplant recipients with the AG genotype (also known as CYP3A4 *1/*22) may have decreased metabolism of tacrolimus, resulting in increased exposure and a lower dose requirement (among other pharmacokinetic parameters), as compared to patients with the GG genotype (CYP3A4 *1/*1). Around half of studies report an association, and half report no association. One study found an association with liver transplant donor genotype but not recipient genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence metabolism of tacrolimus."
PA166135323,rs35599367,1448602369,GG,"Transplant recipients with the GG genotype (also known as CYP3A4 *1/*1) may have increased metabolism of tacrolimus, resulting in decreased exposure and a higher dose requirement (among other pharmacokinetic parameters), as compared to patients with the AG or AA genotype (CYP3A4 *22/*1 and *22/*22). Around half of studies report an association, and half report no association. One study found an association with liver transplant donor genotype but not recipient genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence metabolism of tacrolimus."
PA166135818,rs35599367,1448107579,AA,Patients with the AA genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
PA166135818,rs35599367,1448107580,AG,Patients with the AG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
PA166135818,rs35599367,1448107581,GG,Patients with the GG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
PA166160775,rs35599367,1448266398,AA,"This study did not contain individuals with the AA genotype, though individuals with the AA genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics."
PA166160775,rs35599367,1448266399,AG,Patients with the AG genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
PA166160775,rs35599367,1448266400,GG,Patients with the GG genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the AG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
PA166136049,rs35599367,1448418117,AA,Patients with the AA genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) all as compared to patients with the GG genotype. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine. 
PA166136049,rs35599367,1448418118,AG,Patients with the AG genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the GG genotype. Patients with the AG genotype and organ transplantation administered cyclosporine may have 1) increased metabolism 2) increased clearance and 3) decreased risk of adverse events as compared to patients with the GG genotype. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine. 
PA166136049,rs35599367,1448418119,GG,Patients with the GG genotype and organ transplantation administered cyclosporine may have a 1) increased metabolism of cyclosporine 2) increased clearance of cyclosporine and 3) a decreased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the AA genotype. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine. 
PA166160993,rs3759467,1448276372,CC,Patients with the CC genotype and ANCA-associated vasculitis may have shorter time to failure when treated with rituximab compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to rituximab.
PA166160993,rs3759467,1448276373,CT,Patients with the CT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.
PA166160993,rs3759467,1448276374,TT,Patients with the TT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.
PA166135987,rs3759811,1447681871,CC,"Post-menopausal women with breast cancer and the CC genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT and TT genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer."
PA166135987,rs3759811,1447681872,CT,"Post-menopausal women with breast cancer and the CT genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the TT genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer."
PA166135987,rs3759811,1447681873,TT,"Post-menopausal women with breast cancer and the TT genotype who are taking letrozole, with or without a statin, may have increased plasma concentrations of triglycerides as compared to women with the CT and CC genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer."
PA166135835,rs3758785,1444704952,AA,Patients with the AA genotype may have increased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135835,rs3758785,1444704953,AG,Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135835,rs3758785,1444704954,GG,Patients with the GG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
PA166135836,rs3758785,1444704958,AA,Patients with the AA genotype may have decreased response to candesartan in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to candesartan.
PA166135836,rs3758785,1444704959,AG,Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.
PA166135836,rs3758785,1444704960,GG,Patients with the GG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.
PA166163747,rs3761548,1448616680,GG,Patients with the GG genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis. 
PA166163747,rs3761548,1448616681,GT,Patients with the GT genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the TT genotypes and and an increased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis. 
PA166163747,rs3761548,1448616682,TT,Patients with the TT genotype and psoriasis may experience an increased response to methotrexate as compared to patients with the GT GG genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis. 
PA166162270,rs3761548,1448530597,GG,Patients with the GG genotype and kidney transplantation may have decreased risk of acute renal toxicity when taking tacrolimus compared to patients with the GT or TT genotypes. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
PA166162270,rs3761548,1448530598,GT,Patients with the GT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
PA166162270,rs3761548,1448530599,TT,Patients with the TT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
PA166135690,rs3753380,1444667693,CC,"Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes CT or TT. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP's association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
PA166135690,rs3753380,1444667694,CT,"Patients with the CT genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure)  compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP's association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
PA166135690,rs3753380,1444667695,TT,"Patients with the TT genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP's association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
PA166134667,rs3761555,982030894,CC,Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134667,rs3761555,982030895,CT,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134667,rs3761555,982030896,TT,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134668,rs3761554,982030901,CC,Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134668,rs3761554,982030902,CT,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134668,rs3761554,982030903,TT,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166135759,rs3761847,1444702668,AA,"Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments."
PA166135759,rs3761847,1444702667,AG,"Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments."
PA166135759,rs3761847,1444702666,GG,"Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments."
PA166135799,rs3763980,1444703641,AA,Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135799,rs3763980,1444703642,AT,Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135799,rs3763980,1444703643,TT,Patients with the TT genotype may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134365,rs3761422,655386970,CC,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134365,rs3761422,655386971,CT,"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134365,rs3761422,655386972,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
PA166136335,rs3761422,1444704967,CC,People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
PA166136335,rs3761422,1444704966,CT,People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
PA166136335,rs3761422,1444704965,TT,People with the TT genotype may have increased Anxiety Disorders when exposed to caffeine as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
PA166135837,rs3764043,1444704945,CC,Patients with the CC genotype may have decreased imatinib clearance when treated with imatinib as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the clearance of imatinib.
PA166135837,rs3764043,1444704946,CT,Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.
PA166135837,rs3764043,1444704947,TT,Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.
PA166163296,rs3766246,1448603305,AA,Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166163296,rs3766246,1448603306,AG,Children with the AG genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166163296,rs3766246,1448603307,GG,Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166135745,rs376817657,1444700842,CC,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135745,rs376817657,1444700841,TC,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135745,rs376817657,1444700840,TT,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
PA166135691,rs3766355,1448112087,AA,"Patients with the AA genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AC or CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone.  A single study reported its association with response to latanoprost by comparing the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
PA166135691,rs3766355,1448112088,AC,"Patients with the AC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype AA and a decreased response compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
PA166135691,rs3766355,1448112089,CC,"Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AA or AC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
PA166136171,rs3768142,1444666712,GG,Patients with the GG genotype and acute lymphoblastic leukemia may have an increased risk of granulocytopenia when treated with methotrexate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
PA166136171,rs3768142,1444666713,GT,Patients with the GT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
PA166136171,rs3768142,1444666714,TT,Patients with the TT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
PA166136031,rs3770102,1184749179,GG,Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. 
PA166136031,rs3770102,1184749180,GT,"Patients with the GT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. "
PA166136031,rs3770102,1184749181,TT,"Patients with the TT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. "
PA166135684,rs3772809,1444667258,AA,Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
PA166135684,rs3772809,1444667259,AG,Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
PA166135684,rs3772809,1444667260,GG,Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
PA166136186,rs3772810,1444667265,AA,Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
PA166136186,rs3772810,1444667266,AG,Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
PA166136186,rs3772810,1444667267,GG,Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
PA166158963,rs3765534,1448267813,CC,Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
PA166158963,rs3765534,1448267814,CT,Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
PA166158963,rs3765534,1448267815,TT,Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
PA166135869,rs3784864,1444843406,AA,"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate."
PA166135869,rs3784864,1444843405,AG,"Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
PA166135869,rs3784864,1444843404,GG,"Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
PA166136126,rs3785143,1444607798,CC,"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to atomoxetine."
PA166136126,rs3785143,1444607799,CT,Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.
PA166136126,rs3785143,1444607800,TT,"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to treatment with atomoxetine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine."
PA166135474,rs3785161,1446909073,AA,Patients with the AA genotype and Coronary Disease who are treated with clopidogrel may have a decreased on-treatment platelet activity as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
PA166135474,rs3785161,1446909074,CA,Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
PA166135474,rs3785161,1446909075,CC,Patients with the CC genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
PA166136213,rs3786547,1444673041,CC,"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
PA166136213,rs3786547,1444673042,CT,"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
PA166136213,rs3786547,1444673043,TT,"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
PA166136308,rs3775291,1444703513,CC,"Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166136308,rs3775291,1444703511,CT,Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166136308,rs3775291,1444703512,TT,Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134187,rs3775291,655384915,CC,Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
PA166134187,rs3775291,655384916,CT,Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
PA166134187,rs3775291,655384917,TT,Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
PA166136211,rs3787429,1444673048,CC,Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166136211,rs3787429,1444673049,CT,Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166136211,rs3787429,1444673050,TT,Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166136214,rs3787430,1444673055,CC,Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166136214,rs3787430,1444673056,CT,Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166136214,rs3787430,1444673057,TT,Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166152725,rs3780126,1447960854,AA,Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.
PA166152725,rs3780126,1447960853,AG,"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time."
PA166152725,rs3780126,1447960852,GG,Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence survival time.
PA166136178,rs3788189,1444666805,GG,Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
PA166136178,rs3788189,1444666806,GT,Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
PA166136178,rs3788189,1444666807,TT,Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.
PA166136197,rs3792269,1444667663,AA,"Patients with the AA genotype and diabetes mellitus may have an increased response  when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to metformin.
"
PA166136197,rs3792269,1444667664,AG,"Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin.
"
PA166136197,rs3792269,1444667665,GG,"Patients with the GG genotype and diabetes mellitus may have a decreased response  when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to metformin.
"
PA166134445,rs37973,827863844,AA,Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to glucocorticoids.
PA166134445,rs37973,827863845,AG,Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.
PA166134445,rs37973,827863846,GG,Patients with the GG genotype may have increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with homozygous GG genotype has the lowest GLCC1 expression value compared to AA or AG.
PA166135717,rs3804099,1444686978,CC,Patients with the CC genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135717,rs3804099,1444686979,CT,Patients with the CT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135717,rs3804099,1444686980,TT,Patients with the TT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166134219,rs3803300,1448107924,CC,Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134219,rs3803300,1448107925,CT,Patients with the CT genotype and schizophrenia who are treated with risperidone may be more likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134219,rs3803300,1448107926,TT,Patients with the TT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166152857,rs3789243,1447963993,AA,"Male patients with the AA genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics. "
PA166152857,rs3789243,1447963994,AG,"Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics. "
PA166152857,rs3789243,1447963995,GG,"Male patients with the GG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics. "
PA166136499,rs3793790,1447814426,AA,"Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine."
PA166136499,rs3793790,1447814427,AG,"Patients with the AG genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine."
PA166136499,rs3793790,1447814428,GG,"Patients with the GG genotype and Alzheimer Disease may have increased response to donepezil, galantamine, or rivastigmine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine."
PA166134128,rs3800373,982030672,AA,"Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134128,rs3800373,982030673,AC,"Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134128,rs3800373,982030674,CC,"Patients with the CC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166135712,rs3806598,1444686864,AA,"In human liver microsomes, the AA genotype was associated with increased glucuronidation of SN-38, as compared to the AC or CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
PA166135712,rs3806598,1444686865,AC,"In human liver microsomes, the AC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
PA166135712,rs3806598,1444686866,CC,"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
PA166158742,rs3806596,1448106412,CC,"Patients with HIV and the CC genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CT or TT genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166158742,rs3806596,1448106413,CT,"Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166158742,rs3806596,1448106414,TT,"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
PA166159060,rs3806596,1448106441,CC,"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia. "
PA166159060,rs3806596,1448106442,CT,"Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia."
PA166159060,rs3806596,1448106443,TT,"Patients with the TT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia."
PA166136342,rs3810950,1444706885,AA,Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166136342,rs3810950,1444706886,AG,Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166136342,rs3810950,1444706887,GG,Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134657,rs3810651,982030420,AA,Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. 
PA166134657,rs3810651,982030421,AT,Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. 
PA166134657,rs3810651,982030422,TT,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT  genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. 
PA166134682,rs3794271,1448099852,AA,"Patients with the AA genotype and rheumatoid arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG or AG genotype. However, those with the AA genotype and psoriatic arthritis may be less likely to respond to anti-TNF treatment as compared to those with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134682,rs3794271,1448099853,AG,"Patients with the AG genotype and Rheumatoid Arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG genotype but may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the AG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166134682,rs3794271,1448099854,GG,"Patients with the GG genotype and Rheumatoid Arthritis may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the GG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166134901,rs3808607,1447953219,GG,"Patients with the GG genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
PA166134901,rs3808607,1447953220,GT,"Patients with the GT genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
PA166134901,rs3808607,1447953221,TT,"Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
PA166153183,rs3814055,1447987047,CC,Patients with the CC genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166153183,rs3814055,1447987048,CT,"Patients with the CT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype, or decreased clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine."
PA166153183,rs3814055,1447987049,TT,Patients with the TT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
PA166159202,rs3814055,1448103930,CC,Patients with the CC genotype may have an increased risk for flucloxacillin-induced liver injury as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
PA166159202,rs3814055,1448103931,CT,Patients with the CT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
PA166159202,rs3814055,1448103932,TT,Patients with the TT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
PA166136529,rs3814055,1447947021,CC,"Patients with the CC genotype may have decreased concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations. "
PA166136529,rs3814055,1447947022,CT,"Patients with the CT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations. "
PA166136529,rs3814055,1447947023,TT,"Patients with the TT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations. "
PA166134381,rs3813928,655387246,AA,Patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
PA166134381,rs3813928,655387247,AG,Patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
PA166134381,rs3813928,655387248,GG,Patients with the GG genotype may have better response to risperidone as compared to patients with the AA or AG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
PA166159045,rs3813567,1448101254,AA,Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166159045,rs3813567,1448101255,AG,"Patients with the AG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction."
PA166159045,rs3813567,1448101256,GG,Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166134201,rs3813929,1447960549,CC,"Patients with the CC genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment."
PA166134201,rs3813929,1447960550,CT,"Patients with the CT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain, or an association in the opposite direction. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment."
PA166134201,rs3813929,1447960551,TT,"Patients with the TT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment."
PA166136056,rs3814058,1184986682,CC,Patients with the CC genotype may have a decreased metabolism of repaglinide as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
PA166136056,rs3814058,1184986683,CT,The CT genotype did not differ significantly in metabolism of repaglinide as compared to patients with the CC or TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
PA166136056,rs3814058,1184986684,TT,Patients with the TT genotype may have an metabolism of repaglinide as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
PA166158788,rs3814058,1448099274,CC,Patients with nasopharyngeal cancer and the CC genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158788,rs3814058,1448099275,CT,Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia as compared to patients with the CC or TT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158788,rs3814058,1448099276,TT,Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166135584,rs3815087,1184764214,AA,Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. 
PA166135584,rs3815087,1184764215,AG,"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype.  This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
PA166135584,rs3815087,1184764216,GG,"Patients with genotype GG may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166158989,rs3814995,1448100523,CC,Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.
PA166158989,rs3814995,1448100524,CT,Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.
PA166158989,rs3814995,1448100525,TT,Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.
PA166135687,rs3818822,1444667439,AA,Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135687,rs3818822,1444667440,AG,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135687,rs3818822,1444667441,GG,Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166158962,rs3814637,1448100298,CC,"Patients with the CC genotype may require an increased dose of warfarin, and may be at decreased risk of over-anticoagulation, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of warfarin and risk of over-anticoagulation. "
PA166158962,rs3814637,1448100299,CT,"Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Patients with the CT genotype may also be at increased risk of over-anticoagulation as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dosage of warfarin and risk of over-anticoagulation. "
PA166158962,rs3814637,1448100300,TT,"Patients with the TT genotype may require a decreased dose of warfarin, and may be at increased risk of over-anticoagulation, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin and risk of over-anticoagulation. "
PA166135529,rs3824662,1184512142,AA,Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135529,rs3824662,1184512143,AC,"Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response  as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135529,rs3824662,1184512144,CC,Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166160873,rs3826041,1448267391,AA,Patients with the AA genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.
PA166160873,rs3826041,1448267392,AC,Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.
PA166160873,rs3826041,1448267393,CC,Patients with the CC genotype and heart valve replacement may require increased dose of warfarin compared to patients with the AA and AC genotypes. Other clinical and genetic factors affect warfarin dose.
PA166135870,rs3828913,1444843497,AA,Patients with genotype AA may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
PA166135870,rs3828913,1444843496,AC,Patients with genotype AC may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
PA166135870,rs3828913,1444843495,CC,Patients with genotype CC may have higher rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
PA166136317,rs3836790,1444703908,CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA ,Patients with the CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA genotype and Parkinson Disease who are treated with levodopa may have increased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to levodopa. 
PA166136317,rs3836790,1444703909,CACATACCATGCAACATACACACTCAGACA/del,Patients with the CACATACCATGCAACATACACACTCAGACA/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa. 
PA166136317,rs3836790,1444703910,del/del,Patients with the del/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa. 
PA166134040,rs3812718,1447679812,CC,Patients with the CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
PA166134040,rs3812718,1447679813,CT,Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
PA166134040,rs3812718,1447679814,TT,Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
PA166134041,rs3812718,982030740,CC,Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.
PA166134041,rs3812718,982030741,CT,Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.
PA166134041,rs3812718,982030742,TT,Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.
PA166135067,rs3812718,1447679817,CC,Patients with the CC genotype and epilepsy who are treated with carbamazepine 1) may be more likely to respond to treatment 2) may be less likely to discontinue treatment as compared to patients with the TT genotype. Please note; no association was found in a large cohort and meta-analysis. Other genetic and clinical factors may also influence a patient's response to carbamazepine and treatment retention rate. 
PA166135067,rs3812718,1447679818,CT,Patients with the CT genotype and epilepsy who are treated with carbamazepine 1) may be more likely to respond to treatment 2) may be less likely to discontinue treatment as compared to patients with the TT genotype. Please note; no association was found in a large cohort and meta-analysis. Other genetic and clinical factors may also influence a patient's response to carbamazepine and treatment retention rate. 
PA166135067,rs3812718,1447679819,TT,Patients with the TT genotype and epilepsy who are treated with carbamazepine 1) may be less likely to respond to treatment 2) may be more likely to discontinue treatment as compared to patients with the TT genotype. Please note; no association was found in a large cohort and meta-analysis. Other genetic and clinical factors may also influence a patient's response to carbamazepine and treatment retention rate. 
PA166152777,rs3812718,1447961413,CC,"Patients with the CC genotype and epilepsy may be less likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs."
PA166152777,rs3812718,1447961414,CT,"Patients with the CT genotype and epilepsy may be less likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs."
PA166152777,rs3812718,1447961415,TT,"Patients with the TT genotype and epilepsy may be more likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs."
PA166135978,rs3812718,1447679826,CC,"Patients with epilepsy and the CC genotype may have decreased metabolism of carbamazepine, resulting in increased exposure as compared to patients with the TT genotype. "
PA166135978,rs3812718,1447679827,CT,"Patients with epilepsy and the CT genotype may have decreased metabolism of carbamazepine, resulting in increased exposure as compared to patients with the TT genotype. "
PA166135978,rs3812718,1447679828,TT,"Patients with epilepsy and the TT genotype may have increased metabolism of carbamazepine, resulting in decreased exposure as compared to patients with the CC and CT genotypes. "
PA166134843,rs3832043,1447990603,DEL/DEL,Patients with the DEL/DEL genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/T and TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
PA166134843,rs3832043,1447990604,DEL/T,Patients with the DEL/T genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
PA166134843,rs3832043,1447990605,TT,"Patients with the TT genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
 "
PA166135109,rs3832043,1183631271,T/del,"Patients with the T/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT genotype, or increased glucuronidation of SN-38 as compared to patients with the del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38."
PA166135109,rs3832043,1183631272,TT,"Patients with the TT genotype and non-small cell lung cancer may have increased glucuronidation of SN-38 as compared to patients with the T/del or del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38."
PA166135109,rs3832043,1183631273,del/del,"Patients with the del/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT or T/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38."
PA166135110,rs3832043,1184468880,T/del,"Patients with the T/del genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea."
PA166135110,rs3832043,1184468881,TT,"Patients with the T/T genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea."
PA166135110,rs3832043,1184468882,del/del,"Patients with the del/del genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the T/del or TT genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea."
PA166158751,rs3832043,1448097809,TT,Patients with kidney transplantation and the TT genotype may have increased metabolism of mycophenolic acid as compared to patients with the del/del or del/T or del/del genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
PA166158751,rs3832043,1448097808,del/T,Patients with kidney transplantation and the del/T genotype may have decreased metabolism of mycophenolic acid as compared to patients with the TT genotypes but increased metabolism of mycophenolic acid as compared to patients with the del/del genotype. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
PA166158751,rs3832043,1448097807,del/del,Patients with kidney transplantation and the del/del genotype may have decreased metabolism of mycophenolic acid as compared to patients with the de/T or TT genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
PA166134231,rs3846662,655385131,AA,"This intronic variant is associated with differential induction, upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively spliced transcript lacking exon 13 (HMGCRv_1). In immortalized lymphocytes, A/A homozygotes exhibit 40% greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 transcript relative to A/G or G/G subjects. These differences may have implications for simvastatin efficacy, since increased induction of the alternatively spliced transcript is correlated with reduced percent response to simvastatin."
PA166134231,rs3846662,655385132,AG,The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript  as compared to AA genotype.
PA166134231,rs3846662,655385133,GG,The GG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript  as compared to AA genotype.
PA166135496,rs3842,1185234993,CC,"Patients with CC genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug."
PA166135496,rs3842,1185234994,CT,"Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug."
PA166135496,rs3842,1185234995,TT,"Patients with the TT genotype, and HIV infection, have decreased exposure to efavirenz compared to patients with the CC, or CT genotypes. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug."
PA166159309,rs3873352,1448107279,CC,"Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
"
PA166159309,rs3873352,1448107280,CG,"Patients with retinal disease and the CG genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the GG genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
"
PA166159309,rs3873352,1448107281,GG,"Patients with retinal disease and the GG genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CG or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
"
PA166134786,rs3856806,1043858654,CC,"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity."
PA166134786,rs3856806,1043858653,CT,"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity."
PA166134786,rs3856806,1043858652,TT,"Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.
"
PA166136004,rs3917412,1447814593,CC,"Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil."
PA166136004,rs3917412,1447814594,CT,"Patients with CT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil."
PA166136004,rs3917412,1447814595,TT,"Patients with TT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil."
PA166134065,rs3849942,637879938,CC,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
PA166134065,rs3849942,637879939,CT,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
PA166134065,rs3849942,637879940,TT,Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
PA166134988,rs3917643,1183491827,CC,Patients with the CC genotype were not studied. Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134988,rs3917643,1183491828,CT,Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134988,rs3917643,1183491829,TT,Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166158974,rs3931660,1448100384,AA,Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity. 
PA166158974,rs3931660,1448100385,AT,Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity. 
PA166158974,rs3931660,1448100386,TT,"No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity. "
PA166160702,rs393994,1448265607,AA,Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160702,rs393994,1448265608,AG,Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166160702,rs393994,1448265609,GG,Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
PA166134355,rs3957357,1448108850,AA,Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
PA166134355,rs3957357,1448108851,AG,Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
PA166134355,rs3957357,1448108852,GG,Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
PA166159154,rs3957357,1448102883,AA,Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.
PA166159154,rs3957357,1448102884,AG,Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.
PA166159154,rs3957357,1448102885,GG,Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.
PA166158870,rs3957357,1448099024,AA,Pediatric patients with the AA genotype who are undergoing hematopoietic stem cell transplantation may have increased clearance of busulfan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence busulfan clearance. 
PA166158870,rs3957357,1448099025,AG,Pediatric patients with the AG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance. 
PA166158870,rs3957357,1448099026,GG,Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance. 
PA166136134,rs3957357,1444608065,AA,Patients with the AA genotype and soft tissue sarcoma may have a longer progression-free survival time when treated with doxorubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136134,rs3957357,1444608066,AG,Patients with the AG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136134,rs3957357,1444608067,GG,Patients with the GG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166151954,rs3957356,1447953293,CC,Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
PA166151954,rs3957356,1447953294,CT,Patients with the CT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
PA166151954,rs3957356,1447953295,TT,"Although there is no data on patients with the TT genotype, one might expect patients with the TT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide."
PA166134452,rs3745274,1448265897,GG,Patients with the GG genotype and HIV infection may have decreased plasma concentrations and increased clearance of efavirenz as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134452,rs3745274,1448265898,GT,Patients with the GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134452,rs3745274,1448265899,TT,Patients with the TT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166135412,rs3745274,1447953037,GG,Patients with the GG genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of methadone.
PA166135412,rs3745274,1447953038,GT,Patients with the GT genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of methadone.
PA166135412,rs3745274,1447953039,TT,Patients with the TT genotype who are being treated with methadone for heroin addiction may require a decreased dose of the drug as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence dose of methadone.
PA166134954,rs3745274,1183491047,GG,Patients with the GG genotype and Adrenocortical Carcinoma who are treated with mitotane may have lower mitotane plasma concentrations as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
PA166134954,rs3745274,1183491046,TG,Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
PA166134954,rs3745274,1183491045,TT,Patients with the TT genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
PA166134500,rs3745274,1444666894,GG,Patients with the GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.
PA166134500,rs3745274,1444666895,GT,Patients with the GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.
PA166134500,rs3745274,1444666896,TT,Patients with the TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.
PA166134501,rs3745274,981202335,GG,Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
PA166134501,rs3745274,981202336,GT,Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
PA166134501,rs3745274,981202337,TT,Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
PA166134502,rs3745274,981202357,GG,Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166134502,rs3745274,981202358,GT,"Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements."
PA166134502,rs3745274,981202359,TT,Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166134453,rs3745274,1448265891,GG,"Patients with the GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, patients with the GG genotype may also have an increased risk for immunological failure, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134453,rs3745274,1448265892,GT,"Patients with the GT genotype may have a decreased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the TT genotype. One study shows an increased risk for sleep disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166134453,rs3745274,1448265893,TT,"Patients with the TT genotype may have an increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG or GT genotype. However, patients with the TT genotype may also have a decreased risk for immunological failure, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
PA166136236,rs3745274,1444686791,GG,"Patients with the GG genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a greater risk for side effects as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
PA166136236,rs3745274,1444686792,GT,"Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
PA166136236,rs3745274,1444686793,TT,"Patients with the TT genotype and chronic myeloid leukemia may have a 1) a poorer response to treatment with imatinib as compared to patients with the GG or GT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
PA166135874,rs3745274,1444933024,GG,Patients under general anaesthesia with genotypes GG may need increased dose of propofol as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence the dose of propofol. 
PA166135874,rs3745274,1444933023,GT,Patients under general anaesthesia with genotypes GT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol. 
PA166135874,rs3745274,1444933022,TT,Patients under general anaesthesia with genotypes TT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol. 
PA166152968,rs3745274,1448102922,GG,Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
PA166152968,rs3745274,1448102923,GT,"Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity."
PA166152968,rs3745274,1448102924,TT,Patients with the TT genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
PA166162606,rs3745274,1448573508,GG,"Patients with the GG genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine."
PA166162606,rs3745274,1448573509,GT,"Patients with the GT genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine."
PA166162606,rs3745274,1448573510,TT,"Patients with the TT genotype may have increased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the GG genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine."
PA166135820,rs402007,1444704120,CC,Patients with the CC genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166135820,rs402007,1444704121,CG,Patients with the CG genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype or may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166135820,rs402007,1444704122,GG,Patients with the GG genotype who are treated with hmg coa reductase inhibitors may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
PA166136129,rs4073,1444607858,AA,Patients with the AA genotype and age-related macular degeneration may have a poorer response when treated with bevacizumab as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166136129,rs4073,1444607859,AT,Patients with the AT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166136129,rs4073,1444607860,TT,Patients with the TT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166136442,rs408626,1446900958,CC,"Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia. "
PA166136442,rs408626,1446900959,CT,"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia. "
PA166136442,rs408626,1446900960,TT,"Patients with acute lymphoblastic leukemia and the TT genotype may have an increased risk of leukopenia, as compared to patients with the CC and CT genotypes, but may also experience increased rates of event-free survival, as well as overall survival as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia. "
PA166135634,rs396991,1185003569,AA,Patients with the AA genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.
PA166135634,rs396991,1185003568,AC,Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.
PA166135634,rs396991,1185003567,CC,Patients with the CC genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the response to trastuzumab.
PA166134147,rs396991,655384678,AA,Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
PA166134147,rs396991,655384677,AC,Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
PA166134147,rs396991,655384676,CC,Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
PA166135665,rs396991,1447814489,AA,"Patients with the AA genotype and rheumatoid arthritis or neuromyelitis optica may have a poorer response to rituximab, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rituximab. "
PA166135665,rs396991,1447814490,AC,"Patients with the AC genotype and rheumatoid arthritis or neuromyelitis optica may have a poorer response to rituximab, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rituximab. "
PA166135665,rs396991,1447814491,CC,"Patients with the CC genotype and rheumatoid arthritis or neuromyelitis optica may have a better response to rituximab, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence response to rituximab. "
PA166134505,rs396991,1448099946,AA,Patients with the AA genotype with Colorectal Cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134505,rs396991,1448099947,AC,Patients with the AC genotype with Colorectal Cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134505,rs396991,1448099948,CC,Patients with the CC genotype with Colorectal Cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166136222,rs396991,1448426984,AA,Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136222,rs396991,1448426985,AC,Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136222,rs396991,1448426986,CC,Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135819,rs396991,1444934609,AA,Patients with the AA genotype and Kidney Transplantation may have decreased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
PA166135819,rs396991,1444934610,AC,Patients with the AC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
PA166135819,rs396991,1444934611,CC,Patients with the CC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
PA166136400,rs396991,1447945889,AA,"Patients with the AA genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab."
PA166136400,rs396991,1447945890,AC,"Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab."
PA166136400,rs396991,1447945891,CC,"Patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with infliximab as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab."
PA166134155,rs4086116,655384728,CC,Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
PA166134155,rs4086116,655384727,CT,Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
PA166134155,rs4086116,655384726,TT,Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
PA166136269,rs4086116,1444700560,CC,Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
PA166136269,rs4086116,1444700561,CT,Patients with the CT genotype may require a lower dose of phenprocoumon as compared to patients with the CC genotype and may require an increased dose of phenprocoumon as compared to patients with the TT. Other genetic and clinical factors may also influence phenprocoumon dose.
PA166136269,rs4086116,1444700562,TT,Patients with the TT genotype may require the lowest dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
PA166135552,rs41271330,1184513737,AA,Patients with the AA genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166135552,rs41271330,1184513738,AG,Patients with the AG genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166135552,rs41271330,1184513739,GG,Patients with the GG genotype who are treated with escitalopram may have an increased chance of response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166135196,rs41273215,1183622324,CC,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135196,rs41273215,1183622323,CT,Patients with the CT genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135196,rs41273215,1183622322,TT,Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166163574,rs41273215,1448613361,CC,Patients with the CC genotype may have lower on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166163574,rs41273215,1448613360,CT,Patients with the CT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166163574,rs41273215,1448613359,TT,Patients with the TT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166160020,rs41301394,1448257153,CC,Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also impact the dose of warfarin. 
PA166160020,rs41301394,1448257152,CT,Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin. 
PA166160020,rs41301394,1448257151,TT,Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin. 
PA166135376,rs4124874,1444666086,GG,"Cancer patients with the GG genotype who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. However, several subsequent studies have found no association between the GG genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
PA166135376,rs4124874,1444666087,GT,"Cancer patients with the GT genotype who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. However, several subsequent studies have found no association between the GT genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
PA166135376,rs4124874,1444666088,TT,"Cancer patients with the TT genotype who are treated with irinotecan may have a decreased risk of Neutropenia as compared to patients with the GG genotype. However, several subsequent studies have found no association between the TT genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
PA166136449,rs4124874,1446905041,GG,"Pediatric patients with major thalassemia and the GG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype GT, therefore there is no information for patients with the GG or TT genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox. "
PA166136449,rs4124874,1446905040,GT,"Pediatric patients with major thalassemia and the GT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype GT, therefore there is no information for patients with the GG or TT genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox. "
PA166136449,rs4124874,1446905039,TT,"Pediatric patients with major thalassemia and the TT genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the GT or GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype GT, therefore there is no information for patients with the GG or TT genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox. "
PA166135821,rs4132670,1444704136,AA,Patients with the AA genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166135821,rs4132670,1444704137,AG,"Patients with the AG genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype or may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
PA166135821,rs4132670,1444704138,GG,"Patients with the GG genotype and Hypertension may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
PA166135822,rs4133101,1444704145,CC,"Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
PA166135822,rs4133101,1444704144,CT,"Patients with the CT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype or may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
PA166135822,rs4133101,1444704143,TT,Patients with the TT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
PA166151957,rs4135385,1447953335,AA,"Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of  neutropenia when treated with lenalidomide."
PA166151957,rs4135385,1447953336,AG,"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of  neutropenia when treated with lenalidomide."
PA166151957,rs4135385,1447953337,GG,"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of  neutropenia when treated with lenalidomide."
PA166135338,rs41303343,1183699867,A/del,"Transplant recipients with the A/del (CYP3A5 *1/*7) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the del/del (*1/*1) genotype, and have increased metabolism and require a higher dose of the drug as compared to patients with the AA (*7/*7) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements."
PA166135338,rs41303343,1183699868,AA,"Transplant recipients with the AA (CYP3A5 *7/*7) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the A/del or del/del (*1/*7 or *1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements."
PA166135338,rs41303343,1183699869,del/del,"Transplant recipients with the del/del (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus and require a higher dose of the drug as compared to patients with the A/del or AA (*1/*7 or *7/*7) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements."
PA166153001,rs4148157,1447981315,AA,Infants and children with the AA genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
PA166153001,rs4148157,1447981316,AG,Infants and children with the AG genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
PA166153001,rs4148157,1447981317,GG,Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
PA166159418,rs4148350,1448109785,GG,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159418,rs4148350,1448109786,GT,"Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166159418,rs4148350,1448109787,TT,"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
"
PA166158861,rs4148386,1448098954,AA,Patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance. 
PA166158861,rs4148386,1448098955,AG,Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance. 
PA166158861,rs4148386,1448098956,GG,Patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence carbamazepine clearance. 
PA166136266,rs41282401,1444700499,CC,"Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166136266,rs41282401,1444700498,CG,"Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
PA166136266,rs41282401,1444700497,GG,"Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. "
PA166134731,rs4148416,982036647,CC,"Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134731,rs4148416,982036648,CT,"Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134731,rs4148416,982036649,TT,"Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response."
PA166163295,rs4141964,1448603299,CC,Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166163295,rs4141964,1448603300,CT,Children with the CT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166163295,rs4141964,1448603301,TT,Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
PA166134732,rs4148737,982036596,CC,"Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134732,rs4148737,982036597,CT,"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134732,rs4148737,982036598,TT,"Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135214,rs4148739,1183689596,CC,Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. 
PA166135214,rs4148739,1183689597,CT,Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. 
PA166135214,rs4148739,1183689598,TT,Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. 
PA166153189,rs4148739,1447987089,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
PA166153189,rs4148739,1447987090,CT,Patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166153189,rs4148739,1447987091,TT,Patients with the TT genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166135215,rs4148740,1183629313,AA,"Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135215,rs4148740,1183629312,AG,"Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166135215,rs4148740,1183629311,GG,"Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
PA166153188,rs4148740,1447987082,AA,Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166153188,rs4148740,1447987083,AG,Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166153188,rs4148740,1447987084,GG,"No patients with the GG genotype were available for analysis, but patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
PA166159401,rs4148808,1448109607,CC,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CT or TT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159401,rs4148808,1448109608,CT,"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159401,rs4148808,1448109609,TT,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or CT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
"
PA166159026,rs4148738,1448100944,CC,Patients with genotype CC and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the CT and TT genotypes. Other factors may affect dabigatran plasma concentrations. 
PA166159026,rs4148738,1448100945,CT,Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations. 
PA166159026,rs4148738,1448100946,TT,Patients with genotype TT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations. 
PA166134319,rs4148943,655386132,CC,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134319,rs4148943,655386133,CT,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134319,rs4148943,655386134,TT,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166135371,rs4148323,1183698860,AA,"Patients with the AA (i.e. UGT1A1 *6/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol."
PA166135371,rs4148323,1183698861,AG,"Patients with the AG (i.e. UGT1A1 *1/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol."
PA166135371,rs4148323,1183698862,GG,"Patients with the GG (i.e. UGT1A1 *1/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol."
PA166135372,rs4148323,1183698827,AA,"No patients with this genotype were present in the study. However, patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk. "
PA166135372,rs4148323,1183698828,AG,"Patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk. "
PA166135372,rs4148323,1183698829,GG,"Patients with the GG genotype and HIV may have a decreased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk. "
PA166134473,rs4148323,1448422947,AA,Patients with the AA genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.
PA166134473,rs4148323,1448422948,AG,"Patients with the AG genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the GG genotype, or a decreased risk of neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia."
PA166134473,rs4148323,1448422949,GG,Patients with the GG genotype with cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.
PA166134771,rs4148323,1448422953,AA,"Patients with the AA (UGT1A1 *6/*6) genotype with cancer who are treated with irinotecan-based regimens may have 1) an increased risk of thrombocytopenia or diarrhea as compared to patients with the GG (*1/*1) genotype, and 2) may have decreased tumor response, progression-free survival or overall survival, as compared to patients with the AG (*1/*6) or GG (*1/*1) genotype. However, one study found increased progression-free survival or overall survival for patients who carried the A (*6) allele. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea."
PA166134771,rs4148323,1448422954,AG,"Patients with the AG (*1/*6) genotype with cancer who are treated with irinotecan-based regimens may have 1) an increased risk of thrombocytopenia or diarrhea as compared to patients with the GG (*1/*1) genotype, and 2) may have increased tumor response, progression-free survival or overall survival as compared to patients with the AA (*6/*6) genotype. However, some studies have found no association with diarrhea, tumor response, progression-free survival or overall survival for this genotype as compared to those with the GG genotype. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea."
PA166134771,rs4148323,1448422955,GG,"Patients with the GG (*1/*1) genotype with cancer who are treated with irinotecan-based regimens may have 1) a decreased risk of thrombocytopenia or diarrhea as compared to patients with the AA (*6/*6) or AG (*1/*6) genotype, and 2) may have increased tumor response, progression-free survival or overall survival, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea."
PA166134780,rs4148323,1184747132,AA,"Patients with the AA genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the AG or GG genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38."
PA166134780,rs4148323,1184747133,AG,"Patients with the AG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38."
PA166134780,rs4148323,1184747134,GG,"Patients with the GG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found increased enzyme activity for the G allele compared to the A allele. Other genetic and clinical factors may also influence metabolism of SN-38."
PA166136452,rs4148323,1446905009,AA,"Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136452,rs4148323,1446905010,AG,"Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136452,rs4148323,1446905011,GG,"Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166134317,rs4148947,655386121,CC,Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134317,rs4148947,655386122,CT,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166134317,rs4148947,655386123,TT,Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
PA166134318,rs4148945,655386127,CC,Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134318,rs4148945,655386128,CT,Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
PA166134318,rs4148945,655386129,TT,Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134421,rs3918290,1448605555,CC,"Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of fluoropyrimidine drugs and 2) decreased, but not non-existent, risk for drug toxicity as compared to patients with the CT or TT genotype (DPYD *1/*2A or *2A/*2A). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy."
PA166134421,rs3918290,1448605556,CT,"Patients with the CT genotype (DPYD *1/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy."
PA166134421,rs3918290,1448605557,TT,"Patients with the TT genotype (DPYD *2A/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have complete DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy."
PA166134141,rs4149015,655384628,AA,Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patient's response.
PA166134141,rs4149015,655384629,AG,Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134141,rs4149015,655384630,GG,Patients carrying the GG genotype may have increased chance of response to pravastatin compared to patients carrying the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166135003,rs4149015,1183595193,AA,Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
PA166135003,rs4149015,1183595194,AG,Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
PA166135003,rs4149015,1183595195,GG,Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
PA166135849,rs4149036,1444706211,AA,Patients with the AA genotype may have decreased response to atorvastatin as compared to patients with the CC or AC genotypes.  Other genetic and clinical factors may influence also a patient's atorvastatin response.
PA166135849,rs4149036,1444706212,AC,Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's atorvastatin response.
PA166135849,rs4149036,1444706213,CC,Patients with the CC genotype may have increased response to atorvastatin as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's atorvastatin response.
PA166136340,rs4149032,1444706205,CC,"Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes.  Other genetic and clinical factors may influence also a patient's exposure to rifampicin."
PA166136340,rs4149032,1444706204,TC,"Tuberculosis patients with the TC genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's exposure to rifampicin."
PA166136340,rs4149032,1444706203,TT,"Tuberculosis patients with the TT genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's exposure to rifampicin."
PA166134316,rs4148950,655386115,AA,Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134316,rs4148950,655386116,AG,Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
PA166134316,rs4148950,655386117,GG,Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166163770,rs4149178,1448616906,AA,Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine
PA166163770,rs4149178,1448616907,AG,"Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine"
PA166163770,rs4149178,1448616908,GG,"Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine"
PA166134397,rs4149081,655387939,AA,"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity."
PA166134397,rs4149081,655387940,AG,Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
PA166134397,rs4149081,655387941,GG,Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
PA166134942,rs4149081,1158843286,AA,Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
PA166134942,rs4149081,1158843292,AG,Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
PA166134942,rs4149081,1158843298,GG,Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
PA166135806,rs4149081,1444703871,AA,Patients with the AA genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
PA166135806,rs4149081,1444703872,AG,Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
PA166135806,rs4149081,1444703873,GG,Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin
PA166135723,rs4149570,1444687041,AA,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135723,rs4149570,1444687042,AC,"Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135723,rs4149570,1444687043,CC,"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166134474,rs4149117,1448099936,GG,Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
PA166134474,rs4149117,1448099937,GT,"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid."
PA166134474,rs4149117,1448099938,TT,Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
PA166153036,rs4149117,1447982799,GG ,Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.
PA166153036,rs4149117,1447982800,GT,"Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia."
PA166153036,rs4149117,1447982801,TT,"Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia."
PA166134815,rs4238001,1183594904,CC,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166134815,rs4238001,1183594905,CT,Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166134815,rs4238001,1183594906,TT,Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166136361,rs4240803,1445400882,AA,Patients with the AA genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
PA166136361,rs4240803,1445400883,AG,Patients with the AG genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
PA166136361,rs4240803,1445400884,GG,Patients with the GG genotype and multiple myeloma may have an increased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
PA166135145,rs3892097,1446905363,CC,Patients with the CC genotype (CYP2D6*1/*1) and depression who are treated with tricyclic antidepressants 1) may have a decreased likelihood of switching treatment indicating a reduced risk of side effects 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects. 
PA166135145,rs3892097,1446905364,CT,Patients with the CT genotype (CYP2D6*1/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects as compared to patients with the CC genotype (CYP2D6*1/*1) 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4) or may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects. 
PA166135145,rs3892097,1446905365,TT,Patients with the TT genotype (CYP2D6*4/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects 2) may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects. 
PA166134150,rs3892097,655384702,CC,"Patients with the CC genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse."
PA166134150,rs3892097,655384701,CT,"Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse."
PA166134150,rs3892097,655384700,TT,Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype.
PA166134153,rs3892097,982030493,CC,Patients with the CC genotype who are treated with venlafaxine may have 1) average venlafaxine plasma concentration 2) an average risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CT or TT genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
PA166134153,rs3892097,982030494,CT,Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
PA166134153,rs3892097,982030495,TT,Patients with the TT genotype who are treated with venlafaxine may have 1)  increased venlafaxine plasma concentration 2) an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
PA166135171,rs3892097,1183619084,CC,"Patients with the CC genotype (CYP2D6*1/*1) and depression may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's dose requirement. "
PA166135171,rs3892097,1183619085,CT,"Patients with the CT genotype (CYP2D6*1/*4) and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the CC genotype (CYP2D6*1/*1) or may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's dose requirement. "
PA166135171,rs3892097,1183619086,TT,"Patients with the TT genotype (CYP2D6*4/*4) and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's dose requirement. "
PA166134261,rs3892097,982030643,CC,"Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype."
PA166134261,rs3892097,982030644,CT,"Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype."
PA166134261,rs3892097,982030645,TT,"Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype.  Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype."
PA166134506,rs4149601,1183633754,AA,Asian patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients.  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166134506,rs4149601,1183633755,AG,Asian patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166134506,rs4149601,1183633756,GG,Asian patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype.  The opposite has been found in White patients.  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135245,rs4149601,1447961309,AA,White patients with the AA genotype and hypertension who are treated with hydrochlorothiazide  may have poorer response as compared with patients with genotype GG.  The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.
PA166135245,rs4149601,1447961310,AG,White patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have better response  as compared with patients with genotype AA.  The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.
PA166135245,rs4149601,1447961311,GG,White patients with the GG genotype and hypertension who are treated with hydrochlorothiazide  may have better response as compared with patients with genotype AA.    The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.
PA166136246,rs4251961,1444686929,CC,Patients with the CC genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136246,rs4251961,1444686930,CT,Patients with the CT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136246,rs4251961,1444686931,TT,Patients with the TT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135243,rs4253728,1183631475,AA,Patients with the AA genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166135243,rs4253728,1183631476,AG,Patients with the AG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166135243,rs4253728,1183631477,GG,Patients with the GG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166135309,rs4253728,1183680666,AA,Patients with the AA genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus. 
PA166135309,rs4253728,1183680667,AG,Patients with the AG genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus. 
PA166135309,rs4253728,1183680668,GG,"Patients with the GG genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus. "
PA166136042,rs4253728,1296598912,AA,Patients with the AA genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
PA166136042,rs4253728,1296598913,AG,Patients with the AG genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
PA166136042,rs4253728,1296598914,GG,Patients with the AG genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
PA166134814,rs4253778,1183630715,CC,Patients with the CC genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166134814,rs4253778,1183630716,CG,Patients with the CG genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166134814,rs4253778,1183630717,GG,Patients with the GG genotype and diabetes may be more likely to respond to fenofibrate treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166134161,rs4253778,655384785,CC,Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
PA166134161,rs4253778,655384784,CG,Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
PA166134161,rs4253778,655384783,GG,"Patients with the GG genotype and acute coronary artery syndrome who are treated with beta blockers may have a decreased, but not absent, chance of rehospitalization as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization."
PA166159397,rs4261716,1448109567,GG,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
"
PA166159397,rs4261716,1448109568,GT,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
"
PA166159397,rs4261716,1448109569,TT,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
"
PA166134888,rs4267385,1043880655,CC,"Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
PA166134888,rs4267385,1043880656,CT,"Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
PA166134888,rs4267385,1043880657,TT,Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
PA166134976,rs428785,1447947151,CC,Patients with the CC genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134976,rs428785,1447947152,CG,Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134976,rs428785,1447947153,GG,Patients with the GG genotype may benefit more from pravastatin treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166152635,rs4278350,1447959696,CC,Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152635,rs4278350,1447959697,CT,"Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152635,rs4278350,1447959698,TT,Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152883,rs4271002,1447964326,CC,Patients with the CC genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
PA166152883,rs4271002,1447964327,CG,"Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma."
PA166152883,rs4271002,1447964328,GG,Patients with the GG genotype and asthma may have a decreased risk of aspirin intolerance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
PA166160743,rs4273729,1448266181,CC,"Patients with genotype CC may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy."
PA166160743,rs4273729,1448266180,CG,"Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy."
PA166160743,rs4273729,1448266179,GG,"Patients with genotype GG may have better rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy."
PA166135791,rs4292,1444703497,CC,Patients with the CC genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135791,rs4292,1444703498,CT,Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135791,rs4292,1444703499,TT,"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166152998,rs4292394,1447981291,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152998,rs4292394,1447981292,CG,Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152998,rs4292394,1447981293,GG,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166135030,rs4291,1183594149,AA,"Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels."
PA166135030,rs4291,1183594150,AT,"Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels."
PA166135030,rs4291,1183594151,TT,"Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels."
PA166135792,rs4291,1444703505,AA,Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135792,rs4291,1444703504,AT,Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135792,rs4291,1444703506,TT,"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166160293,rs4291,1448259108,AA,Patients with the AA genotype and Alzheimer's Disease may not experience increasing creatinine levels when taking captopril compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
PA166160293,rs4291,1448259109,AT,Patients with the AT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
PA166160293,rs4291,1448259110,TT,Patients with the TT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
PA166159197,rs4305746,1448106829,AA,Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
PA166159197,rs4305746,1448106830,AG,Patients with the AG genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
PA166159197,rs4305746,1448106831,GG,Patients with the GG genotype and schizophrenia may have slower improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
PA166134813,rs430397,1183593446,CC,"Patients with the CC genotype and non-small cell lung cancer may have decreased resistance, decreased likelihood of early relapse, increased progression free survival and decreased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or non-small cell lung cancer-related death. "
PA166134813,rs430397,1183593447,CT,"Patients with the CT genotype and non-small cell lung cancer may have decreased resistance, decreased likelihood of early relapse, increased progression free survival and decreased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or non-small cell lung cancer-related death. "
PA166134813,rs430397,1183593448,TT,"Patients with the TT genotype and non-small cell lung cancer may have increased resistance, increased likelihood of early relapse, decreased progression free survival and increased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or carcinoma, non-smal cell lung cancer-related death. "
PA166135827,rs4329505,1448526094,CC,"Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab."
PA166135827,rs4329505,1448526095,CT,"Patients with the CT genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab."
PA166135827,rs4329505,1448526096,TT,"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to tocilizumab as compared to patients with the CC or CT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab."
PA166134145,rs429358,655384667,CC,"Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment."
PA166134145,rs429358,655384668,CT,"Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment."
PA166134145,rs429358,655384669,TT,"Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment."
PA166152852,rs4341,1447963848,CC,Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
PA166152852,rs4341,1447963849,CG,Patients with the CG genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
PA166152852,rs4341,1447963850,GG,Patients with the GG genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
PA166152791,rs4341,1447962732,CC,Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with pravastatin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166152791,rs4341,1447962733,CG,Patients with the CG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166152791,rs4341,1447962734,GG,Patients with the GG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166152695,rs4344,1447960561,AA,Patients with the AA genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril. 
PA166152695,rs4344,1447960562,AG,Patients with the AG genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril. 
PA166152695,rs4344,1447960563,GG,Patients with the GG genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril. 
PA166134702,rs4358872,982032451,GG,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134702,rs4358872,982032452,GT,Patients with the GT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134702,rs4358872,982032453,TT,Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166135029,rs4353229,1183614740,CC,"Patients with the CC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
PA166135029,rs4353229,1183614741,CT,"Patients with the CT genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
PA166135029,rs4353229,1183614742,TT,"Patients with the TT genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC or CT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
PA166152696,rs4359,1447960568,CC,Patients with the CC genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril. 
PA166152696,rs4359,1447960569,CT,Patients with the CT genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril. 
PA166152696,rs4359,1447960570,TT,Patients with the TT genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril. 
PA166134149,rs4343,655384697,AA,Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
PA166134149,rs4343,655384696,AG,Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
PA166134149,rs4343,655384695,GG,Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
PA166134410,rs4343,982036382,AA,"Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134410,rs4343,982036383,AG,"Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134410,rs4343,982036384,GG,"Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135642,rs4363657,1444706247,CC,Patients with the CC genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.
PA166135642,rs4363657,1444706248,CT,Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.
PA166135642,rs4363657,1444706249,TT,Patients with the TT genotype may be at decreased risk of myopathy when treated with simvastatin as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.
PA166160035,rs4379440,1448257294,GG,Patients with the GG genotype may have increased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype TT. Other genetic and clinical factors may influence the response to warfarin.
PA166160035,rs4379440,1448257293,GT,Patients with the GT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.
PA166160035,rs4379440,1448257292,TT,Patients with the TT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.
PA166153457,rs4386686,1447990298,CC,"In vitro, the CC genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the CG and GG genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen. "
PA166153457,rs4386686,1447990299,CG,"In vitro, the CG genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the GG genotype and increased expression of TRAF1, decreased expression of MIRLET7I and decreased sensitivity to endoxifen as compared to the CC genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen. "
PA166153457,rs4386686,1447990300,GG,"In vitro, the GG genotype is associated with increased expression of TRAF1, decreased expression of MIRLET7I, and decreased sensitivity to endoxifen as compared to the CG and CC genotypes. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen. "
PA166135816,rs4410790,1444704078,CC,Patients with the CC genotype may have increased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
PA166135816,rs4410790,1444704077,CT,Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
PA166135816,rs4410790,1444704076,TT,Patients with the TT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
PA166134066,rs437943,637879943,CC,Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.
PA166134066,rs437943,637879944,CT,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.
PA166134066,rs437943,637879945,TT,Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to a patient with genotype CC or CT .
PA166159207,rs4402960,1448103965,GG,Patients with the GG genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166159207,rs4402960,1448103966,GT,Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166159207,rs4402960,1448103967,TT,Patients with the TT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
PA166135676,rs4413407,1444666669,AA,Patients with the AA genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135676,rs4413407,1444666670,AG,Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166135676,rs4413407,1444666671,GG,Patients with the GG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166136404,rs4431329,1445594493,AA,Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. 
PA166136404,rs4431329,1445594494,AT,Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. 
PA166136404,rs4431329,1445594495,TT,Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT or AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. 
PA166135653,rs442767,1444607777,GG,"Patients with the GG genotype and non-small-cell lung cancer may be at increased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed. "
PA166135653,rs442767,1444607778,GT,"Patients with the GT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed. "
PA166135653,rs442767,1444607779,TT,"Patients with the TT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed. "
PA166153488,rs442767,1447990934,GT,The GT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with an increased risk of leukopenia when treated with methotrexate as compared to the TT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.
PA166153488,rs442767,1447990935,TT,The TT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with a decreased risk of leukopenia when treated with methotrexate as compared to the GT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.
PA166136206,rs445925,1444668470,AA,Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. 
PA166136206,rs445925,1444668471,AG,Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. 
PA166136206,rs445925,1444668472,GG,Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. 
PA166135859,rs4436578,1444706892,CC,"Patients with the CC genotype and Schizophrenia may have increased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
PA166135859,rs4436578,1444706893,CT,"Patients with the CT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
PA166135859,rs4436578,1444706894,TT,"Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
PA166135828,rs446112,1444704380,AA,Patients with the AA genotype may have increased resistance to etoposide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
PA166135828,rs446112,1444704381,AG,Patients with the AG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
PA166135828,rs446112,1444704382,GG,Patients with the GG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
PA166136302,rs4460839,1448107288,CC,Patients with the CC genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166136302,rs4460839,1448107289,CT,Patients with the CT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype or may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166136302,rs4460839,1448107290,TT,Patients with the TT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
PA166134887,rs4459610,1043880650,AA,"Patients with the AA genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
PA166134887,rs4459610,1043880651,AT,"Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
PA166134887,rs4459610,1043880652,TT,Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
PA166134509,rs4444903,1444665977,AA,Patients with the AA genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.
PA166134509,rs4444903,1444665978,AG,Patients with the AG genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.
PA166134509,rs4444903,1444665979,GG,Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.
PA166135250,rs4483927,1183631567,GG,Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135250,rs4483927,1183631566,GT,Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135250,rs4483927,1183631565,TT,Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166158745,rs4492666,1448097713,AA,Patients with non-small cell lung cancer and the AA genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
PA166158745,rs4492666,1448097714,AC,Patients with non-small cell lung cancer and the AC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
PA166158745,rs4492666,1448097715,CC,Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
PA166135829,rs4506565,1444704389,AA,"Patients with the AA genotype and Hypertension may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
PA166135829,rs4506565,1444704388,AT,"Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype or may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
PA166135829,rs4506565,1444704387,TT,Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166152685,rs451774,1447960405,AA,"Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152685,rs451774,1447960406,AG,"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166152685,rs451774,1447960407,GG,"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
PA166159005,rs4516035,1448100788,CC,"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166159005,rs4516035,1448100789,CT,"Patients with the CT genotype may have decreased clearance of midazolam as compared to patients with the TT genotype, and increased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166159005,rs4516035,1448100790,TT,"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. "
PA166134809,rs4523,1444607846,AA,Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.
PA166134809,rs4523,1444607847,AG,"Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance."
PA166134809,rs4523,1444607848,GG,"Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance."
PA166151958,rs4533622,1447953342,AA,"Patients with the AA genotype and multiple myeloma may have an increased response to thalidomide as compared to patients with the AC and CC genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with genotypes AC and CC. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide."
PA166151958,rs4533622,1447953343,AC,"Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide."
PA166151958,rs4533622,1447953344,CC,"Patients with the CC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide."
PA166136170,rs4541111,1444666697,AA,Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166136170,rs4541111,1444666698,AC,Patients with the AC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166136170,rs4541111,1444666699,CC,Patients with the CC genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
PA166136062,rs4550690,1447990504,CC,Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166136062,rs4550690,1447990505,CT,Patients with the CT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166136062,rs4550690,1447990506,TT,Patients with the TT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166134300,rs45511401,655385982,GG,"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166134300,rs45511401,655385983,GT,"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166134300,rs45511401,655385984,TT,Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166134683,rs4532,982031316,CC,Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134683,rs4532,982031317,CT,Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134683,rs4532,982031318,TT,Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166158952,rs4532,1448100203,CC,Patients with the CC genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
PA166158952,rs4532,1448100204,CT,"Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence."
PA166158952,rs4532,1448100205,TT,Patients with the TT genotype may be at increased risk for nicotine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
PA166135662,rs4532,1444608245,CC,"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have an increased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine. "
PA166135662,rs4532,1444608246,CT,"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine. "
PA166135662,rs4532,1444608247,TT,"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine. "
PA166134904,rs4553808,1043880854,AA,"Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy."
PA166134904,rs4553808,1043880853,AG,"Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy."
PA166134904,rs4553808,1043880852,GG,"Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy."
PA166163556,rs4553808,1448613245,AA,"People with the AA genotype undergoing a kidney transplantation may have increased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus."
PA166163556,rs4553808,1448613246,AG,"People with the AG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
PA166163556,rs4553808,1448613247,GG,"People with the GG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
PA166152992,rs4554144,1447981224,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152992,rs4554144,1447981225,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152992,rs4554144,1447981226,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166136322,rs4570625,1444704085,GG,Patients with the GG genotype and depression may have decreased response to citalopram as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166136322,rs4570625,1444704084,GT,Patients with the GT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166136322,rs4570625,1444704083,TT,Patients with the TT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166136264,rs45605536,1444700483,CC,Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib. 
PA166136264,rs45605536,1444700484,CT,Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
PA166136264,rs45605536,1444700485,TT,Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib. 
PA166135761,rs4586,1447953080,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135761,rs4586,1447953081,CT,Patients with the CT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135761,rs4586,1447953082,TT,Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166152925,rs4604006,1447979502,CC,Patients with the CC genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152925,rs4604006,1447979503,CT,Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
PA166152925,rs4604006,1447979504,TT,Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
PA166134894,rs4606,1043880726,CC,Patients with the CC genotype and Schizophrenia who are treated antipsychotics with may have an increased risk for antipsychotic-induced parkinsonism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.
PA166134894,rs4606,1043880725,GC,"Patients with the GC genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism."
PA166134894,rs4606,1043880724,GG,"Patients with the GG genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism."
PA166134866,rs4630,1043880388,AA,Patients with the AA genotype may have increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166134866,rs4630,1043880389,AG,Patients with the AG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166134866,rs4630,1043880390,GG,Patients with the GG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166151953,rs462779,1447953286,AA,Patients with the AA genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166151953,rs462779,1447953287,AG,Patients with the AG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166151953,rs462779,1447953288,GG,Patients with the GG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
PA166134186,rs4646,655384911,AA,Patients with the AA genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166134186,rs4646,655384912,AC,Patients with the AC genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166134186,rs4646,655384913,CC,Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166136413,rs4646,1446897378,AA,"Post-menopausal women with breast cancer and the AA genotype may have a reduced response to anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, tamoxifen, or radiotherapy as compared to post-menopausal women with the AC and CC genotypes. "
PA166136413,rs4646,1446897379,AC,"Post-menopausal women with breast cancer and the AC genotype may have an improved response to anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, tamoxifen, or radiotherapy as compared to post-menopausal women with the AA genotypes. "
PA166136413,rs4646,1446897380,CC,"Post-menopausal women with breast cancer and the CC genotype may have an improved response to anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, tamoxifen, or radiotherapy as compared to post-menopausal women with the AA genotypes. "
PA166135923,rs4646,1448100378,AA,"Pre-menopausal women with breast cancer and the AA genotype who are treated with anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy and tamoxifen may have improved treatment efficacy compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence a patient's response.
"
PA166135923,rs4646,1448100379,AC,"Pre-menopausal women with breast cancer and the AC genotype who are treated with anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy and tamoxifen may have decreased treatment efficacy as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence a patient's response.
"
PA166135923,rs4646,1448100380,CC,"Pre-menopausal women with breast cancer and the CC genotype who are treated with anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy and tamoxifen may have decreased treatment efficacy as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence a patient's response.
"
PA166135982,rs4646,1447681826,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin. "
PA166135982,rs4646,1447681827,AC,"Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin. "
PA166135982,rs4646,1447681828,CC,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin. "
PA166152866,rs4646244,1447964130,AA,Patients with the AA genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype. Cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs. 
PA166152866,rs4646244,1447964131,AT,"Patients with the AT genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype, or decreased risk as compared to patients with the AA genotype. Patients with the AT genotype may also have decreased clearance of isoniazid as compared to patients with the TT genotype. Additionally, cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs. "
PA166152866,rs4646244,1447964132,TT,"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for anti-TB drug-induced hepatitis as compared to patients with the AA genotype. Patients with the TT genotype may also have increased clearance of isoniazid as compared to patients with the AT genotype. Additionally, cells with the T allele have been shown to result in increased transcription of the NAT2 gene as compared to those with the A allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs. "
PA166135547,rs4633,1184233509,CC,Patients with the CC genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135547,rs4633,1184233510,CT,Patients with the CT genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135547,rs4633,1184233511,TT,Patients with the TT genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135201,rs4646425,1183622625,CC,Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135201,rs4646425,1183622624,TC,Patients with the TC genotype and major depressive disorder who are treated with escitalopram  1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects
PA166135201,rs4646425,1183622623,TT,Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135152,rs4646425,1183617686,CC,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a slower response time but an increased likelihood of experiencing remission as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166135152,rs4646425,1183617687,CT,Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166135152,rs4646425,1183617688,TT,Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166134343,rs4646316,1448616436,CC,Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
PA166134343,rs4646316,1448616437,CT,Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
PA166134343,rs4646316,1448616438,TT,"Children with the TT genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166135710,rs4646437,1448613261,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus."
PA166135710,rs4646437,1448613262,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus."
PA166135710,rs4646437,1448613263,GG,"Patients with the GG genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus."
PA166136243,rs4646437,1444686909,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have lower dose-adjusted trough concentrations of cyclosporine, and have a greater likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine."
PA166136243,rs4646437,1444686910,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine."
PA166136243,rs4646437,1444686911,GG,"Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine."
PA166152949,rs4646437,1447980708,AA,Patients with the AA genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
PA166152949,rs4646437,1447980709,AG,"Patients with the AG genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype, or less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone."
PA166152949,rs4646437,1447980710,GG,Patients with the GG genotype who are heroin dependent may have less severe side effects when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
PA166136523,rs4646437,1447946171,AA,"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole."
PA166136523,rs4646437,1447946172,AG,"Patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole."
PA166136523,rs4646437,1447946173,GG,"Patients with the GG genotype who have invasive fungal infections may have decreased concentrations of voriconazole, as compared to patients with the AG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole."
PA166134898,rs4149056,1183685550,CC,"Patients with the CC genotype who are treated with pravastatin may have a smaller reduction in total cholesterol as compared to patients with the TT genotype. This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134898,rs4149056,1183685551,CT,"Patients with the CT genotype who are treated with pravastatin may have a smaller reduction in total cholesterol as compared to patients with the TT genotype.  This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134898,rs4149056,1183685552,TT,"Patients with the TT genotype who are treated with pravastatin may have a larger reduction in total cholesterol as compared to patients with the CC or CT genotype.  This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. "
PA166134900,rs4149056,1448525343,CC,"Patients with the CC genotype and who are treated with atorvastatin may have 1) lower oral clearance and higher plasma concentrations of atorvastatin 2) an increased risk of composite adverse events but not an increased risk of myalgia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.  "
PA166134900,rs4149056,1448525344,CT,"Patients with the CT genotype and who are treated with atorvastatin may have 1) lower oral clearance and higher plasma concentrations of atorvastatin 2) an increased risk of composite adverse events but not an increased risk of myalgia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.  "
PA166134900,rs4149056,1448525345,TT,"Patients with the TT genotype and who are treated with atorvastatin may have 1) higher oral clearance and lower plasma concentrations of atorvastatin 2) a decreased risk of composite adverse events but not a decreased risk of myalgia, as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.  "
PA166135321,rs4149056,1183684168,CC,"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin."
PA166135321,rs4149056,1183684169,CT,"Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166135321,rs4149056,1183684170,TT,"Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
PA166134143,rs4149056,655384646,CC,Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134143,rs4149056,655384647,CT,Patients with the CT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134143,rs4149056,655384648,TT,Patients with the TT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
PA166135826,rs4149056,1444704361,CC,Patients with the CC genotype may have increased plasma level of lopinavir as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
PA166135826,rs4149056,1444704362,CT,Patients with the CT genotype may have decreased plasma level of lopinavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
PA166135826,rs4149056,1444704363,TT,Patients with the TT genotype may have decreased plasma level of lopinavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
PA166134118,rs4149056,1447983129,CC,Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134118,rs4149056,1447983130,CT,Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134118,rs4149056,1447983131,TT,Patients with the TT genotype may have a lower risk of simvastatin-related myopathy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134399,rs4149056,1444666725,CC,Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166134399,rs4149056,1444666726,CT,Pediatric patients with the CT genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166134399,rs4149056,1444666727,TT,Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166135108,rs4149056,1183615195,CC,"Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea."
PA166135108,rs4149056,1183615196,CT,"Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea."
PA166135108,rs4149056,1183615197,TT,"Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea."
PA166134617,rs4149056,982031455,CC,Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
PA166134617,rs4149056,982031456,CT,Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
PA166134617,rs4149056,982031457,TT,Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
PA166134620,rs4149056,1447947008,CC,Patients with the CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.
PA166134620,rs4149056,1447947009,CT,Patients with the CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.
PA166134620,rs4149056,1447947010,TT,Patients with the TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.
PA166134621,rs4149056,1447947066,CC,Patients with the CC genotype may have decreased plasma concentration of  atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
PA166134621,rs4149056,1447947067,CT,Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
PA166134621,rs4149056,1447947068,TT,Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
PA166134622,rs4149056,1446898004,CC,Patients with the CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.
PA166134622,rs4149056,1446898005,CT,Patients with the CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.
PA166134622,rs4149056,1446898006,TT,Patients with the TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.
PA166134623,rs4149056,1448100041,CC,Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.
PA166134623,rs4149056,1448100042,CT,Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.
PA166134623,rs4149056,1448100043,TT,Patients with the TT genotype may have decreased plasma drug concentrations of particular statins as compared to patients with the CC or CT genotype. For some statins this is associated with decreased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.
PA166135654,rs4149056,1444607786,CC,Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
PA166135654,rs4149056,1444607785,CT,Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
PA166135654,rs4149056,1444607784,TT,Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
PA166134817,rs4149056,1183630765,CC,Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38. 
PA166134817,rs4149056,1183630766,CT,Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38. 
PA166134817,rs4149056,1183630767,TT,Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38. 
PA166134247,rs4149056,982035354,CC,This genotype has no significant effect on the PK or PD of nateglinide.
PA166134247,rs4149056,982035355,CT,This genotype has no significant effect on the PK or PD of nateglinide.
PA166134247,rs4149056,982035356,TT,This genotype has no significant effect on the PK or PD of nateglinide.
PA166151942,rs4149056,1447953132,CC,Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
PA166151942,rs4149056,1447953133,CT,Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
PA166151942,rs4149056,1447953134,TT,Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
PA166160273,rs4149056,1448258745,CC,Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.
PA166160273,rs4149056,1448258744,CT,Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
PA166160273,rs4149056,1448258743,TT,Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
PA166161004,rs4149056,1448276475,CC,Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.
PA166161004,rs4149056,1448276476,CT,Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.
PA166161004,rs4149056,1448276477,TT,Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.
PA166158969,rs4149056,1448100349,CC,Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.
PA166158969,rs4149056,1448100350,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
PA166158969,rs4149056,1448100351,TT,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.
PA166159469,rs4149056,1448112158,CC,"Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea. "
PA166159469,rs4149056,1448112159,CT,"Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea. "
PA166159469,rs4149056,1448112160,TT,"Patients with the TT genotype and hormone insensitive breast cancer may experience increased risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the CT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea. "
PA166135202,rs4646427,1183622652,CC,Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135202,rs4646427,1183622653,CT,Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135202,rs4646427,1183622654,TT,Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects. 
PA166135153,rs4646427,1183617710,CC,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166135153,rs4646427,1183617711,CT,Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166135153,rs4646427,1183617712,TT,Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a slower response time as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166134315,rs4646487,655386110,CC,Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134315,rs4646487,655386111,CT,Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134315,rs4646487,655386112,TT,Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.
PA166135885,rs4646994,1448106234,(289BP ALU)/(289BP ALU),"Patients homozygous for the 289bp ALU insertion (or ""I"" allele) with coronary heart disease may have a better response to treatment with salvianolate as compared to patients with heterozygous for the I allele and the del (or ""D"") allele or homozygous for the D allele. Other genetic and clinical factors may also influence response to salvianolate."
PA166135885,rs4646994,1448106235,(289BP ALU)/del,"Patients heterozygous for the 289bp ALU insertion (or ""I"" allele) and the del (or ""D"") allele with coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients homozygous for the I allele. Other genetic and clinical factors may also influence response to salvianolate."
PA166135885,rs4646994,1448106236,del/del,"Patients homozygous for the del (or ""D"") allele with coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients homozygous for the 289bp ALU insertion (or ""I"" allele). Other genetic and clinical factors may also influence response to salvianolate."
PA166135594,rs4648287,1184986987,AA,Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135594,rs4648287,1184986988,AG,Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135594,rs4648287,1184986989,GG,Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135830,rs4654327,1444704394,AA,Patients with the AA genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
PA166135830,rs4654327,1444704395,AG,Patients with the AG genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
PA166135830,rs4654327,1444704396,GG,Patients with the GG genotype and Alcoholism may have decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
PA166152948,rs4646440,1447980701,AA,Patients with the AA genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
PA166152948,rs4646440,1447980702,AG,"Patients with the AG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or less severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone."
PA166152948,rs4646440,1447980703,GG,Patients with the GG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
PA166162374,rs4661012,1448531870,GG,People with the GG genotype may have increased inhibition of platelet aggregation when taking ticagrelor compared to people with the GT and TT genotypes. Other clinical and genetic factors may affect response to ticagrelor.
PA166162374,rs4661012,1448531871,GT,People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.
PA166162374,rs4661012,1448531872,TT,People with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.
PA166153004,rs4655226,1447981374,CC,"Patients with the CC genotype and cancer may have increased clearance of 2',2'-
difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
PA166153004,rs4655226,1447981375,CT,"Patients with the CT genotype and cancer may have decreased clearance of 2',2'-
difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
PA166153004,rs4655226,1447981376,TT,"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'-
difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
PA166134510,rs4673993,981202610,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134510,rs4673993,981202611,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype or may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134510,rs4673993,981202612,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134745,rs4244285,1183616531,AA,Patients with the AA genotype may have a decreased metabolism of clomipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism. 
PA166134745,rs4244285,1183616532,AG,Patients with the AG genotype may have a decreased metabolism of clomipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism. 
PA166134745,rs4244285,1183616533,GG,Patients with the GG genotype may have an increased metabolism of clomipramine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism. 
PA166134122,rs4244285,1447986893,AA,"Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel."
PA166134122,rs4244285,1447986894,AG,"Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel."
PA166134122,rs4244285,1447986895,GG,Patients with the GG genotype: 1) may have sufficient metabolism of clopidogrel and increased formation of active drug metabolite 2) may have a decreased risk for secondary cardiovascular events with clopidogrel as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for secondary cardiovascular events when taking clopidogrel based on their genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
PA166135159,rs4244285,1183630406,AA,"Patients with the AA genotype (CYP2C19*2/*2) may have a decreased clearance of doxepin as compared to patients with the GG genotype (CYP2C19*1/*1). The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's doxepin metabolism."
PA166135159,rs4244285,1183630407,AG,"Patients with the AG genotype (CYP2C19*1/*2) may have a decreased clearance of doxepin as compared to patients with the GG genotype (CYP2C19*1/*1). The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's doxepin metabolism."
PA166135159,rs4244285,1183630408,GG,"Patients with the GG genotype (CYP2C19*1/*1) may have an increased clearance of doxepin as compared to patients with the AA genotype (CYP2C19*2/*2). The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's doxepin metabolism."
PA166136298,rs4244285,1444703071,AA,Patients with the AA genotype were not studied. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
PA166136298,rs4244285,1444703072,AG,Patients with the AG genotype and depression who are treated with venlafaxine may have an increased risk for agitation and dysphoria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
PA166136298,rs4244285,1444703073,GG,"Patients with the GG genotype and depression who are treated with venlafaxine may have a decreased, but not absent, risk for agitation and dysphoria as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects."
PA166134507,rs4244285,1448260645,AA,Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134507,rs4244285,1448260646,AG,Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134507,rs4244285,1448260647,GG,Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134508,rs4244285,1446907928,AA,"Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity."
PA166134508,rs4244285,1446907929,AG,"Patients with the AG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite, and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity."
PA166134508,rs4244285,1446907930,GG,"Patients with the GG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have increased metabolism of cyclophosphamide, leading to higher concentrations of the active metabolite and an increased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity."
PA166134747,rs4244285,1446903064,AA,"Patients with the AA genotype who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the GG genotype. Other genetic factors, including other CYP2C19 alleles *17  rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient's required dose and should be taken into consideration."
PA166134747,rs4244285,1446903065,GA,"Patients with the AG genotype who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the GG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient's required dose and should be taken into consideration."
PA166134747,rs4244285,1446903066,GG,"Patients with the GG genotype who are treated with amitriptyline may have increased metabolism of amitriptyline (decreased amitriptyline plasma concentrations and increased nortriptyline plasma concentrations) as compared to patients with the AA or AG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient's required dose and should be taken into consideration."
PA166134751,rs4244285,982040588,AA,Patients with AA genotype may have a decreased metabolism of citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's citalopram metabolism. 
PA166134751,rs4244285,982040589,AG,Patients with AG genotype may have a decreased metabolism of citalopram as compared to patients with the GG genotype or an increased metabolism of citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's citalopram metabolism. 
PA166134751,rs4244285,982040590,GG,Patients with GG genotype may have an increased metabolism of citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's citalopram metabolism. 
PA166134752,rs4244285,982040609,AA,"Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel. "
PA166134752,rs4244285,982040610,AG,"Patients with the AG genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel. "
PA166134752,rs4244285,982040611,GG,"Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel. "
PA166135765,rs4244285,1444703078,AA,Patients with the AA genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
PA166135765,rs4244285,1444703079,AG,Patients with the AG genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
PA166135765,rs4244285,1444703080,GG,Patients with the GG genotype who are treated with etravirine may have an increased etravirine clearance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
PA166152800,rs4244285,1447962886,AA,Patients with the AA genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
PA166152800,rs4244285,1447962887,AG,Patients with the AG genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
PA166152800,rs4244285,1447962888,GG,Patients with the GG genotype and pancreatic cancer or HIV may have increased metabolism and decreased concentrations of nelfinavir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
PA166135851,rs4675690,1444706798,CC,Patients with the CC genotype and major depression may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135851,rs4675690,1444706797,CT,Patients with the CT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype or may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135851,rs4675690,1444706796,TT,Patients with the TT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135963,rs4688040,1446906332,GG,Patients with the GG genotype may have decreased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166135963,rs4688040,1446906331,GT,Patients with the GT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype  GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166135963,rs4688040,1446906330,TT,Patients with the TT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype  GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166134630,rs4693075,1446905293,CC,Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134630,rs4693075,1446905294,CG,Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166134630,rs4693075,1446905295,GG,Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
PA166135499,rs4694362,1184472691,CC,Patients with CC genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine. 
PA166135499,rs4694362,1184472692,CT,"Patients with CT genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype, and increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine. "
PA166135499,rs4694362,1184472693,TT,Patients with TT genotype and pancreatic cancer who are treated with gemcitabine may have an increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine. 
PA166136248,rs4696480,1444686949,AA,Patients with the AA genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136248,rs4696480,1444686950,AT,Patients with the AT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136248,rs4696480,1444686951,TT,Patients with the TT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166136232,rs4704559,1444680133,AA,"Patients with the AA genotype and Parkinson's disease may have an increased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa."
PA166136232,rs4704559,1444680134,AG,"Patients with the AG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa."
PA166136232,rs4704559,1444680135,GG,"Patients with the GG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa."
PA166134969,rs4673,1183491350,AA,Patients with the AA genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134969,rs4673,1183491351,AG,Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134969,rs4673,1183491352,GG,Patients with the GG genotype and Hypercholesterolemia may benefit less from simvastatin treatment due to a lower reduction in DNA damage as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134301,rs4673,1448099408,AA,Cancer patients with the AA genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166134301,rs4673,1448099409,AG,Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
PA166134301,rs4673,1448099410,GG,"Cancer patients with the GG genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
PA166159155,rs4673,1448102877,AA,"Patients with the AA genotype and B-cell lymphoma may have a shorter event-free survival time as compared to patients with the AG or GG genotype, and an increased likelihood of cardiotoxicity as compared to patients with the GG genotype, when treated with the CHOP chemotherapy regimen. Other genetic and clinical factors may also influence event-free survival time and cardiotoxicity."
PA166159155,rs4673,1448102878,AG,"Patients with the AG genotype and B-cell lymphoma may have a longer event-free survival time as compared to patients with the AA genotype, and an increased likelihood of cardiotoxicity as compared to patients with the GG genotype, when treated with the CHOP chemotherapy regimen. Other genetic and clinical factors may also influence event-free survival time and cardiotoxicity."
PA166159155,rs4673,1448102879,GG,"Patients with the GG genotype and B-cell lymphoma may have a longer event-free survival time as compared to patients with the AA genotype, and a decreased likelihood of cardiotoxicity as compared to patients with the AA or AG genotype, when treated with the CHOP chemotherapy regimen. Other genetic and clinical factors may also influence event-free survival time and cardiotoxicity."
PA166135860,rs472660,1444706913,AA,"Patients with the AA genotype and Schizophrenia may have increased clearance of olanzapine as compared to patients with the AG or GG genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine."
PA166135860,rs472660,1444706914,AG,"Patients with the AG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine."
PA166135860,rs472660,1444706915,GG,"Patients with the GG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine."
PA166135566,rs4728709,1184749272,AA,"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. "
PA166135566,rs4728709,1184749273,AG,"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. "
PA166135566,rs4728709,1184749274,GG,Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity. 
PA166136323,rs4702484,1444704269,CC,Patients with the CC genotype and Colorectal Neoplasms who are treated with capecitabine may have decreased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
PA166136323,rs4702484,1444704270,CT,Patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
PA166136323,rs4702484,1444704271,TT,"Patients with the TT genotype were not studied. However, patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine."
PA166134926,rs4713916,1146391451,AA,Patients with the AA genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166134926,rs4713916,1146391452,AG,Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166134926,rs4713916,1146391453,GG,Patients with the GG genotype and Crohn Disease who are treated with corticosteroids may have a decreased likelihood of responsiveness as compared to patients with AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166135155,rs4713916,1446905357,AA,Patients with the AA genotype may have a better response to antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. 
PA166135155,rs4713916,1446905358,AG,Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. 
PA166135155,rs4713916,1446905359,GG,Patients with the GG genotype may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. 
PA166158946,rs4737771,1448106568,CC,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158946,rs4737771,1448106569,CT,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158946,rs4737771,1448106570,TT,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
PA166134257,rs45445694,655385325,(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2,"Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients who were carriers of the a third 28-bp repeat (for TSER*3/*3,TSER*2/*3). Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166134257,rs45445694,655385326,(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3,Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134257,rs45445694,655385327,(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3,Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135119,rs45445694,1448102624,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2,Patients with the 2R/2R genotype and colorectal cancer may have a decreased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/3R or 3R/3R genotype. Other genetic and clinical factors may also influence risk of asthenia.
PA166135119,rs45445694,1448102625,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,Patients with the 2R/3R genotype and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.
PA166135119,rs45445694,1448102626,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,Patients with the 3R/3R genotype and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.
PA166134456,rs45445694,1448568533,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2,"Patients with the 2R/2R genotype may have an increased risk for toxicity, an increased survival time, and an increased response to fluoropyrimidine chemotherapy regimens as compared to patients with the 2R/3R or 3R/3R genotype. However, contradictory or non-significant evidence exists for all three of these associations. Other genetic and clinical factors may also influence a patient's risk for toxicity, survival time and response."
PA166134456,rs45445694,1448568534,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,"Patients with the 2R/3R genotype may have an increased survival time and response as compared to patients with the 3R/3R genotype, and a decreased response as compared to patients with the 2R/2R genotype, when receiving fluoropyrimidine chemotherapy regimens. A SNP within the third repeat may modify the actions of the 3R allele. Other genetic and clinical factors may also influence a patient's risk for survival time and response."
PA166134456,rs45445694,1448568535,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,"Patients with the 3R/3R genotype may have a decreased but not absent risk for toxicity, a decreased survival time and a decreased response to with fluoropyrimidine chemotherapy regimens as compared to patients with the 2R/2R or 2R/3R genotype. However, contradictory or non-significant evidence exists for all three of these associations. In addition a SNP within the third repeat may modify the actions of the 3R allele. Other genetic and clinical factors may also influence a patient's risk for toxicity, survival and response."
PA166134457,rs45445694,981188337,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2,Patients with the 2R/2R genotype may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.
PA166134457,rs45445694,981188338,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,Patients with the 2R/3R genotype may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.
PA166134457,rs45445694,981188339,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,Patients with the 3R/3R genotype may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.
PA166135360,rs45445694,1447945934,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2,Pediatric patients with the 2R/2R genotype and acute lymphoblastic leukemia may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/3R or 3R/3R genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166135360,rs45445694,1447945935,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,Pediatric patients with the 2R/3R genotype and acute lymphoblastic leukemia may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166135360,rs45445694,1447945936,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3,Pediatric patients with the 3R/3R genotype and acute lymphoblastic leukemia may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
PA166153055,rs4752219,1448106527,CC,"Patients with the CC genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153055,rs4752219,1448106528,CT,"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153055,rs4752219,1448106529,TT,"Patients with the TT genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166135953,rs4742610,1446902931,CC,Patients with the CC genotype may have decreased risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence the response to verapamil.
PA166135953,rs4742610,1446902930,TC,Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.
PA166135953,rs4742610,1446902929,TT,Patients with the TT genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.
PA166153056,rs4752220,1448106538,AA,"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153056,rs4752220,1448106539,AG,"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153056,rs4752220,1448106540,GG,"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166136492,rs4775936,1447681878,CC,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166136492,rs4775936,1447681879,CT,"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166136492,rs4775936,1447681880,TT,"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
PA166134971,rs4783961,1183491362,AA,Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134971,rs4783961,1183491361,AG,Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134971,rs4783961,1183491360,GG,Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166136108,rs478437,1444607361,CC,"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
PA166136108,rs478437,1444607362,CT,"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
PA166136108,rs478437,1444607363,TT,"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
PA166134204,rs4731426,655384984,CC,"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment."
PA166134204,rs4731426,655384985,CG,"Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment."
PA166134204,rs4731426,655384986,GG,Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of extreme weight gain as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.
PA166152843,rs4790694,1448106654,AA,Patients with the AA genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
PA166152843,rs4790694,1448106655,AC,"Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction."
PA166152843,rs4790694,1448106656,CC,Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
PA166136082,rs4793665,1184998990,CC,Patients with the CC genotype who are treated with morphine may have higher levels of morphine-3-glucuronide and morphine-6-glucuronide metabolite formation as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine. 
PA166136082,rs4793665,1184998991,CT,Patients with the CT genotype who are treated with morphine may have lower levels of morphine-3-glucuronide and morphine-6-glucuronide metabolite formation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine. 
PA166136082,rs4793665,1184998992,TT,Patients with the TT genotype who are treated with morphine may have lower levels of morphine-3-glucuronide and morphine-6-glucuronide metabolite formation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine. 
PA166135258,rs4791040,1183634099,CC,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135258,rs4791040,1183634100,CT,Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a  decreased reduction of diastolic blood pressure as compared to patients with the  CC genotype and increased reduction of diastolic blood pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135258,rs4791040,1183634101,TT,Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135762,rs4795893,1448106101,AA,Patients with the AA genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135762,rs4795893,1448106102,AG,Patients with the AG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166135762,rs4795893,1448106103,GG,Patients with the GG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to risperidone.
PA166158937,rs4796793,1448100069,CC,Patients with the CC genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy. 
PA166158937,rs4796793,1448100070,CG,Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy. 
PA166158937,rs4796793,1448100071,GG,Patients with the GG genotype and renal cell carcinoma may have an increased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy. 
PA166136467,rs4802101,1446908014,CC,"Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus."
PA166136467,rs4802101,1446908015,CT,"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus."
PA166136467,rs4802101,1446908016,TT,"Patients with the TT genotype may have increased metabolism of cyclophosphamide, resulting in increased concentrations of active cyclophosphamide metabolites, and increased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus."
PA166134180,rs4799915,655384889,CC,"Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134180,rs4799915,655384888,CT,Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134180,rs4799915,655384887,TT,Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
PA166159172,rs4803217,1448102805,AA,Patients with the AA genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159172,rs4803217,1448102806,AC,"Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment."
PA166159172,rs4803217,1448102807,CC,Patients with the CC genotype and hepatitis C or HIV may have an increased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166153187,rs4803381,1447987075,CC,Patients with the CC genotype may metabolize nicotine more rapidly as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.
PA166153187,rs4803381,1447987076,CT,Patients with the CT genotype may metabolize nicotine more rapidly as compared to patients with the TT genotype and more slowly as compared to the CC genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.
PA166153187,rs4803381,1447987077,TT,Patients with the TT genotype may metabolize nicotine more slowly as compared to patients with the CT CC genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.
PA166153192,rs4803381,1447987119,CC,Patients with the CC genotype and tobacco use disorder may have a worse response (lack of abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
PA166153192,rs4803381,1447987120,CT,Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder. 
PA166153192,rs4803381,1447987121,TT,Patients with the TT genotype and tobacco use disorder may have an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
PA166135260,rs4815273,1183634107,CC,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the CT or the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135260,rs4815273,1183634108,CT,Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the TT genotype and increased reduction of systolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135260,rs4815273,1183634109,TT,Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of systolic blood pressure as compared to patients with the CC or the CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166135512,rs4818,1184233518,CC,Patients with the CC genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135512,rs4818,1184233519,CG,Patients with the CG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135512,rs4818,1184233520,GG,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166161181,rs4818,1448423797,CC,Patients with the CC genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response. 
PA166161181,rs4818,1448423798,CG,"Patients with the CG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response. "
PA166161181,rs4818,1448423799,GG,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response. 
PA166136454,rs4803419,1447953043,CC,Patients with HIV and the CC genotype may have lower plasma concentrations of efavirenz as compared to patients with the TT genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV.
PA166136454,rs4803419,1447953044,CT,Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. 
PA166136454,rs4803419,1447953045,TT,Patients with HIV and the TT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV.
PA166161872,rs4819554,1448525397,AA,Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs. 
PA166161872,rs4819554,1448525398,AG,Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs. 
PA166161872,rs4819554,1448525399,GG,Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs. 
PA166159168,rs4803219,1448102458,CC,Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159168,rs4803219,1448102459,CT,Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159168,rs4803219,1448102460,TT,Patients with the TT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166135242,rs4823613,1183631468,AA,Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166135242,rs4823613,1183631467,AG,Patients with the AG genotype may have a reduced response to simvastatin treatment (a lower  reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166135242,rs4823613,1183631466,GG,Patients with the GG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. A seperate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166136050,rs4823613,1184986493,AA,Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus. 
PA166136050,rs4823613,1184986494,AG,Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus. 
PA166136050,rs4823613,1184986495,GG,Patients with the GG genotype and organ transplantation administered tacrolimus may have decreased metabolism of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus. 
PA166134842,rs4680,1043880042,AA,Patients with the AA genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
PA166134842,rs4680,1043880041,AG,Patients with the AG genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
PA166134842,rs4680,1043880040,GG,Patients with the GG genotype and major Depressive Disorder may have a decreased response to fluvoxamine treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
PA166134850,rs4680,1043880168,AA,Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
PA166134850,rs4680,1043880167,AG,Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
PA166134850,rs4680,1043880166,GG,Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
PA166135548,rs4680,1448099687,AA,Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135548,rs4680,1448099688,AG,Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135548,rs4680,1448099689,GG,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135609,rs4680,1184987575,AA,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135609,rs4680,1184987576,AG,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135609,rs4680,1184987577,GG,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135850,rs4680,1444706789,AA,Patients with the AA genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166135850,rs4680,1444706790,AG,Patients with the AG genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype or may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166135850,rs4680,1444706791,GG,Patients with the GG genotype and major depression may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134511,rs4680,1448099957,AA,"Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy."
PA166134511,rs4680,1448099958,AG,"Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy."
PA166134511,rs4680,1448099959,GG,"Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy."
PA166134512,rs4680,981202647,AA,Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
PA166134512,rs4680,981202648,AG,Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
PA166134512,rs4680,981202649,GG,Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
PA166134513,rs4680,981202675,AA,Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
PA166134513,rs4680,981202676,AG,Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
PA166134513,rs4680,981202677,GG,Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
PA166134243,rs4680,1448612991,AA,"Patients with the AA genotype who are treated with morphine may require a lower dose as compared to patients with the AG or GG genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's response when treated with morphine.

"
PA166134243,rs4680,1448612992,AG,"Patients with the AG genotype who are treated with morphine may require a higher dose as compared to patients with the AA genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's response when treated with morphine.
"
PA166134243,rs4680,1448612993,GG,Patients with the GG genotype who are treated with morphine may require a higher dose as compared to patients with the AA genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's response when treated with morphine.
PA166136218,rs4680,1444673125,AA,Patients with the AA genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
PA166136218,rs4680,1444673126,AG,Patients with the AG genotype and schizophrenia may have an increased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
PA166136218,rs4680,1444673127,GG,Patients with the GG genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
PA166135831,rs4680,1444704404,AA,Patients with the AA genotype and Parkinson Disease may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
PA166135831,rs4680,1444704403,AG,Patients with the AG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype or may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
PA166135831,rs4680,1444704402,GG,Patients with the GG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
PA166136366,rs4680,1445401144,AA,Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
PA166136366,rs4680,1445401145,AG,Patients with the AG genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
PA166136366,rs4680,1445401146,GG,Patients with the GG genotype may have decreased blood pressure when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
PA166136367,rs4680,1445401151,AA,Patients with the AA genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
PA166136367,rs4680,1445401152,AG,Patients with the AG genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
PA166136367,rs4680,1445401153,GG,Patients with the GG genotype may have reduced fasting glucose levels when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
PA166136390,rs4680,1445402113,AA,Patients with the AA genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166136390,rs4680,1445402114,AG,Patients with the AG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166136390,rs4680,1445402115,GG,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166136393,rs4844880,1445402177,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AT or TT genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166136393,rs4844880,1445402178,AT,"Patients with the AT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166136393,rs4844880,1445402179,TT,"Patients with the TT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166136245,rs4848306,1444686923,AA,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136245,rs4848306,1444686924,AG,"Patients with the AG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136245,rs4848306,1444686925,GG,"Patients with the GG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136411,rs4849127,1448106262,AA,Patients with the AA genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166136411,rs4849127,1448106263,AG,Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166136411,rs4849127,1448106264,GG,Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166136457,rs4825476,1446906339,AA,Patients with the AA genotype may have decreased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to citalopram.
PA166136457,rs4825476,1446906338,AG,Patients with the AG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.
PA166136457,rs4825476,1446906337,GG,Patients with the GG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.
PA166135998,rs4870061,1447814616,CC,"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane."
PA166135998,rs4870061,1447814617,CT,Women with the CT genotype and breast neoplasms may have less bone mineral loss when taking letrozole as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole.
PA166135998,rs4870061,1447814618,TT,"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane."
PA166134705,rs4877900,982032513,CC,Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134705,rs4877900,982032514,CT,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134705,rs4877900,982032515,TT,Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166162591,rs4889606,1448573304,AA,Patients with the AA genotype may have decreased dose of warfarin in African American patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the dose of warfarin.
PA166162591,rs4889606,1448573303,AG,Patients with the AG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
PA166162591,rs4889606,1448573302,GG,Patients with the GG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
PA166134277,rs4846051,655385476,AA,Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
PA166134277,rs4846051,655385477,AG,Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
PA166134277,rs4846051,655385478,GG,Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
PA166134124,rs4880,655384538,AA,Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
PA166134124,rs4880,655384537,AG,Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
PA166134124,rs4880,655384536,GG,Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
PA166136199,rs4880,1444667919,AA,Patients with genotype AA and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid. 
PA166136199,rs4880,1444667920,AG,Patients with genotype AG and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid. 
PA166136199,rs4880,1444667921,GG,Patients with genotype GG and epilepsy may have an increased risk of drug toxicity when taking valproic acid as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid. 
PA166136380,rs4880,1445401806,AA,Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
PA166136380,rs4880,1445401807,AG,Patients with the AG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
PA166136380,rs4880,1445401808,GG,Patients with the GG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
PA166152622,rs4880,1447959510,AA,Patients with the AA genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity. 
PA166152622,rs4880,1447959511,AG,Patients with the AG genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity. 
PA166152622,rs4880,1447959512,GG,Patients with the GG genotype and acute lymphoblastic leukemia (ALL) may have an increased risk for hepatotoxicity when treated with asparaginase as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity. 
PA166153477,rs4880,1447990791,AA,Peripheral blood mononuclear cells (PBMC) from individuals with the AA genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and GG genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
PA166153477,rs4880,1447990792,AG,Peripheral blood mononuclear cells (PBMC) from individuals with the AG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the GG and less sensitive as compared to PBMCs from individuals with the AA genotype. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
PA166153477,rs4880,1447990793,GG,Peripheral blood mononuclear cells (PBMC) from individuals with the GG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and AA genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
PA166159495,rs4910008,1448112495,CC,Patients with the CC genotype and rheumatoid arthritis may have increased response to tocilizumab compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect response to tocilizumab.
PA166159495,rs4910008,1448112496,CT,Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.
PA166159495,rs4910008,1448112497,TT,Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.
PA166136425,rs489693,1448106334,AA,"Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AA may have an increased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AC and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. "
PA166136425,rs489693,1448106335,AC,"Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. "
PA166136425,rs489693,1448106336,CC,"Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype CC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. "
PA166159414,rs4877847,1448109709,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
"
PA166159414,rs4877847,1448109710,AC,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC, or increased likelihood as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
"
PA166159414,rs4877847,1448109711,CC,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
"
PA166134871,rs4918758,1043880393,CC,Patients with the CC genotype may require decreased dose of warfarin  in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134871,rs4918758,1043880394,CT,Patients with the CT genotype may require decreased dose of warfarin  in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134871,rs4918758,1043880395,TT,Patients with the TT genotype may require increased dose of warfarin  in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166158941,rs49411,1448100119,CC,Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158941,rs49411,1448100120,CT,Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158941,rs49411,1448100121,TT,Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
PA166136172,rs4948496,1444666719,CC,Patients with the CC genotype and acute lymphoblastic leukemia may have increased concentrations of methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.
PA166136172,rs4948496,1444666720,CT,Patients with the CT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.
PA166136172,rs4948496,1444666721,TT,Patients with the TT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.
PA166134259,rs4888024,655385337,AA,"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD."
PA166134259,rs4888024,655385336,AG,Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
PA166134259,rs4888024,655385335,GG,Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
PA166135028,rs495794,1183619582,AA,"Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. "
PA166135028,rs495794,1183619583,AG,"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. "
PA166135028,rs495794,1183619584,GG,"Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. "
PA166159029,rs4958381,1448106770,CC,Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype. Other genetic and clinical factors may also influence  hypersensitivity to asparaginase.
PA166159029,rs4958381,1448106771,CT,"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence  hypersensitivity to asparaginase."
PA166159029,rs4958381,1448106772,TT,Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence  hypersensitivity to asparaginase.
PA166134178,rs4933824,655384879,GG,Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype.  Other genetic and clinical factors may also influence a patient's response.
PA166134178,rs4933824,655384880,GT,"Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response."
PA166134178,rs4933824,655384881,TT,"Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response."
PA166134886,rs495828,1043880647,GG,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
PA166134886,rs495828,1043880646,TG,Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
PA166134886,rs495828,1043880645,TT,Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
PA166136319,rs495828,1444703955,GG,"Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril."
PA166136319,rs495828,1444703954,GT,"Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril."
PA166136319,rs495828,1444703953,TT,Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
PA166136311,rs4982133,1444703575,AA,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136311,rs4982133,1444703574,AC,Patients with the AC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype or may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136311,rs4982133,1444703573,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135807,rs4984241,1444703892,AA,Patients with the AA genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
PA166135807,rs4984241,1444703893,AG,Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
PA166135807,rs4984241,1444703894,GG,Patients with the GG genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
PA166134872,rs4917639,1444695561,AA,Patients with the AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134872,rs4917639,1444695562,CA,Patients with the CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134872,rs4917639,1444695563,CC,Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166152788,rs4986910,1447962705,AA,Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
PA166152788,rs4986910,1447962706,AG,Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
PA166152788,rs4986910,1447962707,GG,"No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response."
PA166152786,rs4986910,1447962683,AA,"Patients with the AA genotype who are undergoing kidney transplantation may require an increased dose of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166152786,rs4986910,1447962684,AG,"Patients with the AG genotype who are undergoing kidney transplantation may require an increased dose of tacrolimus as compared to patients with the GG genotype, or a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166152786,rs4986910,1447962685,GG,"Patients with the GG genotype who are undergoing kidney transplantation may require a decreased dose of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
PA166134879,rs4986790,1043880460,AA,Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134879,rs4986790,1043880461,AG,Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134879,rs4986790,1043880462,GG,Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. 
PA166134880,rs4986790,1043880468,AA,Patients with the AA genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment. 
PA166134880,rs4986790,1043880469,AG,"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment. "
PA166134880,rs4986790,1043880470,GG,Patients with the GG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment. 
PA166135877,rs4986790,1445400705,AA,Patients with the AA genotype may have a better response to the pertussis vaccine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
PA166135877,rs4986790,1445400706,AG,Patients with the AG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
PA166135877,rs4986790,1445400707,GG,Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
PA166134169,rs4987161,1000539585,AA,"In vitro, the construct expressing the wild type allelic protein has average nifedipine metabolism."
PA166134169,rs4987161,1000539586,AG,Expression study did not included heterozygous genotype.
PA166134169,rs4987161,1000539587,GG,"In vitro, the recombinant CYP3A4*17 allelic protein exhibits significantly decreased catalytic activity for nifedipine oxidation by 98 to 99% compared to wild-type construct at high concentration of nifedipine."
PA166134235,rs4986938,655385151,CC,Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.
PA166134235,rs4986938,655385152,CT,Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.
PA166134235,rs4986938,655385153,TT,Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.
PA166134198,rs4994,655384961,AA,"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment."
PA166134198,rs4994,655384960,AG,"Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment."
PA166134198,rs4994,655384959,GG,Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
PA166134669,rs502434,982030908,CC,Patients with the CC genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134669,rs502434,982030909,CT,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166134669,rs502434,982030910,TT,Patients with the TT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. 
PA166135380,rs5030743,1183700239,CC,Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better overall survival as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135380,rs5030743,1183700240,CG,Patients with the CG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135380,rs5030743,1183700241,GG,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment. 
PA166135027,rs4961,1448102594,GG,"Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
PA166135027,rs4961,1448102595,GT,"Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
"
PA166135027,rs4961,1448102596,TT,"Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
PA166134514,rs4961,981202715,GG,Patients with the GG genotype may have a poorer response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166134514,rs4961,981202716,GT,Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166134514,rs4961,981202717,TT,Patients with the TT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
PA166134515,rs4961,981202791,GG,"Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics."
PA166134515,rs4961,981202792,GT,"Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics."
PA166134515,rs4961,981202793,TT,"Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics."
PA166134516,rs4961,1446905339,GG,Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
PA166134516,rs4961,1446905340,GT,Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
PA166134516,rs4961,1446905341,TT,Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
PA166135721,rs5030728,1444687027,AA,Patients with the AA genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135721,rs5030728,1444687028,AG,Patients with the AG genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135721,rs5030728,1444687029,GG,Patients with the GG genotype and inflammatory bowel diseases may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135183,rs5030868,1183960821,A,Male patients with the A genotype (hemizygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis. 
PA166135183,rs5030868,1183960822,AA,Female patients with the AA genotype (homozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis. 
PA166135183,rs5030868,1183960823,AG,Female patients with the AG genotype (heterozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the GG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis. 
PA166135183,rs5030868,1183960824,G,Male patients with the G genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the A genotype (hemizygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis. 
PA166135183,rs5030868,1183960825,GG,Female patients with the GG genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the AA genotype (homozygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis. 
PA166135726,rs5030952,1448106092,CC,Patients with the CC genotype who undergo kidney transplant may have a decreased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for PTDM. 
PA166135726,rs5030952,1448106093,CT,Patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM. 
PA166135726,rs5030952,1448106094,TT,"No patients with the TT genotype were present in the population. However, patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM. "
PA166134493,rs5031016,981202047,AA,"Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the GG or AG genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine."
PA166134493,rs5031016,981202048,AG,"Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine."
PA166134493,rs5031016,981202049,GG,"Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine."
PA166136309,rs5050,1444703523,GG,Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166136309,rs5050,1444703524,GT,"Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166136309,rs5050,1444703525,TT,"Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166134812,rs5051,1183565712,CC,Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
PA166134812,rs5051,1183565713,CT,Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
PA166134812,rs5051,1183565714,TT,Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
PA166136158,rs5051,1444666378,CC,Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
PA166136158,rs5051,1444666379,CT,Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
PA166136158,rs5051,1444666380,TT,Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
PA166135370,rs5063,1183698809,CC,"Patients with the CC genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype. Other genetic and clinical factors may also influence response to these drugs."
PA166135370,rs5063,1183698810,CT,"Patients with the CT genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype, or a poorer response as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs."
PA166135370,rs5063,1183698811,TT,"Patients with the TT genotype may have a poorer response to bumetanide, furosemide or torasemide, as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs."
PA166159990,rs50872,1448256866,AA,Patients with the AA genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166159990,rs50872,1448256867,AG,Patients with the AG genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166159990,rs50872,1448256868,GG,Patients with the GG genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
PA166134152,rs5030655,982030512,A/del,Patients with the A/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
PA166134152,rs5030655,982030513,AA,Patients with the A/A genotype who are treated with venlafaxine may have average risk of adverse effects (check other variants for PM phenotype) as compared to patients with the del/del or A/del genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
PA166134152,rs5030655,982030514,del/del,Patients with the del/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
PA166134892,rs5030655,1043880683,AA,"Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL/A or DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics."
PA166134892,rs5030655,1043880682,DEL/A,Patients with the DEL/A genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.
PA166134892,rs5030655,1043880681,DEL/DEL,Patients with the DEL/DEL genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.
PA166134260,rs5030655,982030502,A/del,Patients with the A/del genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.
PA166134260,rs5030655,982030503,AA,Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.
PA166134260,rs5030655,982030504,del/del,"Patients with the del/del genotype who are treated with metoprolol may have an greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure as compared to patients with the A/del or A/A genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol."
PA166158979,rs510432,1448100439,CC,Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
PA166158979,rs510432,1448100440,CT,Patients with the CT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the TT genotypes. Other factors may affect response to adalimumab.
PA166158979,rs510432,1448100441,TT,Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
PA166134890,rs510769,1043880667,CC,Patients with the CC genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.
PA166134890,rs510769,1043880666,CT,Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.
PA166134890,rs510769,1043880665,TT,Patients with the TT genotype may have decreased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the CC or CT genotype.
PA166134224,rs5128,655385096,CC,Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.
PA166134224,rs5128,655385095,CG,"Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation."
PA166134224,rs5128,655385094,GG,"Patients with the GG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation."
PA166134200,rs518147,982034850,CC,"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment."
PA166134200,rs518147,982034851,CG,"Patients with the CG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment."
PA166134200,rs518147,982034852,GG,"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment."
PA166134335,rs518329,655386316,CC,Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134335,rs518329,655386317,CT,Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134335,rs518329,655386318,TT,Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134114,rs5182,1448105941,CC,Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134114,rs5182,1448105942,CT,Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134114,rs5182,1448105943,TT,Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166135838,rs5182,1444705160,CC,"Patients with the CC genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
PA166135838,rs5182,1444705161,CT,"Patients with the CT genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
PA166135838,rs5182,1444705162,TT,"Patients with the TT genotype and Hypertension may have increased risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
PA166152760,rs518350,1447961153,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152760,rs518350,1447961154,CT,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152760,rs518350,1447961155,TT,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166136174,rs520210,1444666740,AA,Patients with the AA genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166136174,rs520210,1444666741,AG,"Patients with the AG genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram."
PA166136174,rs520210,1444666742,GG,Patients with the GG genotype and depression may have a poorer response when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166134159,rs5065,655384769,AA,Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
PA166134159,rs5065,655384770,AG,Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
PA166134159,rs5065,655384771,GG,Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
PA166159195,rs5275,1448103848,AA,Patients with the AA genotype and colorectal cancer may have longer progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166159195,rs5275,1448103849,AG,Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166159195,rs5275,1448103850,GG,Patients with the GG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166158939,rs521093,1448100105,CC,Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158939,rs521093,1448100106,CT,Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158939,rs521093,1448100107,TT,Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
PA166136231,rs529520,1444680096,AA,Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
PA166136231,rs529520,1444680097,AC,"Patients with the AC genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype, or a better response as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine."
PA166136231,rs529520,1444680098,CC,Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
PA166134610,rs5219,981238913,CC,"Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134610,rs5219,981238912,CT,"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134610,rs5219,981238911,TT,"Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134616,rs5219,1444666371,CC,Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
PA166134616,rs5219,1444666372,CT,"Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas."
PA166134616,rs5219,1444666373,TT,Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
PA166134233,rs5219,1448105951,CC,Patients with the CC genotype are less likely to respond to repaglinide  than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
PA166134233,rs5219,1448105952,CT,Patients with the CT genotype are more likely to respond to repaglinide  than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
PA166134233,rs5219,1448105953,TT,Patients with the TT genotype are more likely to respond to repaglinide  than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
PA166135023,rs5370,1183564891,GG,"Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
PA166135023,rs5370,1183564892,GT,"Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
PA166135023,rs5370,1183564893,TT,"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
PA166134167,rs5370,1043737608,GG,"Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment."
PA166134167,rs5370,1043737609,GT,No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
PA166134167,rs5370,1043737610,TT,Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
PA166161231,rs5370,1448427400,GG,Patients with the GG genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166161231,rs5370,1448427401,GT,Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166161231,rs5370,1448427402,TT,Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
PA166135246,rs544093,1183631541,GG,"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135246,rs544093,1183631542,GT,"Patients with the GT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135246,rs544093,1183631543,TT,"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166134881,rs5186,1043880479,AA,Patients with the AA genotype and Coronary Artery Disease may have a decreased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
PA166134881,rs5186,1043880478,CA,Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
PA166134881,rs5186,1043880477,CC,Patients with the CC genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
PA166135024,rs5186,1183564846,AA,Patients with the AA genotype and heart failure may have an increased response when treated with candesartan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence response to candesartan.
PA166135024,rs5186,1183564847,AC,Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.
PA166135024,rs5186,1183564848,CC,"No patients with the CC genotype were present in the study analysis. However, patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan."
PA166134807,rs5186,1183630563,AA,Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to captopril.
PA166134807,rs5186,1183630564,AC,Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.
PA166134807,rs5186,1183630565,CC,Patients with the CC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.
PA166152699,rs5186,1447960601,AA,Patients with the AA genotype and hypertension may have a greater reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence pulse wave velocity.
PA166152699,rs5186,1447960602,AC,Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.
PA166152699,rs5186,1447960603,CC,Patients with the CC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.
PA166152702,rs5186,1447960625,AA,Patients with the AA genotype may have poorer humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
PA166152702,rs5186,1447960626,AC,Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
PA166152702,rs5186,1447960627,CC,Patients with the CC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
PA166152703,rs5186,1447960635,AA,Patients with the AA genotype may have a greater decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence GFR.
PA166152703,rs5186,1447960636,AC,Patients with the AC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.
PA166152703,rs5186,1447960637,CC,Patients with the CC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.
PA166152707,rs5186,1447960658,AA,Patients with the AA genotype and cirrhosis may have a greater decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
PA166152707,rs5186,1447960659,AC,Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
PA166152707,rs5186,1447960660,CC,Patients with the CC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
PA166152853,rs5186,1447963855,AA,Patients with the AA genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
PA166152853,rs5186,1447963856,AC,Patients with the AC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
PA166152853,rs5186,1447963857,CC,Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of diabetes.
PA166152706,rs5186,1447960651,AA,Patients with the AA genotype and hypertension may have a smaller reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
PA166152706,rs5186,1447960652,AC,Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
PA166152706,rs5186,1447960653,CC,Patients with the CC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
PA166135508,rs5522,1184233164,CC,Patients with the CC genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril. 
PA166135508,rs5522,1184233163,CT,Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril. 
PA166135508,rs5522,1184233162,TT,Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril. 
PA166159240,rs5569,1448104066,AA,"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence response to methylphenidate."
PA166159240,rs5569,1448104067,AG,"Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence response to methylphenidate."
PA166159240,rs5569,1448104068,GG,"Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence response to methylphenidate."
PA166134902,rs55754655,1043880831,AA,Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
PA166134902,rs55754655,1043880830,GA,Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
PA166134902,rs55754655,1043880829,GG,Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
PA166159030,rs557881,1448101061,AA,Patients with the AA genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma. 
PA166159030,rs557881,1448101062,AG,"Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma. "
PA166159030,rs557881,1448101063,GG,Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma. 
PA166134486,rs4986893,1444667271,AA,"Patients with the AA genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel."
PA166134486,rs4986893,1444667272,AG,"Patients with the AG genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel."
PA166134486,rs4986893,1444667273,GG,"Patients with the GG genotype 1) may have increased metabolism of clopidogrel and formation of active drug metabolite, resulting in increased response 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel."
PA166135852,rs4986893,1444706803,AA,Patients with the AA genotype and Mental disorders may have increased serum concentration of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166135852,rs4986893,1444706804,AG,Patients with the AG genotype and Mental disorders may have increased serum concentration of escitalopram as compared to patients with the GG genotype or may have decreased serum concentration of escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166135852,rs4986893,1444706805,GG,Patients with the GG genotype and Mental disorders may have decreased serum concentration of escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166163682,rs4986893,1448615591,AA,Patients with the AA genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and GG genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin. 
PA166163682,rs4986893,1448615592,AG,"Patients with the AG genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the GG genotypes, and a decreased likelihood as compared to patients with the AA genotype. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin. "
PA166163682,rs4986893,1448615593,GG,Patients with the GG genotype who are treated with phenytoin may have an decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and AA genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin. 
PA166134708,rs558025,982032658,AA,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
PA166134708,rs558025,982032659,AG,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
PA166134708,rs558025,982032660,GG,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
PA166134375,rs532545,982033426,CC,Patients with the genotype CC who are treated with cytarabine may have reduced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
PA166134375,rs532545,982033427,CT,Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
PA166134375,rs532545,982033428,TT,Patients with the genotype TT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
PA166134415,rs532545,982033452,CC,Patients with the CC genotype and Myeloid Leukemia who are treated with cytarabine may have an increased survival time and a decreased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
PA166134415,rs532545,982033453,CT,"Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.

"
PA166134415,rs532545,982033454,TT,Patients with the TT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
PA166136096,rs55894764,1185002367,CC,Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136096,rs55894764,1185002366,CT,Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136096,rs55894764,1185002365,TT,Patients with the TT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166135473,rs56040400,1183848122,CC,Patients with the CC genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have an increased response to eculizumab as compared with patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
PA166135473,rs56040400,1183848121,CT,Patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
PA166135473,rs56040400,1183848123,TT,Patients with the TT genotype were not part of the study. But patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
PA166136446,rs56113850,1446903558,CC,"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers. "
PA166136446,rs56113850,1446903559,CT,"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers. "
PA166136446,rs56113850,1446903560,TT,"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers. "
PA166135958,rs56061981,1448106358,CC,Patients with chronic hepatitis C genotype 1 and the CC genotype who also carry the CT or TT genotype at rs12979860 may have a decreased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C. 
PA166135958,rs56061981,1448106359,CT,Patients with chronic hepatitis C genotype 1 and the CT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C. 
PA166135958,rs56061981,1448106360,TT,Patients with chronic hepatitis C genotype 1 and the TT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C. 
PA166134725,rs56165452,1183702161,CC,Patients with the CC genotype may required reduced dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence  warfarin dose. This variant rs56165452 defines CYP2C9*4.
PA166134725,rs56165452,1183702162,CT,Patients with the CT genotype may required reduced dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence  warfarin dose. This variant rs56165452 defines CYP2C9*4.
PA166134725,rs56165452,1183702163,TT,Patients with the TT genotype may required higher dose of warfarin as compared to patients with the CT or CC genotype. Other clinical or genetic factors may also influence  warfarin dose. This variant rs56165452 defines CYP2C9*4.
PA166158967,rs56324128,1448100336,CC,Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.
PA166158967,rs56324128,1448100337,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
PA166134693,rs568408,982031796,AA,Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
PA166134693,rs568408,982031797,AG,Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
PA166134693,rs568408,982031798,GG,"Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil."
PA166153035,rs567606867,1447982792,CC,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153035,rs567606867,1447982791,CT,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153035,rs567606867,1447982790,TT,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153170,rs57064725,1447986904,AA,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153170,rs57064725,1447986905,AG,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153170,rs57064725,1447986906,GG,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153413,rs56038477,1448568513,CC,Patients with the CC genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased risk for drug toxicities as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity in patients receiving fluoropyrimidines.
PA166153413,rs56038477,1448568514,CT,Patients with the CT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk for drug toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity in patients receiving fluoropyrimidines.
PA166153413,rs56038477,1448568515,TT,Patients with the TT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk for drug toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity in patients receiving fluoropyrimidines.
PA166135236,rs55886062,1448605325,AA,"Patients with the AA genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AC or CC genotype (DPYD *1/*13 or *13/*13). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135236,rs55886062,1448605326,AC,"Patients with the AC genotype (DPYD *1/*13) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) partial DYPD deficiency and 2) an increased risk and increased severity of drug toxicity as compared to patients with the AA genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135236,rs55886062,1448605327,CC,"Patients with the CC genotype (DPYD *13/*13) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DYPD deficiency and 2) an increased risk and increased severity of drug toxicity as compared to patients with the AA genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166136336,rs5744247,1448603654,CC,"Patients who are undergoing liver transplant and receive a liver with the CC genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus."
PA166136336,rs5744247,1448603655,CG,"Patients who are undergoing liver transplant and receive a liver with the CG genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus."
PA166136336,rs5744247,1448603656,GG,"Patients who are undergoing liver transplant and receive a liver with the GG genotype, or patients undergoing a lung transplant, may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus."
PA166134043,rs5443,982036426,CC,Patients with the CC genotype and cluster headache who are treated with triptans may be less likely to have reduced pain or attack frequency as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
PA166134043,rs5443,982036427,CT,Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
PA166134043,rs5443,982036428,TT,"Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patient's response to sumatriptan."
PA166134230,rs5443,981501182,CC,Patients with the CC genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
PA166134230,rs5443,981501183,CT,Patients with the CT genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
PA166134230,rs5443,981501184,TT,Patients with the TT genotype and erectile dysfunction who are treated with sildenafil may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
PA166134897,rs5443,1183615553,CC,"Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol."
PA166134897,rs5443,1183615554,CT,"Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol."
PA166134897,rs5443,1183615555,TT,"Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol."
PA166135022,rs5443,1448102587,CC,"Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
PA166135022,rs5443,1448102588,CT,"Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
PA166135022,rs5443,1448102589,TT,"Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
PA166135803,rs5443,1444703772,CC,"Patients with the CC genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms, increased likelihood of Sleep Initiation and Maintenance Disorders but decreased risk for weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline."
PA166135803,rs5443,1444703771,CT,"Patients with the CT genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms, increased likelihood of Sleep Initiation and Maintenance Disorders but decreased risk for weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline."
PA166135803,rs5443,1444703770,TT,"Patients with the TT genotype and major depression who are treated with nortriptyline may have more improvement in neurovegetative symptoms, decreased likelihood of Sleep Initiation and Maintenance Disorders but increased risk for weight gain as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline."
PA166134782,rs5443,1043858616,CC,"Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. "
PA166134782,rs5443,1043858617,CT,"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. "
PA166134782,rs5443,1043858618,TT,"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment. "
PA166134194,rs5443,982033845,CC,"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine."
PA166134194,rs5443,982033846,CT,Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
PA166134194,rs5443,982033847,TT,Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
PA166134265,rs5443,1183491771,CC,Patients with the CC genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a smaller reduction in risk of myocardial infarction compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
PA166134265,rs5443,1183491772,CT,Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
PA166134265,rs5443,1183491773,TT,Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
PA166135699,rs5443,1444672791,CC,Patients with the CC genotype may have a poorer response to treatment with clonidine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to clonidine.
PA166135699,rs5443,1444672792,CT,Patients with the CT genotype may have a better response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.
PA166135699,rs5443,1444672793,TT,Patients with the TT genotype may have a betterr response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.
PA166136458,rs5443,1446906347,CC,Patients with the CC genotype may have increased heart rate when treated with Beta Blocking Agents as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
PA166136458,rs5443,1446906346,CT,Patients with the CT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
PA166136458,rs5443,1446906345,TT,Patients with the TT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
PA166159196,rs5443,1448103862,CC,Patients with the CC genotype who are stopping methadone treatment may have less of an increase in pulse rate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
PA166159196,rs5443,1448103863,CT,Patients with the CT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
PA166159196,rs5443,1448103864,TT,Patients with the TT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
PA166152854,rs5443,1447963862,CC,Patients with the CC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diabetes.
PA166152854,rs5443,1447963863,CT,Patients with the CT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
PA166152854,rs5443,1447963864,TT,Patients with the TT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
PA166136507,rs5443,1447943687,CC,Patients with CC genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan. 
PA166136507,rs5443,1447943688,CT,Patients with CT genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan. 
PA166136507,rs5443,1447943689,TT,Patients with TT genotype and essential hypertension may have decreased response to telmisartan compared to patients with genotype CC and CT. Other genetic and clinical factors may influence a patient's response to telmisartan. 
PA166136506,rs5443,1447943680,CC,Patients with the CC genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
PA166136506,rs5443,1447943681,CT,Patients with the CT genotype and heart failure may have decreased response to hydralazine  and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
PA166136506,rs5443,1447943682,TT,Patients with the TT genotype and heart failure may have increased response to hydralazine  and isosorbide dinitrate compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
PA166163575,rs57731889,1448613367,CC,Patients with the CC genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166163575,rs57731889,1448613366,CT,Patients with the CT genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166163575,rs57731889,1448613365,TT,Patients with the TT genotype may have low on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
PA166134061,rs5760410,637879865,AA,"Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment."
PA166134061,rs5760410,637879866,AG,Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
PA166134061,rs5760410,637879867,GG,Patients with the GG genotype  who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
PA166136314,rs578427,1444703788,CC,Patients with the CC genotype who are treated with metformin may have  decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136314,rs578427,1444703787,CT,Patients with the CT genotype who are treated with metformin may have  increased renal clearance and secretion clearance of metformin as compared to patients with the CC genotype or may have  decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136314,rs578427,1444703786,TT,Patients with the TT genotype who are treated with metformin may have  increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166135650,rs58425034,1444607660,CC,Patients with the CC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
PA166135650,rs58425034,1444607661,CG,Patients with the CG genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
PA166135650,rs58425034,1444607662,GG,Patients with the GG genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
PA166135845,rs585719,1444705225,CC,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135845,rs585719,1444705224,CT,Patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135845,rs585719,1444705226,TT,"Patients with the TT genotype were not studied. However, patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
PA166134142,rs58597806,655384637,AA,Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.
PA166134142,rs58597806,655384638,AG,Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.
PA166134142,rs58597806,655384639,GG,Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.
PA166135709,rs581111,1444680103,AA,Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
PA166135709,rs581111,1444680104,AG,Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
PA166135709,rs581111,1444680105,GG,Patients with the GG genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA or AG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
PA166152812,rs578776,1447963091,AA,Patients with the AA genotype may have a decreased risk for tobacco addiction as compared to patients with the GG genotype. Patients with the AA genotype may also show decreased levels of cotinine as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels. 
PA166152812,rs578776,1447963092,AG,"Patients with the AG genotype may have a decreased risk for tobacco addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Patients with the AG genotype may also show decreased levels of cotinine as compared to those with the GG genotype, or increased levels as compared to those with the AA genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels. "
PA166152812,rs578776,1447963093,GG,Patients with the GG genotype may have an increased risk for tobacco addiction as compared to patients with the AA genotype. Patients with the GG genotype may also show increased levels of cotinine as compared to those with the AA genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels. 
PA166159204,rs578776,1448103944,AA,Patients with the AA genotype may have an increased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism. 
PA166159204,rs578776,1448103945,AG,"Patients with the AG genotype may have an increased risk for alcoholism as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism. "
PA166159204,rs578776,1448103946,GG,Patients with the GG genotype may have a decreased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism. 
PA166158876,rs588076,1448099082,CC,Patients with the CC genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers. 
PA166158876,rs588076,1448099083,CG,"Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers. "
PA166158876,rs588076,1448099084,GG,Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with calcium channel blockers as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers. 
PA166136265,rs58818712,1444700492,AA,Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib. 
PA166136265,rs58818712,1444700491,AC,Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
PA166136265,rs58818712,1444700490,CC,Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib. 
PA166135000,rs5888,1183532608,AA,Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166135000,rs5888,1183532609,AG,Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166135000,rs5888,1183532610,GG,Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134974,rs5882,1183491388,AA,"Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. "
PA166134974,rs5882,1183491387,AG,Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134974,rs5882,1183491386,GG,Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. 
PA166134975,rs5882,1183491399,AA,Patients with the AA genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134975,rs5882,1183491400,AG,"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. "
PA166134975,rs5882,1183491401,GG,Patients with the GG genotype who have Hypercholesterolemia may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. 
PA166134694,rs588765,1446900336,CC,Patients with the CC genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the TT genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.
PA166134694,rs588765,1446900337,CT,Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.
PA166134694,rs588765,1446900338,TT,Patients with the TT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.
PA166134517,rs5751876,981203519,CC,Individuals with the CC genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.
PA166134517,rs5751876,981203520,CT,Individuals with the CT genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.
PA166134517,rs5751876,981203521,TT,Individuals with the TT genotype 1) may be more sensitive to caffeine and more likely to experience anxiety 2) may consume less caffeine as compared to individuals with the CC genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.
PA166152972,rs594709,1447980970,AA,Patients with the AA genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin. 
PA166152972,rs594709,1447980971,AG,Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin. 
PA166152972,rs594709,1447980972,GG,Patients with the GG genotype and Type 2 Diabetes may have decreased response to metformin compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affects response to metformin. 
PA166152793,rs5925,1447962746,CC,Patients with the CC genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166152793,rs5925,1447962747,CT,Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166152793,rs5925,1447962748,TT,"Patients with the TT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC genotype, or a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels."
PA166152761,rs6002674,1447961160,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152761,rs6002674,1447961161,CT,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152761,rs6002674,1447961162,TT,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166134808,rs5985,1043858971,AA,Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134808,rs5985,1043858972,AC,Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134808,rs5985,1043858973,CC,Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166158928,rs5985,1448099910,AA,Patients with choroidal neovascularization and the AA genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.
PA166158928,rs5985,1448099911,AC,Patients with choroidal neovascularization and the AC genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.
PA166158928,rs5985,1448099912,CC,Patients with choroidal neovascularization and the CC genotype may have increased response to photodynamic therapy compared to patients with the AA and AC genotypes. Other factors may affect response to photodynamic therapy.
PA166161178,rs5993883,1448423770,GG,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence quetiapine response. 
PA166161178,rs5993883,1448423771,GT,"Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response. "
PA166161178,rs5993883,1448423772,TT,Patients with the TT genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response. 
PA166136430,rs6021191,1446899690,AA,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
PA166136430,rs6021191,1446899691,AT,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
PA166136430,rs6021191,1446899692,TT,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
PA166135156,rs57098334,1448107529,(CCCACCCGA)10/(CCCACCCGA)10,"Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135156,rs57098334,1448107530,(CCCACCCGA)10/(CCCACCCGA)9,"Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135156,rs57098334,1448107531,(CCCACCCGA)12/(CCCACCCGA)10,"Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135156,rs57098334,1448107532,(CCCACCCGA)12/(CCCACCCGA)12 ,"Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with fluoxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135156,rs57098334,1448107533,(CCCACCCGA)12/(CCCACCCGA)9,"Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135156,rs57098334,1448107534,(CCCACCCGA)9/(CCCACCCGA)9,"Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135157,rs57098334,1448107543,(CCCACCCGA)10/(CCCACCCGA)10,Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135157,rs57098334,1448107544,(CCCACCCGA)10/(CCCACCCGA)9,Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135157,rs57098334,1448107545,(CCCACCCGA)12/(CCCACCCGA)10,Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135157,rs57098334,1448107546,(CCCACCCGA)12/(CCCACCCGA)12,Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with antidepressants 1) may have an increased risk of adverse drug reactions after switching treatment for the second time 2) may be more likely to have a lack of a response to treatment as compared to other genotypes. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135157,rs57098334,1448107547,(CCCACCCGA)12/(CCCACCCGA)9,Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166135157,rs57098334,1448107548,(CCCACCCGA)9/(CCCACCCGA)9,Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166153520,rs57098334,1448107488,(CCCACCCGA)10/(CCCACCCGA)10,"Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166153520,rs57098334,1448107489,(CCCACCCGA)10/(CCCACCCGA)9,"Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166153520,rs57098334,1448107490,(CCCACCCGA)12/(CCCACCCGA)10,"Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166153520,rs57098334,1448107491,(CCCACCCGA)12/(CCCACCCGA)12 ,"Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with paroxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166153520,rs57098334,1448107492,(CCCACCCGA)12/(CCCACCCGA)9,"Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166153520,rs57098334,1448107493,(CCCACCCGA)9/(CCCACCCGA)9,"Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166136110,rs57098334,1448115910,(CCCACCCGA)10,"Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166136110,rs57098334,1448115911,(CCCACCCGA)9,"Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166136110,rs57098334,1448115912,CCCACCCGA)12/(CCCACCCGA)12,"Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment. "
PA166135331,rs6025,1183689590,CC,"Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. "
PA166135331,rs6025,1183689591,CT,"Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. "
PA166135331,rs6025,1183689592,TT,"Patients with the TT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. "
PA166134874,rs60282872,1043880422,C/del,"Patients with the CC/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein  A1 and C3 levels as compared to patients with the C/C genotype, or may have a larger  change in apolipoprotein  A1 and C3 levels as compared to patients with the del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.  "
PA166134874,rs60282872,1043880423,CC,"Patients with the CC genotype who are treated with fluvastatin may have a larger  change in apolipoprotein  A1 and C3 levels, as compared to patients with the C/del or del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. "
PA166134874,rs60282872,1043880424,del/del,"Patients with the del/del genotype who are treated with fluvastatin may have a smaller  change in apolipoprotein  A1 and C3 levels, as compared to patients with the CC or C/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. "
PA166134072,rs6028945,637879973,GG,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT.  Other genetic and clinical factors may also influence a patient's response.
PA166134072,rs6028945,637879974,GT,Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134072,rs6028945,637879975,TT,Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166136313,rs6051702,1448107320,AA,Patients with the AA genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have increased risk of anemia as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.
PA166136313,rs6051702,1448107321,AC,"Patients with the AC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin."
PA166136313,rs6051702,1448107322,CC,"Patients with the CC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin."
PA166134810,rs6065,1043858981,CC,Patients with the CC genotype may have an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134810,rs6065,1043858982,CT,"Patients with the CT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166134810,rs6065,1043858983,TT,"Patients with the TT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
PA166134356,rs60369023,1184136447,AA,Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
PA166134356,rs60369023,1184136448,AG,"Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia."
PA166134356,rs60369023,1184136449,GG,Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
PA166135125,rs60369023,1183630681,AA,Purified CDA proteins with the AA genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
PA166135125,rs60369023,1183630682,AG,Purified CDA proteins with the AG genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
PA166135125,rs60369023,1183630683,GG,Purified CDA proteins with the GG genotype may have increased catalytic activity when exposed to cytarabine as compared to those proteins with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
PA166136312,rs6064463,1444703651,CC,Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166136312,rs6064463,1444703652,CT,Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166136312,rs6064463,1444703653,TT,Patients with the TT genotype may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135452,rs6072262,1183704422,AA,Patients with the AA genotype may have increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
PA166135452,rs6072262,1183704421,GA,Patients with the GA genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
PA166135452,rs6072262,1183704420,GG,Patients with the GG genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
PA166135356,rs602950,1183697566,AA,Cancer patients with the AA genotype may have a decreased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
PA166135356,rs602950,1183697567,AG,Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
PA166135356,rs602950,1183697568,GG,Cancer patients with the GG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
PA166134518,rs602950,982033475,AA,Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
PA166134518,rs602950,982033476,AG,Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
PA166134518,rs602950,982033477,GG,Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
PA166158959,rs6092,1448100251,AA,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk. 
PA166158959,rs6092,1448100252,AG,Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk. 
PA166158959,rs6092,1448100253,GG,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk. 
PA166134073,rs6071980,637879978,CC,Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.
PA166134073,rs6071980,637879979,CT,Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.
PA166134073,rs6071980,637879980,TT,Rheumatoid Arthritis patients with the genotype TT may be more likely to respond to TNF inhibitors compared with patients with genotypes CC or CT . Other genetic and clinical factors may also influence a patient's response.
PA166134873,rs61162043,1043880405,AA,Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134873,rs61162043,1043880404,AG,Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166134873,rs61162043,1043880403,GG,Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
PA166160671,rs610604,1448265282,GG,Evidence conflicts as to whether patients with the GG genotype and psoriasis have decreased response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.
PA166160671,rs610604,1448265283,GT,Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.
PA166160671,rs610604,1448265284,TT,Evidence conflicts as to whether patients with the TT genotype and psoriasis have increased response to ustekinumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to ustekinumab.
PA166158888,rs6130615,1448099180,CT,"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
"
PA166158888,rs6130615,1448099181,TT,"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
"
PA166151934,rs6108160,1447952938,AA,Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
PA166151934,rs6108160,1447952939,AG,Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
PA166151934,rs6108160,1447952940,GG,Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
PA166135451,rs6151031,1183704417,CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC,"Patients with the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype may have decreased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/del or del/del. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa."
PA166135451,rs6151031,1183704416,CTGGTGAGGAGAGAACC/del,"Patients with the CTGGTGAGGAGAGAACC/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa."
PA166135451,rs6151031,1183704415,del/del,"Patients with the del/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa."
PA166158965,rs61361928,1448100328,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
PA166158965,rs61361928,1448100329,TT,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.
PA166135846,rs6127921,1444705233,AA,Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135846,rs6127921,1444705232,AC,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype or may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135846,rs6127921,1444705231,CC,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166159205,rs615470,1448103951,CC,Patients with the CC genotype may have an increased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of alcoholism. 
PA166159205,rs615470,1448103952,CT,"Patients with the CT genotype may have an increased risk for alcoholism as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism. "
PA166159205,rs615470,1448103953,TT,Patients with the TT genotype may have a decreased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism. 
PA166134067,rs6138150,637879948,CC,Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT .  Other genetic and clinical factors may also influence a patient's response.
PA166134067,rs6138150,637879949,CT,Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC .  Other genetic and clinical factors may also influence a patient's response.
PA166134067,rs6138150,637879950,TT,Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.
PA166136459,rs6166,1446906358,CC,"Patients with the CC genotype may have poorer response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
PA166136459,rs6166,1446906359,CT,"Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
PA166136459,rs6166,1446906360,TT,"Patients with the TT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
PA166136176,rs61734430,1444666791,CC,Patients with the CC genotype and lung cancer may have a better response to treatment with pemetrexed as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to pemetrexed.
PA166136176,rs61734430,1444666792,CT,Patients with the CT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.
PA166136176,rs61734430,1444666793,TT,Patients with the TT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.
PA166134207,rs61750900,1448105331,GG,Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
PA166134207,rs61750900,1448105332,GT,Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
PA166134207,rs61750900,1448105333,TT,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
PA166134989,rs61764370,1183492026,AA,"Patients with the AA genotype and Adenocarcinoma may have a decreased, but not absent, risk for nonresponse to anti-EGFR-based treatment when treated with cetuximab and panitumumab as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for nonresponse to anti-EGFR-based treatment."
PA166134989,rs61764370,1183492025,CA,Patients with the CA genotype and Adenocarcinoma may have an increased risk for nonresponse to anti-EGFR-based treatment when treated with cetuximab and panitumumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nonresponse to anti-EGFR-based treatment.
PA166134989,rs61764370,1183492024,CC,Patients with the CC genotype and Adenocarcinoma may have an increased risk for nonresponse to anti-EGFR-based treatment when treated with cetuximab and panitumumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nonresponse to anti-EGFR-based treatment.
PA166136095,rs61742245,1185002359,AA,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136095,rs61742245,1185002360,AC,Patients with the AC genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136095,rs61742245,1185002361,CC,Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166135419,rs61742245,1448105766,AA,Patients with the AA genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.
PA166135419,rs61742245,1448105767,AC,Patients with the AC genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.
PA166135419,rs61742245,1448105768,CC,Patients with the CC genotype may have decreased dose of warfarin as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the dose of warfarin.
PA166134770,rs61767072,982046387,GGGGCGGGGCCG/GGGGCGGGGCCG,Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have increased response to bucindolol as compared to patients with the GGGGCGGGGCCG/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.
PA166134770,rs61767072,982046388,GGGGCGGGGCCG/del,Patients with the GGGGCGGGGCCG/del genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.
PA166134770,rs61767072,982046389,del/del,Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.
PA166151944,rs619586,1447953173,AA,Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151944,rs619586,1447953174,AG,Patients with the AG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151944,rs619586,1447953175,GG,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166135021,rs62205366,1183630559,CC,Healthy males with the CC genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.
PA166135021,rs62205366,1183630560,CT,Healthy males with the CT genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.
PA166135021,rs62205366,1183630561,TT,Healthy males with the TT genotype may have a decreased response when given dobutamine as compared to healthy males with the CC or CT genotype. Other genetic and clinical factors may also influence response to dobutamine.
PA166153002,rs61886492,1448102916,AA,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
PA166153002,rs61886492,1448102917,AG,"Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity."
PA166153002,rs61886492,1448102918,GG,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
PA166158968,rs62471956,1448106586,AA,Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.
PA166158968,rs62471956,1448106587,AG,Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.
PA166158968,rs62471956,1448106588,GG,Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.
PA166158890,rs62576288,1448099311,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158890,rs62576288,1448099312,GG,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
PA166158791,rs62576288,1448098346,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to the GG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel. 
PA166158791,rs62576288,1448098347,GG,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel. 
PA166153022,rs62621365,1447982678,CC,Patients with the CC genotype may have increased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
PA166153022,rs62621365,1447982677,CT,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane."
PA166153022,rs62621365,1447982676,TT,Patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
PA166134287,rs61888800,655385706,GG,Patients with the GG genotype with major depressive disorder may experience a greater response when treated with desipramine or fluoxetine compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to antidepressants.
PA166134287,rs61888800,655385707,GT,Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.
PA166134287,rs61888800,655385708,TT,Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.
PA166134735,rs5918,1184989726,CC,"Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. "
PA166134735,rs5918,1184989727,CT,"Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. "
PA166134735,rs5918,1184989728,TT,"Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. "
PA166134736,rs5918,1184989732,CC,Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel. 
PA166134736,rs5918,1184989733,CT,Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel. 
PA166134736,rs5918,1184989734,TT,Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel. 
PA166134165,rs622342,1448099265,AA,"Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment."
PA166134165,rs622342,1448099266,AC,"Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment."
PA166134165,rs622342,1448099267,CC,"Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment."
PA166159032,rs622342,1448101096,AA,"Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality."
PA166159032,rs622342,1448101097,AC,"Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality."
PA166159032,rs622342,1448101098,CC,"Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality."
PA166135511,rs6269,1184233513,AA,Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135511,rs6269,1184233514,AG,Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166135511,rs6269,1184233515,GG,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. 
PA166161180,rs6269,1448423790,AA,Patients with the AA genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response. 
PA166161180,rs6269,1448423791,AG,"Patients with the AG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response. "
PA166161180,rs6269,1448423792,GG,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response. 
PA166159238,rs6279,1448104045,CC,Female patients with the CC genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations. 
PA166159238,rs6279,1448104046,CG,"Female patients with the CG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or increased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations. "
PA166159238,rs6279,1448104047,GG,Female patients with the GG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations. 
PA166135964,rs6277,1446906367,AA,Patients with the genotype AA may have increased response to aripiprazole in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aripiprazole.
PA166135964,rs6277,1446906366,GA,Patients with the genotype GG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Though this association was found not statistically significant. Other genetic and clinical factors may also influence the response to aripiprazole.
PA166135964,rs6277,1446906365,GG,Patients with the genotype GG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to aripiprazole.
PA166134280,rs6277,1000539657,AA,"Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects."
PA166134280,rs6277,1000539658,AG,Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
PA166134280,rs6277,1000539659,GG,Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
PA166158995,rs6277,1448100632,AA,Patients with the AA genotype may have a better response to treatment with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methadone.
PA166158995,rs6277,1448100633,AG,"Patients with the AG genotype may have a better response to treatment with methadone as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone."
PA166158995,rs6277,1448100634,GG,Patients with the GG genotype may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.
PA166135402,rs6265,1448099731,CC,"Patients with the CC genotype may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin. "
PA166135402,rs6265,1448099732,CT,"Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin. "
PA166135402,rs6265,1448099733,TT,"Patients with the TT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin. "
PA166135410,rs6265,1183702965,CC,Patients with the CC genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
PA166135410,rs6265,1183702966,CT,Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
PA166135410,rs6265,1183702967,TT,Patients with the TT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
PA166135606,rs6265,1184987590,CC,"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135606,rs6265,1184987591,CT,"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135606,rs6265,1184987592,TT,"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166136412,rs6265,1446897193,CC,Patients with the CC genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166136412,rs6265,1446897194,CT,Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166136412,rs6265,1446897195,TT,Patients with the TT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. 
PA166135174,rs6265,1183619232,CC,Patients with the CC genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
PA166135174,rs6265,1183619233,CT,Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
PA166135174,rs6265,1183619234,TT,Patients with the TT genotype and major depressive disorder who are treated with fluoxetine may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects. 
PA166134750,rs6265,982040541,CC,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. "
PA166134750,rs6265,982040542,CT,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. "
PA166134750,rs6265,982040543,TT,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. "
PA166134781,rs6265,1444608035,CC,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants."
PA166134781,rs6265,1444608036,CT,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants."
PA166134781,rs6265,1444608037,TT,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants."
PA166135919,rs6265,1446896646,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
PA166135919,rs6265,1446896647,CT,Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.
PA166135919,rs6265,1446896648,TT,Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.
PA166134519,rs6275,981203546,AA,Patients with the AA genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166134519,rs6275,981203547,AG,Patients with the AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166134519,rs6275,981203548,GG,Patients with the GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166135607,rs6275,1184987595,AA,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135607,rs6275,1184987596,AG,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135607,rs6275,1184987597,GG,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166134520,rs6275,981203555,AA,Patients with the AA genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the GG genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166134520,rs6275,981203556,AG,Patients with the AG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the GG genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166134520,rs6275,981203557,GG,Patients with the GG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the AA genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.
PA166159239,rs6275,1448104052,AA,Female patients with the AA genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations. 
PA166159239,rs6275,1448104053,AG,"Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations. "
PA166159239,rs6275,1448104054,GG,Female patients with the GG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations. 
PA166159464,rs6296,1448112054,CC,Patients with the CC genotype and anxiety disorder or major depression may have increased risk of becoming agitated when taking citalopram compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
PA166159464,rs6296,1448112055,CG,Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
PA166159464,rs6296,1448112056,GG,Patients with the GG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
PA166135608,rs6305,1184987558,AA,"Patients with the AA genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135608,rs6305,1184987559,AG,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166135608,rs6305,1184987560,GG,"Patients with the GG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
PA166160513,rs628031,1448263580,AA,"Patients with the AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine."
PA166160513,rs628031,1448263581,AG,"Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine."
PA166160513,rs628031,1448263582,GG,"Patients with the GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine."
PA166136115,rs628031,1444607636,AA,Patients with the AA genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136115,rs628031,1444607637,AG,Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136115,rs628031,1444607638,GG,Patients with the GG genotype who are treated with metformin may have a increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166134378,rs6280,655387222,CC,"Patients with the CC genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response."
PA166134378,rs6280,655387223,CT,"Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response."
PA166134378,rs6280,655387224,TT,"Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135667,rs6280,1444608443,CC,Patients with the CC genotype and autism spectrum disorders may have a better tolerance for methylphenidate treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
PA166135667,rs6280,1444608444,CT,Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
PA166135667,rs6280,1444608445,TT,Patients with the TT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
PA166134521,rs6280,981203579,CC,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
PA166134521,rs6280,981203580,CT,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
PA166134521,rs6280,981203581,TT,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
PA166134776,rs6280,1183619568,CC,Patients with the CC genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134776,rs6280,1183619569,CT,Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134776,rs6280,1183619570,TT,Patients with the TT genotype and major depressive disorder may have a reduced response when treated with paroxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
PA166134199,rs6280,982034816,CC,Patients with the CC genotype and schizophrenia who are treated with olanzapine may have greater positive symptom improvement and positive symptom remission as compared to patients with the TT and CT genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134199,rs6280,982034817,CT,Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134199,rs6280,982034818,TT,Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134213,rs6280,655385040,CC,Patients with the CC genotype may have decreased response to pramipexole in Chinese patients with Parkinson's disease compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134213,rs6280,655385039,CT,Patients with the CT genotype may have lower  response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.
PA166134213,rs6280,655385038,TT,Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinson's disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patient's response.
PA166136009,rs6280,1447943695,CC,People with CC genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
PA166136009,rs6280,1447943696,CT,People with CT genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
PA166136009,rs6280,1447943697,TT,People with TT genotype may have increased clearance of quetiapine compared with people with genotypes CC or CT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
PA166159164,rs6280,1448102409,CC,Patients with the CC genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
PA166159164,rs6280,1448102410,CT,Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
PA166159164,rs6280,1448102411,TT,Patients with the TT genotype and HIV may have decreased cognitive impairment when taking methamphetamines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
PA166161878,rs6280,1448525454,CC,Patients with the CC genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
PA166161878,rs6280,1448525455,CT,Patients with the CT genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
PA166161878,rs6280,1448525456,TT,Patients with the TT genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
PA166134380,rs6311,655387238,CC,Patients with the CC genotype may have poorer response to risperidone in children with autism as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134380,rs6311,655387239,CT,"Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166134380,rs6311,655387240,TT,"Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
PA166135652,rs6311,1444607770,CC,"Patients with the CC genotype who are treated with fluvoxamine may have an  increased risk of gastrointestinal side effects and increased response as compared to patients with the TC or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
PA166135652,rs6311,1444607771,CT,"Patients with the CT genotype who are treated with fluvoxamine may have an  increased risk of gastrointestinal side effects and decreased response as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
PA166135652,rs6311,1444607772,TT,"Patients with the TT genotype who are treated with fluvoxamine may have a decreased, but not absent, risk of gastrointestinal side effects and decreased response as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
PA166136279,rs6311,1444700677,CC,"Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also effect patients' response to escitalopram. "
PA166136279,rs6311,1444700678,CT,Patients with the CT genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram. 
PA166136279,rs6311,1444700679,TT,Patients with the TT genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram. 
PA166135450,rs6311,1183704412,CC,Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
PA166135450,rs6311,1183704411,CT,Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
PA166135450,rs6311,1183704410,TT,Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes CC + CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
PA166135221,rs6313,1183629494,AA,Patients with the AA genotype who are treated with risperidone may have an increased likelihood of cardiovascular adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions. 
PA166135221,rs6313,1183629495,AG,"Patients with the AG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions. "
PA166135221,rs6313,1183629496,GG,"Patients with the GG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions. "
PA166135802,rs6313,1444703743,AA,"Patients with the AA genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine."
PA166135802,rs6313,1444703742,AG,"Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the AA genotype or may have a slower score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine."
PA166135802,rs6313,1444703741,GG,"Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the AA genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine."
PA166135077,rs6313,1183614744,AA,Patients with the AA genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
PA166135077,rs6313,1183614745,AG,Patients with the AG genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
PA166135077,rs6313,1183614746,GG,Patients with the GG genotype and HIV infection who are treated with efavirenz may have an increased risk of sadness as a side effect as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
PA166135166,rs6313,1448099836,AA,Patients with the AA genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions. 
PA166135166,rs6313,1448099837,AG,Patients with the AG genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions. 
PA166135166,rs6313,1448099838,GG,Patients with the GG genotype and depression who are treated with paroxetine may have an increased risk of adverse drug reactions as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions. 
PA166135801,rs6313,1444703706,AA,"Patients with the AA genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine."
PA166135801,rs6313,1444703705,AG,"Patients with the AG genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the AA genotype or may have a faster score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine."
PA166135801,rs6313,1444703704,GG,"Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the AA genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine."
PA166134195,rs6313,982033852,AA,Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
PA166134195,rs6313,982033853,AG,Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
PA166134195,rs6313,982033854,GG,"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment."
PA166134196,rs6313,655384951,AA,Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
PA166134196,rs6313,655384952,AG,Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
PA166134196,rs6313,655384953,GG,Patients with the GG genotype and Alzheimer disease may have decreased but not non-existent risk for treatment-resistance to olanzapine or risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
PA166135891,rs6313,1445401170,AA,"Patients with the AA genotype and major depressive disorder may have a better response to treatment with antidepressants as compared to patients with the GG genotype. However, some studies show no association with response or remission. Other genetic and clinical factors may also influence response to antidepressants. "
PA166135891,rs6313,1445401171,AG,"Patients with the AG genotype and major depressive disorder may have a better response to treatment with antidepressants as compared to patients with the GG genotype. However, some studies show no association with response or remission. Other genetic and clinical factors may also influence response to antidepressants. "
PA166135891,rs6313,1445401172,GG,"Patients with the GG genotype and major depressive disorder may have a poorer response to treatment with antidepressants as compared to patients with the AA or AG genotype. However, some studies show no association with response or remission. Other genetic and clinical factors may also influence response to antidepressants. "
PA166135847,rs6313,1444705238,AA,"Patients with the AA genotype and major depression may have decreased, but not absent, risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
PA166135847,rs6313,1444705239,AG,"Patients with the AG genotype and major depression may have decreased, but not absent, risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype or may have increased risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
PA166135847,rs6313,1444705240,GG,Patients with the GG genotype and major depression may have increased risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166134831,rs6318,1043859495,CC,Male patients with neuropathic pain and the CC genotype may have increased pain relief when treated with escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166134831,rs6318,1043859496,CG,Male patients with the CG genotype and neuropathic pain may have increased pain relief when treated with escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166134831,rs6318,1043859497,GG,Male patients with the GG genotype and neuropathic pain may have decreased pain relief when treated with escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
PA166134197,rs6318,982034805,CC,"Patients with the CC genotype and schizophrenia, treated with olanzapine, may have an increased likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for olanzapine-induced weight gain."
PA166134197,rs6318,982034806,CG,"Patients with the CG genotype and schizophrenia, treated with olanzapine, may have an increased likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for olanzapine-induced weight gain."
PA166134197,rs6318,982034807,GG,"Patients with the GG genotype and schizophrenia, treated with olanzapine, may have decreased likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for olanzapine-induced weight gain."
PA166159047,rs637137,1448101273,AA,Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166159047,rs637137,1448101274,AT,"Patients with the AT genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction."
PA166159047,rs637137,1448101275,TT,Patients with the TT genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166153456,rs639174,1447990285,CC,"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy. "
PA166153456,rs639174,1447990286,CT,"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy. "
PA166153456,rs639174,1447990287,TT,"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy. "
PA166135158,rs6295,1183617838,CC,Patients with the CC genotype with panic disorder who are treated with paroxetine may have an reduced response at 4 weeks of treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166135158,rs6295,1183617839,CG,Patients with the CG genotype with panic disorder who are treated with paroxetine may have an reduced response at 4 weeks of treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166135158,rs6295,1183617840,GG,Patients with the GG genotype with panic disorder who are treated with paroxetine may have a better response at 4 weeks of treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. 
PA166134160,rs6295,1183619218,CC,Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166134160,rs6295,1183619219,CG,Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166134160,rs6295,1183619220,GG,Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
PA166135908,rs6295,1445402087,CC,Patients with the CC genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135908,rs6295,1445402088,CG,Patients with the CG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135908,rs6295,1445402089,GG,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166151955,rs6295,1447953306,CC,"Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran."
PA166151955,rs6295,1447953307,CG,"Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran."
PA166151955,rs6295,1447953308,GG,"Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran."
PA166136116,rs6295,1444607676,CC,Patients with the CC genotype who are treated with fluoxetine may have an increased response as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166136116,rs6295,1444607677,CG,Patients with the CG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166136116,rs6295,1444607678,GG,Patients with the GG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
PA166158886,rs6413517,1448099170,GT,"Patients with nasopharyngeal cancer and the GT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
"
PA166158886,rs6413517,1448099171,TT,"Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the GT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
"
PA166135881,rs63749869,1447992481,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135881,rs63749869,1447992482,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135881,rs63749869,1447992483,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia."
PA166135449,rs6427528,1448265250,AA,"Patients with the AA genotype may have increased response to etanercept in people with Arthritis, Rheumatoid as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept."
PA166135449,rs6427528,1448265251,AG,"Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept."
PA166135449,rs6427528,1448265252,GG,"Patients with the GG genotype may have decreased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to etanercept."
PA166135800,rs642990,1444703672,CC,Patients with the CC genotype may have increased risk for neutropenia when treated with gemcitabine as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
PA166135800,rs642990,1444703671,CT,Patients with the CT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
PA166135800,rs642990,1444703670,TT,Patients with the TT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
PA166134690,rs6431558,982031724,CC,Patients with the CC genotype may have an increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
PA166134690,rs6431558,982031725,CT,Patients with the CT genotype may have an increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
PA166134690,rs6431558,982031726,TT,Patients with the TT genotype may have a decreased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
PA166135554,rs6432512,1184514220,CC,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135554,rs6432512,1184514219,CT,"Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. "
PA166135554,rs6432512,1184514218,TT,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166136104,rs6454674,1444607304,GG,Individuals with the GG genotype may have a decreased risk of cocaine dependence as compared to individuals with the GT or TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
PA166136104,rs6454674,1444607305,GT,Individuals with the GT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
PA166136104,rs6454674,1444607306,TT,Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
PA166134927,rs6413432,1147261609,AA,The AA genotype was not studied but female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of  progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of  progression-free survival.
PA166134927,rs6413432,1147261606,AT,Female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of  progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of  progression-free survival.
PA166134927,rs6413432,1147261604,TT,Female patients with the TT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of  progression-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's likelihood of  progression-free survival.
PA166134712,rs6438552,982032737,AA,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134712,rs6438552,982032736,GA,Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134712,rs6438552,982032735,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166136020,rs6465084,1447945969,AA,"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AG or GG genotype. However, a different study found that the AA genotype was associated with poorer response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
PA166136020,rs6465084,1447945970,AG,"Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the AG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
PA166136020,rs6465084,1447945971,GG,"Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the GG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
PA166135680,rs6467136,1444666758,AA,Patients with the AA genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone.
PA166135680,rs6467136,1444666759,AG,Patients with the AG genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone
PA166135680,rs6467136,1444666760,GG,Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone
PA166136203,rs646776,1444668404,CC,Patients with the CC genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
PA166136203,rs646776,1444668405,CT,Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
PA166136203,rs646776,1444668406,TT,Patients with the TT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
PA166136418,rs6475448,1446897522,AA,Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
PA166136418,rs6475448,1446897523,GG,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
PA166135168,rs6314,1448099819,AA,Patients with the AA genotype and major depressive disorder who are treated with antidepressants and other treatments may have a reduced response and reduced likelihood of remission as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission. 
PA166135168,rs6314,1448099820,AG,Patients with the AG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission. 
PA166135168,rs6314,1448099821,GG,Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission. 
PA166151940,rs6314,1447953118,AA,Patients with the AA genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166151940,rs6314,1447953119,AG,Patients with the AG genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166151940,rs6314,1447953120,GG,Patients with the GG genotype and schizophrenia may have an increased response to olanzapine as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166136242,rs6494223,1444686900,CC,Patients with the CC genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
PA166136242,rs6494223,1444686901,CT,"Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors."
PA166136242,rs6494223,1444686902,TT,Patients with the TT genotype and Alzheimer's disease may be more likely to respond to treatment with cholinesterase inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
PA166162362,rs6498588,1448531654,AA,Patients with the AA genotype and colorectal neoplasm may have decreased exposure to SN-38 compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.
PA166162362,rs6498588,1448531655,AT,Patients with the AT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.
PA166162362,rs6498588,1448531656,TT,Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.
PA166136310,rs6506569,1444703564,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136310,rs6506569,1444703563,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype or may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166136310,rs6506569,1444703562,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166161171,rs651630,1448423698,AA,Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161171,rs651630,1448423699,AG,Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166161171,rs651630,1448423700,GG,Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
PA166153483,rs6500843,1447990875,AA,Women with the AA genotype and breast cancer who are treated with antineoplastic agents may be associated with improved survival as compared to women with the AG and GG genotypes. Other clinical and genetic factors may also influence survival rates in women with breast cancer. 
PA166153483,rs6500843,1447990876,AG,Women with the AG genotype and breast cancer who are treated with antineoplastic agents may be associated improved survival as compared to women with the GG genotypes and worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer. 
PA166153483,rs6500843,1447990877,GG,Women with the GG genotype and breast cancer who are treated with antineoplastic agents may be associated with worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer. 
PA166134631,rs6535454,981419541,AA,"Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
PA166134631,rs6535454,981419542,AG,"Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
PA166134631,rs6535454,981419543,GG,"Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
PA166152874,rs6551665,1447964238,AA,Patients with the AA genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152874,rs6551665,1447964239,AG,Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152874,rs6551665,1447964240,GG,Patients with the GG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152984,rs6600879,1447981160,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone. 
PA166152984,rs6600879,1447981161,CG,Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone. 
PA166152984,rs6600879,1447981162,GG,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone. 
PA166135448,rs658903,1183704400,AA,Patients with the AA genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
PA166135448,rs658903,1183704401,AT,Patients with the AT genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
PA166135448,rs658903,1183704402,TT,Patients with the TT genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
PA166152999,rs6600893,1447981298,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152999,rs6600893,1447981299,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152999,rs6600893,1447981300,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152724,rs6545803,1447960805,GG,Patients with the GG genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152724,rs6545803,1447960806,GT,Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166152724,rs6545803,1447960807,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166151939,rs6493497,1447953111,AA,"Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole. "
PA166151939,rs6493497,1447953112,AG,"Women with the AG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole. "
PA166151939,rs6493497,1447953113,GG,"Women with the GG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole. "
PA166152871,rs6493497,1448106694,AA,"No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy."
PA166152871,rs6493497,1448106695,AG,Women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.
PA166152871,rs6493497,1448106696,GG,Women with the GG genotype and breast cancer may have lesser aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy.
PA166152990,rs6600880,1447981209,AA,Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152990,rs6600880,1447981210,AT,Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152990,rs6600880,1447981211,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166134305,rs6539870,655386003,AA,Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134305,rs6539870,655386004,AG,Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134305,rs6539870,655386005,GG,Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166135124,rs66878317,1183630723,AA,Purified DCK proteins with the AA genotype may have reduced clearance of gemcitabine as compared to those proteins with the AG or GG genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
PA166135124,rs66878317,1183630724,AG,Purified DCK proteins with the AG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
PA166135124,rs66878317,1183630725,GG,Purified DCK proteins with the GG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
PA166135134,rs669,1183615588,CC,Patients with the CC genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
PA166135134,rs669,1183615589,CT,Patients with the CT genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
PA166135134,rs669,1183615590,TT,Patients with the TT genotype who have had a stroke may be at increased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
PA166134522,rs66554220,981203603,ATTTGTTCATGCCT/ATTTGTTCATGCCT,Patients with the ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134522,rs66554220,981203604,ATTTGTTCATGCCT/del,Patients with the ATTTGTTCATGCCT/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134522,rs66554220,981203605,del/del,Patients with the del/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a better response as compared to patients with the ATTTGTTCATGCCT/del and ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166159161,rs671,1448102370,AA,Patients with the AA genotype may have an increased risk for heroin addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.
PA166159161,rs671,1448102371,AG,Patients with the AG genotype may have an increased risk for heroin addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.
PA166159161,rs671,1448102372,GG,Patients with the GG genotype may have a decreased risk for heroin addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.
PA166135447,rs6702335,1183704395,AA,Patients with the AA genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
PA166135447,rs6702335,1183704396,AG,Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
PA166135447,rs6702335,1183704397,GG,Patients with the GG genotype may have decreased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
PA166134991,rs662799,1183492044,AA,"Patients with the AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134991,rs662799,1183492045,AG,"Patients with the AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134991,rs662799,1183492046,GG,"Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134877,rs6755571,1043880443,AA,"Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased  plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism."
PA166134877,rs6755571,1043880444,AC,Patients with the AC genotype and neoplasms may have a decreased  plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
PA166134877,rs6755571,1043880445,CC,Patients with the CC genotype and neoplasms may have an increased  plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
PA166159036,rs660652,1448101170,AA,Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
PA166159036,rs660652,1448101171,AG,Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
PA166159036,rs660652,1448101172,GG,Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for nicotine addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
PA166135445,rs6749447,1183704377,GG,Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.
PA166135445,rs6749447,1183704378,GT,Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.
PA166135445,rs6749447,1183704379,TT,Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.
PA166135954,rs6785049,1446903242,AA,Patients with the AA genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib. 
PA166135954,rs6785049,1446903243,AG,"Patients with the AG genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype, or a decreased risk as compare to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib. "
PA166135954,rs6785049,1446903244,GG,Patients with the GG genotype and cancer may have a decreased risk for hypertension when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib. 
PA166159034,rs676210,1448101116,AA,Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166159034,rs676210,1448101117,AG,Patients with the AG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166159034,rs676210,1448101118,GG,Patients with the GG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate. 
PA166134917,rs6714486,1448107203,AA,"Patients with the AA genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection."
PA166134917,rs6714486,1448107204,AT,"Patients with the AT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection."
PA166134917,rs6714486,1448107205,TT,"Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased, but not absent, risk for acute allograft rejection within 3 month after transplantation as compared to patients with the AA genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection."
PA166158943,rs672170,1448100134,AA,Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158943,rs672170,1448100135,AG,Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158943,rs672170,1448100136,GG,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
PA166134749,rs6785930,1446909037,AA,"Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. "
PA166134749,rs6785930,1446909038,AG,"Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. "
PA166134749,rs6785930,1446909039,GG,"Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. "
PA166134955,rs6787801,1183491064,GG,Patients with the GG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
PA166134955,rs6787801,1183491065,GT,Patients with the GT genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
PA166134955,rs6787801,1183491066,TT,Patients with the TT genotype may have higher ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
PA166134820,rs6787801,1446909049,AA,"Patients with the AA genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134820,rs6787801,1446909050,AG,Patients with the AG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134820,rs6787801,1446909051,GG,Patients with the GG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166135444,rs6759892,1448109573,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances. "
PA166135444,rs6759892,1448109574,GT,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances. "
PA166135444,rs6759892,1448109575,TT,"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances. "
PA166136118,rs6759892,1444607706,GG,"Patients with the GG genotype and beta-thalassemia may have a better response, but also an increased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone."
PA166136118,rs6759892,1444607707,GT,"Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone."
PA166136118,rs6759892,1444607708,TT,"Patients with the TT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone."
PA166134525,rs6759892,981203642,GG,Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
PA166134525,rs6759892,981203643,GT,Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
PA166134525,rs6759892,981203644,TT,Patients with the TT genotype and Epilepsy who are treated with valproic acid may require a lower dose as compared to patients with the GG and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
PA166152878,rs6813183,1447964266,CC,Patients with the CC genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152878,rs6813183,1447964267,CG,Patients with the CG genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152878,rs6813183,1447964268,GG,Patients with the GG genotype and ADHD may show slower improvement of symptoms when treated with methylphenidate as compared to patients with the CC and CG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166136132,rs6822844,1444607974,GG,"Patients with the GG genotype and systemic lupus erythematosus may be more likely to respond to treatment with rituximab, as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to treatment with rituximab."
PA166136132,rs6822844,1444607975,GT,"Patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab."
PA166136132,rs6822844,1444607976,TT,"No patients with the TT genotype were present in the study. However, patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab."
PA166135711,rs683369,1444686852,CC,"Patients with the CC genotype and chronic myeloid leukemia may have increased clearance of imatinib, as well as increased event-free survival time, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time."
PA166135711,rs683369,1444686853,CG,"Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time."
PA166135711,rs683369,1444686854,GG,"Patients with the GG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time."
PA166134677,rs6809699,1446909000,AA,"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134677,rs6809699,1446909001,AC,"Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134677,rs6809699,1446909002,CC,"Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166159048,rs684513,1448101280,CC,Patients with the CC genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166159048,rs684513,1448101281,CG,"Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
PA166159048,rs684513,1448101282,GG,Patients with the GG genotype may have a decreased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
PA166159206,rs684513,1448103958,CC,Patients with the CC genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
PA166159206,rs684513,1448103959,CG,"Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction."
PA166159206,rs684513,1448103960,GG,Patients with the GG genotype may have an increased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
PA166136432,rs6838116,1446899710,AA,Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166136432,rs6838116,1446899711,AC,"Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
"
PA166136432,rs6838116,1446899712,CC,"Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
"
PA166134494,rs662,1446908958,CC,"Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134494,rs662,1446908959,CT,"Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166134494,rs662,1446908960,TT,"Patients with the TT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
PA166152794,rs662,1447962763,CC,Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
PA166152794,rs662,1447962764,CT,"Patients with the CT genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the TT genotype, and a smaller increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence HDL cholesterol levels."
PA166152794,rs662,1447962765,TT,Patients with the TT genotype and hypercholesterolemia may have a smaller increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
PA166135916,rs662,1445722594,CC,"Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.
"
PA166135916,rs662,1445722595,CT,"Patients with the CT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.
"
PA166135916,rs662,1445722596,TT,"Patients with the TT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.
"
PA166136437,rs6900017,1448106340,CC,"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136437,rs6900017,1448106341,CT,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136437,rs6900017,1448106342,TT,"Women with ovarian cancer and the TT genotype may have an increased  likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166158953,rs686,1448100210,AA,Patients with the AA genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
PA166158953,rs686,1448100211,AG,"Patients with the AG genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype, or decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence."
PA166158953,rs686,1448100212,GG,Patients with the GG genotype may be at decreased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
PA166161865,rs6908425,1448522774,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161865,rs6908425,1448522775,CT,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161865,rs6908425,1448522776,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166135443,rs6907567,1183704363,AA,Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
PA166135443,rs6907567,1183704364,AG,Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
PA166135443,rs6907567,1183704365,GG,Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
PA166136063,rs6901146,1184987399,CC,Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166136063,rs6901146,1184987400,CT,Patients with the CT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166136063,rs6901146,1184987401,TT,Patients with the TT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
PA166135442,rs6920220,1183704354,AA,Patients with the AA genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.
PA166135442,rs6920220,1183704355,AG,Patients with the AG genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.
PA166135442,rs6920220,1183704356,GG,Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.
PA166134523,rs67376798,1448605550,AA,"Patients with the AA genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DYPD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134523,rs67376798,1448605551,AT,"Patients with the AT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) DYPD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166134523,rs67376798,1448605552,TT,"Patients with the TT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of the drug and 2) decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166153043,rs6924995,1447982845,A,Patients with the A allele may have increased expression of LDLR as compared to patients with the G allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.
PA166153043,rs6924995,1447982846,G,Patients with the G allele may have increased expression of LDLR as compared to patients with the A allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.
PA166136250,rs6927172,1444686999,CC,"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136250,rs6927172,1444687000,CG,"Patients with the CG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166136250,rs6927172,1444687001,GG,"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
PA166135931,rs6923761,1446898018,AA,Women with obesity and polycystic ovarian syndrome (PCOS) and the AA genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
PA166135931,rs6923761,1446898019,AG,Women with obesity and polycystic ovarian syndrome (PCOS) and the AG genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
PA166135931,rs6923761,1446898020,GG,Women with obesity and polycystic ovarian syndrome (PCOS) and the GG genotype may have a decreased response to liraglutide as compared to women with the AA and AG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
PA166158987,rs6923761,1448100510,AA,Patients with the AA genotype and Type 2 Diabetes may have decreased response to sitagliptin or vildagliptin compared to patients with the GG genotype. Other factors may affect response to sitagliptin and vildagliptin.
PA166158987,rs6923761,1448100511,GG,Patients with the GG genotype and Type 2 Diabetes may have increased response to sitagliptin or vildagliptin compared to patients with the AA genotype. Other factors may affect response to sitagliptin and vildagliptin.
PA166134314,rs6922548,655386105,AA,Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134314,rs6922548,655386106,AG,Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134314,rs6922548,655386107,GG,Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.
PA166135441,rs6977820,1183704344,CC,Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
PA166135441,rs6977820,1183704345,CT,Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
PA166135441,rs6977820,1183704346,TT,Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
PA166134269,rs688,1000539646,CC,Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.
PA166134269,rs688,1000539647,CT,Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.
PA166134269,rs688,1000539648,TT,Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.
PA166152792,rs688,1447962739,CC,"Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the TT genotype, and a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels."
PA166152792,rs688,1447962740,CT,Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166152792,rs688,1447962741,TT,Patients with the TT genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
PA166135848,rs6966038,1444705247,AA,Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135848,rs6966038,1444705246,AG,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135848,rs6966038,1444705245,GG,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166153489,rs696692,1447990946,CC,"The CC genotype in patients with depressive disorder who are taking citalopram or escitalopram may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CT or TT genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.  "
PA166153489,rs696692,1447990947,CT,"The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.  Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.  "
PA166153489,rs696692,1447990948,TT,"The TT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with lower baseline serotonin levels and smaller decreases in serotonin levels as compared to the CT or CC genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.  "
PA166134018,rs698,1184348714,CC,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. 
PA166134018,rs698,1184348715,CT,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. 
PA166134018,rs698,1184348716,TT,Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy. 
PA166151948,rs6983267,1447953225,GG,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151948,rs6983267,1447953226,GT,Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151948,rs6983267,1447953227,TT,Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166134761,rs6988229,982045085,CC,Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134761,rs6988229,982045084,TC,Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134761,rs6988229,982045083,TT,Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166135992,rs700518,1447682295,AA,"Post-menopausal women with breast cancer and the AA genotype may have increased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer. "
PA166135992,rs700518,1447682296,AC,"Post-menopausal women with breast cancer and the AC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AA genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer. "
PA166135992,rs700518,1447682297,CC,"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or AA genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer. "
PA166135132,rs699,1183619613,AA,"Patients with the AA genotype who have hypertension and left ventricular hypertrophy may have a smaller decrease in left ventricular mass when treated with irbesartan as compared to patients with the GG genotype. However, no significant association has been seen between this genotype and change in diastolic or systolic pressure for patients on irbesartan. Other genetic and clinical factors may also influence a patient's response to irbesartan treatment."
PA166135132,rs699,1183619614,AG,"Patients with the AG genotype who have hypertension and left ventricular hypertrophy may have a smaller decrease in left ventricular mass when treated with irbesartan as compared to patients with the GG genotype. However, no significant association has been seen between this genotype and change in diastolic or systolic pressure for patients on irbesartan. Other genetic and clinical factors may also influence a patient's response to irbesartan treatment."
PA166135132,rs699,1183619615,GG,"Patients with the GG genotype who have hypertension and left ventricular hypertrophy may have a greater decrease in left ventricular mass when treated with irbesartan as compared to patients with the AA or AG genotype. However, no significant association has been seen between this genotype and change in diastolic or systolic pressure for patients on irbesartan. Other genetic and clinical factors may also influence a patient's response to irbesartan treatment."
PA166135133,rs699,1183615583,AA,"Patients with the AA genotype who have hypertension and left ventricular hypertrophy may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the AG or GG genotype. However, no significant results have been seen for change in diastolic blood pressure. Additionally, a different study found no association with change in systolic or diastolic blood pressure for this genotype. Other genetic and clinical factors may also influence change in blood pressure."
PA166135133,rs699,1183615584,AG,"Patients with the AG genotype who have hypertension and left ventricular hypertrophy may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the AA genotype. However, no significant results were seen for change in diastolic blood pressure. Additionally, a different study found no association with change in systolic or diastolic pressure for this genotype. Other genetic and clinical factors may also influence change in blood pressure."
PA166135133,rs699,1183615585,GG,"Patients with the GG genotype who have hypertension and left ventricular hypertrophy may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the AA genotype. However, no significant results were seen for change in diastolic blood pressure. Additionally, a different study found no association with change in systolic or diastolic pressure for this genotype. Other genetic and clinical factors may also influence change in blood pressure."
PA166135440,rs699,1183704335,AA,"Patients with the AA genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs."
PA166135440,rs699,1183704336,AG,"Patients with the AG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs."
PA166135440,rs699,1183704337,GG,"Patients with the GG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome  as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to NSAIDs."
PA166152708,rs699,1447960665,AA,Patients with the AA genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.
PA166152708,rs699,1447960666,AG,Patients with the AG genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.
PA166152708,rs699,1447960667,GG,Patients with the GG genotype and coronary artery disease may have a better response when treated with quinapril as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to quinapril.
PA166152827,rs699,1447963434,AA,Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.
PA166152827,rs699,1447963435,AG,Patients with the AG genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.
PA166152827,rs699,1447963436,GG,Patients with the GG genotype and hypertension may have a decreased risk of stroke when treated with ACE inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of stroke.
PA166134948,rs702553,1183490997,AA,Patients with the AA genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
PA166134948,rs702553,1183490996,AT,Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
PA166134948,rs702553,1183490995,TT,Patients with the TT genotype and Nephrosclerosis may have a lower baseline mean arterial blood pressure when treated with diuretics as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
PA166134648,rs699947,1444608422,AA,Patients with the AA genotype and Macular Degeneration who are treated with ranibizumab may have a lack of early response to treatment compared to patients with the AC or CC genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment. 
PA166134648,rs699947,1444608423,AC,Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment. 
PA166134648,rs699947,1444608424,CC,Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an early response  to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment. 
PA166136224,rs699947,1447945834,AA,Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166136224,rs699947,1447945835,AC,Current literature evidence finds no significant effect of the AC genotype on progression-free survival time in patients taking docetaxel.
PA166136224,rs699947,1447945836,CC,Patients with the CC genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
PA166135438,rs699947,1183704317,AA,Patients with the AA genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.
PA166135438,rs699947,1183704318,AC,Patients with the AC genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.
PA166135438,rs699947,1183704319,CC,Patients with the CC genotype may have increased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sildenafil.
PA166135439,rs699947,1183704326,AA,Patients with the AA genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.
PA166135439,rs699947,1183704327,AC,Patients with the AC genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.
PA166135439,rs699947,1183704328,CC,Patients with the CC genotype may have lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sunitinib.
PA166153485,rs699947,1447990904,AA,Patients with hypertension and the AA genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.  
PA166153485,rs699947,1447990905,AC,Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension. 
PA166153485,rs699947,1447990906,CC,Patients with hypertension and the CC genotype may have a worse response to enalapril as compared to patients with the AA or AC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.  
PA166136414,rs699947,1446897487,AC,"Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer."
PA166136414,rs699947,1446897488,CC,"Patients with colorectal cancer and the CC genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the AC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer."
PA166136426,rs699664,1448615808,CC,"Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the CT and TT genotypes, however, no association was found in the majority of studies, and in one study, the CC genotype was associated with an increased dose of warfarin. Other clinical and genetic factors may also influence dose of warfarin. "
PA166136426,rs699664,1448615809,CT,"Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the CT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin. "
PA166136426,rs699664,1448615810,TT,"Patients with the TT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the TT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin. "
PA166160466,rs699664,1448262917,CC,Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160466,rs699664,1448262918,CT,Patients with the CT genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166160466,rs699664,1448262919,TT,Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC or CT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
PA166134805,rs7089580,1043858895,AA,Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166134805,rs7089580,1043858894,TA,Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166134805,rs7089580,1043858893,TT,Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
PA166152905,rs6962291,1447979281,AA,Patients with the AA genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
PA166152905,rs6962291,1447979282,AT,"Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma."
PA166152905,rs6962291,1447979283,TT,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
PA166152795,rs705379,1447962775,AA,Patients with the AA genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
PA166152795,rs705379,1447962776,AG,Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
PA166152795,rs705379,1447962777,GG,Patients with the GG genotype and hypercholesterolemia who have high baseline HDL levels may have a smaller increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
PA166152870,rs705379,1447964166,AA,Patients with the AA genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
PA166152870,rs705379,1447964167,AG,"Patients with the AG genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype, or decreased oxidative stress as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs."
PA166152870,rs705379,1447964168,GG,Patients with the GG genotype and hypercholesterolemia may have decreased oxidative stress in response to treatment with atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
PA166153054,rs7091672,1448106521,CC,"Patients with the CC genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153054,rs7091672,1448106522,CT,"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166153054,rs7091672,1448106523,TT,"Patients with the TT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
PA166134068,rs7046653,1183703652,AA,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
PA166134068,rs7046653,1183703653,AG,Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
PA166134068,rs7046653,1183703654,GG,Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.
PA166134706,rs7118900,982032568,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134706,rs7118900,982032569,AG,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134706,rs7118900,982032570,GG,Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166135106,rs7079,1183630623,GG,Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.
PA166135106,rs7079,1183630624,GT,Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.
PA166135106,rs7079,1183630625,TT,Patients with the TT genotype and hypertension may have greater decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence change in systolic and diastolic blood pressure.
PA166135659,rs7103411,1444608042,CC,Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166135659,rs7103411,1444608043,CT,"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram."
PA166135659,rs7103411,1444608044,TT,Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166136133,rs7124442,1444608029,CC,Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166136133,rs7124442,1444608030,CT,Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166136133,rs7124442,1444608031,TT,Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to citalopram.
PA166152763,rs712830,1447961189,AA,"No patients with the AA genotype are available for analysis, but patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity."
PA166152763,rs712830,1447961190,AC,Patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.
PA166152763,rs712830,1447961191,CC,Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.
PA166134396,rs70991108,982037065,TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT,"Pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/del or del/del genotype. Adult patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for hepatic toxicity as compared to adult patients with the TGGCGCGTCCCGCCCAGGT/del or del/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134396,rs70991108,982037066,TGGCGCGTCCCGCCCAGGT/del,"Adult patients with the TGGCGCGTCCCGCCCAGGT/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for hepatic toxicity as compared to patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or del/del genotype. Pediatric patients with the TGGCGCGTCCCGCCCAGGT/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or del/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166134396,rs70991108,982037067,del/del,"Adult patients with the del/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for hepatic toxicity as compared to patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or TGGCGCGTCCCGCCCAGGT/del genotype. Pediatric patients with the del/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or TGGCGCGTCCCGCCCAGGT/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
PA166152820,rs7142143,1447963263,CC,"Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse."
PA166152820,rs7142143,1447963264,CT,"Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse."
PA166152820,rs7142143,1447963265,TT,"Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse."
PA166134179,rs7142881,655384885,AA,Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134179,rs7142881,655384884,AG,Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134179,rs7142881,655384883,GG,"Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
PA166158938,rs713729,1448100098,AA,Patients with the AA genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methamphetamine addiction. 
PA166158938,rs713729,1448100099,AT,"Patients with the AT genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction. "
PA166158938,rs713729,1448100100,TT,Patients with the TT genotype may have an increased likelihood of developing an addiction to methamphetamines as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction. 
PA166134084,rs712829,637880244,GG,Patients with the GG genotype may be less sensitive to treatment with erlotinib  compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.
PA166134084,rs712829,637880245,GT,Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.
PA166134084,rs712829,637880246,TT,Patients with the TT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.
PA166134085,rs712829,637880251,GG,Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
PA166134085,rs712829,637880252,GT,Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
PA166134085,rs712829,637880253,TT,Cancer patients with genotype TT may be less likely  to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
PA166134086,rs712829,637880259,GG,Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
PA166134086,rs712829,637880260,GT,Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
PA166134086,rs712829,637880261,TT,Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
PA166134087,rs712829,1000539573,GG,Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
PA166134087,rs712829,1000539574,GT,Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
PA166134087,rs712829,1000539575,TT,Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
PA166134088,rs712829,1447961315,GG,Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles.  Other genetic and clinical factors may also influence a patient's response.
PA166134088,rs712829,1447961316,GT,Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134088,rs712829,1447961317,TT,Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134416,rs712829,827831124,GG,Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
PA166134416,rs712829,827831125,GT,Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
PA166134416,rs712829,827831126,TT,Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
PA166135670,rs712829,1444665986,GG,"Patients with the GG genotype and colorectal cancer may have a shorter overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
PA166135670,rs712829,1444665987,GT,"Patients with the GT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
PA166135670,rs712829,1444665988,TT,"Patients with the TT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
PA166135437,rs71486745,1448105778,GT/GT,Patients with the GT/GT genotype may have increased dose of phenytoin in people with Epilepsy as compared to patients with genotype del/del or GT/del. Other genetic and clinical factors may also influence the dose of phenytoin.
PA166135437,rs71486745,1448105779,GT/del,Patients with the GT/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT/GT. Other genetic and clinical factors may also influence the dose of phenytoin.
PA166135437,rs71486745,1448105780,del/del,Patients with the del/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT/GT. Other genetic and clinical factors may also influence the dose of phenytoin.
PA166135436,rs716274,1446905846,AA,"Patients with the AA genotype may have decreased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."
PA166135436,rs716274,1446905847,AG,"Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."
PA166135436,rs716274,1446905848,GG,"Patients with the GG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."
PA166134310,rs714368,1448099604,CC,Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
PA166134310,rs714368,1448099605,CT,Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
PA166134310,rs714368,1448099606,TT,Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
PA166134925,rs7160796,1145963222,CC,Patients with the CC genotype and asthma who are treated with corticosteroids may have increased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166134925,rs7160796,1145963223,CG,Patients with the CG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166134925,rs7160796,1145963225,GG,Patients with the GG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166134661,rs71647872,1448107874,A/del,Patients with the A/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134661,rs71647872,1448107875,AA,Patients with the A/A genotype who are treated with clopidogrel may have an average catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134661,rs71647872,1448107876,del/del,Patients with the del/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166153172,rs7170068,1447986912,AA,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153172,rs7170068,1447986913,AG,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166153172,rs7170068,1447986914,GG,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
"
PA166159991,rs7170924,1448256874,GG,Patients with the GG genotype and non-small cell lung cancer may have decreased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
PA166159991,rs7170924,1448256875,GT,Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
PA166159991,rs7170924,1448256876,TT,Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
PA166135477,rs7176005,1448106711,CC,Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135477,rs7176005,1448106712,CT,Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135477,rs7176005,1448106713,TT,Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166134785,rs7179742,1043858645,AA,"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166134785,rs7179742,1043858644,AG,Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166134785,rs7179742,1043858643,GG,Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166135434,rs7186128,1183704295,AA,"Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan."
PA166135434,rs7186128,1183704294,AG,"Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan."
PA166135434,rs7186128,1183704293,GG,"Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan."
PA166163252,rs7187684,1448602887,CC,Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163252,rs7187684,1448602886,CT,Patients with the CT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166163252,rs7187684,1448602885,TT,Patients with the TT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
PA166135385,rs7194667,1183700280,GG,Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil. 
PA166135385,rs7194667,1183700281,GT,Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil. 
PA166135385,rs7194667,1183700282,TT,Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil. 
PA166134662,rs71647871,1446908994,CC,Patients with the CC genotype who are treated with clopidogrel may have higher on-treatment ADP-induced platelet aggregation and lower levels of clopidogrel active metabolite as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134662,rs71647871,1446908995,CT,Patients with the CT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134662,rs71647871,1446908996,TT,Patients with the TT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134495,rs71647871,1448573562,CC,Patients with the CC genotype and Attention Deficit Disorder may require an increased dose of methylphenidate as compared to patients with the CT genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.
PA166134495,rs71647871,1448573563,CT,Patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.
PA166134495,rs71647871,1448573564,TT,"Patients with the TT genotype were not studied, however patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response."
PA166136428,rs71647871,1446899482,CC,Patients with the CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of enalapril.
PA166136428,rs71647871,1446899483,CT,Patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of enalapril.
PA166152697,rs719235,1447960584,AA,Patients with the AA genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
PA166152697,rs719235,1447960585,AC,Patients with the AC genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
PA166152697,rs719235,1447960586,CC,Patients with the CC genotype and rheumatoid arthritis may have an increased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
PA166135590,rs7196161,1448105120,AA,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence the dose of warfarin. 
PA166135590,rs7196161,1448105121,AG,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin. 
PA166135590,rs7196161,1448105122,GG,Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence the dose of warfarin. 
PA166158749,rs720106,1448097781,CC,Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer. 
PA166158749,rs720106,1448097782,CT,Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer. 
PA166158749,rs720106,1448097783,TT,Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC and CT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer. 
PA166136094,rs7200749,1185002353,AA,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136094,rs7200749,1185002354,AG,Patients with the AG genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166136094,rs7200749,1185002355,GG,Patients with the GG genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
PA166135637,rs7200749,1185002309,AA, Patients with the AA genotype may require increased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose
PA166135637,rs7200749,1185002310,AG, Patients with the AG genotype may require increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose
PA166135637,rs7200749,1185002311,GG, Patients with the GG genotype may require decreased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose
PA166135539,rs724226,1184514470,AA,Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence. 
PA166135539,rs724226,1184514471,AG,Patients with the AG genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype and a decreased risk of Heroin Dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence. 
PA166135539,rs724226,1184514472,GG,Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence. 
PA166134221,rs724226,655385079,AA,Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134221,rs724226,655385080,AG,Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166134221,rs724226,655385081,GG,Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
PA166135589,rs724710,1184986322,CC,Patients with the CC genotype and cancer may have an improved response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib. 
PA166135589,rs724710,1184986323,CT,Patients with the CT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype and an improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib. 
PA166135589,rs724710,1184986324,TT,"Patients with the TT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to imatinib. 
"
PA166135433,rs723685,1183704290,AA,Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
PA166135433,rs723685,1183704289,AG,Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
PA166135433,rs723685,1183704288,GG,Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
PA166159169,rs7248668,1448106805,AA,Patients with the AA genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159169,rs7248668,1448106806,AG,Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159169,rs7248668,1448106807,GG,Patients with the GG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166136466,rs7254579,1448106370,CC,Patients with lupus and the CC genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus. 
PA166136466,rs7254579,1448106371,CT,Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus. 
PA166136466,rs7254579,1448106372,TT,Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus. 
PA166134938,rs72547516,1156497694,AA,Patients with the AA genotype may have an increased metabolism of clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
PA166134938,rs72547516,1156497691,AT,The AT genotype was not studied.
PA166134938,rs72547516,1156497687,TT,Patients with the TT genotype may have a decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
PA166134851,rs708272,1447947097,AA,Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134851,rs708272,1447947098,AG,Patients with the AG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134851,rs708272,1447947099,GG,Patients with the GG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134852,rs708272,1447947085,AA,"Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
PA166134852,rs708272,1447947086,AG,"Patients with the AG genotype who are treated with atorvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype.  However, these results were not statistically significant and there are contradictory studies.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
PA166134852,rs708272,1447947087,GG,"Patients with the GG genotype who are treated with atorvastatin may have an increased response to treatment and a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
PA166134853,rs708272,1043880210,AA,Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment. 
PA166134853,rs708272,1043880211,AG,Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment. 
PA166134853,rs708272,1043880212,GG,Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment. 
PA166134744,rs708272,1043880135,AA,Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134744,rs708272,1043880136,AG,Patients with the AG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134744,rs708272,1043880137,GG,Patients with the GG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of death or cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134849,rs708272,1447947091,AA,Patients with the AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166134849,rs708272,1447947092,AG,"Patients with the AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype, or may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. "
PA166134849,rs708272,1447947093,GG,Patients with the GG genotype and Coronary Artery Disease who are treated with statins may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. 
PA166153410,rs72549306,1448125060,AA,"Patients with the AA genotype (DPYD *11/*11) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Additionally, those with the *11 allele may be at risk for drug toxicity when receiving fluorouracil. Other genetic and clinical factors may also affect DPYD activity and risk for fluorouracil-induced toxicity. "
PA166153410,rs72549306,1448125061,AC,"Patients with the AC genotype (DPYD *1/*11) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Additionally, those with the *11 allele may be at risk for drug toxicity when receiving fluorouracil. Other genetic and clinical factors may also affect DPYD activity and risk for fluorouracil-induced toxicity. "
PA166153410,rs72549306,1448125062,CC,Patients with the CC genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AA or AC genotype (DPYD *11/*11 or *1/*11). Other genetic and clinical factors may also affect DPYD activity.
PA166134936,rs72547517,1155650527,AA,Patients with the AA genotype may have a decreased metabolism of clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
PA166134936,rs72547517,1155650530,AG,The AG genotype was not studied.
PA166134936,rs72547517,1155650533,GG,Patients with the GG genotype may have an increased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
PA166134828,rs72551330,1043859387,CC,Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
PA166134828,rs72551330,1043859388,CT,Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
PA166134828,rs72551330,1043859389,TT,"Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection."
PA166153177,rs72551330,1447986988,CC,Patients with the CC genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
PA166153177,rs72551330,1447986989,CT,"Patients with the CT genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype, or increased clearance as compared to those with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone."
PA166153177,rs72551330,1447986990,TT,Patients with the TT genotype may have increased clearance of sulfinpyrazone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
PA166158896,rs72552713,1448099466,AG,Patients with the AG genotype may have decreased clearance of sulfasalazine as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).
PA166158896,rs72552713,1448099467,GG,Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).
PA166152784,rs72551344,1447962663,GG,Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
PA166152784,rs72551344,1447962664,GT,"Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38."
PA166152784,rs72551344,1447962665,TT,Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
PA166136123,rs72552763,1444607746,GAT/DEL,Patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136123,rs72552763,1444607747,GAT/GAT,Patients with the GAT/GAT genotype who are treated with metformin may have an increased trough metformin steady-state concentration as compared to patients with the GAT/DEL genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166136123,rs72552763,1444607748,del/del,Patients with the del/del genotype were not studied but patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
PA166135105,rs717620,1448102606,CC,"Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes."
PA166135105,rs717620,1448102607,CT,"Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes."
PA166135105,rs717620,1448102608,TT,"Patients with the TT genotype and colorectal cancer may have increased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes."
PA166135527,rs717620,1444705491,CC,Patients with the CC genotype may have decreased clearance and distribution of volume of methotrexate as compared to patients with the TT genotype. Please note: the opposite effect was observed in a study done in an Asian population with various types of lymphomas. The T allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate. 
PA166135527,rs717620,1444705492,CT,Patients with the CT genotype may have increased clearance and distribution of volume of methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in an Asian population with various types of lymphomas. The T allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate. 
PA166135527,rs717620,1444705493,TT,Patients with the TT genotype may have increased clearance and distribution of volume of methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in an Asian population with various types of lymphomas. The C allele was associated with increased clearance of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate. 
PA166135528,rs717620,1444705497,CC,Patients with lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity and increased clearance of methotrexate when treated with methotrexate as compared to patients with the TT genotype. Please note: the opposite effect was observed in a study done in a French population with various types of lymphomas. The C allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate. 
PA166135528,rs717620,1444705498,CT,Patients with lymphoblastic leukemia-lymphoma and the CT genotype may have an increased risk of drug toxicity and decreased clearance of methotrexate when treated with methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in a French population with various types of lymphomas. The C allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate. 
PA166135528,rs717620,1444705499,TT,Patients with lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of drug toxicity and decreased clearance of methotrexate when treated with methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in a French population with various types of lymphomas. The C allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate. 
PA166135104,rs717620,1448102600,CC,"Patients with the CC genotype and colon cancer may have an increased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia."
PA166135104,rs717620,1448102601,CT,"Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia."
PA166135104,rs717620,1448102602,TT,"Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia."
PA166135435,rs717620,1183704300,CC,Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.
PA166135435,rs717620,1183704299,CT,Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.
PA166135435,rs717620,1183704298,TT,Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.
PA166134526,rs717620,1447813534,CC,"Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction."
PA166134526,rs717620,1447813535,CT,"Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction."
PA166134526,rs717620,1447813536,TT,"Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction."
PA166134527,rs717620,1448426845,CC,Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
PA166134527,rs717620,1448426846,CT,Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
PA166134527,rs717620,1448426847,TT,Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
PA166134804,rs717620,1043858890,CC,Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
PA166134804,rs717620,1043858889,CT,Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
PA166134804,rs717620,1043858888,TT,Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
PA166158725,rs717620,1448097407,CC,Patients with the CC genotype and breast neoplasms may have reduced disease-free survival when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.
PA166158725,rs717620,1448097408,CT,Patients with the CT genotype and breast neoplasms may have increased disease-free survival when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.
PA166158725,rs717620,1448097409,TT,No patients with the TT genotype were included in analysis of the association between genotype and disease-free survival in response to tamoxifen treatment in patients with breast neoplasms. 
PA166153034,rs717620,1447982783,CC,"Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity."
PA166153034,rs717620,1447982782,CT,"Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity."
PA166153034,rs717620,1447982781,TT,"Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity."
PA166160279,rs717620,1448258927,CC,"Patients with the CC genotype may have increased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166160279,rs717620,1448258928,CT,"Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166160279,rs717620,1448258929,TT,"Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib."
PA166136003,rs717620,1447814577,CC,Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
PA166136003,rs717620,1447814578,CT,Patients with the CT genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
PA166136003,rs717620,1447814579,TT,Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
PA166136451,rs717620,1446905057,CC,"Pediatric patients with major thalassemia and the CC genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the CT or TT genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136451,rs717620,1446905058,CT,"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136451,rs717620,1446905059,TT,"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166153405,rs72549303,1448125028,G/del,Patients with the G/del genotype (DPYD *1/*3) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153405,rs72549303,1448125029,GG,Patients with the GG genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the G/del or del/del genotype (DPYD *1/*3 or *3/*3). Other genetic and clinical factors may also affect DPYD activity. 
PA166153405,rs72549303,1448125030,del/del,Patients with the del/del genotype (DPYD *3/*3) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153406,rs72549309,1448125022,ATGA/ATGA,Patients with the ATGA/ATGA genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the ATGA/del or del/del genotypes (DPYD *1/*7 or *7/*7). Other genetic and clinical factors may also affect DPYD activity. 
PA166153406,rs72549309,1448125023,ATGA/del,Patients with the ATGA/del genotype (DPYD *1/*7) may have decreased DPYD activity as compared to those with the ATGA/ATGA genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153406,rs72549309,1448125024,del/del,Patients with the del/del genotype (DPYD *7/*7) may have decreased DPYD activity as compared to those with the ATGA/ATGA genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. 
PA166153414,rs72728438,1447989798,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil."
PA166153414,rs72728438,1447989799,CT,Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
PA166153414,rs72728438,1447989800,TT,Patients with the TT genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
PA166135432,rs726501,1183704283,AA,"Patients with the AA genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel."
PA166135432,rs726501,1183704284,AG,"Patients with the AG genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel."
PA166135432,rs726501,1183704285,GG,"Patients with the GG genotype may have increased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel."
PA166160872,rs72800847,1448267383,AA,Patients with the AA genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.
PA166160872,rs72800847,1448267384,AG,Patients with the AG genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.
PA166160872,rs72800847,1448267385,GG,Patients with the GG genotype and heart valve replacement may require higher dose of warfarin compared to patients with the AA and AG genotypes. Other clinical and genetic factors affect warfarin dose.
PA166135961,rs7270101,1448256253,AA,"Patients with chronic hepatitis C and the AA genotype may have an increased risk of anemia but a decreased risk of thrombocytopenia when compared to patients with the AC and CC genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify ""normal ITPas activity"" vs. ""deficient"". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin."
PA166135961,rs7270101,1448256254,AC,"Patients with chronic hepatitis C and the AC genotype may have an decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the AA genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify ""normal ITPas activity"" vs. ""deficient"". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin."
PA166135961,rs7270101,1448256255,CC,"Patients with chronic hepatitis C and the CC genotype may have an decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the AA genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify ""normal ITPas activity"" vs. ""deficient"". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin."
PA166153451,rs72558187,1447990241,CT,Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.
PA166153451,rs72558187,1447990242,TT,Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.
PA166134496,rs7297610,981202104,CC,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166134496,rs7297610,981202105,CT,Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166134496,rs7297610,981202106,TT,Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166135431,rs729147,1448109586,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines."
PA166135431,rs729147,1448109587,AG,"Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines."
PA166135431,rs729147,1448109588,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines."
PA166160814,rs7301582,1448266611,CC,Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
PA166160814,rs7301582,1448266612,CT,Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
PA166160814,rs7301582,1448266613,TT,Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
PA166134044,rs730012,1446908868,AA,"Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
PA166134044,rs730012,1446908869,AC,Patients with the AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
PA166134044,rs730012,1446908870,CC,Patients with the CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
PA166134193,rs730012,1448107361,AA,Patients with the AA genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
PA166134193,rs730012,1448107362,AC,"Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
PA166134193,rs730012,1448107363,CC,"Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
PA166134313,rs730720,655386100,CC,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134313,rs730720,655386101,CT,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134313,rs730720,655386102,TT,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
PA166135898,rs7317112,1445401283,AA,Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for mucositis when treated with methotrexate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of mucositis.
PA166135898,rs7317112,1445401284,AG,Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.
PA166135898,rs7317112,1445401285,GG,Patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.
PA166134360,rs731236,655386874,AA,Patients with the AA genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clodronate.
PA166134360,rs731236,655386875,AG,"Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate."
PA166134360,rs731236,655386876,GG,Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.
PA166134803,rs731236,1043858901,AA,Patients with the AA genotype may have decreased risk of bone fractures when treated with Calcium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
PA166134803,rs731236,1043858902,AG,Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
PA166134803,rs731236,1043858903,GG,Patients with the GG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
PA166135429,rs7319981,1448109728,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166135429,rs7319981,1448109729,AG,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166135429,rs7319981,1448109730,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
PA166135428,rs7325568,1183704265,CC,Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
PA166135428,rs7325568,1183704264,CT,Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
PA166135428,rs7325568,1183704263,TT,Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
PA166152882,rs734644,1447964294,CC,Patients with the CC genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152882,rs734644,1447964295,CT,Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166152882,rs734644,1447964296,TT,Patients with the TT genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
PA166134848,rs7311358,1043880099,AA,"Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166134848,rs7311358,1043880100,AG,"Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166134848,rs7311358,1043880101,GG,"Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166135430,rs7311358,1183704273,AA,Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.
PA166135430,rs7311358,1183704274,AG,Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.
PA166135430,rs7311358,1183704275,GG,Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.
PA166153033,rs7311358,1447982770,AA,Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
PA166153033,rs7311358,1447982771,AG,"Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
PA166153033,rs7311358,1447982772,GG ,"Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
PA166134864,rs735482,1043880321,AA,Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166134864,rs735482,1043880320,AC,Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166134864,rs735482,1043880319,CC,Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
PA166152810,rs73748206,1447963065,CC,Cells with the CC genotype may have decreased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CT genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
PA166152810,rs73748206,1447963066,CT,Cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
PA166152810,rs73748206,1447963067,TT,"No cells with the TT genotype were available for analysis, but cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1."
PA166135913,rs7387065,1445594567,AA,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135913,rs7387065,1445594568,AG,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135913,rs7387065,1445594569,GG,Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166134156,rs7294,1448276190,CC,Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134156,rs7294,1448276191,CT,Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134156,rs7294,1448276192,TT,Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166136399,rs7294,1445585750,CC,"Patients with the CC genotype may require a decreased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or TT genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.
"
PA166136399,rs7294,1445585751,CT,"Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence  a patient's phenprocoumon or acenocoumarol dose requirement."
PA166136399,rs7294,1445585752,TT,"Patients with the TT genotype may require an increased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.
"
PA166159009,rs7349683,1448100834,CC,"Women with the CC genotype and breast or ovarian cancer may have a decreased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CT or TT genotype. However, a large study found opposing results for this association. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
PA166159009,rs7349683,1448100835,CT,"Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, a large study found opposing results for this association. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
PA166159009,rs7349683,1448100836,TT,"Women with the TT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC or CT genotype. However, a large study found opposing results for this association. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
PA166134123,rs742105,655384533,CC,Patients with the CC genotype and Schizophrenia may have a decreased response to clozapine compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166134123,rs742105,655384532,CT,Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166134123,rs742105,655384531,TT,Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
PA166135897,rs7438135,1448531893,AA,"Patients with the AA genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations."
PA166135897,rs7438135,1448531894,AG,"Patients with the AG genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations."
PA166135897,rs7438135,1448531895,GG,"Patients with the GG genotype may have higher levels of morphine as compared to patients with the AA or AG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations."
PA166135796,rs7438135,1444703556,AA,"Patients with the AA genotype and kidney transplantation may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166135796,rs7438135,1444703555,AG,"Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
PA166135796,rs7438135,1444703554,GG,Patients with the GG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
PA166152994,rs7438135,1447981261,AA,Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152994,rs7438135,1447981262,AG,Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152994,rs7438135,1447981263,GG,Patients with the GG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166153032,rs745746329,1447982765,CC,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153032,rs745746329,1447982764,CT,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153032,rs745746329,1447982763,TT,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166134022,rs747199,1184748986,CC,Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel. 
PA166134022,rs747199,1184748987,CG,"Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel. "
PA166134022,rs747199,1184748988,GG,Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel. 
PA166135491,rs74503330,1184472601,AA,"Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135491,rs74503330,1184472602,AG,"Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135491,rs74503330,1184472603,GG,"Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166134105,rs72552784,1000539593,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134105,rs72552784,1000539594,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134105,rs72552784,1000539595,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134106,rs72552784,1000539614,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  calcein compared to cells with other genotypes.
PA166134106,rs72552784,1000539615,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  calcein compared to cells with other genotypes.
PA166134106,rs72552784,1000539616,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  calcein compared to cells with other genotypes.
PA166134107,rs72552784,637880548,CC,Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
PA166134107,rs72552784,637880549,CT,Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport  forskolin compared to cells with other genotypes.
PA166134107,rs72552784,637880550,TT,Cells with the T allele show no difference in P-glycoprotein expression or ability to transport  forskolin compared to cells with other alleles.
PA166134108,rs72552784,637880552,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
PA166134108,rs72552784,637880553,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
PA166134108,rs72552784,637880554,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
PA166134109,rs72552784,637880556,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
PA166134109,rs72552784,637880557,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
PA166134109,rs72552784,637880558,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
PA166134110,rs72552784,637880560,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
PA166134110,rs72552784,637880561,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
PA166134110,rs72552784,637880562,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
PA166134111,rs72552784,1000539622,CC,Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.
PA166134111,rs72552784,1000539623,CT,Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
PA166134111,rs72552784,1000539624,TT,Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
PA166136427,rs74795342,1447813729,AA,"Individuals with the AA genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166136427,rs74795342,1447813730,AG,"Individuals with the AG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GG genotype but may have and an improved response as compared to individuals with the AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166136427,rs74795342,1447813731,GG,"Individuals with the GG genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166135280,rs746647,1183679788,AA,Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
PA166135280,rs746647,1183679787,AG,Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
PA166135280,rs746647,1183679786,GG,Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
PA166135990,rs749292,1447681904,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
"
PA166135990,rs749292,1447681905,AG,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the GG genotypes and increased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
"
PA166135990,rs749292,1447681906,GG,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have increased plasma concentrations of triglycerides as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
"
PA166135989,rs749292,1447681909,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135989,rs749292,1447681910,AG,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotypes and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166135989,rs749292,1447681911,GG,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
PA166134037,rs750332,613976849,CC,Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
PA166134037,rs750332,613976850,CT,Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
PA166134037,rs750332,613976851,TT,"Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment."
PA166151962,rs75039782,1447954392,CC,Patients with the CC genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
PA166151962,rs75039782,1447954393,CT,"Patients with the CT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
PA166151962,rs75039782,1447954394,TT,"Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
PA166153031,rs750996195,1447982758,CC,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153031,rs750996195,1447982757,CT,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153031,rs750996195,1447982756,TT,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166158785,rs75114882,1448099231,AA,Patients with nasopharyngeal cancer and the AA genotype may have a decreased severity of neutropenia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166158785,rs75114882,1448099232,AG,Patients with nasopharyngeal cancer and the AG genotype may have a increased severity of neutropenia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel. 
PA166135795,rs7518660,1444703546,AA,Patients with the AA genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
PA166135795,rs7518660,1444703547,AG,"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
PA166135795,rs7518660,1444703548,GG,"Patients with the GG genotype and Colorectal Neoplasms may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
PA166163081,rs7512462,1448600722,CC,Children with the CC genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the CT or TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
PA166163081,rs7512462,1448600723,CT,Children with the CT genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
PA166163081,rs7512462,1448600724,TT,Children with the TT genotype and gating mutations in cystic fibrosis may have decreased response to ivacaftor compared to children with the CC or CT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
PA166135957,rs7541245,1446903579,AA,Patients with diabetes mellitus and the AA genotype may have a decreased response to metformin as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus. 
PA166135957,rs7541245,1446903580,AC,Patients with diabetes mellitus and the AC genotype may have a decreased response to metformin as compared to patients with the CC genotypes and an increased response as compared to patients with the AA genotype. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus. 
PA166135957,rs7541245,1446903581,CC,Patients with diabetes mellitus and the CC genotype may have an increased response to metformin as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus. 
PA166135994,rs75222709,1448612498,GG,"Individuals with the GG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166135994,rs75222709,1448612499,GT,"Individuals with the GT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166135994,rs75222709,1448612500,TT,"Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the GT or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166135586,rs75017182,1448605330,CC,"Patients with the CC genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk of drug toxicity and increased likelihood of dose intervention as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135586,rs75017182,1448605331,CG,"Patients with the CG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk of drug toxicity and increased likelihood of a dose intervention as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166135586,rs75017182,1448605332,GG,"Patients with the GG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased risk of drug toxicity and decreased likelihood of dose intervention as compared to patients with the CC or CG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
PA166153007,rs7543016,1447981432,CC,Patients with the CC genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer. 
PA166153007,rs7543016,1447981433,CG,Patients with the CG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer. 
PA166153007,rs7543016,1447981434,GG,Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer. 
PA166135790,rs7551789,1444703489,AA,Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135790,rs7551789,1444703490,AT,Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166135790,rs7551789,1444703491,TT,Patients with the TT genotype and asthma who are treated with aspirin may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
PA166134146,rs7412,655384673,CC,Patients with the CC genotype may have decreased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the TT or CT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134146,rs7412,655384672,CT,Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134146,rs7412,655384671,TT,Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
PA166134997,rs7412,1447947145,CC,Patients with the CC genotype who are treated with atorvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134997,rs7412,1447947146,CT,Patients with the CT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134997,rs7412,1447947147,TT,Patients with the TT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134528,rs7412,981203710,CC,Patients with the CC genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166134528,rs7412,981203711,CT,Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166134528,rs7412,981203712,TT,Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
PA166134121,rs7569963,1448105544,AA,"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134121,rs7569963,1448105545,AG,"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134121,rs7569963,1448105546,GG,Patients with the GG genotype may have increased likelihood of remission on anti-depressants as compared to patients with the AA or AG genotype. Male patients with the GG genotype and depression who are treated with citalopram may have an increased risk of suicidal ideation as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
PA166134784,rs7572857,1043858647,AA,Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166134784,rs7572857,1043858648,AG,Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
PA166134784,rs7572857,1043858649,GG,"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
PA166135787,rs757639,1448107312,CC,Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166135787,rs757639,1448107313,CT,Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166135787,rs757639,1448107314,TT,"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir."
PA166134642,rs75527207,1448423775,AA,"Ivacaftor is indicated in cystic fibrosis patients with the AA genotype (two copies of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166134642,rs75527207,1448423776,AG,"Ivacaftor is indicated in cystic fibrosis patients with the AG genotype (one copy of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166134642,rs75527207,1448423777,GG,"Indication of ivacaftor in cystic fibrosis patients with the GG genotype (no copies of the CFTR G551D variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.

"
PA166135534,rs7582141,1184514212,GG,Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135534,rs7582141,1184514211,GT,"Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. "
PA166135534,rs7582141,1184514210,TT,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. 
PA166135279,rs7588295,1183679868,AA,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135279,rs7588295,1183679869,AG,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166135279,rs7588295,1183679870,GG,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
PA166158736,rs7586110,1448106394,GG,"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir. "
PA166158736,rs7586110,1448106395,GT,"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir. "
PA166158736,rs7586110,1448106396,TT,"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir. "
PA166161460,rs75995567,1448428939,CC,Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161460,rs75995567,1448428940,CT,Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166161460,rs75995567,1448428941,TT,Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
PA166152637,rs760316,1447959719,CC,Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166152637,rs760316,1447959720,CT,"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
PA166152637,rs760316,1447959721,TT,Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
PA166134691,rs7439366,1184472961,CC,Patients with the CC genotype may have decreased response to valproic acid as compared to patients with TT or TC genotype. The association was found in individuals with no disease and was not reported in cohort of patients with Epilepsy. Other genetic and clinical factors may also influence response to valproic acid.
PA166134691,rs7439366,1184472962,TC,Patients with the TC genotype may have increased response to valproic acid as compared to patients with CC genotype. The association was found in individuals with no disease and was not reported in cohort of patients with Epilepsy. Other genetic and clinical factors may also influence response to valproic acid.
PA166134691,rs7439366,1184472963,TT,Patients with the TT genotype may have increased response to valproic acid as compared to patients with CC genotype. The association was found in individuals with no disease and was not reported in cohort of patients with Epilepsy. Other genetic and clinical factors may also influence response to valproic acid.
PA166134536,rs7439366,1447945880,CC,Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134536,rs7439366,1447945881,CT,Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134536,rs7439366,1447945882,TT,Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134537,rs7439366,981203971,CC,Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.
PA166134537,rs7439366,981203972,CT,Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.
PA166134537,rs7439366,981203973,TT,Healthy individuals with the TT genotype who are treated with valproic acid and lorazepam may have better responses in psychocognitive function tests as compared to those with the CC genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.
PA166136443,rs7439366,1446903009,CC,Patients with the CC genotype may require an increased dose of codeine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of codeine. 
PA166136443,rs7439366,1446903010,CT,No information is available for the CT genotype. 
PA166136443,rs7439366,1446903011,TT,Patients with the TT genotype may require a decreased dose of codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of codeine. 
PA166152997,rs7439366,1447981284,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152997,rs7439366,1447981285,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152997,rs7439366,1447981286,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166153030,rs76088846,1447982743,CC,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153030,rs76088846,1447982742,CT,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153030,rs76088846,1447982741,TT,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166135735,rs76228616,1444700447,CC,Patients with the CC genotype may have  increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine. 
PA166135735,rs76228616,1444700448,CG,Patients with the CG genotype may have  increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine. 
PA166135735,rs76228616,1444700449,GG,Patients with the GG genotype may have  decreased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine. 
PA166135660,rs76387818,1444608177,AA,"Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine. "
PA166135660,rs76387818,1444608178,AG,"Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine. "
PA166135660,rs76387818,1444608179,GG,"Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine. "
PA166135270,rs760370,1444932376,AA,"Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine. "
PA166135270,rs760370,1444932377,AG,"Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine. "
PA166135270,rs760370,1444932378,GG,"Patients with cancer and the GG genotype may have decreased response to gemcitabine as compared to patients with the AG and AA genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine. "
PA166159040,rs760370,1448101204,AA,Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
PA166159040,rs760370,1448101205,AG,Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
PA166159040,rs760370,1448101206,GG,Patients with the GG genotype and chronic hepatitis C may be more likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
PA166136307,rs7624766,1444703484,AA,Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166136307,rs7624766,1444703483,AG,Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166136307,rs7624766,1444703482,GG,Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135840,rs760761,1444705183,AA,Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135840,rs760761,1444705184,AG,Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype or may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135840,rs760761,1444705185,GG,Patients with the GG genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166158942,rs766127,1448100127,AA,Patients with major depressive disorder and the AA genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158942,rs766127,1448100128,AG,Patients with major depressive disorder and the AG genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
PA166158942,rs766127,1448100129,GG,Patients with major depressive disorder and the GG genotype may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
PA166134775,rs761142,982047854,AA,Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction. 
PA166134775,rs761142,982047855,AC,Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction. 
PA166134775,rs761142,982047856,CC,Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction. 
PA166152995,rs7662029,1447981270,AA,Patients with the AA genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152995,rs7662029,1447981271,AG,Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152995,rs7662029,1447981272,GG,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166136431,rs7661530,1446899704,CC,Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors. 
PA166136431,rs7661530,1446899705,CT,Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors. 
PA166136431,rs7661530,1446899706,TT,Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC and CT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors. 
PA166153185,rs7643645,1447987061,AA,Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166153185,rs7643645,1447987062,AG,"Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
PA166153185,rs7643645,1447987063,GG,Patients with the GG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
PA166136105,rs7643645,1444607322,AA,"Patients with the AA genotype may have increased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the GG genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone. "
PA166136105,rs7643645,1444607321,AG,No information available. 
PA166136105,rs7643645,1444607320,GG,"Patients with the GG genotype may have decreased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the AA genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone. "
PA166135314,rs7668258,1448100482,CC,"Patients with the CC genotype may 1) have increased clearance (CL/F) and 2) require higher doses of lamotrigine as compared to patients with the CT or TT genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine."
PA166135314,rs7668258,1448100483,CT,"Patients with the CT genotype may 1) have decreased clearance (CL/F) and 2) require lower doses of lamotrigine as compared to patients with the CC genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine."
PA166135314,rs7668258,1448100484,TT,"Patients with the TT genotype may 1) have decreased clearance (CL/F) and 2) require lower doses of lamotrigine as compared to patients with the CC genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine."
PA166152996,rs7668258,1447981277,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152996,rs7668258,1447981278,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166152996,rs7668258,1447981279,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
PA166135941,rs7675300,1446899717,AA,Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166135941,rs7675300,1446899718,AC,Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166135941,rs7675300,1446899719,CC,Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
PA166135126,rs767455,1445585665,CC,Patients with the CC genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135126,rs767455,1445585666,CT,Patients with the CT genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135126,rs767455,1445585667,TT,Patients with the TT genotype and rheumatoid arthritis may have a decreased response to treatment with anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
PA166135127,rs767455,1183615425,CC,"Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab."
PA166135127,rs767455,1183615426,CT,"Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab."
PA166135127,rs767455,1183615427,TT,"Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab."
PA166136403,rs7706429,1445594361,AA,"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166136403,rs7706429,1445594362,AG,"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166136403,rs7706429,1445594363,GG,Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135748,rs7699188,1444700862,AA,"Patients with the AA genotype may have increased tumor response rate and  increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin."
PA166135748,rs7699188,1444700863,AG,"Patients with the AA genotype may have increased tumor response rate and  increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and  decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin."
PA166135748,rs7699188,1444700864,GG,"Patients with the GG genotype may have decreased tumor response rate and  decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin."
PA166135138,rs77235035,1183616512,AA,Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135138,rs77235035,1183616513,AC,Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135138,rs77235035,1183616514,CC,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135427,rs7740004,1183704260,AA,Patients with the AA genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or AT. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
PA166135427,rs7740004,1183704259,AT,Patients with the AT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
PA166135427,rs7740004,1183704258,TT,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
PA166153102,rs77107237,1447983956,AA,"Individuals with Tobacco Use Disorder and the AA genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
PA166153102,rs77107237,1447983957,AG,"Individuals with Tobacco Use Disorder and the AG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
PA166153102,rs77107237,1447983958,GG,"Individuals with Tobacco Use Disorder and the GG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
PA166153196,rs7754840,1447987206,CC,Patients with diabetes mellitus and the CC genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus. 
PA166153196,rs7754840,1447987207,CG,Patients with diabetes mellitus and the CG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus. 
PA166153196,rs7754840,1447987208,GG,Patients with diabetes mellitus and the GG genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus. 
PA166151963,rs77010898,1447954399,AA,"Patients with the AA genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
PA166151963,rs77010898,1447954400,AG,"Patients with the AG genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
PA166151963,rs77010898,1447954401,GG,Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
PA166152966,rs77010898,1447980899,AA,Patients with the AA genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
PA166152966,rs77010898,1447980900,AG,Patients with the AG genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
PA166152966,rs77010898,1447980901,GG,Patients with the GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
PA166160728,rs77010898,1448266010,AA,"Patients with the AA genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor."
PA166160728,rs77010898,1448266011,AG,"Patients with the AC genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor."
PA166160728,rs77010898,1448266012,GG,"Patients with the GG genotype and cystic fibrosis may not respond to ivacaftor treatment, depending what other variant is the cause of the cystic fibrosis. Other clinical and genetic factors may affect response to ivacaftor."
PA166153197,rs7756992,1447987213,AA,"Patients with diabetes mellitus and the AA genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
"
PA166153197,rs7756992,1447987214,AG,"Patients with diabetes mellitus and the AG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AA genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
"
PA166153197,rs7756992,1447987215,GG,"Patients with diabetes mellitus and the GG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
"
PA166134075,rs774359,637879988,CC,Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.
PA166134075,rs774359,637879989,CT,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.
PA166134075,rs774359,637879990,TT,Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.
PA166153029,rs7772821,1447982734,GG ,Patients with the GG genotype and asthma who are treated with corticosteroids may have an increased response to corticosteroids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166153029,rs7772821,1447982735,GT,Patients with the GT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166153029,rs7772821,1447982736,TT,Patients with the TT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
PA166153027,rs777560972,1447982747,AA,Patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166153027,rs777560972,1447982748,AG,"No information are available for the AG genotype. However, patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
PA166153027,rs777560972,1447982749,GG,Patients with the GG genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
PA166135426,rs7779029,1183704253,CC,"Patients with the CC genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan."
PA166135426,rs7779029,1183704254,CT,"Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan."
PA166135426,rs7779029,1183704255,TT,"Patients with the TT genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the toxicity to irinotecan."
PA166134312,rs7769719,655386094,AA,Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
PA166134312,rs7769719,655386095,AG,Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
PA166134312,rs7769719,655386096,GG,Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
PA166152770,rs778293,1447961324,CC,Patients with the CC genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
PA166152770,rs778293,1447961325,CT,"Patients with the CT genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis."
PA166152770,rs778293,1447961326,TT,Patients with the TT genotype who use methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
PA166135914,rs77876672,1445616167,CC,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. 
PA166135914,rs77876672,1445616168,CT,Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotypes and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. 
PA166135914,rs77876672,1445616169,TT,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. 
PA166161191,rs77932196,1448423863,AG,Patients with cystic fibrosis and a copy of the A allele resulting in residual CFTR function may respond to ivacaftor treatment. Other genetic and clinical factors may affect response to ivacaftor.
PA166161191,rs77932196,1448423864,GG,"Patients with cystic fibrosis and without residual CFTR function, such as patients with the GG genotype, may not respond to ivacaftor treatment. Other genetic and clinical factors may affect response to ivacaftor."
PA166134363,rs7793837,1446905270,AA,Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
PA166134363,rs7793837,1446905271,AT,"Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists."
PA166134363,rs7793837,1446905272,TT,Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
PA166136417,rs7794356,1446897515,AA,Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
PA166136417,rs7794356,1446897516,AG,Patients with asthma and the AG genotype may have a decreased response to montelukast as compared to patients with the AA genotype and an increased response to GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
PA166136417,rs7794356,1446897517,GG,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
PA166134676,rs7787082,982031027,AA,"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission."
PA166134676,rs7787082,982031028,AG,"Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission."
PA166134676,rs7787082,982031029,GG,"Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission."
PA166135019,rs7787082,1183556310,AA,Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135019,rs7787082,1183556311,AG,Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135019,rs7787082,1183556312,GG,Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
PA166135996,rs78015114,1448612483,CC,"Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166135996,rs78015114,1448612484,CT,"Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166135996,rs78015114,1448612485,TT,"Individuals with the TT genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
"
PA166153458,rs784888,1448106388,CC,Patients with the CC genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence clearance and response to metformin in people with Type II diabetes mellitus.
PA166153458,rs784888,1448106389,CG,Patients with the CG genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the GG genotypes and decreased clearance leading to improved response to metformin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.
PA166153458,rs784888,1448106390,GG,Patients with the GG genotype and Type II diabetes mellitus may have decreased clearance of metformin leading to improved response to metformin as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.
PA166135425,rs7851395,1183704244,AA,Patients with the AA genotype may have increased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AG or GG. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
PA166135425,rs7851395,1183704245,AG,Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
PA166135425,rs7851395,1183704246,GG,Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
PA166134382,rs7799039,1447953231,AA,"Patients with autism spectrum disorder (ASD), or mood disorders and the AA genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone."
PA166134382,rs7799039,1447953232,AG,"Patients with autism spectrum disorder (ASD), or mood disorders and the AG genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype; patients with the AG genotype may have an increased likelihood of weight gain as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone."
PA166134382,rs7799039,1447953233,GG,"Patients with autism spectrum disorder (ASD), or mood disorders and the GG genotype may have an increased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the AG or AA genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone."
PA166136202,rs784892,1448106313,AA,"In healthy volunteers as well as patients with diabetes mellitus the AA genotype may be associated with decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166136202,rs784892,1448106314,AG,"In healthy volunteers as well as patients with diabetes mellitus the AG genotype may be associated with increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the GG genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166136202,rs784892,1448106315,GG,"In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a increased secretory clearance of metformin, leading to decreased exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
PA166134026,rs7856096,1184512436,AA,Patients with the AA genotype who are treated with warfarin may require a higher dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134026,rs7856096,1184512435,GA,Patients with the GA genotype who are treated with warfarin may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134026,rs7856096,1184512434,GG,Patients with the GG genotype who are treated with warfarin may require a lower dose as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166136195,rs7862221,1444667587,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136195,rs7862221,1444667588,CT,Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166136195,rs7862221,1444667589,TT,Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
PA166135424,rs7853758,1448109622,AA,Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
PA166135424,rs7853758,1448109623,AG,Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
PA166135424,rs7853758,1448109624,GG,Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
PA166152872,rs78655421,1448265451,AA,Patients with the AA genotype and cystic fibrosis may have an improved response when treated with ivacaftor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor.
PA166152872,rs78655421,1448265452,AG,Patients with the AG genotype and cystic fibrosis may have an improved response when treated with ivacaftor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor.
PA166152872,rs78655421,1448265453,GG,Patients with the GG genotype and cystic fibrosis may not respond when treated with ivacaftor as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor.
PA166135523,rs7867504,1184472797,CC,Patients with the CC genotype may have increased formation of gemcitabine triphosphate as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine. 
PA166135523,rs7867504,1184472798,CT,Patients with the CT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine. 
PA166135523,rs7867504,1184472799,TT,Patients with the TT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine. 
PA166134863,rs7877,1043880316,CC,Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166134863,rs7877,1043880315,CT,Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166134863,rs7877,1043880314,TT,Patients with TT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
PA166136271,rs7877,1444700578,CC,Patients with the CC genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
PA166136271,rs7877,1444700577,CT,Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
PA166136271,rs7877,1444700576,TT,Patients with the TT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
PA166134659,rs762551,1446908982,AA,"Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel."
PA166134659,rs762551,1446908983,AC,"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel."
PA166134659,rs762551,1446908984,CC,"Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC + CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel."
PA166134692,rs762551,982040487,AA,Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
PA166134692,rs762551,982040488,AC,Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
PA166134692,rs762551,982040489,CC,Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
PA166135278,rs762551,1183679778,AA,"Patients with the AA genotype may have decreased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype CC or AC. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
PA166135278,rs762551,1183679777,AC,"Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
PA166135278,rs762551,1183679776,CC,"Patients with the CC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
PA166134184,rs762551,655384905,AA,"Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment."
PA166134184,rs762551,655384904,AC,"Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment."
PA166134184,rs762551,655384903,CC,Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.
PA166134266,rs762551,655385389,AA,"Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction."
PA166134266,rs762551,655385390,AC,Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
PA166134266,rs762551,655385391,CC,Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
PA166134283,rs762551,982035378,AA,Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134283,rs762551,982035379,AC,Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166134283,rs762551,982035380,CC,Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
PA166153101,rs762551,1447983942,AA,Pediatric patients with epilepsy and the AA genotype may have increased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AC or CC genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
PA166153101,rs762551,1447983943,AC,Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
PA166153101,rs762551,1447983944,CC,Pediatric patients with epilepsy and the CC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
PA166136164,rs762551,1448101458,AA,Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136164,rs762551,1448101459,AC,Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136164,rs762551,1448101460,CC,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166135789,rs7912580,1444703457,AA,"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
PA166135789,rs7912580,1444703455,AG,"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
PA166135789,rs7912580,1444703456,GG,"Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
PA166135788,rs7912580,1444703461,AA,"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
PA166135788,rs7912580,1444703462,AG,Patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
PA166135788,rs7912580,1444703463,GG,Patients with the GG genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
PA166136252,rs7903146,1444694380,CC,"Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence development of NODAT."
PA166136252,rs7903146,1444694381,CT,"Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence development of NODAT."
PA166136252,rs7903146,1444694382,TT,"Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence development of NODAT."
PA166134806,rs7903146,1043858906,CC,"Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives."
PA166134806,rs7903146,1043858907,CT,"Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives."
PA166134806,rs7903146,1043858908,TT,"Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives."
PA166135786,rs7917432,1448107306,CC,Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166135786,rs7917432,1448107307,CT ,Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166135786,rs7917432,1448107308,TT,"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir."
PA166158879,rs79085477,1448106429,CC,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166158879,rs79085477,1448106430,CT,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166158879,rs79085477,1448106431,TT,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
"
PA166135785,rs7917983,1444932410,CC,"Patients with the CC genotype and Hypertension who are treated with hydrochlorothiazide may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus."
PA166135785,rs7917983,1444932411,CT,"Patients with the CT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype or may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus."
PA166135785,rs7917983,1444932412,TT,Patients with the TT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.
PA166160988,rs79206939,1448276323,AA,Patients with the AA genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines. 
PA166160988,rs79206939,1448276324,AG,Patients with the AG genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines. 
PA166160988,rs79206939,1448276325,GG,Patients with the GG genotype may have decreased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to thiopurines. 
PA166134698,rs7934165,982032258,AA,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134698,rs7934165,982032259,AG,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166134698,rs7934165,982032260,GG,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. 
PA166135018,rs7921977,1183555572,CC,"Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time."
PA166135018,rs7921977,1183555573,CT,"Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time."
PA166135018,rs7921977,1183555574,TT,"Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence progression-free survival time."
PA166159502,rs7937567,1448112602,AA,"Patients with the AA genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies."
PA166159502,rs7937567,1448112603,AG,"Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies."
PA166159502,rs7937567,1448112604,GG,"Patients with the GG genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AG genotypes. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies."
PA166160696,rs7958375,1448265559,AA,Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin. 
PA166160696,rs7958375,1448265560,AG,Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin. 
PA166160696,rs7958375,1448265561,GG,Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin. 
PA166151941,rs7958904,1447953125,CC,Patients with the CC genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151941,rs7958904,1447953126,CG,Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166151941,rs7958904,1447953127,GG,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the CG and CG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
PA166163523,rs7968606,1448613013,CC,Patients with the CC genotype and schizophrenia may have increased response to amisulpride as measured by the PANSS general as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to amisulpride.
PA166163523,rs7968606,1448613014,CT,Patients with the CT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.
PA166163523,rs7968606,1448613015,TT,Patients with the TT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.
PA166135995,rs79663003,1448612488,CC,Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
PA166135995,rs79663003,1448612489,CT,Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
PA166135995,rs79663003,1448612490,TT,Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
PA166152847,rs7973796,1448106670,AA,Patients with the AA genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
PA166152847,rs7973796,1448106671,AG,"Patients with the AG genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine."
PA166152847,rs7973796,1448106672,GG,Patients with the GG genotype and schizophrenia may have an increased likelihood of obesity when treated with olanzapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
PA166134059,rs7900194,1447813507,AA,Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype.  Other clinical or genetic factors may also influence warfarin dose.
PA166134059,rs7900194,1447813508,AG,Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype.  Other clinical or genetic factors may also influence warfarin dose.
PA166134059,rs7900194,1447813509,GG,Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AG or GG genotype.  Other clinical or genetic factors may also influence warfarin dose.
PA166152976,rs800292,1447981077,AA,Patients with the AA genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to bevacizumab. 
PA166152976,rs800292,1447981078,AG,"Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab. "
PA166152976,rs800292,1447981079,GG,Patients with the GG genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab. 
PA166135926,rs7984870,1446897542,CC,"Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes.	"
PA166135926,rs7984870,1446897543,CG,"Patients with breast cancer and the genotype CG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.	"
PA166135926,rs7984870,1446897544,GG,"Patients with breast cancer and the genotype GG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.	"
PA166134408,rs8012552,699639352,CC,Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
PA166134408,rs8012552,699639353,CT,Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
PA166134408,rs8012552,699639354,TT,"Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors."
PA166135525,rs80143932,1184472903,CC,Patients with acute myeloid leukemia and the CC genotype may have an decreased response to cytarabine and idarubicin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
PA166135525,rs80143932,1184472902,CG,"Patients with acute myeloid leukemia and the CG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin."
PA166135525,rs80143932,1184472901,GG,Patients with acute myeloid leukemia and the GG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
PA166134878,rs8016905,1043880450,AA,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
PA166134878,rs8016905,1043880449,AG,"Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
PA166134878,rs8016905,1043880448,GG,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
PA166158894,rs80223967,1448099432,AA,"Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia. "
PA166158894,rs80223967,1448099433,AG,"Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia. "
PA166158894,rs80223967,1448099434,GG,"Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia. "
PA166135316,rs80338792,1444667287,CC,"No patients with this genotype were present in the population. However, patients with the CT genotype and myotonia permanens may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166135316,rs80338792,1444667288,CT,Patients with the CT genotype and myotonia permanens may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166135316,rs80338792,1444667289,TT,Patients with the TT genotype and myotonia permanens may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
PA166134275,rs7992226,655385467,AA,Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166134275,rs7992226,655385468,AG,Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166134275,rs7992226,655385469,GG,Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
PA166135492,rs80282562,1184472572,AA,"Patients with the AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135492,rs80282562,1184472573,AG,"Patients with the AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. "
PA166135492,rs80282562,1184472574,GG,"Patients with the GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
PA166134801,rs8060157,1043858897,AA,Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
PA166134801,rs8060157,1043858898,AG,Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
PA166134801,rs8060157,1043858899,GG,Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
PA166136103,rs806368,1444607311,CC,Individuals with the CC genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
PA166136103,rs806368,1444607312,CT,Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
PA166136103,rs806368,1444607313,TT,Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to those with the CC or CT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
PA166135839,rs809736,1444705170,AA,Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135839,rs809736,1444705169,AG,Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135839,rs809736,1444705168,GG,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
PA166135932,rs806378,1446898859,CC,"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CC genotype, may have a decreased likelihood of weight gain as compared to patients with the CT and TT genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients with ASD or schizophrenia who are taking risperidone, clozapine, or olanzapine."
PA166135932,rs806378,1446898860,CT,"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine."
PA166135932,rs806378,1446898861,TT,"Patients with schizophrenia, or autism spectrum disorder (ASD) and the TT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine."
PA166134211,rs8050894,1444694179,CC,Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134211,rs8050894,1444694180,CG,Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134211,rs8050894,1444694181,GG,Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166135408,rs8103142,1183702420,CC,"Patients with the CC genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy."
PA166135408,rs8103142,1183702419,CT,"Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy."
PA166135408,rs8103142,1183702418,TT,"Patients with the TT genotype may have increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy."
PA166159170,rs8105790,1448106811,CC,Patients with the CC genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159170,rs8105790,1448106812,CT,Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159170,rs8105790,1448106813,TT,Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159173,rs8113007,1448102799,AA,Patients with the AA genotype and hepatitis C or HIV may have an increased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159173,rs8113007,1448102800,AT,Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166159173,rs8113007,1448102801,TT,Patients with the TT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
PA166134090,rs7997012,1446906307,AA,"Patients with the AA genotype and depression who are treated with citalopram or antidepressants may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134090,rs7997012,1446906308,AG,"Patients with the AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134090,rs7997012,1446906309,GG,"Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient's response to antidepressants."
PA166134284,rs7997012,982035385,AA,Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.
PA166134284,rs7997012,982035386,AG,"Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment."
PA166134284,rs7997012,982035387,GG,"Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment."
PA166134748,rs7997012,982038276,AA,Patients with the AA genotype may be less likely to respond to venlafaxine as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.  
PA166134748,rs7997012,982038275,GA,Patients with the GA genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.  
PA166134748,rs7997012,982038274,GG ,Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.  
PA166134117,rs8133052,652882847,AA,Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
PA166134117,rs8133052,652882848,AG,"Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity."
PA166134117,rs8133052,652882849,GG,Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
PA166135784,rs8187707,1444703415,CC,Patients with the CC genotype and HIV who are treated with tenofovir may have  increased creatinine clearance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166135784,rs8187707,1444703416,CT,Patients with the CT genotype and HIV who are treated with tenofovir may have  decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166135784,rs8187707,1444703417,TT,Patients with the TT genotype and HIV who are treated with tenofovir may have  decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
PA166152774,rs8187725,1447961373,CC,Cells with the CC genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype. Other factors may also influence uptake of these drugs.
PA166152774,rs8187725,1447961374,CT,"Cells with the CT genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype, or decreased uptake as compared to those with the CC genotype. Other factors may also influence uptake of these drugs."
PA166152774,rs8187725,1447961375,TT,Cells with the TT genotype may have decreased uptake of catecholamines or metformin as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.
PA166134309,rs8187710,655386080,AA,Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.
PA166134309,rs8187710,655386081,AG,"Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity."
PA166134309,rs8187710,655386082,GG,"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity."
PA166134951,rs8187710,1183491022,AA,Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.
PA166134951,rs8187710,1183491023,AG,The AG genotype was not studied.
PA166134951,rs8187710,1183491024,GG,Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.
PA166134952,rs8187710,1183491031,AA,Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
PA166134952,rs8187710,1183491032,AG,Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
PA166134952,rs8187710,1183491033,GG,Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
PA166136453,rs8187710,1446905021,AA,"Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136453,rs8187710,1446905020,AG,"Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166136453,rs8187710,1446905022,GG,"Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
PA166159970,rs8192675,1448256691,CC,Patients with the CC genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
PA166159970,rs8192675,1448256692,CT,Patients with the CT genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
PA166159970,rs8192675,1448256693,TT,Patients with the TT genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.
PA166134675,rs8192440,982031020,AA,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134675,rs8192440,982031021,GA,Patients with the GA genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134675,rs8192440,982031022,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. 
PA166134370,rs8192709,655387000,CC,"Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis."
PA166134370,rs8192709,655387001,CT,Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
PA166134370,rs8192709,655387002,TT,Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
PA166135962,rs8192709,1446906372,CC,Patients with genotype CC may have decreased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CT. Other genetic and clinical factors may also influence the metabolism of efavirenz.
PA166135962,rs8192709,1446906373,CT,Patients with genotype CT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.
PA166135962,rs8192709,1446906374,TT,Patients with genotype TT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.
PA166152764,rs8192719,1447961196,CC,"Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz. "
PA166152764,rs8192719,1447961197,CT,"Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz. "
PA166152764,rs8192719,1447961198,TT,"Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz. "
PA166152929,rs8192725,1447979534,AA,"Hepatic cells with the AA genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152929,rs8192725,1447979535,AG,"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152929,rs8192725,1447979536,GG,"Hepatic cells with the GG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166135083,rs8192726,1447953049,AA,Patients with the AA genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. 
PA166135083,rs8192726,1447953050,AC,Patients with the AC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. 
PA166135083,rs8192726,1447953051,CC,Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. 
PA166134615,rs8099917,1448102581,GG,"Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients. "
PA166134615,rs8099917,1448102582,GT,"Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients. "
PA166134615,rs8099917,1448102583,TT,"Patients with the  TT genotype may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients. "
PA166135480,rs8099917,1446908328,GG,"Patients with the GG genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy."
PA166135480,rs8099917,1446908329,GT,"Patients with the GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy."
PA166135480,rs8099917,1446908330,TT,"Patients with the TT genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy."
PA166136488,rs8099917,1448106107,GG,Patients with genotype GG may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
PA166136488,rs8099917,1448106108,GT,Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
PA166136488,rs8099917,1448106109,TT,Patients with genotype TT may have increased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
PA166162415,rs8099917,1448532367,GG,Patients with genotype GG may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
PA166162415,rs8099917,1448532366,GT,Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
PA166162415,rs8099917,1448532365,TT,Patients with genotype TT may have increased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes GG or GT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
PA166152930,rs8192720,1447979555,AA,"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152930,rs8192720,1447979556,AG,"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166152930,rs8192720,1447979557,GG,"Hepatic cells with the GG genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
PA166162330,rs8192950,1448531103,GG,Patients with the GG genotype and stenosis may be less likely to suffer from a transient ischemic attack than patients with the GT or TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel. 
PA166162330,rs8192950,1448531104,GT,Patients with the GT genotype and stenosis may be less likely to suffer from a transient ischemic attack than patients with the TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel. 
PA166162330,rs8192950,1448531105,TT,Patients with the TT genotype and stenosis may be more likely to suffer from a transient ischemic attack than patients with the GG or GT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel. 
PA166159027,rs8192935,1448100957,AA,Patients with the AA genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.
PA166159027,rs8192935,1448100958,AG,Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.
PA166159027,rs8192935,1448100959,GG,Patients with the GG genotype and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the AA and AG genotypes. Other clinical factors may affect plasma concentrations of dabigatran.
PA166135198,rs822442,1183622369,AA,Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135198,rs822442,1183622370,AC,Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135198,rs822442,1183622371,CC,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135197,rs822441,1183622349,CC,Patients with the CC genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135197,rs822441,1183622350,CG,Patients with the CG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166135197,rs822441,1183622351,GG,Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment. 
PA166134799,rs833061,1043858846,CC,Patients with the CC genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
PA166134799,rs833061,1043858847,CT,Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
PA166134799,rs833061,1043858848,TT,Patients with the TT genotype may be associated with a decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
PA166136091,rs8330,1448106300,CC,Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
PA166136091,rs8330,1448106301,CG,Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
PA166136091,rs8330,1448106302,GG,Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
PA166135014,rs8330,1183614877,CC,Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135014,rs8330,1183614878,CG,Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135014,rs8330,1183614879,GG,Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
PA166135015,rs8330,1444667455,CC,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135015,rs8330,1444667456,CG,Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166135015,rs8330,1444667457,GG,Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
PA166163455,rs8450,1448605499,AA,"Patients with the AA genotype who are undergoing organ transplantation may have an increased risk for new-onset diabetes after transplantation (NODAT), or conditions relating to metabolic syndrome, when treated with tacrolimus or cyclosporine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for NODAT or metabolic syndrome. "
PA166163455,rs8450,1448605500,AG,"Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT), or conditions relating to metabolic syndrome, when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT or metabolic syndrome. "
PA166163455,rs8450,1448605501,GG,"Patients with the GG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT), or conditions relating to metabolic syndrome, when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for NODAT or metabolic syndrome. "
PA166152773,rs846664,1447961346,AA,Patients with the AA genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence alcoholism risk.
PA166152773,rs846664,1447961347,AC,"Patients with the AC genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype, or more likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk."
PA166152773,rs846664,1447961348,CC,Patients with the CC genotype who are African-American may be more likely to become addicted to alcohol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.
PA166136392,rs846908,1445402165,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166136392,rs846908,1445402166,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166136392,rs846908,1445402167,GG,"Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166135909,rs846910,1445402184,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166135909,rs846910,1445402185,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166135909,rs846910,1445402186,GG,"Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
PA166135361,rs833069,1183697624,CC,"Patients with the CC genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab."
PA166135361,rs833069,1183697625,CT,"Patients with the CT genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab."
PA166135361,rs833069,1183697626,TT,"Patients with the TT genotype and macular degeneration may have greater increases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the CC or CT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab."
PA166134071,rs854547,1448107963,AA,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134071,rs854547,1448107964,AG,Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134071,rs854547,1448107965,GG,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG.  Other genetic and clinical factors may also influence a patient's response.
PA166134070,rs854548,1448107973,AA,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134070,rs854548,1448107974,AG,Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134070,rs854548,1448107975,GG,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG.  Other genetic and clinical factors may also influence a patient's response.
PA166134069,rs854555,1448107979,AA,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.
PA166134069,rs854555,1448107980,AC,Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.
PA166134069,rs854555,1448107981,CC,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC.  Other genetic and clinical factors may also influence a patient's response.
PA166134658,rs854560,1446909093,AA,The AA genotype is not associated with differences in clopi-H4 formation or antiplatelet response or increased risk of major cardiovascular events when treated with clopidogrel as compared to the TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134658,rs854560,1446909094,AT,The AT genotype is not associated with differences in clopi-H4 formation or antiplatelet response or increased risk of major cardiovascular events when treated with clopidogrel as compared to the TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134658,rs854560,1446909095,TT,The TT genotype is not associated with differences in clopi-H4 formation or antiplatelet response or increased risk of major cardiovascular events when treated with clopidogrel as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
PA166134832,rs861539,1043872991,AA,"Patients with the AG genotype may have increased progression free survival  in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response."
PA166134832,rs861539,1043872990,AG,"Patients with the AG genotype may have increased progression free survival  in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response."
PA166134832,rs861539,1043872989,GG,"Patients with the GG genotype may have decreased progression free survival  in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's response."
PA166134833,rs861539,1448105557,AA,"Patients with the AA genotype may have decreased response when treated with platinum compounds, docetaxel and irinotecan in people with Neoplasms as compared to patients with genotypes AG or GG. Other clinical or genetic factors may also influence a patient's response to platinum compounds, docetaxel or irinotecan in people with Neoplasms."
PA166134833,rs861539,1448105558,AG,"Patients with the AG genotype may have increased response when treated with platinum compounds, docetaxel and irinotecan in people with Neoplasms as compared to patients with genotypes AA. Other clinical or genetic factors may also influence a patient's response to platinum compounds, docetaxel or irinotecan in people with Neoplasms."
PA166134833,rs861539,1448105559,GG,"Patients with the GG genotype may have increased response when treated with platinum compounds, docetaxel and irinotecan in people with Neoplasms as compared to patients with genotypes AA. Other clinical or genetic factors may also influence a patient's response to platinum compounds, docetaxel or irinotecan in people with Neoplasms."
PA166134076,rs868856,637879993,AA,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
PA166134076,rs868856,637879994,AG,Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
PA166134076,rs868856,637879995,GG,Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.
PA166134334,rs870995,655386311,AA,Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134334,rs870995,655386312,AC,Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166134334,rs870995,655386313,CC,Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
PA166153201,rs875858,1447987266,CC,Patients with the CC genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
PA166153201,rs875858,1447987267,CT,Patients with the CT genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the TT genotypes and an increased risk of neuropathy as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
PA166153201,rs875858,1447987268,TT,Patients with the TT genotype and prostate cancer who are treated with docetaxel may have an increased risk of neuropathy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
PA166152772,rs878567,1447961339,AA,Patients with the AA genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
PA166152772,rs878567,1447961340,AG,"Patients with the AC genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis."
PA166152772,rs878567,1447961341,GG,Patients with the GG genotype who take methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
PA166135263,rs878949,1183632153,CC,Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the TT genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166135263,rs878949,1183632152,CT,Patients with the CT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166135263,rs878949,1183632151,TT,Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
PA166136439,rs879825,1448106352,AA,"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136439,rs879825,1448106353,AG,"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136439,rs879825,1448106354,GG,"Women with ovarian cancer and the GG genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166135247,rs879207,1183631550,AA,"Patients with the AA genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135247,rs879207,1183631551,AG,"Patients with the AG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135247,rs879207,1183631552,GG,"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity. "
PA166135261,rs885004,1448109628,AA,Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
PA166135261,rs885004,1448109629,AG,Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
PA166135261,rs885004,1448109630,GG,Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
PA166153487,rs885036,1447990927,AA,"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
PA166153487,rs885036,1447990928,AG,"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the GG genotypes and increased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
"
PA166153487,rs885036,1447990929,GG,"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
"
PA166153486,rs885036,1447990919,AA,"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer. "
PA166153486,rs885036,1447990920,AG,"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the GG genotypes and decreased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer. "
PA166153486,rs885036,1447990921,GG,"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer. "
PA166135478,rs887829,1446903300,CC,"Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation."
PA166135478,rs887829,1446903301,CT,"Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation."
PA166135478,rs887829,1446903302,TT,"Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation."
PA166136161,rs887829,1444666546,CC,Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136161,rs887829,1444666547,CT,Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166136161,rs887829,1444666545,TT,Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
PA166161473,rs887829,1448431547,CC,Patients with the CC genotype and heart valve replacement may require a lower stable dose of warfarin compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect stable dose of warfarin.
PA166161473,rs887829,1448431548,CT,Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes. Other clinical and genetic factors affect stable dose of warfarin.
PA166161473,rs887829,1448431549,TT,Patients with the TT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes. Other clinical and genetic factors affect stable dose of warfarin.
PA166136461,rs889299,1446906407,AA,"Patients with genotype AA may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar."
PA166136461,rs889299,1446906408,AG,"Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar."
PA166136461,rs889299,1446906409,GG,"Patients with genotype GG may have decreased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to Farglitazar."
PA166152771,rs881152,1447961331,AA,Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166152771,rs881152,1447961332,AG,"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
PA166152771,rs881152,1447961333,GG,Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
PA166136111,rs889895,1444607422,AA,"Patients with the AA genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder. "
PA166136111,rs889895,1444607423,AG,"Patients with the AG genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder. "
PA166136111,rs889895,1444607424,GG,"Patients with the GG genotype and major depressive disorder may be more likely to enter remission when treated with antidepressants, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder. "
PA166158744,rs895819,1448255331,CC,"Patients with the CC genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment. "
PA166158744,rs895819,1448255332,CT,"Patients with the CT genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype, or a decreased risk and increased activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment. "
PA166158744,rs895819,1448255333,TT,"Patients with the TT genotype and cancer may have a decreased risk for toxicity when treated with fluoropyrimidines, as well as increased DPYD activity, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment. "
PA166134177,rs909706,655384869,CC,Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.
PA166134177,rs909706,655384868,CT,Patients with the CT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the  the CC genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.
PA166134177,rs909706,655384867,TT,"Patients with the TT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the  the CC genotype. Please note, while the CT genotype was associated with suggestively better response to haloperidol in unrelated schizophrenic inpatients, no results were shown for the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
PA166134696,rs8832,982031985,AA,Patients with the AA genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra. 
PA166134696,rs8832,982031986,AG,Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra. 
PA166134696,rs8832,982031987,GG,Patients with the GG genotype and Asthma may be more likely to respond when treated with pitrakinra as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to pitrakinra. 
PA166136179,rs914232,1444666820,CC,Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
PA166136179,rs914232,1444666821,CT,Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
PA166136179,rs914232,1444666822,TT,Patients with the TT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival time.
PA166135252,rs915120,1183631788,CC,"Patients with the CC genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram. "
PA166135252,rs915120,1183631789,CT,"Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram. "
PA166135252,rs915120,1183631790,TT,"Patients with the TT genotype may have increased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the CC or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram. "
PA166135262,rs880054,1183632148,CC,Patients with the CC genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166135262,rs880054,1183632147,CT,Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166135262,rs880054,1183632146,TT,Patients with the TT genotype may have decreased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
PA166134442,rs9272105,827849110,AA,Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.
PA166134442,rs9272105,827849111,AG,Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.
PA166134442,rs9272105,827849112,GG,Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.
PA166135783,rs924607,1448602510,CC,"Patients with the CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine."
PA166135783,rs924607,1448602511,CT,"Patients with the CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine."
PA166135783,rs924607,1448602512,TT,Patients with the TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.
PA166134307,rs9024,1448105712,AA,"In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin."
PA166134307,rs9024,1448105713,AG,Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
PA166134307,rs9024,1448105714,GG,Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
PA166134541,rs9024,981204091,AA,"Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies."
PA166134541,rs9024,981204092,AG,"Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies."
PA166134541,rs9024,981204093,GG,Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.
PA166134441,rs9274407,827849096,AA,Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.
PA166134441,rs9274407,827849097,AT,Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.
PA166134441,rs9274407,827849098,TT,Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.
PA166134440,rs9282861,827849080,CC,Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
PA166134440,rs9282861,827849081,CT,Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
PA166134440,rs9282861,827849082,TT,Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
PA166136405,rs9285669,1445594500,AA,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136405,rs9285669,1445594501,AT,Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166136405,rs9285669,1445594502,TT,"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
"
PA166161867,rs9304742,1448522786,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161867,rs9304742,1448522787,CT,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161867,rs9304742,1448522788,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166134077,rs928655,637879998,AA,Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134077,rs928655,637879999,AG,Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134077,rs928655,637880000,GG,Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotype AA or AG.  Other genetic and clinical factors may also influence a patient's response.
PA166158949,rs9315310,1448106580,CC,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158949,rs9315310,1448106581,CT,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
PA166158949,rs9315310,1448106582,TT,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
PA166134439,rs9316233,827848786,CC,Patients with the CC genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.
PA166134439,rs9316233,827848787,CG,Patients with the CG genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.
PA166134439,rs9316233,827848788,GG,Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.
PA166134798,rs9332096,1043858843,CC,Patients with the CC genotype may require increased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
PA166134798,rs9332096,1043858842,CT,Patients with the CT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
PA166134798,rs9332096,1043858841,TT,Patients with the TT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
PA166136498,rs9322335,1447814600,CC,Patients with the CC genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
PA166136498,rs9322335,1447814601,CT,Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
PA166136498,rs9322335,1447814602,TT,Patients with the TT genotype and Breast Neoplasms may be at increased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
PA166134060,rs9332131,1183703115,A/del,Patients with A/del genotype may require a lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134060,rs9332131,1183703116,AA,Patients with the AA genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the del/A or del/del genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134060,rs9332131,1183703117,del/del,Patients with del/del genotype may require significantly lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
PA166134438,rs9332131,827848777,A/del,Patients with the A/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.
PA166134438,rs9332131,827848778,AA,Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the A/del or del/del genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.
PA166134438,rs9332131,827848779,del/del,Patients with the del/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.
PA166134437,rs9332239,1000539666,CC,Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.
PA166134437,rs9332239,1000539667,CT,Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.
PA166134437,rs9332239,1000539668,TT,Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.
PA166134346,rs9332377,1448616441,CC,"Children with the CC genotype and cancer who are treated with cisplatin may have an lower, but not absent, risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134346,rs9332377,1448616442,CT,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134346,rs9332377,1448616443,TT,"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
PA166134101,rs9282564,637880523,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
PA166134101,rs9282564,637880524,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
PA166134101,rs9282564,637880525,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
PA166134098,rs9282564,1000539581,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134098,rs9282564,1000539582,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134098,rs9282564,1000539583,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
PA166134099,rs9282564,1000539589,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
PA166134099,rs9282564,1000539590,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
PA166134099,rs9282564,1000539591,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
PA166134100,rs9282564,637880519,CC,Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
PA166134100,rs9282564,637880520,CT,Cells with the CT genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes(inferred).
PA166134100,rs9282564,637880521,TT,Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
PA166134102,rs9282564,637880527,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
PA166134102,rs9282564,637880528,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
PA166134102,rs9282564,637880529,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
PA166134103,rs9282564,637880531,CC,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
PA166134103,rs9282564,637880532,CT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
PA166134103,rs9282564,637880533,TT,Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastinel compared to cells with other genotypes.
PA166134104,rs9282564,1000539618,CC,Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.
PA166134104,rs9282564,1000539619,CT,Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.
PA166134104,rs9282564,1000539620,TT,Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.
PA166135896,rs9282564,1445401269,CC,Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.
PA166135896,rs9282564,1445401270,CT,Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.
PA166135896,rs9282564,1445401271,TT,Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.
PA166158991,rs9282564,1448100554,CT,Patients with the CT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.
PA166158991,rs9282564,1448100555,TT,Patients with the TT genotype and lung transplantation may have decreased concentrations of tacrolimus compared to patients with the CT genotype. Other factors may affect concentration of tacrolimus.
PA166134120,rs9344,655384489,AA,"Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab."
PA166134120,rs9344,655384488,AG,"Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab."
PA166134120,rs9344,655384487,GG,"Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab."
PA166134434,rs9344,827848733,AA,"Patients with the AA genotype may have 1) decreased but not absent risk for drug toxicity 2) decreased event free survival when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033."
PA166134434,rs9344,827848734,AG,"Patients with the AG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033."
PA166134434,rs9344,827848735,GG,"Patients with the GG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033."
PA166134759,rs9344,982044868,AA,"Patients with the AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.
"
PA166134759,rs9344,982044869,AG,"Patients with the AG or GG genotypes may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil."
PA166134759,rs9344,982044870,GG,"Patients with the AG or GG genotypes may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil."
PA166135475,rs934635,1183863776,AA,Patients with the AA genotype may have a significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135475,rs934635,1183863777,AG,Patients with the AG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166135475,rs934635,1183863778,GG,Patients with the GG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
PA166134258,rs9345389,655385332,AA,"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD)."
PA166134258,rs9345389,655385331,AG,Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
PA166134258,rs9345389,655385330,GG,Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
PA166134433,rs9349256,827848726,AA,Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134433,rs9349256,827848727,AG,Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166134433,rs9349256,827848728,GG,Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
PA166135976,rs9346455,1447678616,GG,Patients with the GG genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
PA166135976,rs9346455,1447678617,GT,Patients with the GT genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
PA166135976,rs9346455,1447678618,TT,Patients with the TT genotype and schizophrenia may lower weight gain when treated with antipsychotics as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
PA166135588,rs9351963,1184986311,AA,Patients with the AA genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer. 
PA166135588,rs9351963,1184986312,AC,Patients with the AC genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype and an increased risk of diarrhea as compared to the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer. 
PA166135588,rs9351963,1184986313,CC,Patients with the CC genotype and cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer. 
PA166134023,rs9340799,1184472747,AA,Patients with cancer and the AA genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain. 
PA166134023,rs9340799,1184472748,AG,Patients with cancer and the AG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain. 
PA166134023,rs9340799,1184472749,GG,Patients with cancer and the GG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain. 
PA166134435,rs9340799,827848741,AA,"Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
PA166134435,rs9340799,827848742,AG,"Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
PA166134435,rs9340799,827848743,GG,"Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
PA166134436,rs9340799,827848752,AA,"Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density."
PA166134436,rs9340799,827848753,AG,"Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density."
PA166134436,rs9340799,827848754,GG,"Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density."
PA166134236,rs9340799,655385158,AA,The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers
PA166134236,rs9340799,655385157,AG,The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.
PA166134236,rs9340799,655385156,GG,The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.
PA166135563,rs9370867,1184747858,AA,Patients with the AA genotype and hypercholesterolemia who are treated with atorvastatin may have better LDL-C responses and are more likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
PA166135563,rs9370867,1184747859,AG,Patients with the AG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
PA166135563,rs9370867,1184747860,GG,Patients with the GG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
PA166163190,rs9361233,1448602212,CC,Children with the CC genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.
PA166163190,rs9361233,1448602213,CT,Children with the CT genotype and major depressive disorder may respond worse to fluoxetine therapy compared to patients with the CC and TT genotypes. Other clinical and genetic factors may affect response to fluoxetine.
PA166163190,rs9361233,1448602214,TT,Children with the TT genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.
PA166135943,rs9369421,1448106346,CC,"Women with ovarian cancer and the CC genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166135943,rs9369421,1448106347,CT,"Women with ovarian cancer and the CT genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166135943,rs9369421,1448106348,TT,"Women with ovarian cancer and the TT genotype may have a worse response, such as shorter survival times, when treated with carboplatin and taxanes as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166136438,rs9369421,1448115866,CC,"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CT or TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136438,rs9369421,1448115867,CT,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166136438,rs9369421,1448115868,TT,"Women with ovarian cancer and the TT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
PA166158978,rs9373839,1448100428,CC,Patients with the CC genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
PA166158978,rs9373839,1448100429,CT,Patients with the CT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
PA166158978,rs9373839,1448100430,TT,Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
PA166134674,rs9376230,982031001,AA,Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134674,rs9376230,982031000,AC,Patients with the AC genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or AA. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134674,rs9376230,982030999,CC,Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134818,rs9380524,1043859124,AA,Patients with the AA genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134818,rs9380524,1043859125,AC,Patients with the AC genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166134818,rs9380524,1043859126,CC,Patients with the CC genotype may have an increased chance of response to citalopram or ecitalopram treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
PA166135921,rs9384179,1446897337,AA,Patients with the AA genotype and post-operative pain may require an increased dose of fentanyl as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain. 
PA166135921,rs9384179,1446897338,AG,Patients with the AG genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain. 
PA166135921,rs9384179,1446897339,GG,Patients with the GG genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain. 
PA166135423,rs9394992,1183704236,CC,Patients with the CC genotype may have decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
PA166135423,rs9394992,1183704235,CT,Patients with the CT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
PA166135423,rs9394992,1183704234,TT,Patients with the TT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
PA166135979,rs9380142,1447679984,AA,Patients with the AA genotype and colorectal cancer may have a decreased response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence a patient's response to capecitabine or fluorouracil. 
PA166135979,rs9380142,1447679985,AG,Patients with the AG genotype and colorectal cancer may have a decreased response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence a patient's response to capecitabine or fluorouracil. 
PA166135979,rs9380142,1447679986,GG,Patients with the GG genotype and colorectal cancer may have an increased response to capecitabine or fluorouracil as compared to patients with the AA and AG genotype. Other clinical and genetic factors may also influence a patient's response to capecitabine or fluorouracil. 
PA166135981,rs9380142,1447680037,AA,Patients with colorectal cancer and the AA genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166135981,rs9380142,1447680038,AG,Patients with colorectal cancer and the AG genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166135981,rs9380142,1447680039,GG,Patients with colorectal cancer and the GG genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
PA166134432,rs943580,827848564,AA,Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
PA166134432,rs943580,827848565,AG,Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
PA166134432,rs943580,827848566,GG,Patients with the GG genotype may have decreased but not non-existent risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
PA166135585,rs9469003,1448115859,CC,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. 
PA166135585,rs9469003,1448115860,CT,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
PA166135585,rs9469003,1448115861,TT,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. "
PA166134540,rs9461684,981204081,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166134540,rs9461684,981204082,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166134540,rs9461684,981204083,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
PA166136460,rs944050,1448105912,CC,Patients with genotype CC may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.
PA166136460,rs944050,1448105913,CT,Patients with genotype CT may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.
PA166136460,rs944050,1448105914,TT,Patients with genotype TT may have increased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to gemcitabine.
PA166135592,rs9479757,1184986781,AA,The AA genotype was only present in one individual and could not be evaluated for its influence on risk of opioid dependence upon exposure to opioids. Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids. 
PA166135592,rs9479757,1184986782,AG,Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
PA166135592,rs9479757,1184986783,GG,Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
PA166134673,rs9483947,982031006,CC,Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134673,rs9483947,982031007,CT,Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134673,rs9483947,982031008,TT,Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment. 
PA166134670,rs948854,982030922,CC,"Female patients with the CC genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. "
PA166134670,rs948854,982030923,CT,"Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. "
PA166134670,rs948854,982030924,TT,"Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants. "
PA166136058,rs948854,1184986776,CC,Patients with the CC genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the CT genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids. 
PA166136058,rs948854,1184986777,CT,Patients with the CT genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids. 
PA166136058,rs948854,1184986778,TT,The TT genotype was not evaluated for its influence on risk of opioid dependence upon exposure to opioids.Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids. 
PA166134136,rs951439,655384604,CC,Patients with the CC genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
PA166134136,rs951439,655384605,CT,Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
PA166134136,rs951439,655384606,TT,Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
PA166134137,rs951439,655384608,CC,Patients with the CC genotype and schizophrenia: 1) may have increased treatment response with perphanzine and olanzapine treatment 2) may have decreased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.
PA166134137,rs951439,655384609,CT,Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.
PA166134137,rs951439,655384610,TT,Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.
PA166135751,rs9516519,1444700890,GG,Patients with the GG genotype who are treated with methotrexate may have  decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135751,rs9516519,1444700891,GT,Patients with the GT genotype who are treated with methotrexate may have  decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166135751,rs9516519,1444700892,TT,Patients with the TT genotype who are treated with methotrexate may have  increased risk for toxicity and increased plasma level as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134431,rs9514091,1448109720,AA,"Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
PA166134431,rs9514091,1448109721,AG,"Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
PA166134431,rs9514091,1448109722,GG,"Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
PA166136052,rs9535826,1184986596,GG,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer. 
PA166136052,rs9535826,1184986597,GT,Patients with the GT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer. 
PA166136052,rs9535826,1184986598,TT,Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer. 
PA166135251,rs9552679,1183631783,CC,Patients with the CC genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
PA166135251,rs9552679,1183631784,CT,Patients with the CT genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
PA166135251,rs9552679,1183631785,TT,Patients with the TT genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the CC or CT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
PA166135924,rs953977,1446897528,GG,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma. 
PA166135924,rs953977,1446897529,GT,Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma. 
PA166135924,rs953977,1446897530,TT,Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GT and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma. 
PA166136053,rs9535828,1184986591,AA,Patients with the AA genotype and lung cancer may have an improved response to platinum compounds as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer. 
PA166136053,rs9535828,1184986592,AG,Patients with the AG genotype and lung cancer may have a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer. 
PA166136053,rs9535828,1184986593,GG,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer. 
PA166135123,rs9561765,1183615384,AA,Patients with the AA genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the AG genotype. Other genetic and clinical factors may also influence time to progression.
PA166135123,rs9561765,1183615385,AG,Patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.
PA166135123,rs9561765,1183615386,GG,"No patients with the GG genotype were present in this study. However, patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression."
PA166161298,rs9567733,1448428153,AA,Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166161298,rs9567733,1448428154,AG,Patients with the AG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166161298,rs9567733,1448428155,GG,Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
PA166134371,rs9561778,655387005,GG,"Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
PA166134371,rs9561778,655387006,GT,"Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
PA166134371,rs9561778,655387007,TT,"Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
PA166134430,rs9561778,827848549,GG,"Patients with the GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs."
PA166134430,rs9561778,827848550,GT,"Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs."
PA166134430,rs9561778,827848551,TT,"Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs."
PA166135886,rs9590353,1445619123,GG,Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135886,rs9590353,1445619124,GT,Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135886,rs9590353,1445619125,TT,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166134427,rs9597,1448108896,CC,Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
PA166134427,rs9597,1448108897,CG,Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
PA166134427,rs9597,1448108898,GG,"Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment."
PA166134664,rs9606186,982031999,CC,Patients with the CC genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's response to risperidone. 
PA166134664,rs9606186,982032000,CG,Patients with the CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's response to risperidone. 
PA166134664,rs9606186,982032001,GG,Patients with the GG genotype and Schizophrenia may be more likely to respond when treated with risperidone as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may influence a patient's response to risperidone. 
PA166135390,rs9626730,1183700484,CC,Patients with the CC genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
PA166135390,rs9626730,1183700485,CT,Patients with the CT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
PA166135390,rs9626730,1183700486,TT,Patients with the TT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
PA166135013,rs964184,1183545770,CC,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135013,rs964184,1183545769,CG,Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166135013,rs964184,1183545768,GG,Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
PA166136143,rs967676,1444608293,CC,"Patients with the CC genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
PA166136143,rs967676,1444608294,CT,"Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
PA166136143,rs967676,1444608295,TT,"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
PA166134426,rs963468,827847760,AA,Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
PA166134426,rs963468,827847761,AG,Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
PA166134426,rs963468,827847762,GG,Patients with the GG genotype may have decreased response to duloxetine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
PA166134671,rs962369,982030960,CC,Patients with the CC genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
PA166134671,rs962369,982030961,CT,Patients with the CT genotype and depression may have increased likelihood  of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
PA166134671,rs962369,982030962,TT,Patients with the TT genotype and depression may have decreased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
PA166134425,rs9657182,827847752,CC,Patients with the CC genotype may have increased risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.
PA166134425,rs9657182,827847753,CT,"Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects."
PA166134425,rs9657182,827847754,TT,"Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects."
PA166134641,rs8175347,1448522500,(TA)6/(TA)6,"Patients with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) and cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia and diarrhea at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, overall gastrointestinal toxicities (diarrhea, nausea, vomiting, and mucositis combined) or tumor response. One study found a decreased risk of vomiting for this genotype, and another found a decreased risk of treatment-related death, both compared to the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death.  "
PA166134641,rs8175347,1448522501,(TA)6/(TA)7,"Patients with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype, and a decreased risk compared to those with the (TA)7/(TA)7 (*28/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, or tumor response. One study found a decreased overall survival time for carriers of the (TA)7 allele. One study found an increased risk of vomiting for this genotype, and another found an increased risk of treatment-related death, both compared to the (TA)6/(TA)6 genotype. Other genetic and clinical factors may also influence a patient's survival time and risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death.  "
PA166134641,rs8175347,1448522502,(TA)7/(TA)7,"Patients with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia and diarrhea at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, overall gastrointestinal toxicities (diarrhea, nausea, vomiting, and mucositis combined), or tumor response. One study found a decreased overall survival time for carriers of the (TA)7 allele. One study found an increased risk of vomiting for this genotype, and another found an increased risk of treatment-related death, both compared to the (TA)6/(TA)6 genotype. Other genetic and clinical factors may also influence a patient's survival time and risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death.  "
PA166135324,rs8175347,1183685071,(TA)6/(TA)6,Patients with the UGT1A1 (TA)6/(TA)6 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.
PA166135324,rs8175347,1183685070,(TA)6/(TA)7,Patients with the UGT1A1 (TA)6/(TA)7 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.
PA166135324,rs8175347,1183685069,(TA)7/(TA)7,Patients with the UGT1A1 (TA)7/(TA)7 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)6/(TA)6 or (TA)6/(TA)7 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.
PA166135016,rs8175347,1444667480,(TA)6/(TA)6,"Women with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, an in vitro study found an increased clearance of raloxifene as compared to the *1/*28 and *28/*28 gentoype. Other genetic and clinical factors may also influence metabolism of raloxifene."
PA166135016,rs8175347,1444667481,(TA)6/(TA)7,"Women with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, an in vitro study found a decreased clearance as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of raloxifene."
PA166135016,rs8175347,1444667482,(TA)7/(TA)7,"Women with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) genotype and osteoporosis may have increased metabolism of raloxifene as compared to patients with the (TA)6/(TA)7 (*1/*28) or (TA)6/(TA)6 (*1/*1) genotype. However, an in vitro study found a decreased clearance of raloxifene as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of raloxifene."
PA166135017,rs8175347,1183552880,(TA)6/(TA)6,Women with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence bone mineral density. 
PA166135017,rs8175347,1183552881,(TA)6/(TA)7,Women with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence bone mineral density. 
PA166135017,rs8175347,1183552882,(TA)7/(TA)7,Women with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) genotype and osteoporosis may have increased hip bone mineral density when treated with raloxifene as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. Other genetic and clinical factors may also influence bone mineral density. 
PA166134033,rs8175347,1184747676,(TA)6/(TA)6,"Patients with the (TA)6/(TA)6 (UGT1A1 *1/*1) genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir."
PA166134033,rs8175347,1184747677,(TA)6/(TA)7,"Patients with the (TA)6/(TA)7 (UGT1A1 *1/*28) genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir."
PA166134033,rs8175347,1184747678,(TA)7/(TA)7,"Patients with the (TA)7/(TA)7 (UGT1A1 *28/*28) genotype and HIV may be at increased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir."
PA166134773,rs8175347,1448097607,(TA)6/(TA)6,"Patients with the (TA)6/(TA)6 (UGT1A1 *1/*1) genotype and HIV may have 1) a decreased likelihood for hyperbilirubinemia (up to jaundice range), 2) a decreased risk for treatment discontinuation when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence a patient's response to atazanavir."
PA166134773,rs8175347,1448097608,(TA)6/(TA)7,"Patients with the (TA)6/(TA)7 (UGT1A1 *1/*28) genotype and HIV may have increased levels of bilirubin leading to an increased likelihood for hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)6/(TA)6 (*1/*1). However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atazanavir."
PA166134773,rs8175347,1448097609,(TA)7/(TA)7,"Patients with the (TA)7/(TA)7 (UGT1A1 *28/*28) genotype and HIV may have 1) increased levels of  bilirubin leading to an increased likelihood for hyperbilirubinemia (up to jaundice range), 2) an increased risk for treatment discontinuation when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype. Other genetic and clinical factors may also influence a patient's response to atazanavir."
PA166134774,rs8175347,1448097463,(TA)6/(TA)6,"Patients with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) with Neoplasms who are treated with irinotecan-based regimens may require an increased dose of irinotecan, as compared to patients with the (TA)6/(TA)7 (*1/*28) or (TA)7/(TA)7 (*28/*28) genotype. However, no association was found in the majority of studies. Other genetic and clinical factors may also influence a patient's irinotecan dose requirement. "
PA166134774,rs8175347,1448097464,(TA)6/(TA)7,"Patients with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) with Neoplasms who are treated with irinotecan-based regimens may require a decreased dose of irinotecan as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype. However, no association was found in the majority of studies. Other genetic and clinical factors may also influence a patient's irinotecan dose requirement. "
PA166134774,rs8175347,1448097465,(TA)7/(TA)7,"Patients with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) with Neoplasms who are treated with irinotecan-based regimens may require a decreased dose of irinotecan, as compared to patients with the (TA)6/(TA)6 (*28/*28) genotype. However, no association was found in the majority of studies. Other genetic and clinical factors may also influence a patient's irinotecan dose requirement. "
PA166134779,rs8175347,1184747136,(TA)6/(TA)6,"Patients with the (TA)6/(TA)6 genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that patients with the (TA)6/(TA)6 genotype had increased UGT1A1 enzyme activity compared to those with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38."
PA166134779,rs8175347,1184747137,(TA)6/(TA)7,"Patients with the (TA)6/(TA)7 genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)6 genotype, or increased metabolism compared to patients with the (TA)7/(TA)7 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that livers with the (TA)6/(TA)7 genotype had decreased UGT1A1 enzyme activity compared to livers with the (TA)6/(TA)6 genotype, and increased activity compared to livers with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38."
PA166134779,rs8175347,1184747138,(TA)7/(TA)7,"Patients with the (TA)7/(TA)7 genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)7 or (TA)6/(TA)6 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that patients with the (TA)7/(TA)7 genotype had decreased UGT1A1 enzyme activity compared to those with the (TA)6/(TA)6 or (TA)6/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38."
PA166134800,rs8175347,1448258729,(TA)6/6,Patients with the (TA)6/6 genotype may be associated with decreased risk of Hyperbilirubinemia when treated with sorafenib in people with hepatocellular carcinoma as compared to patients with the (TA)7/6 or (TA)7/7 genotype. Other clinical and genetic factors may also influence a patient's response to sorafenib.
PA166134800,rs8175347,1448258730,(TA)6/7,Patients with the (TA)6/7 genotype may be associated with increased risk of Hyperbilirubinemia and treatment interruption when treated with sorafenib in people with hepatocellular carcinoma as compared to patients with the (TA)6/6 genotype. Other clinical and genetic factors may also influence a patient's response to sorafenib.
PA166134800,rs8175347,1448258731,(TA)7/7,Patients with the (TA)7/7 genotype may be associated with increased risk of Hyperbilirubinemia and treatment interruption when treated with sorafenib in people with hepatocellular carcinoma as compared to patients with the (TA)6/6 genotype. Other clinical and genetic factors may also influence a patient's response to sorafenib.
PA166136209,rs8175347,1444672917,(TA)6/(TA)6,"Patients with the (TA)6/(TA)6 (UGT1A1*1/*1) genotype may have lower glucuronidation of carvedilol as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol."
PA166136209,rs8175347,1444672918,(TA)6/(TA)7,"Patients with the (TA)6/(TA)7 (UGT1A1*1/*28) genotype may have higher glucuronidation of carvedilol as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype, or lower glucuronidation as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol."
PA166136209,rs8175347,1444672919,(TA)7/(TA)7,"Patients with the (TA)7/(TA)7 (UGT1A1*28/*28) genotype may have higher glucuronidation of carvedilol as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol."
PA166136359,rs8175347,1445400715,(TA)6/(TA)6,"In human liver microsomes, the (TA)6/(TA)6 genotype was found to result in the increased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the (TA)7/(TA)7 genotype."
PA166136359,rs8175347,1445400714,(TA)7/(TA)7,"In human liver microsomes, the (TA)7/(TA)7 genotype was found to result in the decreased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the (TA)6/(TA)6 genotype."
PA166135959,rs8175347,1447959947,(TA)6/(TA)6,Patients with transfusion-dependent anemias (such as thalassemia) and the (TA)6/(TA)6 genotype may have increased concentrations of deferasirox as compared to patients with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. Other clinical and genetic factors may also influence concentrations of deferasirox.
PA166135959,rs8175347,1447959948,(TA)6/(TA)7,"Patients with transfusion-dependent anemias (such as thalassemia) and the (TA)6/(TA)7 genotype may have decreased concentrations of deferasirox as compared to patients with the (TA)6/(TA)6 genotype and increased concentrations as compared to patients with the (TA)7/(TA)7 genotype. Additionally, a 3 year old female patient with major thalassemia and this genotype developed a series of adverse reactions when receiving deferasirox. Other clinical and genetic factors may also influence concentrations of deferasirox."
PA166135959,rs8175347,1447959949,(TA)7/(TA)7,Patients with transfusion-dependent anemias (such as thalassemia) and the (TA)7/(TA)7 genotype may have decreased concentrations of deferasirox as compared to patients with the (TA)6/(TA)6 and (TA)6/(TA)7 genotype. Other clinical and genetic factors may also influence concentrations of deferasirox.
PA166152787,rs8175347,1447962700,(TA)6/(TA)6,Patients with the (TA)6/(TA)6 (UGT1A1*1/*1) genotype and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence risk for hyperbilirubinemia.
PA166152787,rs8175347,1447962699,(TA)6/(TA)7,Patients with the (TA)6/(TA)7 (UGT1A1*1/*28) genotype and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence risk for hyperbilirubinemia.
PA166152787,rs8175347,1447962698,(TA)7/(TA)7,Patients with the (TA)7/(TA)7 (UGT1A1*28/*28) genotype and ischemic heart disease may have an increased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the (TA)6/(TA)7 (*1/*28) or (TA)6/(TA)6 (*1/*1) genotype. Other genetic and clinical factors may also influence risk for hyperbilirubinemia.
PA166152775,rs8175347,1447961384,(TA)6/(TA)6,Liver microsomes with the (TA)6/(TA)6 genotype may have increased glucuronidation activity for belinostat as compared to those with the (TA)7/(TA)7 genotype. No association with pharmacokinetic parameters in human subjects has been seen. Other genetic and clinical factors may also influence glucuronidation of belinostat.
PA166152775,rs8175347,1447961386,(TA)6/(TA)7,"Liver microsomes with the (TA)6/(TA)7 genotype may have increased glucuronidation activity for belinostat as compared to those with the (TA)7/(TA)7 genotype, or decreased glucuronidation activity as compared to those with the (TA)6/(TA)6 genotype. No association with pharmacokinetic parameters in human subjects has been seen. Other genetic and clinical factors may also influence glucuronidation of belinostat."
PA166152775,rs8175347,1447961385,(TA)7/(TA)7,Liver microsomes with the (TA)7/(TA)7 genotype may have decreased glucuronidation activity for belinostat as compared to those with the (TA)6/(TA)6 genotype. No association with pharmacokinetic parameters in human subjects has been seen. Other genetic and clinical factors may also influence glucuronidation of belinostat.
PA166134424,rs9679162,827847745,GG,"Patients with the GG genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134424,rs9679162,827847746,GT,"Patients with the GT genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134424,rs9679162,827847747,TT,"Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to treatment."
PA166134532,rs776746,1444705364,CC,Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.
PA166134532,rs776746,1444705365,CT,"Patients with the CT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia."
PA166134532,rs776746,1444705366,TT,"Patients with the TT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia."
PA166135362,rs776746,1183697629,CC,Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
PA166135362,rs776746,1183697630,CT,Pregnant women with the CT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
PA166135362,rs776746,1183697631,TT,Pregnant women with the TT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
PA166135632,rs776746,1448423997,CC,"Patients undergoing a liver transplant who carry the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement."
PA166135632,rs776746,1448423998,CT,"Patients undergoing a liver transplant who carry the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement."
PA166135632,rs776746,1448423999,TT,"Patients undergoing a liver transplant who carry the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement."
PA166135633,rs776746,1184999959,CC,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection."
PA166135633,rs776746,1184999960,CT,Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
PA166135633,rs776746,1184999961,TT,Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
PA166136083,rs776746,1447946946,CC,Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence risk for renal dysfunction. 
PA166136083,rs776746,1447946947,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction. 
PA166136083,rs776746,1447946948,TT,Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction. 
PA166135601,rs776746,1447946952,CC,Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus. 
PA166135601,rs776746,1447946953,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus. 
PA166135601,rs776746,1447946954,TT,"No individuals with the TT genotype (CYP3A5 *1/*1) were available for analysis. However, patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus. "
PA166136085,rs776746,1444705382,CC,"Patients with the CC genotype (CYP3A5 *3/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus."
PA166136085,rs776746,1444705383,CT,"Patients with the CT genotype (CYP3A5 *1/*3) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the CT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus."
PA166136085,rs776746,1444705384,TT,"Patients with the TT genotype (CYP3A5 *1/*1) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the TT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus."
PA166136086,rs776746,1448255845,CC,Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
PA166136086,rs776746,1448255846,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
PA166136086,rs776746,1448255847,TT,Patients with the TT genotype (CYP3A5 *1/*1) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
PA166136087,rs776746,1448573606,CC,"Patients with the CC genotype (CYP3A5 *3/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis. "
PA166136087,rs776746,1448573607,CT,"Patients with the CT genotype (CYP3A5 *1/*3) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis. "
PA166136087,rs776746,1448573608,TT,"Patients with the TT genotype (CYP3A5 *1/*1) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis. "
PA166136088,rs776746,1444705394,CC,"Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity. "
PA166136088,rs776746,1444705395,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity. 
PA166136088,rs776746,1444705396,TT,Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity. 
PA166134376,rs776746,1448422642,CC,"Patients with the CC genotype (CYP3A5 *3/*3) may require a lower dose of cyclosporine to reach target blood concentration as compared to patients with the CT (CYP3A5 *1/*3) or TT (CYP3A5 *1/*1) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine."
PA166134376,rs776746,1448422643,CT,"Patients with the CT (CYP3A5 *1/*3) genotype may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine."
PA166134376,rs776746,1448422644,TT,"Patients with the TT genotype (CYP3A5 *1/*1) may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype,  although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine."
PA166134402,rs776746,1448108861,CC,Patients with the CC genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.
PA166134402,rs776746,1448108862,CT,Patients with the CT genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.
PA166134402,rs776746,1448108863,TT,Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.
PA166134941,rs776746,1444666125,CC,"Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
PA166134941,rs776746,1444666126,CT,"Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
PA166134941,rs776746,1444666127,TT,Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
PA166134958,rs776746,1447947103,CC,Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134958,rs776746,1447947104,CT,Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134958,rs776746,1447947105,TT,Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. 
PA166134959,rs776746,1447947109,CC,Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin  may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
PA166134959,rs776746,1447947110,CT,Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
PA166134959,rs776746,1447947111,TT,"Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment."
PA166134960,rs776746,1448099845,CC,Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment. 
PA166134960,rs776746,1448099846,CT,"Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment. "
PA166134960,rs776746,1448099847,TT,Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment. 
PA166135020,rs776746,1183556912,CC,Patients with the CC genotype may have increased metabolism of ondansetron as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
PA166135020,rs776746,1183556913,CT,Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
PA166135020,rs776746,1183556914,TT,Patients with the TT genotype may have decreased metabolism of ondansetron as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
PA166135107,rs776746,1183615182,CC,Healthy males with the CC (CYP3A5 *3/*3) genotype may have increased metabolism of amlodipine as compared to healthy males with the CT or TT (*3/*1 or *1/*1) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.
PA166135107,rs776746,1183615183,CT,Healthy males with the CT (CYP3A5 *3/*1) genotype may have decreased metabolism of amlodipine as compared to patients with the CC (*3/*3) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.
PA166135107,rs776746,1183615184,TT,Healthy males with the TT (CYP3A5 *1/*1) genotype may have decreased metabolism of amlodipine as compared to patients with the CC (*3/*3) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.
PA166136306,rs776746,1444703477,CC,Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
PA166136306,rs776746,1444703476,CT,Male patients with the CT genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
PA166136306,rs776746,1444703475,TT,Male patients with the TT genotype may have increased clearance of vardenafil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
PA166134529,rs776746,1448613233,CC,"Patients with the CC genotype (CYP3A5*3/*3) who are recipients of a kidney, heart, lung or hematopoeitic stem cell transplant, or have other diseases, who are treated with tacrolimus may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement."
PA166134529,rs776746,1448613234,CT,"Patients with the CT genotype (CYP3A5*1/*3) who are recipients of a kidney, heart, lung or hematopoeitic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement."
PA166134529,rs776746,1448613235,TT,"Patients with the TT genotype (CYP3A5*1/*1) who are recipients of a kidney, heart, lung or hematopoeitic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement."
PA166134530,rs776746,1448427705,CC,"Patients with the CC (*3/*3) genotype and are recipients of a kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). However, some studies show a decreased risk of nephrotoxicity for patients with the CC genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity."
PA166134530,rs776746,1448427706,CT,"Patients with the CT genotype (*1/*3) and are recipients of a kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). However, some studies show an increased risk of nephrotoxicity for patients with the CT genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity."
PA166134530,rs776746,1448427707,TT,"Patients with the TT (*1/*1) genotype and are recipients of kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). However, some studies show an increased risk of nephrotoxicity for patients with the TT genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity."
PA166134531,rs776746,1448604371,CC,"Patients with the CC (*3/*3) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection."
PA166134531,rs776746,1448604372,CT,Patients with the CT genotype (*1/*3) and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3) or a decreased risk of transplant rejection as compared to patients with the TT genotype (*1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
PA166134531,rs776746,1448604373,TT,Patients with the TT (*1/*1) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
PA166134533,rs776746,981203887,CC,"Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine."
PA166134533,rs776746,981203888,CT,"Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine."
PA166134533,rs776746,981203889,TT,"Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine."
PA166134534,rs776746,1448108239,CC,Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134534,rs776746,1448108240,CT,Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134534,rs776746,1448108241,TT,Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
PA166134535,rs776746,1448567989,CC,Patients with the CC genotype (*3/*3) and who are recipients of transplants may have decreased metabolism of sirolimus and require a lower dose as compared to patients with the CT and TT genotype (*1/*3 and *3*/3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.
PA166134535,rs776746,1448567990,CT,Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.
PA166134535,rs776746,1448567991,TT,Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.
PA166134769,rs776746,1448568187,CC,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement. "
PA166134769,rs776746,1448568188,CT,"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement. "
PA166134769,rs776746,1448568189,TT,"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement. "
PA166135752,rs776746,1444700898,CC,Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
PA166135752,rs776746,1444700899,CT,Patients with the CT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
PA166135752,rs776746,1444700900,TT,Patients with the TT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
PA166135905,rs776746,1448266831,CC,"Patients with the CC genotype (CYP3A5 *3/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine."
PA166135905,rs776746,1448266832,CT,"Patients with the CT genotype (CYP3A5 *1/*3) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine."
PA166135905,rs776746,1448266833,TT,"Patients with the TT genotype (CYP3A5 *1/*1) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine."
PA166134961,rs776746,1448107630,CC,Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. 
PA166134961,rs776746,1448107631,CT,"Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. "
PA166134961,rs776746,1448107632,TT,Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. 
PA166159855,rs776746,1448125855,CC,Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.
PA166159855,rs776746,1448125856,CT,Patients with the CT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.
PA166159855,rs776746,1448125857,TT,Patients with the TT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.
PA166135938,rs776746,1446899622,CC,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement."
PA166135938,rs776746,1446899623,CT,"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype who is also a CYP3A4 low or intermediate expresser. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement."
PA166135938,rs776746,1446899624,TT,"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement."
PA166161465,rs776746,1448430655,CC,"Patients with the CC genotype and organ transplantation may have reduced clearance of everolimus compared to patients with the TT genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus. "
PA166161465,rs776746,1448430656,CT,"Patients with the CT genotype and organ transplantation may have reduced clearance of everolimus compared to patients with the TT genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus. "
PA166161465,rs776746,1448430657,TT,"Patients with the TT genotype and organ transplantation may have increased clearance of everolimus compared to patients with the CC genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus. "
PA166161863,rs96844,1448522762,AA,Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161863,rs96844,1448522763,AG,Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166161863,rs96844,1448522764,GG,Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
PA166135275,rs9806699,1448106486,AA,Patients with the AA genotype may be less likely to experience myopathy when treated with statins as compared to patients with the AG or GG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins. 
PA166135275,rs9806699,1448106487,AG,"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins. "
PA166135275,rs9806699,1448106488,GG,Patients with the GG genotype may be more likely to experience myopathy when treated with statins as compared to patients with the AA or AG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins. 
PA166158780,rs9725457,1448099190,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
PA166158780,rs9725457,1448099191,AG,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
PA166158780,rs9725457,1448099192,GG,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
PA166136436,rs9825762,1446899932,CC,"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166136436,rs9825762,1446899933,CT,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166136436,rs9825762,1446899934,TT,"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes. "
PA166134074,rs983332,637879983,GG,Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes .  Other genetic and clinical factors may also influence a patient's response.
PA166134074,rs983332,637879984,GT,Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166134074,rs983332,637879985,TT,Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
PA166136121,rs9852,1444607732,CC,"Patients with the CC genotype and schizophrenia may experience a greater weight gain when treated with clozapine or olanzapine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
PA166136121,rs9852,1444607733,CT,"Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
PA166136121,rs9852,1444607734,TT,"Patients with the TT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
PA166134672,rs9859552,982030981,GG,Patients with the GG genotype may have more inhibition of platelet aggregation with crangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
PA166134672,rs9859552,982030982,GT,"No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor."
PA166134672,rs9859552,982030983,TT,Patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
PA166135915,rs9915451,1445619588,AA,Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135915,rs9915451,1445619589,AG,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166135915,rs9915451,1445619590,GG,Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
PA166134423,rs9895420,827847739,AA,Patients with the AA genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134423,rs9895420,827847740,AT,Patients with the AT genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
PA166134423,rs9895420,827847741,TT,"Patients with the TT genotype may have 1) increased event free survival 2) decreased, but not non-existent, risk of central nervous system relapse 3) increased risk of thrombocytopenia when treated with methotrexate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate."
PA166152750,rs992160,1447981504,CC,Patients with the CC genotype and pancreatic cancer may have a shorter overall survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival times.
PA166152750,rs992160,1447981505,CT,Patients with the CT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
PA166152750,rs992160,1447981506,TT,Patients with the TT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
PA166134944,rs9922316,1183490960,GG,Patients with the GG genotype may have decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
PA166134944,rs9922316,1183490959,TG,Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
PA166134944,rs9922316,1183490958,TT ,Patients with the TT genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
PA166134181,rs993648,655384893,CC,Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166134181,rs993648,655384892,CT,"Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype.   It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype."
PA166134181,rs993648,655384891,TT,Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
PA166135479,rs9936750,1183863990,CC,Patients with the CC genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.
PA166135479,rs9936750,1183863991,CT,"Patients with the CT genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype and may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity."
PA166135479,rs9936750,1183863992,TT,"Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity."
PA166135600,rs9940629,1184987072,AA,Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135600,rs9940629,1184987073,AG,Patients with genotype AG and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the GG genotype and an greater reduction in HDL-C as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135600,rs9940629,1184987074,GG,Patients with genotype GG and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
PA166135422,rs9934438,1446905852,AA,Patients with the AA genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.
PA166135422,rs9934438,1446905853,AG,Patients with the AG genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.
PA166135422,rs9934438,1446905854,GG,Patients with the GG genotype may have increased dose of acenocoumarol or phenprocoumon as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.
PA166134762,rs9934438,1448105562,AA,Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134762,rs9934438,1448105563,AG,Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134762,rs9934438,1448105564,GG,Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
PA166134267,rs9934438,1448602258,AA,Patients with the AA genotype who are treated with warfarin may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166134267,rs9934438,1448602259,AG,"Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patients required dose of warfarin. "
PA166134267,rs9934438,1448602260,GG,Patients with the GG genotype who are treated with warfarin may require higher dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
PA166136484,rs9934438,1447673034,AA,Patients with the AA genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.
PA166136484,rs9934438,1447673035,AG,Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.
PA166136484,rs9934438,1447673036,GG,Patients with the GG genotype may have increased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype AG or AA. Other genetic and clinical factors may also influence the response to warfarin.
PA166134765,rs9934438,1448108072,AA,Subjects with AA genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy. 
PA166134765,rs9934438,1448108073,AG,Subjects with AG genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy. 
PA166134765,rs9934438,1448108074,GG,Subjects with GG genotypes may have decreased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with AA genotypes. Other genetic and clinical factors may also influence a subject's response to therapy. 
PA166134048,rs9937,1447963731,AA,"Patients with the AA genotype with cancer who are treated with gemcitabine 1) may be more likely to experience neutropenia and 2) may have decreased progression-free survival (PFS) as compared to patients with the AG or GG genotype. However, evidence is very contradictory for this association: one study found a decreased risk for hematological toxicity in those with the AA genotype, one study found increased PFS in those with the AA genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine."
PA166134048,rs9937,1447963732,AG,"Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine."
PA166134048,rs9937,1447963733,GG,"Patients with the GG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, evidence is very contradictory for this association: one study found an increased risk for hematological toxicity in those with the GG genotype, one study found decreased PFS in those with the GG genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine."
PA166134539,rs9923231,1447963130,CC,Patients with the CC genotype who are treated with acenocoumarol or phenprocoumon may require a higher dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's acenocoumarol or phenprocoumon maintenance dose requirement.
PA166134539,rs9923231,1447963131,CT,Patients with the CT genotype who are treated with acenocoumarol or phenprocoumon may require a lower dose as compared to patients with the CC genotype or may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol or phenprocoumon maintenance dose requirement.
PA166134539,rs9923231,1447963132,TT,Patients with the TT genotype who are treated with acenocoumarol or phenprocoumon may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol or phenprocoumon maintenance dose requirement.
PA166134208,rs9923231,1448615828,CC,Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose requirement.
PA166134208,rs9923231,1448615829,CT,Patients with the CT genotype may require a lower dose of warfarin as compared to patients with the CC genotype or may require a higher dose as compared to patients with the TT genotype.  Other genetic and clinical factors may also influence a patient's warfarin dose requirement.
PA166134208,rs9923231,1448615830,TT,Patients with the TT genotype may require a lower dose of warfarin as compared to patients with the CC or CT genotype.  Other genetic and clinical factors may also influence a patient's warfarin dose requirement.
PA166135591,rs9923231,1447673002,CC,Patients with genotype CC may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to warfarin. 
PA166135591,rs9923231,1447673001,CT,Patients with genotype CT may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the response to warfarin. 
PA166135591,rs9923231,1447673000,TT,Patients with genotype TT may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the response to warfarin. 
PA166135969,rs9923231,1448602433,CC,Patients with the CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to warfarin.
PA166135969,rs9923231,1448602434,CT,Patients with the CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to warfarin.
PA166135969,rs9923231,1448602435,TT,Patients with the TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to warfarin.
PA166136483,rs9923231,1447673022,CC,Patients with the CC genotype may spent more time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype TT or CT. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the response to warfarin.
PA166136483,rs9923231,1447673023,CT,Patients with the CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the response to warfarin.
PA166136483,rs9923231,1447673024,TT,Patients with the TT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the response to warfarin.
PA166136208,rs9939609,1444668599,AA,Patients with genotype AA may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
PA166136208,rs9939609,1444668600,AT,Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
PA166136208,rs9939609,1444668601,TT,Patients with genotype TT may have higher likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
PA166134538,rs9977268,981204027,CC,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134538,rs9977268,981204028,CT,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166134538,rs9977268,981204029,TT,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
PA166135668,rs9996584,1444665959,AA,"Patients with the AA genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166135668,rs9996584,1444665960,AG,"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment as compared to patients with the AA genotype, but a longer overall survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166135668,rs9996584,1444665961,GG,"Patients with the GG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
PA166134422,rs9981861,827847726,CC,Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.
PA166134422,rs9981861,827847727,CT,Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.
PA166134422,rs9981861,827847728,TT,Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.
